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INTRODUCTION 
 
Content 
 
The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and 
towns of Massachusetts for the five-year time period 2009 through 2013.  For each city and town, 
Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for 
all invasive cancer types combined.  These ratios compare the cancer incidence experience of each city 
or town with the cancer experience of the state as a whole.  The method involves comparing the 
number of cases that were observed for a city or town to the number of cases that would be expected if 
the city or town had the same cancer rates as the state as whole.  The report is organized into the 
following sections: 
 
METHODS provides a detailed explanation of the data collection, data processing, and statistical 
techniques employed in this report. 
 
TABLES present data for selected types of cancer by city/town and sex. 
 
APPENDIX I provides a listing of International Classification of Diseases for Oncology codes 
used in the preparation of this report. 
 
APPENDIX II provides selected resources for information on cancer. 
 
APPENDIX III describes the Massachusetts Department of Public Health’s current cancer 
control initiatives, and provides links to bureaus within the department that address some aspect 
of cancer.  Links to resources for publications are also provided. 
 
Comparison with Previous Reports 
 
This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR).   
It is available on line at http://www.mass.gov/dph/mcr.  For questions about the report, contact the 
MCR at: 
  
 Massachusetts Cancer Registry 
 Office of Data Management and Outcomes Assessment 
 Massachusetts Department of Public Health 
 250 Washington Street, 6
th
 floor 
 Boston, MA 02108-4619 
telephone 617-624-5642; fax 617-624-5695  
 
The preceding report, Cancer Incidence in Massachusetts 2008-2012:  City and Town Supplement, 
included data for diagnosis years 2008 through 2012.  This report contains data for the diagnosis years 
2009 through 2013.  There have been no changes in this report’s format from the previous report.   
  
 
METHODS 
 
Data Sources 
 
Cancer Incidence 
 
The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners 
throughout Massachusetts. Facilities that  reported the 2009-2013 diagnoses that comprise this report  
include 69 Massachusetts  acute care hospitals, 18 independent laboratories, 10 surgical centers, 5  
radiation/oncology centers, 5 medical practice associations, 4 endoscopy centers, and approximately 
500 private practice physicians. The MCR signed the modified National Data Exchange Agreement on 
March 28, 2013. This is a single agreement that allows participating states to exchange data on cases 
diagnosed or treated in other areas.  Together with states participating in the agreement, and states 
with individual agreements, the MCR now has reciprocal reporting agreements with 43 states and with 
Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the 
MCR collects information on in situ and invasive cancers and benign tumors of the brain and 
associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of 
the skin. 
 
The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff 
physician offices when this information is available. Not all hospitals report this type of case, 
however, some hospitals report such cases as if the patients had been diagnosed and treated by the 
hospital directly. Collecting these types of data makes the MCR’s overall case ascertainment more 
complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, 
colon/rectum, and oral cancers. 
 
In addition, the MCR identifies previously unreported cancer cases through review of death certificate 
data to further improve case completeness. This process is referred to as death clearance and identifies 
cancers mentioned on death certificates that were not previously reported to the MCR. In some 
instances, the MCR obtains additional information on these cases through follow-up activities with 
hospitals, nursing homes, hospice residences, and physicians’ offices. In other instances, a cancer-
related cause of death recorded on a Massachusetts death certificate is the only source of information 
for a cancer case. Thus these “death certificate only” cancer diagnoses are poorly documented and 
have not been confirmed by review of clinical and pathological information. Such cases are included 
in this report, but they comprise less than 3% of all cancer cases. 
 
All case reports that provided the basis for this report were coded following the International 
Classification of Diseases for Oncology, Third Edition (ICD-O-3), which was implemented in North 
America with cases diagnosed as of January 1, 2001. (1)  Please see Appendix A for the classification 
of cancers by ICD-O3 codes. 
 
Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer 
registry data for quality, completeness, and timeliness.  For 2009-2013, the MCR’s annual case count 
was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the 
gold standard for this certification element as well as for six other certification elements for each case 
year since 1997.  
 
The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among 
Massachusetts residents during 2009-2013 and reported to the MCR as of December 1, 2016.  These 
data include some additional cases diagnosed in 2008-2012 that were not counted in the previous 
report,   Cancer Incidence in Massachusetts 2008-2012:  City and Town Supplement.   The lag time 
between this report and the annual statewide report of 2009-2013 cancer cases is due to the fact that 
data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts.  
  
The statewide report presented data at the state level and did not require such accuracy of city and 
town of residence.  The numbers presented in this report may change slightly in future reports, 
reflecting late reported cases or corrections based on subsequent details from the reporting facilities.  
Such changes might result in slight differences in numbers and rates in future reports of MCR data, 
reflecting the nature of population-based cancer registries that receive case reports on an ongoing 
basis. 
Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among 
Massachusetts residents during 2009-2013.  The Massachusetts data presented include invasive 
cancers only (except cancer of the urinary bladder, where in situ cancers are also included).  Invasive 
cancers have spread beyond the layer of cells where they started and have the potential to spread to 
other parts of the body.  In situ cancers are neoplasms diagnosed at the earliest stage, before they have 
spread, when they are limited to a small number of cells and have not invaded the organ itself.  
Typically, published incidence rates do not combine invasive and in situ cancers due to differences in 
the biologic significance, survival prognosis and types of treatment of the tumors.  Cancer of the 
urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and 
treatment patterns. 
  
Presentation of Data 
 
Each city and town in Massachusetts is listed alphabetically in the TABLES section.  The observed 
number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence 
intervals are presented for twenty-three main types of cancer and for all cancer types combined.  The 
“all cancers combined” category includes the twenty-three main types presented in this report and 
other malignant neoplasms.  This category is meant to provide a summary of the total cancer 
experience in a community.  As different cancers have different causes, this category does not reflect 
any specific risk factor that may be important for this community. 
 
Observed and Expected Case Counts 
 
The observed case count (Obs) for a particular type of cancer in a city/town is the actual number of 
newly diagnosed cases among residents of that city/town for a given time period.  
 
A city/town’s expected case count (Exp) for a certain type of cancer for this time period is a calculated 
number based on that city/town’s population distribution2 (by sex and among eighteen age groups) for 
the time period 2009-2013, and the corresponding statewide average annual age-specific incidence 
rates.  The source of the city and town population data for the 2009-2013 period was the US Census 
American Community Survey (ACS), an ongoing national survey that provides demographic estimates 
on a yearly basis.
2
  
 
Standardized Incidence Ratios 
 
A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that 
describes in numerical terms how a city/town’s cancer experience in a given time period compares 
with that of the state as a whole. 
 An SIR of exactly 100 indicates that a city/town’s incidence of a certain type of cancer is equal 
to that expected based on statewide average age-specific incidence rates. 
 An SIR of more than 100 indicates that a city/town’s incidence of a certain type of cancer is 
higher than expected for that type of cancer based on statewide average annual age-specific 
  
incidence rates.  For example, an SIR of 105 indicates that a city/town’s cancer incidence is 5% 
higher than expected based on statewide average annual age-specific incidence rates. 
 An SIR of less than 100 indicates that a city/town’s incidence of a certain type of cancer is 
lower than expected based on statewide average age-specific incidence rates.  For example, an 
SIR of 85 indicates that a city/town’s cancer incidence is 15% lower than expected based on 
statewide average annual age-specific incidence rates.  
 
Statistical Significance and Interpretation of SIRs 
 
The interpretation of the SIR depends on both how large it is and how stable it is.  Stability in this 
context refers to how much the SIR changes when there are small increases or decreases in the 
observed or expected number of cases.  Two SIRs may have the same size but not the same stability.  
For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed 
cases and 400 expected cases.  Both represent a 50 percent excess of observed cases.  However, in the 
first instance, one or two fewer cases would change the SIR a great deal, whereas in the second 
instance, even if there were several fewer cases, the SIR would only change minimally.  When the 
observed and expected numbers of cases are relatively small, their ratio is easily affected by one or 
two cases.  Conversely, when the observed and expected numbers of cases are relatively large, the 
value of the SIR is stable. 
 
A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the 
observed number of cases is at least 5), to indicate if the observed number of cases is significantly 
different from the expected number, or if the difference is most likely due to chance.  A confidence 
interval is a range of values around a measurement that indicates the precision of the measurement.  In 
this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability 
of including the true SIR for a specific city or town.  If the 95% confidence interval range does not 
include the value 100.0, then the number of observed cases is significantly different from the expected 
number of cases.  “Significantly different” means there is at most a 5% chance that the difference 
between the number of observed and expected cancer cases is due solely to chance alone.  If the 
confidence interval does contain the value 100, there is no significant difference between the observed 
and expected numbers.  Statistically, the width of the interval reflects the size of the population and 
the number of events; smaller populations and smaller observed numbers of cases yield less precise 
estimates that have wider confidence intervals.  Wide confidence intervals indicate instability, 
meaning that small changes in the observed or expected number of cases would change the SIR a great 
deal. 
 
Examples: 
 SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the 
interval is above 100.0, indicating that the number of observed cases is statistically significantly 
higher than the expected number. 
 
 SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval 
is below 100.0, indicating that the number of observed cases is statistically significantly lower 
than the expected number. 
 
 SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that 
the number of observed cases is NOT statistically significantly different from what is expected, 
and the difference is likely due to chance.  When the interval includes 100.0, then the true SIR 
may be 100.0. 
  
Example of Calculation of an SIR and Its Significance 
 
 
SIR = 
OBSERVED CASES 
X 100 
 EXPECTED CASES 
 
The following example illustrates the method of calculation for a hypothetical town for one type of 
cancer and one sex for the years 2007-2011: 
 
 
 Town X State Town X Town X 
 Age  Age-Specific Expected Observed 
 Group Population Incidence Rate Cases Cases 
 (A) (B) (C) = (A) x (B) (D) 
 00-04 74,657 0.0001 7.47 11 
 05-09 134,957 0.0002 26.99 25 
 10-14 54,463 0.0005 27.23 30 
 15-19 25,136 0.0015 37.70 40 
 20-24 17,012 0.0018 30.62 30 
    UP TO 
 85+ 6,337 0.0010 6.34 8 
  Total:     136.35 144 
 
 
SIR = 
Observed Cases 
X 100 = 
(column D total) 
X 100 = 
144 
X 100 ≈ 106 
Expected Cases (column C total) 136.35 
 
Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in 
Town X is 6% higher than the corresponding statewide average incidence for this cancer.  However, 
the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true 
value may be as low as 89.1 or as high as 124.3  Also, since the range includes the value 100, it means 
that the observed number of cases is not statistically significantly higher or lower than what is 
expected. 
 
Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated 
nor tested for statistical significance. This is indicated with an (nc) (“not calculated”).  However, the 
number of observed and expected cases is shown in these circumstances. 
 
Notes about Data Interpretation 
 
The SIR is a useful indication of the disease categories that have relatively high or low rates for a 
given community.  These statistics, however, should be used with care.  Such statistics provide a 
starting point for further research and investigation into a possible health problem, but they do not by 
themselves confirm or deny the existence of a particular health problem.  Many factors unrelated to 
disease causation may contribute to an elevated SIR, including demographic factors, changes in 
diagnostic techniques, and changes in data collection or recording methods over time, as well as the 
natural variation in disease occurrence.   
  
 
 
When reviewing the data tables, it is important to keep in mind that an SIR compares the observed 
cancer incidence in a particular community with the expected incidence based on statewide average 
annual age-specific incidence rates.  This means that valid comparisons can only be made between a 
community and the state as a whole.  SIRs for different cities and towns CANNOT and SHOULD NOT be 
compared to each other.  (Comparisons between two communities would be valid only if there were 
no differences in the age and sex distributions of the two communities’ populations.) 
 
Another point to keep in mind when reviewing these data is the large number of statistical tests being 
performed in this report.  For each of the 351 cities and towns, we evaluate 18 types of cancer that can 
occur in both males and females, 3 types that occur only in females and 2 types that occur only in 
males, resulting in 41 gender/cancer categories.  This results in 14,391 possible calculations (351 cities 
and towns x 41 gender cancer categories).  Note that gender/cancer categories with less than 5 
observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly 
lower than 14,391. This is important for the reader because when multiple significance tests are 
performed, some will result in a significant finding due to chance alone. Based on the number of 
calculations in this report, we expect 720 significant findings to be due to chance alone.  Half of these 
would be significant excesses (360) and half would be significant deficits (360).  There are statistical 
techniques that can be used to reduce this number, however use of these techniques leads to the 
opposite problem – true significant differences that may be missed.  We choose to err on the side of 
caution and identify more significant results, knowing that some will be due to chance alone.   
 
Data Limitations 
 
It should be emphasized that apparent increases or decreases in cancer incidence over time might 
reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence.  
Four other limitations must be considered when interpreting cancer incidence data for Massachusetts 
cities and towns:  under-reporting in areas close to neighboring states; under-reporting for cancers that 
may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized 
incidence ratios based on small numbers of cases. 
 
Border Areas and Neighboring States 
 
Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of 
Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the 
MCR. The MCR has reciprocal reporting agreements with 29 states and with Puerto Rico. 
 
Cases Diagnosed in Non-Hospital Settings 
 
During the time period covered by this report, the MCR’s primary information source for most newly 
diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting 
hospitals on cases diagnosed and treated in staff physician offices, when this information was 
available. Other reporting sources include dermatologists and dermatopathology laboratories, 
urologists’ offices and a general laboratory. Some types of cancer in this report may be under-reported 
because they are diagnosed primarily by private physicians, private laboratories, health maintenance 
organizations, radiotherapy centers that escape identification systems used by hospitals.  The most 
common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate 
cancer.   The exact extent of this under-reporting has not been determined, but cases included in this 
report represent the great majority of cases statewide and provide an essential basis for evaluating 
statewide cancer incidence patterns. 
  
 
 
City/Town Misassignment 
 
In accordance with standard central cancer registry procedures, each case reported to the MCR ideally 
should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the 
address provided by the reporting hospital.  In practice, however, a patient may provide the hospital 
with his/her mailing address (e.g., a post office box located outside the patient’s city/town of 
residence); a business address; a temporary address (e.g., the patient is staying with a relative while 
receiving treatment and reports the relative’s address as his/her own); or a locality or post office name 
(e.g., “Chestnut Hill” rather than “Boston,” “Brookline,” or “Newton”).  In addition, if a patient has 
moved since being diagnosed, the hospital may report the patient’s current address.  Because of the 
large number of cases reported to the MCR, and because data are reported to the MCR via electronic 
media, most city/town case assignments are performed by an automated computer process.  This 
simplified matching process may misassign some cases based on the reported locality name.  When 
MCR staff become aware of such misassignments, they manually correct the errors.  Furthermore, in 
order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment 
are reviewed manually. 
 
Small Numbers of Cases 
 
Standardized incidence ratios based on small numbers of cases result in estimates that are very 
unstable.  This situation is common when the population of a city or town is small or if the particular 
cancer type is rare.  SIRs and statistical significance are not calculated when the number of observed 
cases for a specific category is less than five.  In these instances, the observed and expected cases are 
presented in the tables for qualitative comparison only. 
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A P P E N D I C E S 
  
APPENDIX I:  INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD 
EDITION) 
CODES USED FOR THIS REPORT 
1
 
 
Cancer Site / Type Primary Site Codes
 
Histologic Type Codes 
2
 
 
Bladder, Urinary C67.0 - C67.9 all except 9590 - 9989 
 
Brain and Other  C70.0 - C72.9 all except 9590 - 9989 
Nervous System   
 
Breast C50.0 - C50.9 all except 9590 - 9989 
 
Cervix Uteri C53.0 - C53.9 all except 9590 - 9989 
 
Colon / Rectum C18.0 - C18.9, C19.9, all except 9590 - 9989 
 C20.9, C26.0  
 
Esophagus C15.0 - C15.9 all except 9590 - 9989 
 
Hodgkin Lymphoma  C00.0 - C80.9 9650 - 9667 
 
Kidney and Renal Pelvis 3 C64.9, C65.9 all except 9590 - 9989 
 
Larynx C32.0 - C32.9 all except 9590 - 9989 
 
Leukemia  C00.0 - C80.9 9733, 9742, 9800 - 9820, 9826, 
 9831 - 9948, 9963, 9964 
 C42.0, C42.1, C42.4 9823, 9827 
 
Liver and Intrahepatic Bile Ducts C22.0, C22.1 all except 9590 - 9989 
 
Lung and Bronchus C34.0 - C34.9 all except 9590 - 9989 
 
Melanoma of Skin C44.0 - C44.9 8720 - 8790 
 
Multiple Myeloma C00.0 - C80.9 9731, 9732, 9734 
 
Non-Hodgkin Lymphoma C00.0 - C80.9 9590 - 9595, 9670 - 9729 
 all except C42.0, C42.1, C42.4 9823, 9827 
 
Oral Cavity and Pharynx C00.0 - C14.8 all except 9590 - 9989 
 
Ovary C56.9 all except 9590 - 9989 
 
Pancreas C25.0 - C25.9 all except 9590 - 9989 
 
Prostate C61.9 all except 9590 - 9989 
 
Stomach C16.0 - C16.9 all except 9590 - 9989 
 
Testis C62.0 - C62.9 all except 9590 - 9989 
 
Thyroid C73.9 all except 9590 - 9989 
 
Uteri, Corpus and Uterus, NOS C54.0 - C54.9, C55.9 all except 9590 - 9989 
 
All Sites / Types C00.0 - C80.9 8000 - 9989 
 
1 includes codes added to the International Classification of Diseases for Oncology, Third Edition since its publication. 
2 Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which 
includes invasive and in situ behaviors.  Non-invasive (in situ) cancers are not included. 
3 Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category 
that is not included in this cancer type. 
  
APPENDIX II:  SELECTED RESOURCES FOR 
INFORMATION ON CANCER 
 
This Appendix contains a listing of selected resources for additional information on cancer. 
Cancers are complex diseases, many of which have multiple factors that may contribute to their 
development.   
 
For information on cancer risk factors or prevention, you may wish to contact the following: 
Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237) 
Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345) 
 
In addition, the following selected Internet websites provide information on cancer.  Many of 
these also provide links to other sites (not listed) which may be of interest. 
Massachusetts Department of Public Health:  http://www.mass.gov/dph 
 
American Cancer Society:  http://www.cancer.org 
 
Centers for Disease Control and Prevention 
 Home Page:  http://www.cdc.gov 
 Cancer Prevention and Control Program:  http://www.cdc.gov/cancer 
Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):   
http://www.fruitsandveggiesmorematters.org/ 
 
National Cancer Institute 
 Information:  http://www.cancer.gov 
 Cancer Literature in PubMed:  
https://www.ncbi.nlm.nih.gov/pubmed?cmd_current=Limits&pmfilter_Subsets=Cancer 
 Surveillance, Epidemiology, and End Results (SEER) Program data:  http://seer.cancer.gov 
 
Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington 
University School of Medicine; formerly at Harvard Center for Cancer Prevention):  
http://www.yourdiseaserisk.wustl.edu 
 
OncoLink (Abramson Cancer Center of the University of Pennsylvania): 
http://www.oncolink.org 
 
Cancerquest (Emory University – Winship Cancer Institute):  www.cancerquest.org 
 
National Coalition for Cancer Survivorship:  http://www.canceradvocacy.org 
  
 
APPENDIX III:  MDPH CANCER PREVENTION AND CONTROL INITIATIVES  
 
The Massachusetts Department of Public Health is working to reduce the incidence and mortality 
of cancer in the Commonwealth.  Partnerships between MDPH programs, researchers, healthcare 
providers and nonprofit organizations collect information about cancer, lead quality improvement 
projects, coordinate evidenced-based workshops for managing living with chronic disease 
(including cancer), provide education for health professionals and bring shared messages to the 
public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through 
healthy lifestyles, early diagnosis, and increased access to care. The Department’s programs 
address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, 
along with environmental and occupational hazards for cancer. Throughout all of our efforts there 
is an emphasis on reducing disparate health outcomes and unequal access to cancer care. 
 
MDPH Bureaus and Programs:  
Bureau of Environmental Health, www.mass.gov/dph/environmental_health  
Bureau of Substance Abuse Services, www.mass.gov/dph/bsas 
Comprehensive Cancer Prevention and Control Program, www.mass.gov/compcancer 
Men’s Health/Women’s Health/Care Coordination Program 
Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp  
Occupational Health Surveillance Program, www.mass.gov/dph/ohsp 
Office of Elder Affairs www.mass.gov/elders/ 
Oral Health Program, www.mass.gov/dph/oralhealth  
Division of Prevention and Wellness www.mass.gov/dph/healthpromotion 
 
MDPH publications on cancer prevention and screening are available at the Massachusetts Health 
Promotion Clearinghouse, www.maclearinghouse.com.  
 
Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer 
Registry, telephone: 617-624-5642 and on the web at www.mass.gov/dph/mcr. 
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Abington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 14.6 103.0 (57.6-169.9)   Male 12 9.9 121.3 (62.6-211.9) 
Female 7 5.3 131.2 (52.6-270.3)   Female 9 8.3 108.9 (49.7-206.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.1 nc (nc-nc)   Male 6 3.1 193.4 (70.6-420.9) 
Female 4 2.7 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 4 8.9 nc (nc-nc) 
Female 62 63.6 97.4 (74.7-124.9)   Female 5 7.7 64.5 (20.8-150.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.5 79.5 (29.0-173.0) 
Female 3 2.3 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 16.4 116.0 (69.8-181.2)             
Female 24 16.2 148.5 (95.1-221.0)   Female 7 5.6 124.4 (49.8-256.3) 
Esophagus            Pancreas     
Male 5 4.1 120.9 (39.0-282.2)   Male 8 5.3 151.1 (65.0-297.7) 
Female 0 1.1 nc (nc-nc)   Female 3 5.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 55 54.7 100.6 (75.8-130.9) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 8.9 158.1 (86.4-265.3)   Male 4 3.5 nc (nc-nc) 
Female 8 4.9 161.7 (69.6-318.7)   Female 4 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.4 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 6 0.7 812.9 (296.8-1769.3)             
Leukemia            Thyroid     
Male 1 6.1 nc (nc-nc)   Male 5 4.2 117.9 (38.0-275.0) 
Female 8 4.7 170.4 (73.4-335.9)   Female 17 12.6 134.4 (78.3-215.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.5 91.3 (29.4-213.0)             
Female 2 1.8 nc (nc-nc)   Female 20 14.8 135.3 (82.6-208.9) 
Lung and Bronchus            All Sites / Types     
Male 41 26.6 154.0 (110.5-209.0)   Male 227 204.2 111.2 (97.2-126.6) 
Female 36 28.2 127.7 (89.4-176.8)   Female 250 211.4 118.3 (104.1-133.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
10 
Acton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 20.8 81.8 (47.6-131.0)   Male 14 14.3 97.9 (53.5-164.2) 
Female 7 7.2 97.7 (39.1-201.3)   Female 18 11.3 159.9 (94.7-252.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.6 152.8 (61.2-314.9)   Male 4 4.5 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 5 3.3 149.4 (48.1-348.6) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 17 12.9 131.7 (76.7-210.9) 
Female 96 91.5 104.9 (85.0-128.1)   Female 11 10.6 103.8 (51.8-185.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 11.1 108.1 (55.8-188.9) 
Female 2 3.2 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 24.3 65.9 (37.6-107.0)             
Female 17 22.7 74.8 (43.5-119.7)   Female 15 7.9 189.9 (106.2-313.3) 
Esophagus            Pancreas     
Male 6 5.9 102.3 (37.3-222.6)   Male 7 7.6 92.2 (36.9-190.0) 
Female 4 1.4 nc (nc-nc)   Female 6 7.2 83.6 (30.5-182.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.8 nc (nc-nc)   Male 73 76.0 96.1 (75.3-120.8) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 12.8 62.5 (26.9-123.2)   Male 1 5.1 nc (nc-nc) 
Female 7 6.9 101.7 (40.7-209.5)   Female 2 2.9 nc (nc-nc) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.9 78.7 (31.5-162.3)   Male 7 6.2 113.1 (45.3-233.0) 
Female 12 6.1 195.6 (100.9-341.7)   Female 15 17.5 85.5 (47.8-141.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 8.1 nc (nc-nc)             
Female 3 2.4 nc (nc-nc)   Female 19 20.4 92.9 (55.9-145.1) 
Lung and Bronchus            All Sites / Types     
Male 20 37.8 52.9 (32.3-81.8)   Male 242 292.2 82.8 (72.7-93.9) 
Female 24 38.6 62.2 (39.8-92.5)   Female 292 293.9 99.3 (88.3-111.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
11 
Acushnet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 12.6 150.4 (90.5-234.8)   Male 8 7.9 100.9 (43.4-198.8) 
Female 4 4.4 nc (nc-nc)   Female 6 6.1 98.8 (36.1-215.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.3 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 7.1 140.2 (67.1-257.9) 
Female 44 48.6 90.6 (65.8-121.6)   Female 7 6.1 115.6 (46.3-238.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 5.6 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 13.4 112.1 (62.7-184.9)             
Female 12 12.9 92.7 (47.8-161.9)   Female 4 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.2 nc (nc-nc)   Male 7 4.4 159.2 (63.8-328.1) 
Female 0 0.9 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 51 39.8 128.1 (95.4-168.5) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 6.6 136.7 (62.4-259.6)   Male 1 2.9 nc (nc-nc) 
Female 4 3.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.0 100.0 (32.2-233.4)   Male 0 3.0 nc (nc-nc) 
Female 6 3.4 176.5 (64.4-384.1)   Female 9 8.5 105.3 (48.1-199.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.1 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 9 11.1 80.8 (36.9-153.5) 
Lung and Bronchus            All Sites / Types     
Male 29 21.9 132.4 (88.6-190.1)   Male 182 160.3 113.5 (97.6-131.3) 
Female 22 23.8 92.3 (57.8-139.8)   Female 151 163.2 92.5 (78.3-108.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
12 
Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.6 83.1 (35.8-163.8)   Male 3 6.1 nc (nc-nc) 
Female 6 3.8 160.0 (58.4-348.2)   Female 4 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.5 91.0 (29.3-212.3) 
Female 35 39.5 88.6 (61.7-123.3)   Female 8 5.1 157.2 (67.7-309.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.5 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 10.5 113.9 (58.8-199.0)             
Female 14 11.4 122.8 (67.1-206.0)   Female 3 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.6 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 5 3.7 133.7 (43.1-311.9) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 38 33.2 114.3 (80.9-157.0) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.3 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.8 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 7 7.0 100.6 (40.3-207.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 6 8.7 69.3 (25.3-150.8) 
Lung and Bronchus            All Sites / Types     
Male 18 17.2 104.7 (62.0-165.5)   Male 125 126.8 98.6 (82.1-117.5) 
Female 32 19.7 162.3 (111.0-229.1)   Female 145 135.6 107.0 (90.3-125.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
13 
Agawam 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 32.4 111.2 (77.9-154.0)   Male 20 20.7 96.7 (59.0-149.3) 
Female 11 13.6 81.1 (40.4-145.2)   Female 16 17.9 89.5 (51.1-145.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.1 81.8 (26.4-191.0)   Male 9 6.5 137.7 (62.8-261.3) 
Female 3 5.5 nc (nc-nc)   Female 5 6.0 83.1 (26.8-193.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 23 18.5 124.3 (78.8-186.5) 
Female 153 139.6 109.6 (92.9-128.4)   Female 19 18.3 103.7 (62.4-162.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 15.0 153.5 (97.2-230.3) 
Female 9 4.5 201.1 (91.8-381.9)   Female 13 7.6 170.1 (90.5-290.9) 
Colon / Rectum            Ovary     
Male 43 34.8 123.4 (89.3-166.2)             
Female 35 41.1 85.2 (59.3-118.5)   Female 12 12.6 95.1 (49.1-166.2) 
Esophagus            Pancreas     
Male 5 8.6 58.2 (18.8-135.9)   Male 11 11.4 96.6 (48.1-172.8) 
Female 3 2.6 nc (nc-nc)   Female 17 13.8 123.5 (71.9-197.8) 
Hodgkin Lymphoma            Prostate     
Male 2 2.3 nc (nc-nc)   Male 92 108.6 84.7 (68.3-103.9) 
Female 3 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 17.6 130.7 (82.8-196.2)   Male 11 7.6 144.8 (72.2-259.2) 
Female 7 11.2 62.5 (25.0-128.7)   Female 5 5.3 93.7 (30.2-218.6) 
Larynx            Testis     
Male 7 5.0 140.0 (56.1-288.5)   Male 3 4.0 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 12.9 101.0 (53.7-172.7)   Male 7 7.9 88.8 (35.6-183.0) 
Female 9 10.6 84.6 (38.6-160.6)   Female 19 24.0 79.2 (47.6-123.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 11.2 80.0 (36.5-151.9)             
Female 3 4.1 nc (nc-nc)   Female 28 31.7 88.3 (58.6-127.6) 
Lung and Bronchus            All Sites / Types     
Male 82 57.6 142.3 (113.2-176.6)   Male 448 423.2 105.9 (96.3-116.1) 
Female 84 68.3 122.9 (98.1-152.2)   Female 490 482.5 101.6 (92.8-111.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Alford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.1 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 2 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 2.1 nc (nc-nc)   Male 4 14.1 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 9 10.0 90.0 (41.1-170.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
15 
Amesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 13.6 169.7 (107.5-254.7)   Male 8 9.9 80.6 (34.7-158.8) 
Female 10 6.0 167.8 (80.3-308.6)   Female 6 9.0 66.6 (24.3-145.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.2 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 6 2.8 218.0 (79.6-474.6)   Female 0 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 11 8.9 124.2 (61.9-222.2) 
Female 77 70.3 109.5 (86.4-136.8)   Female 11 8.6 128.1 (63.9-229.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 7.9 151.2 (78.1-264.2) 
Female 1 2.5 nc (nc-nc)   Female 5 3.7 136.9 (44.1-319.4) 
Colon / Rectum            Ovary     
Male 24 16.0 149.6 (95.8-222.6)             
Female 25 18.6 134.2 (86.8-198.1)   Female 5 6.2 81.0 (26.1-189.1) 
Esophagus            Pancreas     
Male 4 4.1 nc (nc-nc)   Male 9 5.1 175.1 (79.9-332.4) 
Female 1 1.2 nc (nc-nc)   Female 7 6.0 116.4 (46.6-239.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 61 54.8 111.4 (85.2-143.1) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 9.1 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 4 5.4 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.0 133.2 (57.4-262.5)   Male 5 4.6 108.7 (35.0-253.6) 
Female 7 5.0 140.1 (56.1-288.7)   Female 16 13.7 116.9 (66.8-189.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.7 nc (nc-nc)             
Female 3 1.9 nc (nc-nc)   Female 11 15.7 69.9 (34.8-125.0) 
Lung and Bronchus            All Sites / Types     
Male 31 25.7 120.7 (82.0-171.4)   Male 237 202.7 116.9 (102.5-132.8) 
Female 40 31.3 127.9 (91.4-174.2)   Female 252 233.2 108.1 (95.1-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
16 
Amherst 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 18.6 86.0 (49.1-139.7)   Male 11 12.4 88.4 (44.1-158.2) 
Female 3 7.1 nc (nc-nc)   Female 13 12.0 108.7 (57.8-185.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.8 nc (nc-nc)   Male 5 3.7 136.2 (43.9-317.9) 
Female 1 4.4 nc (nc-nc)   Female 0 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 6 12.0 49.9 (18.2-108.6) 
Female 72 75.9 94.8 (74.2-119.4)   Female 15 10.5 142.3 (79.6-234.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.7 103.9 (47.4-197.2) 
Female 2 2.7 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 19.7 81.3 (46.4-132.0)             
Female 25 21.5 116.2 (75.2-171.5)   Female 12 7.6 158.1 (81.6-276.2) 
Esophagus            Pancreas     
Male 2 4.9 nc (nc-nc)   Male 9 6.5 138.9 (63.4-263.8) 
Female 0 1.3 nc (nc-nc)   Female 7 7.0 99.5 (39.9-205.0) 
Hodgkin Lymphoma            Prostate     
Male 0 3.8 nc (nc-nc)   Male 47 62.6 75.1 (55.2-99.9) 
Female 0 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 10.0 49.9 (16.1-116.4)   Male 1 4.3 nc (nc-nc) 
Female 5 6.2 80.2 (25.9-187.2)   Female 1 2.9 nc (nc-nc) 
Larynx            Testis     
Male 2 2.8 nc (nc-nc)   Male 2 6.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 9.2 109.2 (52.3-200.8)   Male 6 5.7 105.7 (38.6-230.0) 
Female 5 7.0 71.8 (23.1-167.6)   Female 4 19.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.5 nc (nc-nc)             
Female 2 2.4 nc (nc-nc)   Female 12 17.6 68.1 (35.1-118.9) 
Lung and Bronchus            All Sites / Types     
Male 15 33.3 45.0 (25.2-74.2)   Male 179 258.3 69.3 (59.5-80.2) 
Female 20 37.0 54.1 (33.0-83.5)   Female 225 277.8 81.0 (70.7-92.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
17 
Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 34.6 72.3 (46.8-106.8)   Male 23 22.5 102.4 (64.9-153.7) 
Female 9 13.3 67.7 (30.9-128.6)   Female 27 19.0 141.9 (93.5-206.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.8 102.5 (41.1-211.3)   Male 9 7.2 125.3 (57.2-237.8) 
Female 5 6.0 83.2 (26.8-194.1)   Female 9 6.0 148.8 (67.9-282.4) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 26 20.2 128.8 (84.1-188.7) 
Female 159 153.8 103.4 (87.9-120.8)   Female 21 18.8 111.8 (69.2-171.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 16.8 101.3 (59.0-162.1) 
Female 2 5.1 nc (nc-nc)   Female 4 8.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 30 38.1 78.8 (53.1-112.5)             
Female 29 40.7 71.3 (47.7-102.4)   Female 14 13.5 103.9 (56.7-174.3) 
Esophagus            Pancreas     
Male 8 9.5 84.6 (36.4-166.7)   Male 11 12.3 89.3 (44.5-159.7) 
Female 4 2.6 nc (nc-nc)   Female 11 13.4 82.3 (41.0-147.2) 
Hodgkin Lymphoma            Prostate     
Male 3 2.5 nc (nc-nc)   Male 113 122.1 92.6 (76.3-111.3) 
Female 3 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 19.6 91.6 (54.3-144.8)   Male 5 8.2 61.0 (19.7-142.4) 
Female 11 12.0 91.8 (45.8-164.3)   Female 4 5.2 nc (nc-nc) 
Larynx            Testis     
Male 3 5.5 nc (nc-nc)   Male 7 4.2 166.9 (66.9-343.9) 
Female 3 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 14.0 143.3 (87.5-221.3)   Male 15 8.9 168.8 (94.4-278.5) 
Female 10 10.9 91.5 (43.8-168.3)   Female 37 27.6 134.2 (94.5-185.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 12.5 64.1 (27.6-126.3)             
Female 3 4.3 nc (nc-nc)   Female 24 34.8 69.0 (44.2-102.6) 
Lung and Bronchus            All Sites / Types     
Male 38 62.4 60.9 (43.1-83.6)   Male 421 464.5 90.6 (82.2-99.7) 
Female 38 70.6 53.8 (38.1-73.8)   Female 454 509.6 89.1 (81.1-97.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
18 
Aquinnah 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.4 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 4.5 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
19 
Arlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 45.9 93.7 (67.8-126.2)   Male 25 29.8 83.9 (54.3-123.8) 
Female 16 17.8 89.9 (51.3-145.9)   Female 26 25.4 102.3 (66.8-149.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 9.0 89.1 (38.4-175.7)   Male 10 9.3 107.8 (51.6-198.2) 
Female 9 7.7 117.1 (53.4-222.3)   Female 4 8.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.6 nc (nc-nc)   Male 19 26.7 71.2 (42.8-111.2) 
Female 212 195.0 108.7 (94.6-124.4)   Female 33 24.9 132.4 (91.1-185.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 21.3 89.4 (53.8-139.6) 
Female 2 6.9 nc (nc-nc)   Female 15 10.5 142.9 (79.9-235.8) 
Colon / Rectum            Ovary     
Male 43 50.2 85.7 (62.0-115.4)             
Female 45 54.8 82.1 (59.9-109.9)   Female 16 17.4 91.8 (52.4-149.1) 
Esophagus            Pancreas     
Male 13 12.0 108.5 (57.7-185.5)   Male 18 16.1 111.8 (66.2-176.8) 
Female 2 3.5 nc (nc-nc)   Female 21 18.2 115.5 (71.5-176.6) 
Hodgkin Lymphoma            Prostate     
Male 3 3.5 nc (nc-nc)   Male 149 149.8 99.5 (84.1-116.8) 
Female 5 2.8 175.9 (56.7-410.5)             
Kidney & Renal Pelvis            Stomach     
Male 29 25.3 114.7 (76.8-164.8)   Male 9 10.9 82.9 (37.8-157.5) 
Female 13 15.3 84.8 (45.1-145.1)   Female 5 7.1 70.4 (22.7-164.3) 
Larynx            Testis     
Male 4 7.0 nc (nc-nc)   Male 8 6.6 120.8 (52.0-238.0) 
Female 3 2.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 18.6 85.9 (49.1-139.5)   Male 12 11.8 101.6 (52.5-177.6) 
Female 11 14.5 75.6 (37.7-135.3)   Female 35 36.9 94.7 (66.0-131.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 15.7 108.0 (62.9-173.0)             
Female 2 5.6 nc (nc-nc)   Female 49 43.8 112.0 (82.8-148.0) 
Lung and Bronchus            All Sites / Types     
Male 69 80.8 85.4 (66.4-108.1)   Male 554 599.8 92.4 (84.8-100.4) 
Female 87 90.7 95.9 (76.8-118.3)   Female 670 663.6 101.0 (93.5-108.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
20 
Ashburnham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.4 110.6 (40.4-240.6)   Male 2 3.9 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 18 26.4 68.1 (40.3-107.6)   Female 3 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.2 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 6.4 nc (nc-nc)             
Female 5 6.1 81.6 (26.3-190.5)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.7 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 21 23.4 89.6 (55.5-137.0) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.7 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.4 209.5 (67.5-489.0)   Male 2 1.8 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 4 5.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 5 6.0 83.3 (26.9-194.5) 
Lung and Bronchus            All Sites / Types     
Male 6 10.4 57.4 (21.0-125.0)   Male 69 82.7 83.5 (64.9-105.6) 
Female 6 11.3 53.1 (19.4-115.6)   Female 63 83.6 75.4 (57.9-96.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
21 
Ashby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.2 nc (nc-nc)   Male 5 2.2 229.9 (74.1-536.4) 
Female 3 1.1 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.7 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 12 14.2 84.5 (43.6-147.6)   Female 0 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.8 nc (nc-nc)             
Female 1 3.5 nc (nc-nc)   Female 4 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 11 11.8 93.5 (46.6-167.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.3 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 2 0.4 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.8 nc (nc-nc)   Male 45 44.7 100.6 (73.4-134.6) 
Female 4 6.3 nc (nc-nc)   Female 45 46.1 97.6 (71.2-130.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
22 
Ashfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.0 nc (nc-nc) 
Female 9 9.8 91.9 (41.9-174.5)   Female 1 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.8 nc (nc-nc)             
Female 3 2.5 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 6.9 72.2 (23.3-168.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 2 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.8 nc (nc-nc)   Male 24 23.5 101.9 (65.3-151.7) 
Female 1 4.6 nc (nc-nc)   Female 24 32.4 74.1 (47.4-110.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
23 
Ashland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 15.7 95.4 (53.3-157.3)   Male 8 10.8 74.1 (31.9-146.1) 
Female 2 6.5 nc (nc-nc)   Female 4 9.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.4 nc (nc-nc)   Male 5 3.3 149.7 (48.3-349.4) 
Female 2 3.0 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 8 9.8 81.9 (35.3-161.4) 
Female 67 77.6 86.4 (66.9-109.7)   Female 7 9.3 75.1 (30.1-154.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 8.5 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 5 4.0 124.0 (39.9-289.3) 
Colon / Rectum            Ovary     
Male 12 18.5 64.9 (33.5-113.4)             
Female 22 19.9 110.6 (69.3-167.5)   Female 9 6.8 131.9 (60.2-250.4) 
Esophagus            Pancreas     
Male 9 4.4 203.7 (93.0-386.7)   Male 5 5.8 86.5 (27.9-201.8) 
Female 2 1.3 nc (nc-nc)   Female 5 6.5 76.9 (24.8-179.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.3 nc (nc-nc)   Male 40 57.0 70.2 (50.1-95.5) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.6 83.2 (35.8-163.9)   Male 6 3.9 154.7 (56.5-336.6) 
Female 2 6.0 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 6.7 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 8 5.4 148.4 (63.9-292.3)   Female 21 14.3 146.7 (90.8-224.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.1 82.4 (26.5-192.2)             
Female 4 2.2 nc (nc-nc)   Female 17 18.1 94.0 (54.7-150.5) 
Lung and Bronchus            All Sites / Types     
Male 26 28.2 92.1 (60.2-135.0)   Male 178 220.0 80.9 (69.5-93.7) 
Female 39 34.1 114.3 (81.2-156.2)   Female 234 254.6 91.9 (80.5-104.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
24 
Athol 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 14.1 127.3 (75.4-201.2)   Male 4 9.2 nc (nc-nc) 
Female 4 4.4 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.7 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 5 8.0 62.1 (20.0-145.0) 
Female 36 47.8 75.4 (52.8-104.4)   Female 3 6.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.6 121.6 (52.4-239.7) 
Female 0 1.6 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 14.9 120.6 (71.5-190.7)             
Female 15 13.2 113.3 (63.4-186.9)   Female 5 4.3 116.4 (37.5-271.6) 
Esophagus            Pancreas     
Male 5 3.8 131.2 (42.3-306.3)   Male 4 5.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 29 48.6 59.7 (39.9-85.7) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.7 103.7 (44.6-204.3)   Male 2 3.3 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 5.6 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 5 3.5 141.7 (45.7-330.6)   Female 12 8.7 138.4 (71.4-241.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.1 nc (nc-nc)             
Female 3 1.4 nc (nc-nc)   Female 23 11.1 207.4 (131.4-311.2) 
Lung and Bronchus            All Sites / Types     
Male 37 26.0 142.6 (100.4-196.5)   Male 175 186.8 93.7 (80.3-108.6) 
Female 25 22.9 109.2 (70.6-161.2)   Female 162 162.9 99.5 (84.7-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
25 
Attleboro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 46 41.3 111.4 (81.6-148.6)   Male 30 27.9 107.4 (72.5-153.4) 
Female 17 15.3 111.0 (64.6-177.7)   Female 21 23.0 91.4 (56.6-139.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 8.8 79.3 (31.8-163.4)   Male 5 8.7 57.6 (18.6-134.4) 
Female 7 7.2 97.6 (39.1-201.0)   Female 6 7.0 86.1 (31.4-187.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 16 24.9 64.1 (36.6-104.2) 
Female 173 178.3 97.0 (83.1-112.6)   Female 19 21.9 86.8 (52.2-135.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 20.7 101.6 (62.8-155.3) 
Female 6 6.3 95.2 (34.8-207.3)   Female 12 9.4 128.3 (66.2-224.2) 
Colon / Rectum            Ovary     
Male 56 46.3 120.9 (91.3-157.1)             
Female 45 46.9 96.0 (70.0-128.4)   Female 24 15.8 151.9 (97.3-226.1) 
Esophagus            Pancreas     
Male 11 11.3 97.0 (48.4-173.7)   Male 17 14.8 114.7 (66.8-183.7) 
Female 4 3.0 nc (nc-nc)   Female 14 15.3 91.6 (50.0-153.7) 
Hodgkin Lymphoma            Prostate     
Male 9 3.6 247.7 (113.0-470.3)   Male 135 146.3 92.3 (77.3-109.2) 
Female 2 2.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 24.4 65.5 (37.4-106.4)   Male 5 9.9 50.4 (16.2-117.5) 
Female 10 14.0 71.6 (34.3-131.7)   Female 8 6.0 133.9 (57.7-263.9) 
Larynx            Testis     
Male 10 6.7 149.4 (71.5-274.7)   Male 8 6.9 115.2 (49.6-226.9) 
Female 3 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 17.4 80.5 (43.9-135.0)   Male 12 11.8 101.9 (52.6-178.0) 
Female 6 12.9 46.4 (16.9-100.9)   Female 21 34.7 60.4 (37.4-92.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 15.2 92.3 (50.4-154.9)             
Female 10 5.0 201.2 (96.3-370.1)   Female 47 40.2 117.0 (86.0-155.6) 
Lung and Bronchus            All Sites / Types     
Male 98 75.4 130.0 (105.6-158.5)   Male 570 567.2 100.5 (92.4-109.1) 
Female 80 82.0 97.5 (77.3-121.4)   Female 589 595.7 98.9 (91.0-107.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
26 
Auburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 20.5 131.9 (86.9-191.9)   Male 11 12.5 87.7 (43.7-157.0) 
Female 12 7.7 155.4 (80.2-271.5)   Female 8 10.1 79.1 (34.1-155.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 6 3.4 176.9 (64.6-385.0) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 9 11.2 80.3 (36.6-152.4) 
Female 73 79.0 92.4 (72.4-116.2)   Female 11 10.5 105.1 (52.4-188.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 8.6 116.7 (55.9-214.6) 
Female 0 2.5 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 21.6 87.9 (52.9-137.3)             
Female 18 23.5 76.5 (45.3-120.9)   Female 11 7.1 155.5 (77.5-278.3) 
Esophagus            Pancreas     
Male 7 5.1 137.7 (55.2-283.7)   Male 6 7.0 85.8 (31.3-186.7) 
Female 2 1.5 nc (nc-nc)   Female 5 7.9 63.3 (20.4-147.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 52 62.1 83.8 (62.5-109.8) 
Female 3 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.3 126.3 (67.2-216.0)   Male 4 4.7 nc (nc-nc) 
Female 5 6.3 79.3 (25.5-185.0)   Female 2 3.1 nc (nc-nc) 
Larynx            Testis     
Male 7 2.9 237.9 (95.3-490.1)   Male 3 2.2 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.8 102.5 (44.1-202.0)   Male 2 4.4 nc (nc-nc) 
Female 6 6.1 99.0 (36.1-215.5)   Female 15 13.5 110.8 (62.0-182.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 6.5 138.8 (63.3-263.5)             
Female 0 2.4 nc (nc-nc)   Female 21 17.5 120.0 (74.2-183.4) 
Lung and Bronchus            All Sites / Types     
Male 29 35.7 81.3 (54.4-116.7)   Male 237 253.2 93.6 (82.0-106.3) 
Female 42 39.0 107.6 (77.5-145.4)   Female 269 273.8 98.3 (86.9-110.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
27 
Avon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.2 115.2 (42.1-250.8)   Male 6 3.4 177.6 (64.8-386.6) 
Female 0 2.0 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 7 3.0 233.9 (93.7-482.0) 
Female 25 21.9 114.3 (74.0-168.7)   Female 4 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.7 87.9 (28.3-205.2)             
Female 5 5.9 85.2 (27.4-198.8)   Female 3 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.4 nc (nc-nc)   Male 8 18.9 42.3 (18.2-83.3) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.0 169.5 (54.6-395.5)   Male 2 1.2 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.0 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 5 3.8 132.6 (42.7-309.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 2 5.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 14 9.6 145.5 (79.5-244.1)   Male 78 70.3 111.0 (87.7-138.5) 
Female 16 10.9 146.8 (83.8-238.4)   Female 78 74.4 104.9 (82.9-130.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
28 
Ayer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.5 93.5 (37.5-192.6)   Male 2 5.2 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 0 4.6 nc (nc-nc) 
Female 36 33.1 108.9 (76.2-150.7)   Female 4 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.8 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 8.4 82.8 (33.2-170.7)             
Female 8 9.7 82.9 (35.7-163.3)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 2.0 293.1 (107.0-638.1)   Male 4 2.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 18 25.2 71.6 (42.4-113.1) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.5 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.2 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 3 6.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 11 6.9 160.3 (79.9-286.8) 
Lung and Bronchus            All Sites / Types     
Male 17 13.9 122.5 (71.3-196.2)   Male 86 102.5 83.9 (67.1-103.6) 
Female 16 16.3 98.2 (56.1-159.5)   Female 113 113.9 99.2 (81.7-119.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
29 
Barnstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 99 70.7 140.1 (113.8-170.5)   Male 54 42.6 126.7 (95.2-165.4) 
Female 25 24.5 102.2 (66.2-150.9)   Female 46 30.6 150.5 (110.2-200.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 11.4 96.2 (48.0-172.2)   Male 12 13.7 87.9 (45.4-153.5) 
Female 11 9.4 117.6 (58.6-210.4)   Female 17 10.9 156.5 (91.1-250.5) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.4 nc (nc-nc)   Male 40 37.7 106.2 (75.9-144.7) 
Female 304 247.9 122.6 (109.2-137.2)   Female 45 32.6 138.0 (100.6-184.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 32 29.4 109.0 (74.5-153.9) 
Female 9 7.3 123.0 (56.1-233.5)   Female 17 13.6 124.8 (72.7-199.9) 
Colon / Rectum            Ovary     
Male 59 71.9 82.0 (62.4-105.8)             
Female 71 70.5 100.7 (78.6-127.0)   Female 24 22.2 108.1 (69.3-160.9) 
Esophagus            Pancreas     
Male 22 18.0 122.3 (76.6-185.1)   Male 31 24.4 127.3 (86.5-180.7) 
Female 3 4.7 nc (nc-nc)   Female 21 24.4 86.2 (53.3-131.7) 
Hodgkin Lymphoma            Prostate     
Male 3 3.9 nc (nc-nc)   Male 267 226.6 117.8 (104.1-132.8) 
Female 1 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 40 35.0 114.3 (81.6-155.6)   Male 20 16.0 124.8 (76.2-192.8) 
Female 17 20.3 83.6 (48.7-133.9)   Female 9 9.1 99.2 (45.3-188.3) 
Larynx            Testis     
Male 8 10.4 77.2 (33.2-152.2)   Male 9 6.1 146.8 (67.0-278.7) 
Female 2 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 31 26.2 118.4 (80.4-168.1)   Male 14 14.2 98.4 (53.7-165.1) 
Female 29 18.4 157.9 (105.7-226.8)   Female 27 38.5 70.1 (46.2-102.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 28 22.6 123.8 (82.2-178.9)             
Female 7 7.6 91.9 (36.8-189.3)   Female 54 58.5 92.3 (69.3-120.5) 
Lung and Bronchus            All Sites / Types     
Male 88 125.3 70.2 (56.3-86.5)   Male 947 877.7 107.9 (101.1-115.0) 
Female 124 129.9 95.4 (79.4-113.8)   Female 935 857.1 109.1 (102.2-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
30 
Barre 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.1 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 15 23.2 64.5 (36.1-106.4)   Female 0 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.6 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 5.9 136.0 (58.6-268.0)             
Female 3 6.7 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 19 18.1 104.9 (63.1-163.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.0 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 4.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 6 5.1 117.3 (42.8-255.4) 
Lung and Bronchus            All Sites / Types     
Male 11 9.0 122.8 (61.2-219.8)   Male 67 70.3 95.3 (73.9-121.0) 
Female 5 10.9 46.0 (14.8-107.3)   Female 56 79.1 70.8 (53.5-92.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
31 
Becket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.2 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 8 10.8 73.9 (31.8-145.6)   Female 2 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.1 nc (nc-nc)             
Female 1 2.7 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 6 9.1 66.1 (24.1-143.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 6 2.5 236.7 (86.4-515.3) 
Lung and Bronchus            All Sites / Types     
Male 4 5.6 nc (nc-nc)   Male 30 37.4 80.3 (54.1-114.6) 
Female 4 5.2 nc (nc-nc)   Female 28 35.4 79.2 (52.6-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
32 
Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 19.6 117.3 (74.3-176.0)   Male 17 11.5 148.1 (86.2-237.1) 
Female 5 6.1 82.1 (26.5-191.6)   Female 2 8.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 0 2.5 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 13 10.3 125.9 (67.0-215.3) 
Female 61 63.3 96.3 (73.7-123.7)   Female 6 8.2 72.9 (26.6-158.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.5 66.8 (21.5-155.9) 
Female 0 2.0 nc (nc-nc)   Female 5 3.4 146.8 (47.3-342.5) 
Colon / Rectum            Ovary     
Male 20 20.3 98.4 (60.1-151.9)             
Female 15 18.6 80.8 (45.2-133.2)   Female 0 5.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 4.6 nc (nc-nc)   Male 7 6.5 107.1 (42.9-220.6) 
Female 3 1.2 nc (nc-nc)   Female 8 6.1 130.5 (56.2-257.2) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 53 51.5 102.9 (77.1-134.6) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.9 78.7 (31.5-162.2)   Male 4 4.4 nc (nc-nc) 
Female 3 5.1 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.4 134.8 (64.5-247.9)   Male 1 3.7 nc (nc-nc) 
Female 7 4.8 146.0 (58.5-300.8)   Female 10 10.9 91.7 (43.9-168.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.7 nc (nc-nc)             
Female 1 1.9 nc (nc-nc)   Female 10 13.8 72.4 (34.7-133.2) 
Lung and Bronchus            All Sites / Types     
Male 25 32.5 77.0 (49.8-113.7)   Male 217 227.3 95.4 (83.2-109.0) 
Female 27 31.5 85.8 (56.5-124.8)   Female 182 217.9 83.5 (71.8-96.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
33 
Belchertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 15.4 65.1 (31.2-119.7)   Male 9 10.3 87.1 (39.8-165.4) 
Female 4 4.3 nc (nc-nc)   Female 6 7.5 80.5 (29.4-175.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.2 188.8 (68.9-410.9)   Male 3 3.3 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 11 9.2 119.7 (59.7-214.2) 
Female 63 59.9 105.1 (80.8-134.5)   Female 14 6.7 208.6 (113.9-349.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.9 76.1 (27.8-165.6) 
Female 1 2.2 nc (nc-nc)   Female 6 3.0 201.7 (73.7-439.1) 
Colon / Rectum            Ovary     
Male 18 17.1 105.5 (62.5-166.7)             
Female 18 13.7 131.6 (77.9-208.0)   Female 5 5.2 96.9 (31.2-226.0) 
Esophagus            Pancreas     
Male 0 4.3 nc (nc-nc)   Male 3 5.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 6 4.3 139.1 (50.8-302.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 48 58.0 82.7 (61.0-109.7) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.2 76.4 (30.6-157.5)   Male 7 3.7 188.4 (75.5-388.1) 
Female 4 4.4 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.3 79.4 (25.6-185.2)   Male 1 4.2 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 9 12.2 73.9 (33.7-140.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.9 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 20 14.0 143.1 (87.4-221.0) 
Lung and Bronchus            All Sites / Types     
Male 15 28.7 52.3 (29.3-86.3)   Male 169 214.5 78.8 (67.4-91.6) 
Female 20 24.1 83.0 (50.7-128.2)   Female 202 189.0 106.9 (92.7-122.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
34 
Bellingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 15.2 78.9 (40.7-137.9)   Male 9 10.4 86.9 (39.6-165.0) 
Female 3 5.6 nc (nc-nc)   Female 10 8.8 113.7 (54.4-209.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.2 185.1 (67.6-402.9)   Male 2 3.2 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 17 9.3 183.0 (106.5-293.0) 
Female 72 69.7 103.3 (80.8-130.0)   Female 11 8.2 134.8 (67.2-241.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.9 76.0 (27.8-165.5) 
Female 1 2.5 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 17.2 92.9 (53.1-150.9)             
Female 17 16.7 102.0 (59.4-163.3)   Female 2 6.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 4.3 187.4 (80.7-369.3)   Male 6 5.5 108.7 (39.7-236.5) 
Female 2 1.1 nc (nc-nc)   Female 7 5.6 125.9 (50.5-259.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 72 55.6 129.4 (101.3-163.0) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.1 87.5 (37.7-172.5)   Male 5 3.7 135.5 (43.7-316.1) 
Female 5 5.4 92.9 (29.9-216.8)   Female 2 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.4 94.0 (34.3-204.5)   Male 4 4.4 nc (nc-nc) 
Female 5 4.8 104.0 (33.5-242.8)   Female 14 13.7 101.9 (55.7-170.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.8 86.8 (28.0-202.6)             
Female 0 1.9 nc (nc-nc)   Female 17 16.1 105.7 (61.6-169.3) 
Lung and Bronchus            All Sites / Types     
Male 30 27.8 108.1 (72.9-154.3)   Male 233 211.9 110.0 (96.3-125.0) 
Female 21 31.1 67.5 (41.8-103.2)   Female 212 227.0 93.4 (81.2-106.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
35 
Belmont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 26.9 96.6 (63.1-141.6)   Male 16 16.9 94.6 (54.1-153.7) 
Female 5 9.9 50.4 (16.3-117.7)   Female 8 14.1 56.7 (24.4-111.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.1 137.8 (55.2-284.0)   Male 6 5.3 113.7 (41.5-247.6) 
Female 4 4.4 nc (nc-nc)   Female 5 4.4 112.6 (36.3-262.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 16 15.2 105.3 (60.1-171.0) 
Female 130 109.9 118.3 (98.8-140.5)   Female 10 13.9 72.2 (34.5-132.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 11.8 42.5 (13.7-99.1) 
Female 1 3.9 nc (nc-nc)   Female 6 5.8 103.5 (37.8-225.3) 
Colon / Rectum            Ovary     
Male 21 28.8 73.0 (45.2-111.6)             
Female 25 30.3 82.5 (53.4-121.8)   Female 10 9.6 103.7 (49.7-190.8) 
Esophagus            Pancreas     
Male 5 6.8 73.1 (23.6-170.6)   Male 10 9.3 107.3 (51.3-197.3) 
Female 4 1.9 nc (nc-nc)   Female 8 10.0 80.1 (34.5-157.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 84 85.2 98.6 (78.6-122.0) 
Female 2 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 14.2 91.5 (48.7-156.5)   Male 4 6.2 nc (nc-nc) 
Female 5 8.7 57.5 (18.5-134.2)   Female 5 3.9 128.2 (41.3-299.1) 
Larynx            Testis     
Male 1 3.9 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 10.8 nc (nc-nc)   Male 7 6.3 110.4 (44.2-227.4) 
Female 5 8.2 61.1 (19.7-142.6)   Female 26 20.7 125.5 (81.9-183.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 8.6 nc (nc-nc)             
Female 2 3.1 nc (nc-nc)   Female 28 24.3 115.1 (76.5-166.4) 
Lung and Bronchus            All Sites / Types     
Male 32 47.1 68.0 (46.5-95.9)   Male 293 342.3 85.6 (76.1-96.0) 
Female 41 51.6 79.5 (57.0-107.8)   Female 354 371.7 95.2 (85.6-105.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
36 
Berkley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.3 nc (nc-nc)   Male 5 4.3 117.5 (37.9-274.2) 
Female 1 1.5 nc (nc-nc)   Female 5 2.9 172.0 (55.4-401.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 30 23.7 126.5 (85.4-180.7)   Female 6 2.5 242.1 (88.4-526.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.2 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.0 128.2 (58.5-243.4)             
Female 6 5.0 120.2 (43.9-261.6)   Female 0 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.8 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 19 22.5 84.3 (50.7-131.6) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.7 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.6 nc (nc-nc)   Male 5 1.8 284.0 (91.5-662.8) 
Female 4 1.5 nc (nc-nc)   Female 4 5.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.4 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 7 5.3 133.1 (53.3-274.3) 
Lung and Bronchus            All Sites / Types     
Male 11 11.7 94.1 (46.9-168.4)   Male 80 86.8 92.2 (73.1-114.7) 
Female 10 9.1 110.0 (52.6-202.3)   Female 90 72.6 124.1 (99.7-152.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
37 
Berlin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 4.1 122.0 (39.3-284.7)   Male 7 2.6 271.8 (108.9-560.0) 
Female 1 1.2 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 14 13.7 101.8 (55.6-170.9)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.4 nc (nc-nc)             
Female 4 3.4 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 12 13.5 88.6 (45.7-154.8) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.2 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.5 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.4 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 7.3 136.4 (65.3-250.8)   Male 58 52.6 110.2 (83.7-142.5) 
Female 4 6.5 nc (nc-nc)   Female 40 44.9 89.0 (63.6-121.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
38 
Bernardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.7 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 5 1.4 346.9 (111.8-809.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 5 2.0 256.0 (82.5-597.5) 
Female 12 12.0 100.3 (51.7-175.1)   Female 3 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.8 nc (nc-nc)             
Female 2 3.3 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 16 11.6 137.8 (78.7-223.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.3 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 6.3 nc (nc-nc)   Male 42 45.1 93.2 (67.1-125.9) 
Female 4 5.9 nc (nc-nc)   Female 39 40.3 96.7 (68.8-132.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
39 
Beverly 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 51 42.7 119.6 (89.0-157.2)   Male 37 27.2 136.2 (95.9-187.7) 
Female 21 15.9 132.1 (81.8-202.0)   Female 33 22.6 146.0 (100.5-205.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 8.1 147.5 (76.1-257.7)   Male 12 8.5 141.0 (72.8-246.4) 
Female 6 7.0 85.7 (31.3-186.5)   Female 5 7.1 70.2 (22.6-163.8) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.4 nc (nc-nc)   Male 25 24.3 102.9 (66.5-151.8) 
Female 176 172.3 102.2 (87.6-118.4)   Female 20 22.2 90.1 (55.0-139.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 25 19.4 128.9 (83.4-190.2) 
Female 4 5.9 nc (nc-nc)   Female 14 9.3 149.7 (81.8-251.3) 
Colon / Rectum            Ovary     
Male 32 45.7 69.9 (47.8-98.8)             
Female 48 48.3 99.4 (73.3-131.8)   Female 16 15.6 102.8 (58.7-167.0) 
Esophagus            Pancreas     
Male 13 11.2 116.5 (62.0-199.2)   Male 15 15.0 100.2 (56.0-165.3) 
Female 5 3.1 161.5 (52.0-376.9)   Female 17 16.2 104.8 (61.0-167.8) 
Hodgkin Lymphoma            Prostate     
Male 1 3.2 nc (nc-nc)   Male 161 139.9 115.1 (98.0-134.3) 
Female 0 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 22.8 96.5 (60.5-146.2)   Male 3 9.9 nc (nc-nc) 
Female 18 13.6 132.3 (78.4-209.2)   Female 4 6.3 nc (nc-nc) 
Larynx            Testis     
Male 6 6.4 93.7 (34.2-203.9)   Male 10 5.8 171.7 (82.2-315.8) 
Female 3 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 17.1 134.4 (85.2-201.7)   Male 13 10.4 125.3 (66.6-214.2) 
Female 14 13.0 107.5 (58.7-180.3)   Female 35 32.6 107.2 (74.7-149.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 14.5 103.2 (57.7-170.2)             
Female 12 5.0 239.6 (123.7-418.6)   Female 34 39.2 86.7 (60.1-121.2) 
Lung and Bronchus            All Sites / Types     
Male 84 75.5 111.3 (88.8-137.8)   Male 615 553.0 111.2 (102.6-120.4) 
Female 95 81.5 116.6 (94.3-142.5)   Female 648 590.2 109.8 (101.5-118.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
40 
Billerica 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 38.5 135.1 (100.9-177.1)   Male 30 26.2 114.4 (77.2-163.3) 
Female 17 13.5 125.7 (73.2-201.3)   Female 22 21.0 104.9 (65.7-158.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 8.3 108.1 (49.3-205.2)   Male 11 8.2 134.2 (66.9-240.1) 
Female 4 6.6 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.4 nc (nc-nc)   Male 23 23.6 97.5 (61.8-146.3) 
Female 158 164.9 95.8 (81.4-112.0)   Female 19 19.7 96.5 (58.1-150.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 20.0 64.9 (34.5-111.1) 
Female 4 5.9 nc (nc-nc)   Female 9 8.4 107.1 (48.9-203.3) 
Colon / Rectum            Ovary     
Male 33 43.9 75.2 (51.7-105.6)             
Female 54 41.5 130.2 (97.8-169.9)   Female 15 14.4 104.2 (58.3-171.9) 
Esophagus            Pancreas     
Male 9 10.9 82.6 (37.7-156.7)   Male 14 14.0 100.0 (54.6-167.7) 
Female 2 2.7 nc (nc-nc)   Female 10 13.5 74.0 (35.4-136.1) 
Hodgkin Lymphoma            Prostate     
Male 4 3.4 nc (nc-nc)   Male 140 143.4 97.7 (82.2-115.2) 
Female 1 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 32 23.4 136.8 (93.6-193.2)   Male 10 9.3 107.5 (51.4-197.6) 
Female 9 12.7 70.6 (32.2-134.0)   Female 8 5.3 151.6 (65.3-298.6) 
Larynx            Testis     
Male 3 6.3 nc (nc-nc)   Male 4 6.5 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 27 16.2 166.2 (109.5-241.8)   Male 14 11.3 123.6 (67.5-207.3) 
Female 19 11.5 165.0 (99.3-257.6)   Female 29 32.5 89.3 (59.8-128.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 14.5 69.0 (33.0-126.9)             
Female 3 4.4 nc (nc-nc)   Female 29 37.2 78.0 (52.2-112.0) 
Lung and Bronchus            All Sites / Types     
Male 74 69.9 105.8 (83.1-132.9)   Male 562 539.6 104.1 (95.7-113.1) 
Female 104 73.5 141.5 (115.6-171.4)   Female 559 541.3 103.3 (94.9-112.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
41 
Blackstone 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 7.0 171.3 (88.4-299.2)   Male 6 5.0 119.6 (43.7-260.3) 
Female 5 3.1 160.6 (51.7-374.7)   Female 5 4.9 102.0 (32.9-238.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.7 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.2 nc (nc-nc)   Male 5 4.5 111.1 (35.8-259.2) 
Female 31 39.0 79.5 (54.0-112.8)   Female 4 4.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.9 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 8.3 84.7 (33.9-174.6)             
Female 5 9.7 51.5 (16.6-120.1)   Female 4 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 2.0 391.1 (168.4-770.6)   Male 0 2.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 27 26.6 101.6 (66.9-147.8) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.5 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.2 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 3 7.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 10 8.7 114.5 (54.8-210.5) 
Lung and Bronchus            All Sites / Types     
Male 20 13.2 152.0 (92.8-234.7)   Male 125 101.9 122.6 (102.1-146.1) 
Female 13 16.2 80.1 (42.6-136.9)   Female 117 125.8 93.0 (76.9-111.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Blandford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 5.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.4 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 4.9 143.9 (57.7-296.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 2 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.1 nc (nc-nc)   Male 19 17.1 111.3 (67.0-173.8) 
Female 2 2.0 nc (nc-nc)   Female 17 15.8 107.8 (62.8-172.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
43 
Bolton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.5 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 22 19.5 113.0 (70.8-171.2)   Female 1 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 5.4 129.7 (52.0-267.3)             
Female 2 3.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 24 17.8 134.9 (86.4-200.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 10 4.4 225.3 (107.9-414.4) 
Lung and Bronchus            All Sites / Types     
Male 4 8.5 nc (nc-nc)   Male 63 65.9 95.6 (73.5-122.3) 
Female 5 7.0 71.2 (22.9-166.0)   Female 48 58.2 82.5 (60.9-109.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
44 
Boston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 344 466.1 73.8 (66.2-82.0)   Male 253 319.6 79.2 (69.7-89.6) 
Female 140 179.4 78.1 (65.7-92.1)   Female 203 294.0 69.1 (59.9-79.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 72 107.4 67.0 (52.4-84.4)   Male 114 95.7 119.2 (98.3-143.2) 
Female 71 91.8 77.3 (60.4-97.5)   Female 127 81.4 156.1 (130.1-185.7) 
Breast            Non-Hodgkin Lymphoma     
Male 15 16.0 93.7 (52.4-154.5)   Male 284 287.5 98.8 (87.6-111.0) 
Female 1903 2058.3 92.5 (88.3-96.7)   Female 256 262.0 97.7 (86.1-110.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 262 225.7 116.1 (102.4-131.0) 
Female 96 81.4 117.9 (95.5-144.0)   Female 114 109.2 104.4 (86.1-125.4) 
Colon / Rectum            Ovary     
Male 561 515.8 108.8 (100.0-118.2)             
Female 577 549.2 105.1 (96.7-114.0)   Female 188 187.1 100.5 (86.6-115.9) 
Esophagus            Pancreas     
Male 118 124.3 95.0 (78.6-113.7)   Male 157 164.7 95.3 (81.0-111.5) 
Female 36 34.9 103.2 (72.3-142.9)   Female 179 179.6 99.7 (85.6-115.4) 
Hodgkin Lymphoma            Prostate     
Male 61 56.6 107.7 (82.4-138.4)   Male 1865 1570.7 118.7 (113.4-124.2) 
Female 48 51.2 93.8 (69.2-124.4)             
Kidney & Renal Pelvis            Stomach     
Male 229 268.2 85.4 (74.7-97.2)   Male 164 110.9 147.9 (126.1-172.3) 
Female 172 163.8 105.0 (89.9-121.9)   Female 104 70.7 147.0 (120.1-178.2) 
Larynx            Testis     
Male 90 72.5 124.2 (99.9-152.7)   Male 98 118.9 82.5 (66.9-100.5) 
Female 17 23.7 71.7 (41.7-114.8)             
Leukemia            Thyroid     
Male 156 204.6 76.2 (64.7-89.2)   Male 153 141.3 108.3 (91.8-126.9) 
Female 129 160.0 80.6 (67.3-95.8)   Female 473 475.3 99.5 (90.7-108.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 273 164.1 166.4 (147.2-187.3)             
Female 91 58.0 156.8 (126.2-192.5)   Female 438 460.0 95.2 (86.5-104.6) 
Lung and Bronchus            All Sites / Types     
Male 911 831.9 109.5 (102.5-116.9)   Male 6682 6365.2 105.0 (102.5-107.5) 
Female 850 948.4 89.6 (83.7-95.9)   Female 6758 7078.4 95.5 (93.2-97.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
45 
Bourne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 28.1 117.4 (80.8-164.9)   Male 23 17.0 135.2 (85.7-202.9) 
Female 10 10.2 98.2 (47.0-180.5)   Female 14 12.5 112.1 (61.2-188.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.7 128.6 (47.0-280.0)   Male 8 5.5 145.1 (62.5-285.9) 
Female 3 3.9 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 11 15.1 72.7 (36.2-130.0) 
Female 83 98.3 84.4 (67.2-104.6)   Female 9 13.4 67.2 (30.7-127.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 11.5 147.5 (85.9-236.2) 
Female 2 3.0 nc (nc-nc)   Female 5 5.5 90.6 (29.2-211.5) 
Colon / Rectum            Ovary     
Male 21 28.6 73.4 (45.4-112.1)             
Female 27 30.0 90.0 (59.3-130.9)   Female 12 8.9 134.7 (69.5-235.3) 
Esophagus            Pancreas     
Male 12 7.1 169.7 (87.6-296.5)   Male 9 9.5 94.4 (43.1-179.1) 
Female 3 1.9 nc (nc-nc)   Female 10 10.3 97.4 (46.6-179.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.7 nc (nc-nc)   Male 90 86.3 104.3 (83.9-128.2) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 13.8 65.1 (29.7-123.6)   Male 6 6.4 94.2 (34.4-205.0) 
Female 7 8.2 85.9 (34.4-176.9)   Female 5 3.9 128.1 (41.3-299.0) 
Larynx            Testis     
Male 10 4.1 244.6 (117.1-449.8)   Male 1 2.8 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 10.5 66.4 (26.6-136.7)   Male 2 5.8 nc (nc-nc) 
Female 5 7.8 64.3 (20.7-149.9)   Female 19 15.7 120.8 (72.7-188.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.0 77.6 (31.1-159.9)             
Female 1 3.1 nc (nc-nc)   Female 18 22.4 80.4 (47.6-127.0) 
Lung and Bronchus            All Sites / Types     
Male 55 49.5 111.2 (83.7-144.7)   Male 358 346.2 103.4 (93.0-114.7) 
Female 62 52.1 119.1 (91.3-152.7)   Female 324 347.7 93.2 (83.3-103.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
46 
Boxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.8 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 26 20.1 129.1 (84.3-189.1)   Female 3 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.6 88.9 (28.6-207.4)             
Female 5 4.2 118.7 (38.2-276.9)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.5 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 19 20.3 93.8 (56.4-146.5) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.6 108.5 (35.0-253.3) 
Lung and Bronchus            All Sites / Types     
Male 6 9.1 65.7 (24.0-143.1)   Male 61 71.8 85.0 (65.0-109.2) 
Female 9 7.3 123.3 (56.3-234.1)   Female 70 60.9 115.0 (89.7-145.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
47 
Boxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 10.1 59.1 (21.6-128.7)   Male 18 6.6 273.6 (162.0-432.4) 
Female 1 2.9 nc (nc-nc)   Female 9 4.4 205.2 (93.6-389.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 5.9 nc (nc-nc) 
Female 41 36.4 112.6 (80.8-152.8)   Female 3 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 11.1 nc (nc-nc)             
Female 4 8.7 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 46 36.7 125.3 (91.7-167.2) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.8 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.0 126.3 (40.7-294.7)   Male 2 2.5 nc (nc-nc) 
Female 5 2.4 208.2 (67.1-485.9)   Female 11 6.6 166.4 (83.0-297.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.7 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 5 8.6 58.2 (18.8-135.8) 
Lung and Bronchus            All Sites / Types     
Male 9 18.5 48.5 (22.1-92.1)   Male 116 136.7 84.9 (70.1-101.8) 
Female 9 15.9 56.5 (25.8-107.3)   Female 115 116.8 98.5 (81.3-118.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
48 
Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.0 99.3 (32.0-231.8)   Male 3 3.3 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 8 2.3 348.3 (150.0-686.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 4 1.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 27 18.7 144.5 (95.2-210.3)   Female 0 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.6 nc (nc-nc)             
Female 8 4.7 171.1 (73.7-337.2)   Female 4 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 11 17.2 63.8 (31.8-114.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.9 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 9.0 nc (nc-nc)   Male 53 67.1 79.0 (59.1-103.3) 
Female 5 8.0 62.5 (20.2-146.0)   Female 72 60.2 119.6 (93.6-150.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
49 
Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 40.0 129.8 (97.0-170.3)   Male 33 25.2 130.9 (90.1-183.9) 
Female 24 16.5 145.5 (93.2-216.5)   Female 23 21.7 105.9 (67.1-158.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 7.4 94.0 (37.7-193.8)   Male 7 7.9 89.0 (35.6-183.3) 
Female 5 6.7 75.1 (24.2-175.3)   Female 7 7.2 97.1 (38.9-200.1) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 25 22.5 111.0 (71.8-163.8) 
Female 183 165.0 110.9 (95.4-128.2)   Female 21 22.1 95.0 (58.8-145.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 17.6 119.5 (73.9-182.7) 
Female 10 5.5 180.7 (86.5-332.3)   Female 10 9.1 109.7 (52.5-201.8) 
Colon / Rectum            Ovary     
Male 54 42.5 127.1 (95.5-165.8)             
Female 67 50.1 133.7 (103.6-169.8)   Female 13 14.9 87.0 (46.3-148.8) 
Esophagus            Pancreas     
Male 15 10.2 146.9 (82.1-242.3)   Male 14 13.9 101.0 (55.2-169.4) 
Female 3 3.1 nc (nc-nc)   Female 18 16.7 107.8 (63.9-170.4) 
Hodgkin Lymphoma            Prostate     
Male 4 2.9 nc (nc-nc)   Male 122 125.1 97.5 (81.0-116.4) 
Female 4 2.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 20.8 91.5 (55.1-142.9)   Male 10 9.3 107.8 (51.6-198.3) 
Female 15 13.4 111.7 (62.5-184.2)   Female 7 6.5 107.3 (43.0-221.1) 
Larynx            Testis     
Male 4 5.9 nc (nc-nc)   Male 5 5.1 98.0 (31.6-228.6) 
Female 6 1.9 308.1 (112.5-670.6)             
Leukemia            Thyroid     
Male 10 15.9 62.7 (30.0-115.4)   Male 8 9.3 85.9 (37.0-169.3) 
Female 21 13.1 159.9 (99.0-244.5)   Female 36 29.7 121.3 (84.9-167.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 13.2 136.2 (80.7-215.3)             
Female 5 5.0 100.7 (32.5-235.0)   Female 36 36.4 98.9 (69.3-137.0) 
Lung and Bronchus            All Sites / Types     
Male 61 70.0 87.1 (66.6-111.9)   Male 528 507.5 104.0 (95.4-113.3) 
Female 88 82.5 106.7 (85.6-131.5)   Female 648 579.4 111.8 (103.4-120.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
50 
Brewster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 17.8 101.2 (59.9-159.9)   Male 15 10.3 145.1 (81.2-239.4) 
Female 8 6.5 123.8 (53.3-243.9)   Female 13 7.5 173.6 (92.3-296.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.6 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.6 nc (nc-nc)   Male 14 9.0 154.8 (84.5-259.7) 
Female 84 60.7 138.4 (110.4-171.3)   Female 13 8.4 155.2 (82.5-265.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.7 105.0 (42.1-216.3) 
Female 1 1.7 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 17.4 69.0 (35.6-120.5)             
Female 16 18.6 86.0 (49.1-139.7)   Female 4 5.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 4.4 nc (nc-nc)   Male 6 5.9 101.5 (37.1-221.0) 
Female 3 1.2 nc (nc-nc)   Female 3 6.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 70 53.2 131.7 (102.7-166.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 8.2 73.1 (26.7-159.1)   Male 1 3.9 nc (nc-nc) 
Female 5 5.1 98.3 (31.7-229.3)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 3 2.5 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 6.2 112.2 (45.0-231.2)   Male 0 3.1 nc (nc-nc) 
Female 6 4.7 126.8 (46.3-276.1)   Female 7 8.7 80.8 (32.4-166.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.4 nc (nc-nc)             
Female 0 2.0 nc (nc-nc)   Female 11 14.2 77.3 (38.6-138.4) 
Lung and Bronchus            All Sites / Types     
Male 28 31.8 87.9 (58.4-127.1)   Male 213 211.4 100.7 (87.7-115.2) 
Female 18 33.7 53.4 (31.7-84.5)   Female 215 215.8 99.6 (86.8-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
51 
Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 23.7 80.1 (48.2-125.2)   Male 15 16.3 91.9 (51.4-151.6) 
Female 13 7.3 177.4 (94.4-303.4)   Female 17 11.7 145.5 (84.7-233.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.3 112.7 (41.2-245.4)   Male 2 5.0 nc (nc-nc) 
Female 6 3.7 161.3 (58.9-351.0)   Female 3 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 10 14.8 67.5 (32.3-124.1) 
Female 92 88.5 104.0 (83.8-127.5)   Female 12 10.8 111.5 (57.5-194.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 12.4 113.0 (61.7-189.6) 
Female 4 3.2 nc (nc-nc)   Female 5 4.6 108.7 (35.0-253.6) 
Colon / Rectum            Ovary     
Male 23 27.1 84.8 (53.8-127.3)             
Female 25 22.4 111.4 (72.1-164.4)   Female 11 7.9 139.3 (69.4-249.2) 
Esophagus            Pancreas     
Male 6 6.6 91.2 (33.3-198.6)   Male 13 8.6 151.0 (80.3-258.3) 
Female 1 1.4 nc (nc-nc)   Female 10 7.3 137.2 (65.7-252.2) 
Hodgkin Lymphoma            Prostate     
Male 1 2.4 nc (nc-nc)   Male 81 84.4 96.0 (76.3-119.3) 
Female 0 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 14.4 55.6 (24.0-109.6)   Male 5 5.8 86.4 (27.8-201.6) 
Female 7 6.8 102.5 (41.1-211.3)   Female 4 2.9 nc (nc-nc) 
Larynx            Testis     
Male 3 3.9 nc (nc-nc)   Male 1 4.5 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 10.3 48.3 (15.6-112.8)   Male 11 7.2 152.4 (76.0-272.7) 
Female 4 6.4 nc (nc-nc)   Female 26 18.4 141.4 (92.3-207.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 8.8 158.6 (86.6-266.1)             
Female 3 2.4 nc (nc-nc)   Female 15 20.1 74.5 (41.7-122.9) 
Lung and Bronchus            All Sites / Types     
Male 51 42.4 120.2 (89.5-158.1)   Male 314 330.5 95.0 (84.8-106.1) 
Female 29 39.1 74.1 (49.6-106.5)   Female 304 293.9 103.4 (92.1-115.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
52 
Brimfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.3 nc (nc-nc)   Male 0 2.4 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 16 18.5 86.6 (49.5-140.7)   Female 4 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.0 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.9 nc (nc-nc)             
Female 1 4.5 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 10 14.1 70.7 (33.9-130.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 2.2 225.8 (72.8-526.9)   Male 0 0.8 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.4 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 6.3 126.5 (54.5-249.3)   Male 50 50.0 100.1 (74.3-132.0) 
Female 9 8.7 103.5 (47.2-196.5)   Female 45 60.0 75.0 (54.7-100.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
53 
Brockton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 81 82.4 98.3 (78.1-122.2)   Male 27 54.4 49.7 (32.7-72.2) 
Female 34 31.4 108.3 (75.0-151.3)   Female 25 47.0 53.2 (34.4-78.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 17 17.6 96.4 (56.1-154.4)   Male 10 16.9 59.3 (28.4-109.0) 
Female 18 15.0 119.8 (71.0-189.3)   Female 13 14.2 91.6 (48.7-156.6) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.9 nc (nc-nc)   Male 47 49.1 95.7 (70.3-127.3) 
Female 302 357.4 84.5 (75.2-94.6)   Female 37 44.8 82.6 (58.2-113.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 41 39.5 103.7 (74.4-140.7) 
Female 26 12.9 200.9 (131.2-294.4)   Female 20 18.9 105.9 (64.6-163.5) 
Colon / Rectum            Ovary     
Male 114 91.1 125.1 (103.2-150.3)             
Female 108 96.5 111.9 (91.8-135.1)   Female 42 31.8 132.0 (95.1-178.4) 
Esophagus            Pancreas     
Male 20 22.0 91.0 (55.6-140.6)   Male 31 29.2 106.2 (72.2-150.8) 
Female 8 6.1 131.2 (56.5-258.5)   Female 43 31.6 136.3 (98.6-183.5) 
Hodgkin Lymphoma            Prostate     
Male 5 7.3 68.1 (21.9-158.9)   Male 286 278.3 102.8 (91.2-115.4) 
Female 5 6.3 79.3 (25.5-184.9)             
Kidney & Renal Pelvis            Stomach     
Male 57 46.6 122.2 (92.6-158.4)   Male 25 19.6 127.7 (82.6-188.5) 
Female 27 28.3 95.4 (62.9-138.8)   Female 13 12.4 105.1 (55.9-179.7) 
Larynx            Testis     
Male 19 12.8 148.0 (89.1-231.1)   Male 13 13.7 94.9 (50.5-162.2) 
Female 4 4.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 27 35.0 77.0 (50.8-112.1)   Male 32 22.2 144.1 (98.5-203.4) 
Female 21 27.1 77.5 (47.9-118.4)   Female 90 71.4 126.0 (101.3-154.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 40 29.2 136.9 (97.8-186.4)             
Female 16 10.1 159.2 (90.9-258.5)   Female 79 79.7 99.2 (78.5-123.6) 
Lung and Bronchus            All Sites / Types     
Male 186 146.9 126.6 (109.1-146.2)   Male 1171 1104.2 106.0 (100.1-112.3) 
Female 206 165.7 124.3 (107.9-142.5)   Female 1254 1209.5 103.7 (98.0-109.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
54 
Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 4.1 121.5 (39.2-283.6)   Male 4 2.7 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 2.4 nc (nc-nc) 
Female 13 15.5 83.9 (44.6-143.5)   Female 3 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.5 nc (nc-nc)             
Female 6 4.3 140.2 (51.2-305.1)   Female 1 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 13 16.1 80.9 (43.0-138.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.6 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 3 0.5 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 7.6 91.5 (36.7-188.6)   Male 41 57.2 71.7 (51.5-97.3) 
Female 13 7.6 170.1 (90.5-290.9)   Female 61 52.9 115.2 (88.1-148.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
55 
Brookline 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 51 53.0 96.3 (71.7-126.6)   Male 46 34.4 133.8 (98.0-178.5) 
Female 14 22.7 61.6 (33.6-103.3)   Female 34 33.4 101.7 (70.4-142.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 10.5 114.2 (58.9-199.5)   Male 13 10.7 121.7 (64.7-208.0) 
Female 12 10.4 115.5 (59.6-201.8)   Female 8 10.2 78.5 (33.8-154.7) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.8 nc (nc-nc)   Male 39 30.5 127.8 (90.9-174.7) 
Female 238 242.5 98.2 (86.1-111.5)   Female 38 31.9 119.2 (84.4-163.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 24.0 87.5 (54.2-133.8) 
Female 1 8.8 nc (nc-nc)   Female 7 13.2 53.0 (21.2-109.1) 
Colon / Rectum            Ovary     
Male 38 55.9 68.0 (48.1-93.3)             
Female 41 67.8 60.5 (43.4-82.0)   Female 33 22.1 149.0 (102.6-209.3) 
Esophagus            Pancreas     
Male 5 14.0 35.6 (11.5-83.2)   Male 17 18.5 91.9 (53.5-147.1) 
Female 3 4.4 nc (nc-nc)   Female 25 23.0 108.7 (70.4-160.5) 
Hodgkin Lymphoma            Prostate     
Male 4 4.5 nc (nc-nc)   Male 175 180.8 96.8 (83.0-112.3) 
Female 7 5.0 140.1 (56.1-288.6)             
Kidney & Renal Pelvis            Stomach     
Male 31 29.0 106.8 (72.6-151.7)   Male 8 12.3 64.8 (27.9-127.8) 
Female 17 19.7 86.4 (50.3-138.4)   Female 9 8.8 102.4 (46.7-194.5) 
Larynx            Testis     
Male 2 8.2 nc (nc-nc)   Male 14 9.0 156.3 (85.4-262.2) 
Female 2 2.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 21.3 140.5 (94.8-200.6)   Male 16 13.6 117.5 (67.1-190.9) 
Female 26 19.1 136.4 (89.1-199.9)   Female 50 49.6 100.8 (74.8-132.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 17.9 39.1 (15.7-80.6)             
Female 5 7.2 69.8 (22.5-162.9)   Female 42 55.7 75.4 (54.4-102.0) 
Lung and Bronchus            All Sites / Types     
Male 62 95.4 65.0 (49.8-83.3)   Male 640 699.4 91.5 (84.6-98.9) 
Female 80 118.6 67.5 (53.5-84.0)   Female 764 845.6 90.4 (84.1-97.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
56 
Buckland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 11 11.9 92.8 (46.3-166.0)   Female 0 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.9 nc (nc-nc)             
Female 4 3.3 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 8.7 114.6 (54.9-210.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.6 nc (nc-nc)   Male 30 34.0 88.2 (59.5-125.9) 
Female 5 6.2 80.5 (25.9-187.8)   Female 36 41.0 87.8 (61.5-121.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
57 
Burlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 30.7 87.8 (57.9-127.8)   Male 18 19.2 93.6 (55.4-147.9) 
Female 5 10.8 46.3 (14.9-108.2)   Female 15 14.5 103.1 (57.7-170.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 5.5 162.8 (74.3-309.2)   Male 7 6.1 115.7 (46.3-238.3) 
Female 4 4.5 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 21 17.0 123.7 (76.6-189.1) 
Female 127 115.4 110.0 (91.7-130.9)   Female 14 14.7 95.0 (51.9-159.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 13.1 91.9 (47.4-160.5) 
Female 2 3.8 nc (nc-nc)   Female 5 6.2 80.8 (26.0-188.5) 
Colon / Rectum            Ovary     
Male 31 32.0 96.9 (65.8-137.5)             
Female 27 31.7 85.3 (56.2-124.1)   Female 7 10.2 68.4 (27.4-141.0) 
Esophagus            Pancreas     
Male 3 7.8 nc (nc-nc)   Male 12 10.5 113.8 (58.7-198.8) 
Female 0 2.0 nc (nc-nc)   Female 10 10.6 94.5 (45.2-173.8) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 97 94.8 102.3 (83.0-124.8) 
Female 1 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 15.6 128.0 (78.2-197.7)   Male 3 7.0 nc (nc-nc) 
Female 5 9.3 53.5 (17.2-124.9)   Female 4 4.1 nc (nc-nc) 
Larynx            Testis     
Male 3 4.5 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 11.9 142.6 (83.0-228.3)   Male 12 6.9 172.9 (89.2-302.0) 
Female 7 8.5 82.7 (33.1-170.4)   Female 28 20.7 135.5 (90.0-195.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 10.0 100.1 (47.9-184.1)             
Female 3 3.4 nc (nc-nc)   Female 31 25.9 119.6 (81.3-169.8) 
Lung and Bronchus            All Sites / Types     
Male 40 54.5 73.4 (52.5-100.0)   Male 394 385.3 102.2 (92.4-112.9) 
Female 63 58.3 108.1 (83.1-138.3)   Female 392 394.2 99.5 (89.8-109.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
58 
Cambridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 46 74.4 61.8 (45.3-82.5)   Male 56 51.6 108.5 (81.9-140.8) 
Female 17 30.0 56.7 (33.0-90.9)   Female 44 49.7 88.5 (64.3-118.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 20 17.6 113.8 (69.5-175.7)   Male 18 15.0 119.7 (70.9-189.2) 
Female 12 15.2 78.9 (40.7-137.8)   Female 7 13.6 51.5 (20.6-106.2) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.5 nc (nc-nc)   Male 42 46.1 91.2 (65.7-123.2) 
Female 299 338.6 88.3 (78.6-98.9)   Female 34 43.8 77.6 (53.7-108.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 37 35.3 104.7 (73.7-144.4) 
Female 9 13.7 65.5 (29.9-124.4)   Female 16 18.2 88.0 (50.3-142.9) 
Colon / Rectum            Ovary     
Male 71 80.9 87.7 (68.5-110.7)             
Female 69 90.6 76.1 (59.2-96.3)   Female 21 31.2 67.3 (41.7-102.9) 
Esophagus            Pancreas     
Male 14 19.7 71.1 (38.9-119.4)   Male 32 26.1 122.5 (83.8-172.9) 
Female 5 5.9 85.4 (27.5-199.3)   Female 26 30.1 86.5 (56.5-126.7) 
Hodgkin Lymphoma            Prostate     
Male 7 10.2 68.5 (27.4-141.1)   Male 247 250.3 98.7 (86.7-111.8) 
Female 3 8.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 42.4 77.8 (53.6-109.3)   Male 11 17.6 62.5 (31.2-111.9) 
Female 14 27.1 51.6 (28.2-86.6)   Female 8 11.7 68.2 (29.4-134.4) 
Larynx            Testis     
Male 4 11.4 nc (nc-nc)   Male 26 22.7 114.7 (74.9-168.1) 
Female 1 4.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 26 32.8 79.2 (51.7-116.1)   Male 27 23.3 115.7 (76.2-168.4) 
Female 18 26.6 67.8 (40.1-107.1)   Female 78 80.6 96.8 (76.5-120.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 25.5 70.5 (41.7-111.4)             
Female 13 9.7 133.8 (71.2-228.9)   Female 67 76.7 87.3 (67.7-110.9) 
Lung and Bronchus            All Sites / Types     
Male 106 132.7 79.9 (65.4-96.6)   Male 901 1018.5 88.5 (82.8-94.4) 
Female 103 158.1 65.1 (53.2-79.0)   Female 940 1176.9 79.9 (74.8-85.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
59 
Canton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 26.0 80.6 (49.9-123.2)   Male 18 16.2 111.2 (65.9-175.8) 
Female 7 9.6 72.8 (29.2-150.1)   Female 16 13.0 123.0 (70.3-199.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.7 nc (nc-nc)   Male 9 5.2 174.5 (79.6-331.2) 
Female 6 4.0 148.3 (54.1-322.8)   Female 6 4.3 139.8 (51.0-304.2) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 10 14.5 69.0 (33.0-127.0) 
Female 100 103.0 97.1 (79.0-118.1)   Female 16 13.2 121.6 (69.5-197.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 11.3 97.5 (48.6-174.4) 
Female 3 3.4 nc (nc-nc)   Female 9 5.5 163.1 (74.4-309.7) 
Colon / Rectum            Ovary     
Male 28 27.4 102.1 (67.9-147.6)             
Female 30 28.8 104.2 (70.3-148.8)   Female 6 9.1 65.6 (24.0-142.9) 
Esophagus            Pancreas     
Male 8 6.7 120.2 (51.8-236.9)   Male 9 9.0 100.3 (45.8-190.4) 
Female 1 1.9 nc (nc-nc)   Female 8 9.7 82.7 (35.6-163.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.7 nc (nc-nc)   Male 83 81.9 101.4 (80.7-125.7) 
Female 2 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 13.5 66.8 (30.5-126.7)   Male 3 6.0 nc (nc-nc) 
Female 4 8.3 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Larynx            Testis     
Male 1 3.8 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 10.1 167.6 (97.6-268.3)   Male 10 5.9 169.5 (81.2-311.8) 
Female 7 7.7 91.3 (36.6-188.1)   Female 29 18.0 160.8 (107.7-230.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 8.5 nc (nc-nc)             
Female 0 3.0 nc (nc-nc)   Female 30 23.3 128.8 (86.9-183.9) 
Lung and Bronchus            All Sites / Types     
Male 46 45.7 100.6 (73.6-134.1)   Male 327 328.5 99.5 (89.0-110.9) 
Female 54 50.5 106.9 (80.3-139.5)   Female 371 351.1 105.7 (95.2-117.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
60 
Carlisle 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.1 nc (nc-nc)   Male 7 4.0 174.0 (69.7-358.5) 
Female 1 2.1 nc (nc-nc)   Female 5 2.9 170.2 (54.8-397.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 21 24.8 84.6 (52.4-129.4)   Female 5 2.9 170.8 (55.1-398.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 6.8 73.8 (23.8-172.3)             
Female 4 6.4 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.7 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 27 23.4 115.6 (76.2-168.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.6 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.4 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 5 4.2 119.8 (38.6-279.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.4 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 7 5.6 124.4 (49.8-256.4) 
Lung and Bronchus            All Sites / Types     
Male 5 11.6 43.3 (13.9-101.0)   Male 67 84.4 79.4 (61.5-100.8) 
Female 3 11.2 nc (nc-nc)   Female 71 80.3 88.4 (69.1-111.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
61 
Carver 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 13.4 134.7 (79.8-212.9)   Male 9 8.5 105.3 (48.0-199.9) 
Female 7 5.0 139.9 (56.0-288.3)   Female 12 6.9 174.0 (89.8-303.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.5 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 6 7.6 79.0 (28.8-171.9) 
Female 41 56.7 72.3 (51.9-98.1)   Female 14 7.0 199.8 (109.2-335.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.2 129.6 (55.8-255.4) 
Female 1 1.8 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 14.2 105.5 (59.0-174.1)             
Female 10 14.8 67.4 (32.2-123.9)   Female 4 4.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 3.6 168.7 (61.6-367.1)   Male 4 4.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 46 45.5 101.1 (74.0-134.8) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.3 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 6 4.4 136.2 (49.7-296.4)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 2 2.1 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.3 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 6 9.7 61.9 (22.6-134.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.6 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 12 13.1 91.5 (47.2-159.9) 
Lung and Bronchus            All Sites / Types     
Male 31 24.0 129.3 (87.9-183.6)   Male 175 175.0 100.0 (85.8-116.0) 
Female 36 26.5 135.6 (95.0-187.7)   Female 178 188.1 94.6 (81.2-109.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
62 
Charlemont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.1 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 8 6.1 131.0 (56.4-258.2)   Female 1 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.1 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.7 nc (nc-nc)   Male 21 25.4 82.6 (51.1-126.3) 
Female 1 3.0 nc (nc-nc)   Female 21 20.6 101.8 (63.0-155.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
63 
Charlton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 14.2 98.8 (54.0-165.8)   Male 2 9.2 nc (nc-nc) 
Female 5 4.1 122.5 (39.5-285.8)   Female 6 6.6 90.6 (33.1-197.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.8 179.3 (57.8-418.5)   Male 2 2.9 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 5 1.9 259.9 (83.8-606.6) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 8.4 107.3 (49.0-203.8) 
Female 54 52.7 102.4 (76.9-133.6)   Female 5 6.1 81.7 (26.3-190.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 7.0 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 16.1 68.2 (34.0-122.1)             
Female 12 13.1 91.6 (47.3-160.0)   Female 1 4.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.8 nc (nc-nc)   Male 6 5.1 118.2 (43.2-257.4) 
Female 0 0.8 nc (nc-nc)   Female 6 4.1 145.0 (53.0-315.6) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 27 48.6 55.6 (36.6-80.9) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 8.0 112.2 (51.2-213.0)   Male 1 3.4 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.8 86.5 (27.9-201.8)   Male 1 3.8 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 13 10.4 124.9 (66.4-213.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.1 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 11 12.0 91.7 (45.7-164.2) 
Lung and Bronchus            All Sites / Types     
Male 20 24.7 81.1 (49.5-125.3)   Male 140 189.3 74.0 (62.2-87.3) 
Female 31 21.5 144.3 (98.0-204.8)   Female 179 169.4 105.7 (90.8-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
64 
Chatham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 14.4 118.2 (68.8-189.3)   Male 22 8.1 270.6 (169.5-409.7) 
Female 10 5.1 196.6 (94.1-361.7)   Female 11 5.4 204.9 (102.2-366.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.0 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 5 2.2 229.0 (73.8-534.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 5 7.1 70.1 (22.6-163.5) 
Female 49 44.4 110.3 (81.6-145.8)   Female 7 6.4 110.1 (44.1-226.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 5.3 152.3 (65.6-300.2) 
Female 3 1.1 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 13.9 137.2 (82.6-214.2)             
Female 14 14.1 99.3 (54.2-166.5)   Female 3 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.5 nc (nc-nc)   Male 7 4.8 146.7 (58.8-302.3) 
Female 0 1.0 nc (nc-nc)   Female 6 5.1 118.5 (43.3-257.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 48 42.5 112.9 (83.2-149.6) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.4 93.1 (34.0-202.7)   Male 3 3.2 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 0 2.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 4.9 161.7 (69.6-318.7)   Male 4 2.3 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 1 5.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 4.2 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 11 10.5 104.5 (52.1-187.0) 
Lung and Bronchus            All Sites / Types     
Male 22 25.4 86.7 (54.3-131.3)   Male 192 167.9 114.4 (98.8-131.7) 
Female 27 26.7 101.0 (66.5-146.9)   Female 181 161.5 112.0 (96.3-129.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
65 
Chelmsford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 39.9 117.9 (86.6-156.7)   Male 22 25.5 86.3 (54.1-130.7) 
Female 14 13.9 100.6 (55.0-168.9)   Female 25 19.6 127.7 (82.6-188.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 7.5 160.1 (82.6-279.6)   Male 13 8.1 160.9 (85.6-275.2) 
Female 7 6.1 115.0 (46.1-236.9)   Female 9 6.3 143.5 (65.5-272.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 26 22.7 114.7 (74.9-168.1) 
Female 173 156.5 110.6 (94.7-128.3)   Female 17 19.5 87.3 (50.8-139.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 18.1 110.7 (67.6-171.0) 
Female 6 5.2 114.6 (41.8-249.4)   Female 8 8.2 97.2 (41.8-191.5) 
Colon / Rectum            Ovary     
Male 39 43.0 90.7 (64.5-124.0)             
Female 47 41.6 112.9 (83.0-150.2)   Female 21 13.7 152.8 (94.5-233.5) 
Esophagus            Pancreas     
Male 7 10.4 67.4 (27.0-138.9)   Male 17 13.9 122.2 (71.2-195.7) 
Female 3 2.7 nc (nc-nc)   Female 16 13.9 114.9 (65.6-186.6) 
Hodgkin Lymphoma            Prostate     
Male 3 2.8 nc (nc-nc)   Male 117 128.7 90.9 (75.2-109.0) 
Female 3 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 21.4 107.5 (68.1-161.3)   Male 4 9.3 nc (nc-nc) 
Female 9 12.3 72.9 (33.3-138.4)   Female 5 5.3 93.7 (30.2-218.6) 
Larynx            Testis     
Male 5 6.0 82.9 (26.7-193.4)   Male 5 5.0 100.2 (32.3-233.9) 
Female 2 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 15.8 107.8 (62.8-172.7)   Male 12 9.6 124.4 (64.2-217.3) 
Female 22 11.2 196.5 (123.1-297.6)   Female 36 28.2 127.5 (89.3-176.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 13.6 73.4 (35.1-134.9)             
Female 2 4.4 nc (nc-nc)   Female 49 35.4 138.3 (102.3-182.9) 
Lung and Bronchus            All Sites / Types     
Male 67 71.1 94.3 (73.1-119.7)   Male 513 514.5 99.7 (91.3-108.7) 
Female 76 75.0 101.4 (79.9-126.9)   Female 599 524.7 114.2 (105.2-123.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
66 
Chelsea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 23.0 73.8 (43.0-118.2)   Male 8 16.7 47.8 (20.6-94.2) 
Female 9 8.4 107.0 (48.8-203.1)   Female 8 14.3 56.0 (24.1-110.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 6.3 127.7 (55.0-251.6)   Male 3 4.8 nc (nc-nc) 
Female 6 4.8 126.2 (46.1-274.7)   Female 5 3.8 130.5 (42.1-304.6) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 18 15.2 118.6 (70.2-187.4) 
Female 88 99.8 88.2 (70.7-108.6)   Female 14 12.6 111.5 (60.9-187.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 12.0 50.0 (18.2-108.7) 
Female 7 4.3 164.0 (65.7-337.9)   Female 9 5.2 171.5 (78.3-325.6) 
Colon / Rectum            Ovary     
Male 31 27.1 114.2 (77.6-162.1)             
Female 16 26.5 60.3 (34.5-98.0)   Female 4 9.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 6.2 96.9 (35.4-210.8)   Male 8 8.3 96.6 (41.6-190.3) 
Female 0 1.6 nc (nc-nc)   Female 18 8.6 210.5 (124.7-332.7) 
Hodgkin Lymphoma            Prostate     
Male 2 3.1 nc (nc-nc)   Male 59 78.2 75.5 (57.5-97.4) 
Female 1 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 14.5 34.5 (11.1-80.5)   Male 10 5.7 176.3 (84.4-324.2) 
Female 10 7.9 127.0 (60.8-233.5)   Female 3 3.4 nc (nc-nc) 
Larynx            Testis     
Male 6 3.6 165.5 (60.4-360.3)   Male 3 6.8 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 11.2 124.5 (68.0-208.8)   Male 8 8.1 99.2 (42.7-195.5) 
Female 10 8.1 123.5 (59.1-227.1)   Female 41 24.1 170.4 (122.2-231.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 8.4 178.9 (100.1-295.1)             
Female 7 2.7 258.4 (103.5-532.5)   Female 16 21.6 74.0 (42.3-120.2) 
Lung and Bronchus            All Sites / Types     
Male 56 40.7 137.7 (104.0-178.8)   Male 320 327.0 97.9 (87.4-109.2) 
Female 58 43.6 133.0 (101.0-171.9)   Female 354 341.0 103.8 (93.3-115.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
67 
Cheshire 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 4.4 137.9 (50.4-300.1)   Male 5 2.7 187.9 (60.6-438.5) 
Female 2 1.5 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 12 17.0 70.6 (36.4-123.3)   Female 1 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 4.6 129.4 (47.3-281.7)             
Female 3 4.5 nc (nc-nc)   Female 5 1.5 333.3 (107.4-777.9) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.2 nc (nc-nc)   Male 19 14.8 128.2 (77.2-200.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.3 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.7 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.5 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.0 124.0 (40.0-289.5) 
Lung and Bronchus            All Sites / Types     
Male 14 7.6 184.5 (100.8-309.6)   Male 68 55.9 121.7 (94.5-154.3) 
Female 3 8.0 nc (nc-nc)   Female 40 56.4 70.9 (50.7-96.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
68 
Chester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.4 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 3 5.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 1.7 360.4 (131.6-784.4)             
Female 1 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 5.8 102.6 (37.5-223.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.6 nc (nc-nc)   Male 26 20.7 125.6 (82.0-184.1) 
Female 4 2.4 nc (nc-nc)   Female 14 18.5 75.7 (41.4-127.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
69 
Chesterfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 5.7 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.6 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.3 94.6 (30.5-220.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.4 nc (nc-nc)   Male 14 19.0 73.6 (40.2-123.4) 
Female 1 2.4 nc (nc-nc)   Female 10 18.1 55.1 (26.4-101.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
70 
Chicopee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 66 65.7 100.4 (77.7-127.7)   Male 22 40.9 53.8 (33.7-81.4) 
Female 14 24.2 57.7 (31.5-96.9)   Female 20 32.4 61.6 (37.6-95.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 12.0 75.0 (34.2-142.4)   Male 14 12.9 108.2 (59.1-181.6) 
Female 10 9.9 100.5 (48.1-184.9)   Female 7 10.8 65.1 (26.1-134.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 2.2 nc (nc-nc)   Male 28 36.4 76.8 (51.0-111.0) 
Female 246 249.0 98.8 (86.8-112.0)   Female 33 33.0 100.0 (68.8-140.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 32 28.0 114.2 (78.1-161.2) 
Female 8 8.2 97.8 (42.1-192.7)   Female 25 13.7 183.1 (118.5-270.3) 
Colon / Rectum            Ovary     
Male 93 68.4 136.0 (109.8-166.6)             
Female 73 72.5 100.7 (78.9-126.6)   Female 31 22.4 138.1 (93.8-196.1) 
Esophagus            Pancreas     
Male 16 16.7 95.7 (54.7-155.5)   Male 20 22.6 88.5 (54.0-136.7) 
Female 5 4.7 107.3 (34.6-250.4)   Female 26 24.4 106.4 (69.5-155.9) 
Hodgkin Lymphoma            Prostate     
Male 5 4.7 106.9 (34.4-249.4)   Male 141 206.8 68.2 (57.4-80.4) 
Female 2 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 40 33.6 118.9 (84.9-161.9)   Male 12 15.1 79.6 (41.1-139.0) 
Female 27 20.3 133.3 (87.8-194.0)   Female 13 9.4 138.8 (73.8-237.3) 
Larynx            Testis     
Male 9 9.7 93.0 (42.4-176.6)   Male 11 8.3 131.9 (65.8-236.1) 
Female 2 3.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 25.8 89.2 (56.5-133.9)   Male 8 14.8 54.0 (23.3-106.4) 
Female 12 19.2 62.7 (32.3-109.4)   Female 31 44.4 69.9 (47.5-99.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 21.4 60.9 (32.4-104.1)             
Female 4 7.5 nc (nc-nc)   Female 53 56.5 93.9 (70.3-122.8) 
Lung and Bronchus            All Sites / Types     
Male 142 116.2 122.2 (103.0-144.1)   Male 762 829.1 91.9 (85.5-98.7) 
Female 141 125.8 112.1 (94.3-132.2)   Female 855 867.0 98.6 (92.1-105.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
71 
Chilmark 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 5 5.2 95.4 (30.7-222.6)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 1.3 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.5 134.1 (49.0-291.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.3 nc (nc-nc)   Male 21 16.4 128.3 (79.4-196.1) 
Female 2 2.5 nc (nc-nc)   Female 13 16.9 76.8 (40.8-131.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clarksburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.7 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 5 8.0 62.2 (20.0-145.2)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.7 nc (nc-nc)             
Female 5 2.3 220.3 (71.0-514.0)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.7 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 8.2 85.2 (34.1-175.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 4.7 nc (nc-nc)   Male 27 32.8 82.4 (54.3-119.9) 
Female 4 4.1 nc (nc-nc)   Female 25 27.6 90.7 (58.7-134.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 13.0 176.9 (112.1-265.4)   Male 4 8.7 nc (nc-nc) 
Female 4 5.8 nc (nc-nc)   Female 8 8.1 99.0 (42.6-195.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.7 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 5 7.8 63.9 (20.6-149.1) 
Female 58 62.4 92.9 (70.5-120.1)   Female 7 8.1 86.6 (34.7-178.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.5 107.5 (43.1-221.4) 
Female 3 2.1 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 14.5 110.7 (63.2-179.8)             
Female 14 17.8 78.8 (43.0-132.2)   Female 3 5.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.6 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 4 1.1 nc (nc-nc)   Female 5 5.9 84.4 (27.2-196.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 48 47.0 102.1 (75.3-135.4) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.6 65.5 (21.1-153.0)   Male 3 3.1 nc (nc-nc) 
Female 5 4.9 101.3 (32.7-236.5)   Female 1 2.3 nc (nc-nc) 
Larynx            Testis     
Male 3 2.1 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 5.4 147.5 (63.5-290.7)   Male 1 3.7 nc (nc-nc) 
Female 5 4.7 105.7 (34.0-246.6)   Female 6 11.4 52.6 (19.2-114.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.7 106.3 (34.2-248.0)             
Female 2 1.9 nc (nc-nc)   Female 13 14.3 91.1 (48.4-155.7) 
Lung and Bronchus            All Sites / Types     
Male 29 23.5 123.4 (82.6-177.2)   Male 176 178.6 98.6 (84.5-114.3) 
Female 35 29.7 117.9 (82.1-164.0)   Female 196 214.2 91.5 (79.1-105.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cohasset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.4 85.2 (36.7-167.8)   Male 5 6.1 82.3 (26.5-192.2) 
Female 5 3.2 155.4 (50.1-362.7)   Female 14 4.3 324.3 (177.1-544.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.4 111.9 (40.8-243.5) 
Female 40 35.0 114.3 (81.7-155.7)   Female 1 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.4 114.5 (36.9-267.2) 
Female 0 1.1 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 10.0 120.0 (62.0-209.7)             
Female 5 9.5 52.7 (17.0-123.0)   Female 4 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.5 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.6 nc (nc-nc)   Male 26 30.6 85.0 (55.5-124.6) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.1 137.7 (55.2-283.7)   Male 0 2.2 nc (nc-nc) 
Female 5 2.8 177.2 (57.1-413.4)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.7 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 8 6.0 133.1 (57.3-262.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.4 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 8 8.0 99.7 (42.9-196.5) 
Lung and Bronchus            All Sites / Types     
Male 10 17.0 58.9 (28.2-108.4)   Male 107 122.2 87.6 (71.8-105.8) 
Female 10 17.3 57.7 (27.6-106.2)   Female 132 118.5 111.4 (93.2-132.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Colrain 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.8 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 8 8.0 99.8 (43.0-196.6)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.9 nc (nc-nc)             
Female 3 2.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 9 8.6 104.1 (47.5-197.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 5 1.9 263.6 (85.0-615.2) 
Lung and Bronchus            All Sites / Types     
Male 3 4.9 nc (nc-nc)   Male 29 34.7 83.6 (56.0-120.1) 
Female 4 3.6 nc (nc-nc)   Female 30 26.6 112.8 (76.1-161.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Concord 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 27.1 103.2 (68.5-149.1)   Male 29 16.6 174.5 (116.9-250.7) 
Female 7 9.1 76.6 (30.7-157.8)   Female 18 11.1 161.8 (95.8-255.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.6 107.6 (34.7-251.2)   Male 5 5.4 93.3 (30.1-217.6) 
Female 5 3.5 144.5 (46.6-337.1)   Female 4 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 13 14.9 87.4 (46.5-149.5) 
Female 114 89.3 127.6 (105.3-153.3)   Female 9 12.0 74.7 (34.1-141.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 11.5 86.7 (41.5-159.4) 
Female 3 2.6 nc (nc-nc)   Female 5 5.0 99.8 (32.1-232.8) 
Colon / Rectum            Ovary     
Male 19 28.5 66.7 (40.1-104.2)             
Female 35 27.6 126.7 (88.2-176.2)   Female 15 8.1 185.1 (103.5-305.4) 
Esophagus            Pancreas     
Male 3 6.9 nc (nc-nc)   Male 14 9.3 150.2 (82.0-252.0) 
Female 0 1.7 nc (nc-nc)   Female 8 9.3 85.7 (36.9-168.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 86 84.8 101.4 (81.1-125.2) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 13.8 94.2 (50.1-161.1)   Male 3 6.2 nc (nc-nc) 
Female 7 7.3 96.5 (38.6-198.8)   Female 0 3.6 nc (nc-nc) 
Larynx            Testis     
Male 1 3.9 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 10.3 58.1 (21.2-126.5)   Male 2 5.9 nc (nc-nc) 
Female 4 7.0 nc (nc-nc)   Female 12 13.7 87.6 (45.2-153.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.8 68.4 (25.0-149.0)             
Female 4 2.7 nc (nc-nc)   Female 25 20.2 124.0 (80.2-183.1) 
Lung and Bronchus            All Sites / Types     
Male 19 47.3 40.1 (24.1-62.7)   Male 295 338.6 87.1 (77.5-97.7) 
Female 27 45.6 59.1 (39.0-86.1)   Female 334 312.9 106.8 (95.6-118.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Conway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 11 9.5 116.1 (57.9-207.8)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.4 nc (nc-nc)             
Female 1 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 7.7 65.1 (21.0-151.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 3.8 nc (nc-nc)   Male 29 28.7 101.0 (67.6-145.1) 
Female 1 4.1 nc (nc-nc)   Female 26 29.9 86.9 (56.7-127.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cummington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.5 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 3 0.8 nc (nc-nc) 
Female 7 4.5 155.2 (62.2-319.7)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.6 nc (nc-nc)             
Female 5 1.3 389.3 (125.5-908.5)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 4.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.6 nc (nc-nc)   Male 16 18.0 88.9 (50.8-144.4) 
Female 1 2.1 nc (nc-nc)   Female 21 15.3 137.2 (84.9-209.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Dalton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 10.3 106.5 (53.1-190.5)   Male 8 6.2 128.3 (55.2-252.8) 
Female 2 3.2 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.6 nc (nc-nc) 
Female 27 33.2 81.4 (53.6-118.4)   Female 2 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 10.7 102.8 (51.3-184.0)             
Female 11 9.6 115.0 (57.3-205.8)   Female 3 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.5 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 33 29.5 111.8 (77.0-157.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.0 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.9 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 1 5.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.2 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 7 7.7 91.1 (36.5-187.8) 
Lung and Bronchus            All Sites / Types     
Male 13 18.0 72.2 (38.4-123.5)   Male 102 124.5 81.9 (66.8-99.4) 
Female 19 16.8 113.3 (68.2-176.9)   Female 94 114.3 82.2 (66.4-100.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Danvers 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 37 35.1 105.3 (74.1-145.2)   Male 18 21.6 83.3 (49.3-131.7) 
Female 15 12.3 121.6 (68.0-200.5)   Female 14 16.0 87.7 (47.9-147.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 6.1 196.4 (101.4-343.1)   Male 4 6.9 nc (nc-nc) 
Female 4 4.9 nc (nc-nc)   Female 4 5.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 14 19.2 72.8 (39.7-122.1) 
Female 141 123.9 113.8 (95.8-134.2)   Female 28 16.5 169.6 (112.7-245.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 14.7 95.1 (52.0-159.6) 
Female 3 4.0 nc (nc-nc)   Female 7 6.8 103.3 (41.4-212.8) 
Colon / Rectum            Ovary     
Male 29 36.5 79.4 (53.2-114.1)             
Female 39 37.1 105.2 (74.8-143.8)   Female 11 11.1 99.0 (49.3-177.1) 
Esophagus            Pancreas     
Male 11 8.8 125.2 (62.4-224.0)   Male 12 12.0 99.7 (51.5-174.2) 
Female 2 2.3 nc (nc-nc)   Female 9 12.5 72.2 (33.0-137.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 119 106.6 111.6 (92.5-133.6) 
Female 4 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 17.6 141.9 (91.8-209.5)   Male 5 8.0 62.2 (20.1-145.3) 
Female 8 10.0 79.6 (34.3-156.9)   Female 7 4.8 144.5 (57.9-297.7) 
Larynx            Testis     
Male 3 5.1 nc (nc-nc)   Male 5 3.8 130.3 (42.0-304.0) 
Female 0 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 13.5 88.9 (45.9-155.3)   Male 11 7.6 144.2 (71.9-258.0) 
Female 13 9.7 133.9 (71.2-229.0)   Female 23 21.4 107.4 (68.1-161.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 11.2 107.3 (55.4-187.4)             
Female 6 3.7 161.1 (58.8-350.7)   Female 38 27.4 138.5 (98.0-190.2) 
Lung and Bronchus            All Sites / Types     
Male 65 61.4 105.8 (81.6-134.9)   Male 446 434.9 102.5 (93.2-112.5) 
Female 52 62.2 83.7 (62.5-109.7)   Female 467 432.2 108.1 (98.5-118.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
81 
Dartmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 57 43.1 132.2 (100.1-171.3)   Male 24 26.6 90.4 (57.9-134.5) 
Female 17 15.4 110.1 (64.1-176.3)   Female 18 19.7 91.4 (54.1-144.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 7.6 92.2 (37.0-190.1)   Male 5 8.3 60.0 (19.3-140.0) 
Female 7 6.1 115.5 (46.3-238.0)   Female 5 6.8 73.7 (23.7-171.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.4 nc (nc-nc)   Male 21 24.0 87.6 (54.2-133.9) 
Female 126 153.1 82.3 (68.6-98.0)   Female 17 20.6 82.6 (48.1-132.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 18.3 87.3 (49.9-141.7) 
Female 5 4.8 104.3 (33.6-243.3)   Female 13 8.6 151.7 (80.7-259.5) 
Colon / Rectum            Ovary     
Male 42 45.5 92.4 (66.6-124.9)             
Female 44 46.2 95.2 (69.2-127.8)   Female 8 14.0 57.1 (24.6-112.5) 
Esophagus            Pancreas     
Male 11 10.8 101.7 (50.7-182.0)   Male 14 14.8 94.6 (51.7-158.8) 
Female 2 3.0 nc (nc-nc)   Female 8 15.8 50.7 (21.8-99.9) 
Hodgkin Lymphoma            Prostate     
Male 3 3.2 nc (nc-nc)   Male 160 131.6 121.6 (103.5-141.9) 
Female 1 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 24 21.7 110.8 (71.0-164.9)   Male 12 9.9 121.7 (62.8-212.6) 
Female 15 12.4 120.7 (67.5-199.2)   Female 7 6.1 115.5 (46.3-238.0) 
Larynx            Testis     
Male 7 6.1 114.5 (45.9-235.8)   Male 6 5.7 105.9 (38.7-230.4) 
Female 1 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 16.8 101.4 (59.0-162.4)   Male 8 9.7 82.3 (35.5-162.3) 
Female 8 12.0 66.9 (28.8-131.9)   Female 32 25.7 124.4 (85.1-175.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 13.7 65.7 (30.0-124.8)             
Female 1 4.7 nc (nc-nc)   Female 37 35.0 105.7 (74.4-145.7) 
Lung and Bronchus            All Sites / Types     
Male 69 74.2 93.0 (72.4-117.7)   Male 544 537.2 101.3 (92.9-110.2) 
Female 44 77.4 56.9 (41.3-76.3)   Female 456 537.1 84.9 (77.3-93.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
82 
Dedham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 33.0 106.1 (73.9-147.5)   Male 21 20.0 105.0 (65.0-160.5) 
Female 11 12.1 91.1 (45.4-163.1)   Female 20 15.2 131.2 (80.1-202.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 5.6 160.8 (73.4-305.2)   Male 9 6.4 140.3 (64.0-266.4) 
Female 4 4.7 nc (nc-nc)   Female 1 5.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 20 17.9 111.4 (68.0-172.1) 
Female 146 117.3 124.4 (105.1-146.3)   Female 15 15.9 94.1 (52.6-155.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 13.2 106.1 (58.0-178.1) 
Female 5 3.8 133.2 (42.9-310.8)   Female 12 6.5 183.7 (94.8-320.9) 
Colon / Rectum            Ovary     
Male 24 34.1 70.4 (45.1-104.8)             
Female 29 36.3 79.8 (53.4-114.6)   Female 11 10.6 103.6 (51.6-185.4) 
Esophagus            Pancreas     
Male 6 8.0 74.8 (27.3-162.9)   Male 11 11.0 99.8 (49.7-178.5) 
Female 0 2.3 nc (nc-nc)   Female 17 12.2 139.1 (81.0-222.7) 
Hodgkin Lymphoma            Prostate     
Male 1 2.1 nc (nc-nc)   Male 94 93.8 100.2 (81.0-122.6) 
Female 3 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 16.1 86.8 (47.4-145.6)   Male 9 7.5 120.3 (54.9-228.3) 
Female 12 9.6 124.6 (64.3-217.7)   Female 7 4.7 147.6 (59.1-304.1) 
Larynx            Testis     
Male 4 4.6 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 12.6 71.5 (32.6-135.7)   Male 5 7.0 71.4 (23.0-166.7) 
Female 7 9.4 74.7 (29.9-153.9)   Female 30 20.0 149.8 (101.1-213.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 10.0 109.9 (54.8-196.7)             
Female 6 3.6 167.4 (61.1-364.5)   Female 25 25.8 96.9 (62.7-143.0) 
Lung and Bronchus            All Sites / Types     
Male 50 56.7 88.2 (65.5-116.3)   Male 390 398.2 97.9 (88.5-108.2) 
Female 77 60.6 127.1 (100.3-158.9)   Female 468 415.0 112.8 (102.8-123.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
83 
Deerfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 4.5 nc (nc-nc)   Male 5 3.2 155.1 (50.0-361.9) 
Female 3 2.1 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 19 24.6 77.4 (46.6-120.8)   Female 3 2.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.3 112.6 (41.1-245.2)             
Female 5 6.3 80.0 (25.8-186.6)   Female 0 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 19 19.4 97.9 (58.9-152.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.1 162.4 (52.3-379.0)   Male 0 1.1 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 4 5.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 8.6 nc (nc-nc)   Male 54 68.0 79.5 (59.7-103.7) 
Female 5 11.4 43.7 (14.1-101.9)   Female 60 80.8 74.3 (56.7-95.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
84 
Dennis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 28.9 145.4 (104.8-196.6)   Male 37 16.2 228.2 (160.7-314.6) 
Female 15 10.4 144.8 (81.0-238.9)   Female 20 11.7 171.6 (104.8-265.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.0 nc (nc-nc)   Male 10 5.3 187.7 (89.8-345.2) 
Female 1 3.6 nc (nc-nc)   Female 2 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 15 14.2 105.5 (59.0-174.1) 
Female 114 96.2 118.5 (97.7-142.3)   Female 10 13.3 75.4 (36.1-138.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 10.1 159.0 (90.8-258.2) 
Female 2 2.6 nc (nc-nc)   Female 3 5.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 29 27.4 105.8 (70.9-152.0)             
Female 24 28.5 84.3 (54.0-125.5)   Female 13 8.6 150.4 (80.0-257.3) 
Esophagus            Pancreas     
Male 10 6.8 146.9 (70.3-270.2)   Male 17 9.5 179.1 (104.3-286.8) 
Female 5 2.0 251.6 (81.1-587.2)   Female 11 10.2 107.7 (53.7-192.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 108 81.8 132.0 (108.3-159.4) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 12.6 79.6 (38.1-146.4)   Male 2 6.3 nc (nc-nc) 
Female 6 8.2 73.1 (26.7-159.1)   Female 2 3.7 nc (nc-nc) 
Larynx            Testis     
Male 4 3.9 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 10.1 139.2 (76.0-233.6)   Male 1 4.4 nc (nc-nc) 
Female 7 7.3 95.8 (38.4-197.3)   Female 17 13.1 129.4 (75.3-207.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 8.1 98.7 (42.5-194.6)             
Female 4 3.1 nc (nc-nc)   Female 20 22.8 87.6 (53.5-135.3) 
Lung and Bronchus            All Sites / Types     
Male 44 50.7 86.9 (63.1-116.6)   Male 401 331.3 121.0 (109.5-133.5) 
Female 54 56.3 95.9 (72.1-125.2)   Female 366 342.3 106.9 (96.3-118.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
85 
Dighton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.8 71.6 (28.7-147.4)   Male 5 5.9 84.9 (27.3-198.0) 
Female 1 2.7 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.3 94.7 (30.5-220.9) 
Female 16 29.6 54.1 (30.9-87.9)   Female 1 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 10.2 147.0 (82.2-242.5)             
Female 5 8.2 60.9 (19.6-142.1)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 30 28.7 104.4 (70.4-149.0) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.8 126.0 (46.0-274.2)   Male 3 2.2 nc (nc-nc) 
Female 5 2.4 211.3 (68.1-493.1)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.7 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 3 5.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.0 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 7 6.6 106.1 (42.5-218.7) 
Lung and Bronchus            All Sites / Types     
Male 10 16.9 59.2 (28.4-109.0)   Male 110 119.0 92.5 (76.0-111.4) 
Female 14 14.2 98.6 (53.9-165.5)   Female 75 100.3 74.7 (58.8-93.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
86 
Douglas 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.1 84.4 (30.8-183.8)   Male 6 5.2 116.3 (42.5-253.1) 
Female 4 2.0 nc (nc-nc)   Female 6 3.8 156.5 (57.1-340.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 4 4.6 nc (nc-nc) 
Female 29 31.4 92.2 (61.7-132.5)   Female 2 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 8.4 59.3 (19.1-138.3)             
Female 5 6.5 77.0 (24.8-179.6)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.1 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 24 28.4 84.7 (54.2-126.0) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 4.7 170.2 (73.3-335.4)   Male 2 1.8 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.1 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 9 6.7 134.1 (61.2-254.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.0 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 9 7.1 126.6 (57.8-240.4) 
Lung and Bronchus            All Sites / Types     
Male 14 13.4 104.5 (57.1-175.3)   Male 101 105.8 95.5 (77.8-116.0) 
Female 11 11.8 93.3 (46.5-166.9)   Female 98 95.5 102.6 (83.3-125.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
87 
Dover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 7.6 nc (nc-nc)   Male 11 4.7 234.9 (117.1-420.4) 
Female 0 2.0 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 7 4.2 168.7 (67.6-347.5) 
Female 27 25.1 107.4 (70.8-156.3)   Female 3 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.9 75.7 (27.6-164.7)             
Female 5 6.2 80.2 (25.9-187.2)   Female 0 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 27 23.4 115.4 (76.0-167.9) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.8 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.9 nc (nc-nc)   Male 4 1.6 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 5 4.3 115.1 (37.1-268.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 2.5 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 1 5.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 13.6 58.8 (25.3-115.8)   Male 92 94.8 97.0 (78.2-119.0) 
Female 6 11.5 52.2 (19.1-113.7)   Female 63 81.2 77.6 (59.6-99.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
88 
Dracut 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 29.9 133.9 (95.6-182.3)   Male 10 20.1 49.7 (23.8-91.4) 
Female 16 10.4 153.7 (87.8-249.5)   Female 15 15.8 95.0 (53.2-156.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.3 110.7 (44.3-228.0)   Male 7 6.3 111.7 (44.7-230.1) 
Female 3 4.9 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 15 17.9 83.7 (46.8-138.1) 
Female 138 123.2 112.0 (94.1-132.3)   Female 10 15.0 66.7 (32.0-122.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 15.2 52.8 (22.7-104.0) 
Female 5 4.3 115.3 (37.2-269.1)   Female 10 6.4 155.9 (74.6-286.7) 
Colon / Rectum            Ovary     
Male 38 33.3 114.2 (80.8-156.8)             
Female 48 31.8 151.0 (111.4-200.3)   Female 12 10.8 110.6 (57.1-193.3) 
Esophagus            Pancreas     
Male 13 8.4 155.5 (82.7-266.0)   Male 7 10.8 64.7 (25.9-133.4) 
Female 3 2.1 nc (nc-nc)   Female 12 10.4 115.0 (59.4-200.9) 
Hodgkin Lymphoma            Prostate     
Male 0 2.5 nc (nc-nc)   Male 99 108.7 91.1 (74.0-110.9) 
Female 2 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 17.5 114.0 (69.6-176.0)   Male 6 7.2 83.8 (30.6-182.3) 
Female 7 9.6 73.0 (29.3-150.5)   Female 5 4.1 123.3 (39.7-287.7) 
Larynx            Testis     
Male 8 4.9 164.1 (70.6-323.3)   Male 3 4.5 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 12.5 144.2 (85.4-228.0)   Male 7 8.3 84.6 (33.9-174.4) 
Female 10 8.7 114.4 (54.8-210.5)   Female 28 23.7 118.0 (78.4-170.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 11.3 nc (nc-nc)             
Female 5 3.4 145.9 (47.0-340.4)   Female 13 28.2 46.1 (24.5-78.9) 
Lung and Bronchus            All Sites / Types     
Male 61 54.7 111.6 (85.4-143.4)   Male 408 412.2 99.0 (89.6-109.1) 
Female 75 55.9 134.1 (105.5-168.1)   Female 461 408.6 112.8 (102.8-123.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
89 
Dudley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 11.2 107.1 (55.3-187.0)   Male 5 7.3 68.6 (22.1-160.0) 
Female 3 3.1 nc (nc-nc)   Female 2 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.3 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 4 6.6 nc (nc-nc) 
Female 42 39.6 106.0 (76.4-143.3)   Female 5 4.6 108.4 (34.9-252.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 12.0 100.1 (51.7-174.9)             
Female 11 9.5 115.4 (57.6-206.6)   Female 8 3.4 233.5 (100.5-460.1) 
Esophagus            Pancreas     
Male 4 2.9 nc (nc-nc)   Male 5 3.9 129.8 (41.8-303.0) 
Female 2 0.6 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 33 34.5 95.5 (65.8-134.2) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.1 132.2 (56.9-260.5)   Male 5 2.6 190.4 (61.3-444.2) 
Female 4 3.0 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 1.7 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 4.6 194.5 (88.8-369.2)   Male 1 2.9 nc (nc-nc) 
Female 5 2.7 185.0 (59.6-431.7)   Female 11 8.0 138.1 (68.8-247.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.8 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 17 8.9 190.3 (110.8-304.7) 
Lung and Bronchus            All Sites / Types     
Male 26 19.9 130.5 (85.2-191.2)   Male 149 144.7 103.0 (87.1-120.9) 
Female 26 17.0 152.6 (99.6-223.6)   Female 158 128.1 123.3 (104.9-144.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
90 
Dunstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.9 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.7 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 18 14.1 127.6 (75.6-201.7)   Female 2 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.5 144.6 (46.6-337.5)             
Female 1 3.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 7 12.3 57.1 (22.9-117.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.9 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.2 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.5 nc (nc-nc)   Male 39 43.3 90.1 (64.0-123.1) 
Female 8 5.7 140.2 (60.4-276.3)   Female 45 45.1 99.8 (72.8-133.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
91 
Duxbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 18.0 138.6 (89.7-204.6)   Male 29 11.3 255.7 (171.2-367.3) 
Female 1 6.7 nc (nc-nc)   Female 15 9.1 164.4 (91.9-271.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.3 nc (nc-nc)   Male 7 3.7 189.8 (76.0-391.0) 
Female 1 2.9 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 18 10.2 176.6 (104.6-279.1) 
Female 82 74.5 110.0 (87.5-136.5)   Female 4 9.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 8.4 71.4 (26.1-155.5) 
Female 1 2.3 nc (nc-nc)   Female 4 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 19.3 51.9 (24.8-95.4)             
Female 14 20.4 68.5 (37.4-114.9)   Female 6 6.6 90.7 (33.1-197.4) 
Esophagus            Pancreas     
Male 6 4.9 122.9 (44.9-267.5)   Male 5 6.3 78.8 (25.4-183.9) 
Female 1 1.3 nc (nc-nc)   Female 6 6.8 88.4 (32.3-192.4) 
Hodgkin Lymphoma            Prostate     
Male 3 1.1 nc (nc-nc)   Male 73 62.9 116.1 (91.0-146.0) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 9.9 161.3 (92.2-262.0)   Male 0 4.2 nc (nc-nc) 
Female 3 5.8 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.1 99.2 (39.7-204.4)   Male 0 4.2 nc (nc-nc) 
Female 4 5.3 nc (nc-nc)   Female 10 12.5 79.8 (38.2-146.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 6.3 nc (nc-nc)             
Female 0 2.1 nc (nc-nc)   Female 8 17.0 47.1 (20.3-92.7) 
Lung and Bronchus            All Sites / Types     
Male 28 32.4 86.4 (57.4-124.8)   Male 261 237.0 110.1 (97.2-124.4) 
Female 17 34.9 48.6 (28.3-77.9)   Female 207 249.3 83.0 (72.1-95.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
92 
East Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 12.2 130.9 (74.8-212.6)   Male 10 8.4 119.5 (57.2-219.8) 
Female 6 5.8 102.6 (37.5-223.4)   Female 8 8.3 96.2 (41.4-189.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.6 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 0 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 8 7.5 106.3 (45.8-209.5) 
Female 47 66.9 70.3 (51.6-93.4)   Female 11 8.3 132.8 (66.2-237.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 6.4 124.6 (53.6-245.5) 
Female 2 2.2 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 14.1 121.0 (70.4-193.7)             
Female 11 17.7 62.3 (31.0-111.4)   Female 6 5.9 101.5 (37.1-220.9) 
Esophagus            Pancreas     
Male 6 3.4 175.2 (64.0-381.3)   Male 2 4.5 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 8 5.8 137.2 (59.1-270.3) 
Hodgkin Lymphoma            Prostate     
Male 2 1.1 nc (nc-nc)   Male 46 44.7 102.8 (75.3-137.2) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 7.5 160.5 (82.8-280.3)   Male 2 3.0 nc (nc-nc) 
Female 4 5.2 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.2 nc (nc-nc)   Male 5 3.6 138.3 (44.6-322.7) 
Female 4 4.7 nc (nc-nc)   Female 11 12.1 91.1 (45.4-163.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.6 109.1 (35.2-254.6)             
Female 0 1.9 nc (nc-nc)   Female 11 15.3 71.9 (35.8-128.6) 
Lung and Bronchus            All Sites / Types     
Male 27 22.4 120.7 (79.6-175.7)   Male 192 171.0 112.3 (97.0-129.3) 
Female 24 31.6 75.8 (48.6-112.8)   Female 183 223.2 82.0 (70.5-94.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
93 
East Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.6 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 8 10.0 80.0 (34.4-157.6)   Female 0 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 2.9 nc (nc-nc)             
Female 0 2.4 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 9.5 84.4 (36.4-166.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 4.7 nc (nc-nc)   Male 29 35.3 82.1 (55.0-117.9) 
Female 5 4.6 108.6 (35.0-253.5)   Female 29 32.8 88.4 (59.2-127.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
94 
East Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 20.2 89.2 (52.8-141.0)   Male 19 12.3 154.1 (92.7-240.6) 
Female 5 8.6 58.3 (18.8-136.0)   Female 10 10.4 96.2 (46.1-177.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.5 nc (nc-nc)   Male 1 4.0 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 14 11.1 125.9 (68.8-211.2) 
Female 75 80.7 92.9 (73.1-116.5)   Female 9 11.3 80.0 (36.5-151.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 8.7 104.0 (47.5-197.4) 
Female 0 2.5 nc (nc-nc)   Female 5 4.6 108.7 (35.0-253.6) 
Colon / Rectum            Ovary     
Male 21 21.4 98.2 (60.8-150.1)             
Female 23 25.8 89.0 (56.4-133.5)   Female 12 7.4 163.0 (84.1-284.8) 
Esophagus            Pancreas     
Male 3 5.1 nc (nc-nc)   Male 5 6.9 72.1 (23.2-168.4) 
Female 2 1.6 nc (nc-nc)   Female 11 8.8 125.2 (62.4-224.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 53 63.2 83.8 (62.8-109.6) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.3 126.2 (67.1-215.9)   Male 5 4.6 107.8 (34.7-251.5) 
Female 8 6.7 119.9 (51.6-236.3)   Female 4 3.4 nc (nc-nc) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.7 90.5 (36.3-186.5)   Male 2 4.4 nc (nc-nc) 
Female 2 6.6 nc (nc-nc)   Female 8 12.8 62.4 (26.9-123.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.5 nc (nc-nc)             
Female 1 2.6 nc (nc-nc)   Female 16 18.0 88.8 (50.7-144.2) 
Lung and Bronchus            All Sites / Types     
Male 36 34.9 103.0 (72.1-142.6)   Male 234 252.4 92.7 (81.2-105.4) 
Female 51 42.7 119.5 (89.0-157.1)   Female 273 288.8 94.5 (83.7-106.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
95 
Eastham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 11.1 89.9 (43.0-165.3)   Male 8 6.4 124.7 (53.7-245.8) 
Female 4 3.6 nc (nc-nc)   Female 13 4.2 307.7 (163.7-526.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 5.6 nc (nc-nc) 
Female 45 35.8 125.8 (91.8-168.4)   Female 7 4.7 149.6 (59.9-308.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 10.8 101.6 (50.7-181.9)             
Female 12 9.9 121.5 (62.7-212.2)   Female 4 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 6 3.5 169.5 (61.9-369.0) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 42 36.6 114.8 (82.7-155.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.2 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 3.9 230.0 (104.9-436.6)   Male 2 1.9 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 3 4.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.4 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 7 8.7 80.7 (32.3-166.3) 
Lung and Bronchus            All Sites / Types     
Male 25 20.0 124.9 (80.8-184.4)   Male 141 135.5 104.0 (87.6-122.7) 
Female 14 19.9 70.4 (38.4-118.0)   Female 140 123.3 113.5 (95.5-134.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
96 
Easthampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 18.4 49.0 (22.3-93.0)   Male 9 12.0 74.9 (34.2-142.1) 
Female 2 7.0 nc (nc-nc)   Female 7 9.7 72.3 (29.0-149.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 3 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 9 10.7 84.5 (38.5-160.3) 
Female 66 73.9 89.3 (69.1-113.6)   Female 11 9.6 114.6 (57.1-205.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 8.8 113.8 (54.5-209.2) 
Female 0 2.5 nc (nc-nc)   Female 7 4.0 174.8 (70.0-360.1) 
Colon / Rectum            Ovary     
Male 32 20.1 159.3 (108.9-224.8)             
Female 25 21.0 119.1 (77.0-175.8)   Female 3 6.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 4.9 nc (nc-nc)   Male 4 6.5 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 9 6.9 129.7 (59.2-246.2) 
Hodgkin Lymphoma            Prostate     
Male 3 1.4 nc (nc-nc)   Male 52 62.2 83.6 (62.4-109.6) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.1 69.0 (27.6-142.2)   Male 3 4.4 nc (nc-nc) 
Female 8 6.0 134.0 (57.7-264.0)   Female 2 2.7 nc (nc-nc) 
Larynx            Testis     
Male 4 2.9 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.3 95.4 (38.2-196.7)   Male 1 4.7 nc (nc-nc) 
Female 3 5.5 nc (nc-nc)   Female 8 13.8 58.1 (25.0-114.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.6 nc (nc-nc)             
Female 3 2.2 nc (nc-nc)   Female 19 16.8 113.3 (68.2-176.9) 
Lung and Bronchus            All Sites / Types     
Male 29 32.8 88.3 (59.1-126.8)   Male 206 243.5 84.6 (73.4-97.0) 
Female 34 36.4 93.3 (64.6-130.4)   Female 231 254.8 90.7 (79.3-103.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
97 
Easton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 20.9 115.1 (73.7-171.2)   Male 19 14.2 134.1 (80.7-209.5) 
Female 9 7.2 124.2 (56.7-235.8)   Female 18 11.4 157.6 (93.4-249.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.6 131.8 (48.1-286.9)   Male 5 4.4 112.5 (36.3-262.5) 
Female 4 3.7 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 8 12.7 62.9 (27.1-123.9) 
Female 117 89.0 131.5 (108.8-157.6)   Female 14 10.7 130.8 (71.5-219.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 10.8 92.4 (44.2-169.9) 
Female 2 3.2 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 23.3 77.3 (45.8-122.2)             
Female 31 22.3 139.0 (94.4-197.3)   Female 9 7.8 115.4 (52.7-219.2) 
Esophagus            Pancreas     
Male 6 5.9 101.0 (36.9-219.9)   Male 8 7.6 105.6 (45.5-208.1) 
Female 3 1.4 nc (nc-nc)   Female 8 7.2 111.3 (47.9-219.3) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 71 78.5 90.4 (70.6-114.1) 
Female 2 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 12.6 118.8 (66.4-195.9)   Male 5 5.0 99.2 (32.0-231.4) 
Female 6 6.8 87.7 (32.0-191.0)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 8.9 146.6 (78.0-250.7)   Male 10 6.0 167.1 (80.0-307.4) 
Female 7 6.3 111.3 (44.6-229.3)   Female 19 17.9 106.2 (63.9-165.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 8.0 125.5 (60.1-230.8)             
Female 3 2.4 nc (nc-nc)   Female 15 20.1 74.5 (41.7-122.9) 
Lung and Bronchus            All Sites / Types     
Male 47 38.6 121.7 (89.4-161.8)   Male 312 293.4 106.3 (94.9-118.8) 
Female 47 39.2 119.8 (88.0-159.4)   Female 351 292.5 120.0 (107.8-133.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
98 
Edgartown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.0 99.3 (39.8-204.7)   Male 12 4.5 269.2 (138.9-470.3) 
Female 2 1.6 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 24 19.0 126.1 (80.8-187.7)   Female 3 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.5 120.2 (54.9-228.3)             
Female 3 5.0 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.0 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 4 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 30 25.6 117.0 (78.9-167.0) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.9 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.7 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 6 3.3 180.9 (66.1-393.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 12.7 39.5 (12.7-92.1)   Male 87 93.7 92.9 (74.4-114.6) 
Female 11 8.8 125.5 (62.6-224.6)   Female 71 62.7 113.3 (88.5-142.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
99 
Egremont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 4 7.9 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 2.2 229.2 (73.9-534.9)             
Female 2 2.3 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 7.7 64.5 (20.8-150.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.9 nc (nc-nc)   Male 21 27.7 75.8 (46.9-115.8) 
Female 3 4.2 nc (nc-nc)   Female 16 27.4 58.4 (33.4-94.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Erving 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.8 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 4 7.3 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 2.0 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 6.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.2 nc (nc-nc)   Male 15 23.9 62.7 (35.1-103.4) 
Female 2 3.4 nc (nc-nc)   Female 16 24.7 64.9 (37.1-105.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Essex 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.9 127.7 (41.1-298.0)   Male 5 2.6 190.7 (61.4-445.0) 
Female 1 1.3 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 13 16.6 78.5 (41.8-134.2)   Female 2 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 2.0 246.1 (79.3-574.3) 
Female 1 0.6 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 4.4 nc (nc-nc)             
Female 2 3.7 nc (nc-nc)   Female 5 1.4 348.4 (112.3-813.0) 
Esophagus            Pancreas     
Male 2 1.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 7 15.0 46.6 (18.7-96.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.6 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 7.2 138.1 (66.1-254.1)   Male 55 54.7 100.6 (75.7-130.9) 
Female 8 7.3 109.7 (47.2-216.1)   Female 54 52.7 102.4 (77.0-133.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Everett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 37.7 76.9 (51.5-110.5)   Male 19 25.2 75.3 (45.3-117.5) 
Female 10 13.6 73.7 (35.3-135.6)   Female 6 20.8 28.9 (10.6-62.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 8.1 nc (nc-nc)   Male 9 7.7 117.6 (53.7-223.3) 
Female 3 6.4 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 15 22.5 66.6 (37.3-109.9) 
Female 137 153.3 89.4 (75.0-105.6)   Female 18 19.3 93.3 (55.2-147.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 17.7 101.9 (60.4-161.1) 
Female 15 5.8 258.6 (144.6-426.5)   Female 9 8.0 112.0 (51.1-212.6) 
Colon / Rectum            Ovary     
Male 38 41.6 91.4 (64.6-125.4)             
Female 33 42.3 78.0 (53.7-109.6)   Female 10 13.6 73.3 (35.1-134.8) 
Esophagus            Pancreas     
Male 11 9.8 112.7 (56.2-201.6)   Male 11 13.2 83.5 (41.6-149.5) 
Female 2 2.6 nc (nc-nc)   Female 16 13.6 118.0 (67.4-191.6) 
Hodgkin Lymphoma            Prostate     
Male 1 3.7 nc (nc-nc)   Male 104 118.2 88.0 (71.9-106.6) 
Female 5 2.9 173.4 (55.9-404.6)             
Kidney & Renal Pelvis            Stomach     
Male 25 21.0 119.3 (77.2-176.1)   Male 15 8.9 168.3 (94.1-277.6) 
Female 18 12.2 147.5 (87.4-233.2)   Female 6 5.4 110.9 (40.5-241.5) 
Larynx            Testis     
Male 6 5.6 106.3 (38.8-231.3)   Male 7 7.4 95.2 (38.1-196.1) 
Female 2 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 16.1 62.3 (29.8-114.5)   Male 8 10.5 76.3 (32.9-150.3) 
Female 13 11.7 110.7 (58.9-189.3)   Female 24 32.3 74.2 (47.6-110.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 12.9 115.9 (64.8-191.1)             
Female 9 4.3 211.5 (96.5-401.5)   Female 27 33.3 81.1 (53.5-118.1) 
Lung and Bronchus            All Sites / Types     
Male 79 66.8 118.2 (93.6-147.3)   Male 454 496.0 91.5 (83.3-100.3) 
Female 98 70.6 138.8 (112.7-169.2)   Female 500 521.9 95.8 (87.6-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Fairhaven 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 20.0 144.6 (96.9-207.7)   Male 6 12.7 47.4 (17.3-103.1) 
Female 16 8.3 193.2 (110.3-313.7)   Female 11 10.6 103.9 (51.8-185.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.5 nc (nc-nc)   Male 5 4.0 123.9 (39.9-289.1) 
Female 5 3.2 155.3 (50.0-362.3)   Female 0 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 7 11.3 61.9 (24.8-127.6) 
Female 79 81.1 97.4 (77.1-121.4)   Female 15 11.0 136.5 (76.4-225.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 9.3 64.6 (23.6-140.6) 
Female 4 2.6 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 21.5 60.5 (32.2-103.4)             
Female 21 25.1 83.8 (51.9-128.1)   Female 12 7.5 160.5 (82.9-280.4) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 3 7.1 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 10 8.5 118.0 (56.5-217.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 75 70.0 107.2 (84.3-134.4) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 10.9 156.1 (90.9-249.9)   Male 6 4.7 128.1 (46.8-278.7) 
Female 10 6.6 151.0 (72.3-277.6)   Female 3 3.3 nc (nc-nc) 
Larynx            Testis     
Male 4 3.1 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.7 130.3 (62.4-239.7)   Male 5 4.7 105.6 (34.0-246.3) 
Female 9 6.5 138.8 (63.3-263.5)   Female 14 13.8 101.7 (55.6-170.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.9 nc (nc-nc)             
Female 1 2.5 nc (nc-nc)   Female 17 18.5 92.0 (53.6-147.3) 
Lung and Bronchus            All Sites / Types     
Male 50 35.8 139.5 (103.5-183.9)   Male 274 263.0 104.2 (92.2-117.3) 
Female 46 40.9 112.5 (82.4-150.1)   Female 300 286.4 104.7 (93.2-117.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
104 
Fall River 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 102 88.3 115.6 (94.2-140.3)   Male 29 57.1 50.8 (34.0-73.0) 
Female 37 38.0 97.3 (68.5-134.1)   Female 25 51.6 48.4 (31.3-71.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 18 17.5 102.9 (60.9-162.6)   Male 13 17.7 73.4 (39.1-125.6) 
Female 11 16.1 68.3 (34.1-122.2)   Female 16 16.8 95.0 (54.3-154.3) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.0 nc (nc-nc)   Male 44 51.1 86.1 (62.6-115.6) 
Female 297 390.4 76.1 (67.7-85.2)   Female 54 52.0 103.9 (78.1-135.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 39 40.6 96.0 (68.3-131.3) 
Female 17 13.3 127.8 (74.4-204.7)   Female 15 21.6 69.5 (38.9-114.6) 
Colon / Rectum            Ovary     
Male 115 95.4 120.6 (99.5-144.7)             
Female 119 114.8 103.6 (85.8-124.0)   Female 19 35.5 53.5 (32.2-83.6) 
Esophagus            Pancreas     
Male 18 23.1 77.8 (46.1-122.9)   Male 33 30.9 106.7 (73.4-149.8) 
Female 4 7.3 nc (nc-nc)   Female 39 38.5 101.2 (72.0-138.4) 
Hodgkin Lymphoma            Prostate     
Male 12 7.2 165.8 (85.5-289.6)   Male 287 292.7 98.1 (87.0-110.1) 
Female 6 6.5 92.4 (33.7-201.1)             
Kidney & Renal Pelvis            Stomach     
Male 47 48.3 97.3 (71.5-129.5)   Male 36 20.7 173.7 (121.6-240.5) 
Female 31 31.7 97.7 (66.4-138.7)   Female 29 14.9 194.5 (130.8-279.4) 
Larynx            Testis     
Male 23 13.5 170.8 (108.2-256.3)   Male 14 13.6 103.1 (56.3-173.0) 
Female 12 4.8 251.7 (129.9-439.8)             
Leukemia            Thyroid     
Male 34 36.0 94.4 (65.3-131.9)   Male 18 22.4 80.3 (47.6-126.9) 
Female 34 30.9 110.0 (76.2-153.8)   Female 77 72.3 106.5 (84.0-133.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 32 30.1 106.5 (72.8-150.3)             
Female 14 11.7 119.7 (65.4-200.9)   Female 99 87.6 113.1 (91.9-137.6) 
Lung and Bronchus            All Sites / Types     
Male 231 157.4 146.8 (128.4-167.0)   Male 1243 1157.9 107.3 (101.5-113.5) 
Female 218 195.0 111.8 (97.4-127.7)   Female 1311 1365.9 96.0 (90.9-101.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
105 
Falmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 58.7 91.9 (69.1-119.9)   Male 35 33.7 103.9 (72.3-144.4) 
Female 13 21.0 61.9 (32.9-105.8)   Female 41 24.5 167.1 (119.9-226.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 8.6 162.9 (89.0-273.4)   Male 7 11.0 63.8 (25.6-131.5) 
Female 9 7.4 121.4 (55.4-230.5)   Female 7 9.2 76.0 (30.4-156.6) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.9 nc (nc-nc)   Male 31 29.8 104.1 (70.7-147.8) 
Female 216 200.0 108.0 (94.1-123.4)   Female 24 27.2 88.1 (56.4-131.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 22.0 109.1 (69.9-162.3) 
Female 3 5.6 nc (nc-nc)   Female 7 11.3 61.9 (24.8-127.6) 
Colon / Rectum            Ovary     
Male 53 57.6 92.0 (68.9-120.4)             
Female 52 59.9 86.9 (64.9-113.9)   Female 24 18.2 132.2 (84.7-196.7) 
Esophagus            Pancreas     
Male 13 14.3 91.2 (48.5-155.9)   Male 15 19.7 76.1 (42.6-125.5) 
Female 6 4.0 149.4 (54.6-325.3)   Female 17 21.0 81.1 (47.2-129.9) 
Hodgkin Lymphoma            Prostate     
Male 4 2.7 nc (nc-nc)   Male 195 175.6 111.1 (96.0-127.8) 
Female 1 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 26.8 111.8 (75.4-159.6)   Male 10 13.0 77.1 (36.9-141.9) 
Female 16 16.8 95.4 (54.5-154.9)   Female 5 7.7 64.7 (20.8-151.0) 
Larynx            Testis     
Male 9 8.2 110.1 (50.2-209.0)   Male 4 3.6 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 20.9 86.0 (50.9-135.9)   Male 7 9.9 70.5 (28.3-145.4) 
Female 9 15.2 59.3 (27.1-112.6)   Female 14 28.8 48.6 (26.5-81.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 17.3 98.5 (57.3-157.6)             
Female 3 6.3 nc (nc-nc)   Female 39 47.2 82.6 (58.7-112.9) 
Lung and Bronchus            All Sites / Types     
Male 65 103.3 62.9 (48.6-80.2)   Male 667 694.7 96.0 (88.9-103.6) 
Female 109 110.8 98.4 (80.8-118.7)   Female 667 706.2 94.4 (87.4-101.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
106 
Fitchburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 41 39.6 103.4 (74.2-140.3)   Male 15 25.6 58.5 (32.7-96.5) 
Female 14 14.9 93.8 (51.3-157.5)   Female 13 20.7 62.7 (33.4-107.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.1 nc (nc-nc)   Male 12 8.0 150.2 (77.5-262.5) 
Female 9 6.5 138.4 (63.1-262.7)   Female 7 6.6 105.9 (42.4-218.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 16 22.9 69.7 (39.8-113.2) 
Female 133 155.9 85.3 (71.4-101.1)   Female 15 20.4 73.6 (41.1-121.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 18.0 133.6 (85.5-198.7) 
Female 9 5.3 169.5 (77.3-321.8)   Female 11 8.5 129.4 (64.5-231.5) 
Colon / Rectum            Ovary     
Male 34 42.3 80.3 (55.6-112.2)             
Female 43 44.4 96.9 (70.1-130.5)   Female 16 14.1 113.2 (64.6-183.8) 
Esophagus            Pancreas     
Male 9 10.4 86.9 (39.7-165.0)   Male 11 13.8 79.6 (39.7-142.5) 
Female 2 2.9 nc (nc-nc)   Female 7 15.0 46.8 (18.7-96.3) 
Hodgkin Lymphoma            Prostate     
Male 5 3.5 142.1 (45.8-331.6)   Male 101 129.7 77.9 (63.4-94.6) 
Female 0 2.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 21.5 88.6 (53.3-138.3)   Male 14 9.2 151.8 (82.9-254.8) 
Female 9 12.7 70.7 (32.3-134.3)   Female 5 5.7 87.0 (28.0-203.1) 
Larynx            Testis     
Male 1 6.0 nc (nc-nc)   Male 6 6.5 92.9 (33.9-202.2) 
Female 2 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 16.5 72.9 (37.6-127.3)   Male 4 10.0 nc (nc-nc) 
Female 11 12.2 90.0 (44.8-161.0)   Female 27 29.5 91.6 (60.3-133.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 13.5 96.3 (51.2-164.7)             
Female 5 4.6 108.3 (34.9-252.7)   Female 29 35.3 82.1 (55.0-118.0) 
Lung and Bronchus            All Sites / Types     
Male 95 71.2 133.4 (107.9-163.1)   Male 478 518.8 92.1 (84.1-100.8) 
Female 84 78.1 107.6 (85.8-133.2)   Female 492 542.7 90.7 (82.8-99.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
107 
Florida 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 3 3.7 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.8 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.3 nc (nc-nc)   Male 9 9.7 92.6 (42.3-175.8) 
Female 3 1.7 nc (nc-nc)   Female 11 12.1 90.9 (45.3-162.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
108 
Foxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 17.5 68.5 (35.4-119.7)   Male 22 11.4 193.6 (121.3-293.2) 
Female 4 6.2 nc (nc-nc)   Female 12 9.2 130.3 (67.2-227.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.5 144.2 (46.5-336.6)   Male 2 3.6 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 12 10.2 117.4 (60.6-205.0) 
Female 92 73.9 124.5 (100.4-152.7)   Female 7 8.9 78.2 (31.3-161.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.3 84.8 (34.0-174.8) 
Female 2 2.5 nc (nc-nc)   Female 0 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 19.3 103.6 (63.2-160.0)             
Female 20 18.4 108.6 (66.3-167.7)   Female 10 6.4 155.1 (74.2-285.2) 
Esophagus            Pancreas     
Male 5 4.6 107.5 (34.7-250.9)   Male 3 6.2 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 6 6.1 98.9 (36.1-215.3) 
Hodgkin Lymphoma            Prostate     
Male 5 1.4 365.9 (117.9-853.9)   Male 66 58.0 113.8 (88.0-144.7) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 9.7 92.5 (42.2-175.6)   Male 7 4.1 169.6 (68.0-349.5) 
Female 6 5.8 104.2 (38.1-226.9)   Female 1 2.3 nc (nc-nc) 
Larynx            Testis     
Male 0 2.7 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.1 112.5 (48.4-221.6)   Male 8 4.5 177.0 (76.2-348.7) 
Female 7 5.1 137.4 (55.1-283.2)   Female 19 13.8 137.9 (83.0-215.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.1 nc (nc-nc)             
Female 1 2.1 nc (nc-nc)   Female 21 17.1 122.6 (75.9-187.5) 
Lung and Bronchus            All Sites / Types     
Male 32 31.1 103.0 (70.4-145.4)   Male 251 230.5 108.9 (95.8-123.2) 
Female 35 34.3 102.0 (71.0-141.8)   Female 276 243.4 113.4 (100.4-127.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
109 
Framingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 66.5 84.2 (63.6-109.4)   Male 42 43.6 96.3 (69.4-130.1) 
Female 29 26.0 111.6 (74.7-160.3)   Female 29 37.5 77.4 (51.8-111.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 13.4 81.9 (40.8-146.5)   Male 17 13.5 126.3 (73.5-202.2) 
Female 5 11.7 42.6 (13.7-99.3)   Female 13 11.6 112.1 (59.6-191.6) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.3 nc (nc-nc)   Male 42 39.0 107.8 (77.7-145.7) 
Female 273 282.1 96.8 (85.6-109.0)   Female 31 36.2 85.7 (58.2-121.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 31 30.8 100.6 (68.3-142.8) 
Female 18 10.1 177.8 (105.3-281.1)   Female 7 15.1 46.3 (18.6-95.4) 
Colon / Rectum            Ovary     
Male 74 72.4 102.2 (80.3-128.4)             
Female 85 79.1 107.4 (85.8-132.8)   Female 28 25.3 110.7 (73.5-160.0) 
Esophagus            Pancreas     
Male 15 17.4 86.3 (48.3-142.4)   Male 29 23.3 124.6 (83.4-178.9) 
Female 7 5.0 140.4 (56.3-289.3)   Female 29 26.1 110.9 (74.3-159.3) 
Hodgkin Lymphoma            Prostate     
Male 4 5.6 nc (nc-nc)   Male 197 216.7 90.9 (78.7-104.5) 
Female 9 5.0 181.6 (82.9-344.8)             
Kidney & Renal Pelvis            Stomach     
Male 46 36.7 125.2 (91.6-167.0)   Male 22 15.7 140.1 (87.8-212.1) 
Female 15 22.6 66.5 (37.2-109.6)   Female 11 10.2 107.4 (53.5-192.1) 
Larynx            Testis     
Male 4 10.2 nc (nc-nc)   Male 9 11.0 81.9 (37.4-155.6) 
Female 3 3.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 29 27.4 105.9 (70.9-152.1)   Male 22 17.6 125.2 (78.5-189.6) 
Female 21 21.8 96.4 (59.6-147.3)   Female 56 55.6 100.7 (76.1-130.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 28 22.8 122.6 (81.4-177.2)             
Female 8 8.1 98.9 (42.6-194.8)   Female 56 62.7 89.3 (67.5-116.0) 
Lung and Bronchus            All Sites / Types     
Male 109 117.7 92.6 (76.0-111.7)   Male 848 873.4 97.1 (90.7-103.8) 
Female 138 133.9 103.1 (86.6-121.8)   Female 969 968.3 100.1 (93.9-106.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
110 
Franklin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 27.0 103.7 (68.9-149.9)   Male 16 18.4 86.8 (49.6-141.0) 
Female 9 9.9 91.2 (41.6-173.1)   Female 16 15.5 103.0 (58.9-167.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.1 82.1 (26.5-191.7)   Male 9 5.7 158.1 (72.1-300.1) 
Female 5 5.0 100.8 (32.5-235.2)   Female 4 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 14 16.6 84.1 (46.0-141.2) 
Female 130 121.4 107.1 (89.5-127.2)   Female 14 14.4 97.3 (53.2-163.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 13.7 123.8 (72.1-198.2) 
Female 6 4.4 136.0 (49.7-296.0)   Female 3 6.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 30.7 81.4 (52.7-120.2)             
Female 30 30.9 97.2 (65.6-138.7)   Female 10 10.6 94.7 (45.3-174.2) 
Esophagus            Pancreas     
Male 11 7.4 149.2 (74.4-267.0)   Male 13 9.7 133.7 (71.1-228.7) 
Female 3 1.9 nc (nc-nc)   Female 7 9.8 71.1 (28.5-146.6) 
Hodgkin Lymphoma            Prostate     
Male 1 2.5 nc (nc-nc)   Male 92 93.3 98.6 (79.5-120.9) 
Female 6 2.0 294.6 (107.6-641.2)             
Kidney & Renal Pelvis            Stomach     
Male 16 16.1 99.1 (56.6-161.0)   Male 7 6.5 107.1 (42.9-220.8) 
Female 14 9.3 150.7 (82.3-252.8)   Female 3 3.9 nc (nc-nc) 
Larynx            Testis     
Male 10 4.3 230.3 (110.3-423.6)   Male 8 4.6 174.8 (75.3-344.5) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 11.8 110.4 (58.7-188.8)   Male 13 7.9 164.7 (87.6-281.7) 
Female 5 8.6 58.1 (18.7-135.6)   Female 31 24.5 126.4 (85.9-179.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 9.9 101.0 (48.3-185.7)             
Female 1 3.2 nc (nc-nc)   Female 32 26.6 120.3 (82.2-169.8) 
Lung and Bronchus            All Sites / Types     
Male 43 49.0 87.7 (63.4-118.1)   Male 377 371.3 101.5 (91.5-112.3) 
Female 38 52.9 71.8 (50.8-98.6)   Female 392 397.7 98.6 (89.1-108.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
111 
Freetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.3 85.9 (37.0-169.3)   Male 4 6.3 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.6 88.6 (28.5-206.6) 
Female 41 34.5 118.8 (85.2-161.2)   Female 7 3.9 180.3 (72.2-371.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.9 101.5 (32.7-236.9) 
Female 3 1.3 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 10.4 95.8 (45.9-176.2)             
Female 6 7.9 75.8 (27.7-164.9)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.7 nc (nc-nc)   Male 0 3.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 45 35.7 126.1 (92.0-168.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.7 105.7 (38.6-230.0)   Male 3 2.3 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.6 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.9 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 6 7.0 85.4 (31.2-185.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.6 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 11 7.9 139.5 (69.5-249.6) 
Lung and Bronchus            All Sites / Types     
Male 19 17.3 110.1 (66.2-171.9)   Male 130 131.4 98.9 (82.6-117.5) 
Female 25 14.4 174.2 (112.7-257.1)   Female 137 109.5 125.1 (105.0-147.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gardner 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 22.1 90.5 (55.3-139.8)   Male 6 14.3 41.9 (15.3-91.1) 
Female 9 8.5 105.4 (48.1-200.0)   Female 7 11.3 62.0 (24.8-127.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.3 nc (nc-nc)   Male 3 4.5 nc (nc-nc) 
Female 6 3.5 171.1 (62.5-372.3)   Female 3 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 9 12.9 69.9 (31.9-132.8) 
Female 72 85.7 84.0 (65.7-105.8)   Female 13 11.5 112.9 (60.1-193.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 10.2 117.1 (60.4-204.5) 
Female 0 2.9 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 24.2 99.3 (63.6-147.8)             
Female 26 25.7 101.1 (66.0-148.2)   Female 7 7.7 90.4 (36.2-186.3) 
Esophagus            Pancreas     
Male 10 5.8 172.3 (82.5-316.9)   Male 8 7.7 103.7 (44.7-204.4) 
Female 2 1.6 nc (nc-nc)   Female 8 8.7 92.1 (39.7-181.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 67 71.4 93.8 (72.7-119.1) 
Female 2 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 12.1 140.8 (82.0-225.4)   Male 2 5.2 nc (nc-nc) 
Female 8 7.0 114.3 (49.2-225.2)   Female 5 3.4 149.1 (48.0-347.9) 
Larynx            Testis     
Male 2 3.3 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 8.9 123.2 (61.4-220.4)   Male 2 5.7 nc (nc-nc) 
Female 11 6.8 160.6 (80.1-287.5)   Female 12 15.3 78.3 (40.4-136.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 7.7 130.6 (62.5-240.2)             
Female 3 2.6 nc (nc-nc)   Female 22 19.3 114.1 (71.5-172.8) 
Lung and Bronchus            All Sites / Types     
Male 53 38.9 136.3 (102.1-178.3)   Male 285 288.2 98.9 (87.7-111.1) 
Female 49 43.0 113.8 (84.2-150.5)   Female 299 301.1 99.3 (88.4-111.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Georgetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 8.8 nc (nc-nc)   Male 8 5.8 136.8 (58.9-269.5) 
Female 1 2.8 nc (nc-nc)   Female 5 4.3 115.4 (37.2-269.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 9 5.2 172.2 (78.6-327.0) 
Female 33 35.7 92.5 (63.7-129.9)   Female 2 4.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.8 61.1 (22.3-132.9)             
Female 7 8.4 83.6 (33.5-172.3)   Female 0 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.4 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 36 32.1 112.3 (78.6-155.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.2 134.0 (53.7-276.2)   Male 2 2.1 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.6 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 5 6.7 74.7 (24.1-174.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 12 8.3 144.5 (74.6-252.5) 
Lung and Bronchus            All Sites / Types     
Male 7 16.3 43.1 (17.3-88.7)   Male 101 120.6 83.7 (68.2-101.8) 
Female 20 15.6 127.8 (78.0-197.4)   Female 114 114.1 99.9 (82.4-120.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.8 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 8 7.3 109.9 (47.3-216.6)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.1 nc (nc-nc)             
Female 3 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 9 7.6 117.8 (53.8-223.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 3.4 205.3 (82.2-423.0)   Male 26 26.3 98.8 (64.5-144.8) 
Female 6 3.2 189.6 (69.2-412.6)   Female 28 23.4 119.7 (79.5-173.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
115 
Gloucester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 39.0 107.8 (77.7-145.7)   Male 29 24.4 118.7 (79.5-170.5) 
Female 23 14.7 156.8 (99.3-235.3)   Female 23 19.4 118.8 (75.3-178.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 6.9 nc (nc-nc)   Male 9 7.8 114.9 (52.4-218.1) 
Female 5 5.9 84.2 (27.1-196.4)   Female 2 6.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.4 nc (nc-nc)   Male 24 21.7 110.4 (70.7-164.3) 
Female 168 157.5 106.6 (91.1-124.0)   Female 21 20.1 104.7 (64.8-160.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 18.0 116.8 (72.3-178.6) 
Female 3 4.9 nc (nc-nc)   Female 11 8.5 129.9 (64.7-232.4) 
Colon / Rectum            Ovary     
Male 43 40.7 105.7 (76.5-142.3)             
Female 35 43.1 81.3 (56.6-113.0)   Female 18 14.0 128.9 (76.3-203.7) 
Esophagus            Pancreas     
Male 15 10.6 141.4 (79.1-233.2)   Male 22 13.8 159.1 (99.7-241.0) 
Female 2 2.8 nc (nc-nc)   Female 12 14.6 82.2 (42.4-143.6) 
Hodgkin Lymphoma            Prostate     
Male 4 2.4 nc (nc-nc)   Male 141 140.9 100.1 (84.2-118.0) 
Female 4 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 21.3 75.3 (43.0-122.2)   Male 10 9.1 110.1 (52.7-202.5) 
Female 17 12.6 134.5 (78.3-215.3)   Female 2 5.5 nc (nc-nc) 
Larynx            Testis     
Male 8 6.3 127.7 (55.0-251.7)   Male 4 3.8 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 21 14.9 141.3 (87.4-216.0)   Male 10 8.9 112.7 (53.9-207.2) 
Female 9 11.3 79.8 (36.4-151.5)   Female 33 25.9 127.6 (87.8-179.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 13.4 74.4 (35.6-136.8)             
Female 6 4.7 128.7 (47.0-280.0)   Female 28 36.9 75.8 (50.4-109.6) 
Lung and Bronchus            All Sites / Types     
Male 87 71.1 122.4 (98.0-151.0)   Male 565 514.6 109.8 (100.9-119.2) 
Female 100 78.3 127.6 (103.8-155.2)   Female 562 533.9 105.3 (96.7-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Goshen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.2 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 3 5.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.3 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.4 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 2.2 nc (nc-nc)   Male 12 16.1 74.5 (38.5-130.2) 
Female 0 2.4 nc (nc-nc)   Female 8 18.3 43.8 (18.8-86.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gosnold 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.2 nc (nc-nc)             
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 4.6 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Grafton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 15.3 117.8 (69.8-186.2)   Male 9 10.6 85.2 (38.9-161.7) 
Female 4 5.2 nc (nc-nc)   Female 10 8.6 116.7 (55.9-214.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 3.5 315.5 (157.3-564.6)   Male 4 3.2 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 4 9.5 nc (nc-nc) 
Female 80 65.9 121.3 (96.2-151.0)   Female 11 7.7 142.2 (70.9-254.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 7.9 214.6 (124.9-343.6) 
Female 2 2.5 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 17.6 79.4 (43.3-133.1)             
Female 22 16.2 136.0 (85.2-205.9)   Female 6 5.7 104.4 (38.1-227.2) 
Esophagus            Pancreas     
Male 5 4.2 119.6 (38.6-279.2)   Male 4 5.5 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.4 nc (nc-nc)   Male 59 52.4 112.6 (85.7-145.3) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 9.2 119.9 (59.8-214.5)   Male 1 3.7 nc (nc-nc) 
Female 5 5.1 98.9 (31.9-230.9)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 6 2.5 243.6 (89.0-530.3)   Male 4 2.8 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 6.7 179.0 (92.4-312.7)   Male 7 4.6 152.6 (61.2-314.5) 
Female 10 4.6 216.4 (103.6-397.9)   Female 13 13.9 93.4 (49.7-159.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.8 103.5 (37.8-225.3)             
Female 0 1.7 nc (nc-nc)   Female 13 14.7 88.7 (47.2-151.7) 
Lung and Bronchus            All Sites / Types     
Male 34 27.4 123.9 (85.8-173.1)   Male 235 211.0 111.4 (97.6-126.6) 
Female 35 28.5 122.7 (85.5-170.7)   Female 248 215.2 115.2 (101.3-130.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.7 74.6 (24.0-174.0)   Male 1 4.4 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.3 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 6 3.9 154.7 (56.5-336.7) 
Female 18 32.6 55.3 (32.8-87.4)   Female 3 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.2 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.2 124.4 (56.8-236.1)             
Female 6 8.7 69.2 (25.3-150.7)   Female 5 2.9 174.8 (56.3-407.9) 
Esophagus            Pancreas     
Male 4 1.8 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 18 23.0 78.2 (46.3-123.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 4 2.5 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.7 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.5 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 11 7.4 149.2 (74.4-267.0) 
Lung and Bronchus            All Sites / Types     
Male 13 11.9 109.2 (58.1-186.8)   Male 79 89.0 88.7 (70.2-110.6) 
Female 13 14.7 88.5 (47.1-151.3)   Female 82 107.5 76.3 (60.7-94.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 7 7.7 91.2 (36.5-188.0)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.4 nc (nc-nc)             
Female 2 1.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 8.4 118.9 (56.9-218.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 4.1 nc (nc-nc)   Male 32 30.1 106.1 (72.6-149.9) 
Female 5 3.5 141.4 (45.6-330.0)   Female 26 24.7 105.1 (68.6-154.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Great Barrington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 8.4 142.7 (73.6-249.2)   Male 9 5.2 172.4 (78.7-327.3) 
Female 9 3.9 230.8 (105.3-438.1)   Female 3 4.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 2 4.7 nc (nc-nc) 
Female 39 36.8 106.1 (75.5-145.1)   Female 5 5.1 98.4 (31.7-229.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.6 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 8.9 90.2 (38.8-177.8)             
Female 10 11.5 87.2 (41.7-160.4)   Female 3 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 0 2.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 4.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 32 25.3 126.7 (86.6-178.9) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.3 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 3 1.2 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.3 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 9 5.7 158.4 (72.3-300.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 2.7 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 7 8.4 83.1 (33.3-171.2) 
Lung and Bronchus            All Sites / Types     
Male 14 14.3 97.9 (53.5-164.2)   Male 115 104.7 109.9 (90.7-131.9) 
Female 21 19.7 106.5 (65.9-162.9)   Female 131 131.0 100.0 (83.6-118.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Greenfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 20.2 94.0 (56.6-146.8)   Male 13 13.0 100.1 (53.2-171.1) 
Female 5 8.0 62.5 (20.1-145.9)   Female 5 10.7 46.6 (15.0-108.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.8 130.4 (42.0-304.4)   Male 4 4.1 nc (nc-nc) 
Female 7 3.3 214.9 (86.1-442.9)   Female 3 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 5 11.5 43.4 (14.0-101.3) 
Female 74 82.8 89.4 (70.2-112.2)   Female 13 10.8 119.9 (63.8-205.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 9.4 95.5 (43.6-181.3) 
Female 3 2.7 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 28 21.7 129.2 (85.8-186.7)             
Female 26 24.3 107.0 (69.9-156.7)   Female 9 7.4 120.9 (55.2-229.5) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 7 7.1 97.9 (39.2-201.8) 
Female 1 1.5 nc (nc-nc)   Female 5 8.1 61.5 (19.8-143.6) 
Hodgkin Lymphoma            Prostate     
Male 6 1.5 412.8 (150.8-898.6)   Male 46 69.1 66.6 (48.7-88.8) 
Female 3 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 11.0 54.6 (20.0-118.9)   Male 3 4.8 nc (nc-nc) 
Female 6 6.7 90.2 (32.9-196.3)   Female 3 3.2 nc (nc-nc) 
Larynx            Testis     
Male 2 3.2 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 8.0 nc (nc-nc)   Male 1 5.0 nc (nc-nc) 
Female 6 6.4 94.4 (34.5-205.5)   Female 3 14.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.2 69.1 (22.3-161.2)             
Female 5 2.5 203.8 (65.7-475.5)   Female 21 18.7 112.6 (69.6-172.1) 
Lung and Bronchus            All Sites / Types     
Male 33 36.2 91.1 (62.7-127.9)   Male 222 266.3 83.4 (72.7-95.1) 
Female 44 40.4 109.0 (79.2-146.3)   Female 273 286.4 95.3 (84.4-107.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 9.5 125.8 (64.9-219.8)   Male 3 6.9 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 2 5.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.2 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 6.2 nc (nc-nc) 
Female 38 45.1 84.3 (59.6-115.6)   Female 4 4.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.6 89.1 (28.7-208.0) 
Female 1 1.6 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 11.4 140.8 (80.4-228.7)             
Female 9 9.8 91.5 (41.7-173.6)   Female 2 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.9 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 31 38.4 80.6 (54.8-114.5) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.3 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 1 3.3 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 7 1.4 486.1 (194.7-1001.6) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.2 120.0 (38.7-280.1)   Male 4 3.1 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 7 8.8 79.4 (31.8-163.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.1 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 10 10.3 97.1 (46.5-178.7) 
Lung and Bronchus            All Sites / Types     
Male 11 18.1 60.8 (30.3-108.7)   Male 128 141.8 90.3 (75.3-107.4) 
Female 10 17.9 56.0 (26.8-103.0)   Female 104 138.7 75.0 (61.3-90.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groveland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 8.0 99.9 (43.0-196.9)   Male 6 5.1 117.1 (42.8-254.9) 
Female 2 2.7 nc (nc-nc)   Female 11 3.9 281.5 (140.3-503.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.6 174.3 (75.1-343.5) 
Female 39 32.6 119.5 (85.0-163.4)   Female 6 3.9 155.2 (56.7-337.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.7 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 8.8 nc (nc-nc)             
Female 9 8.0 112.6 (51.4-213.8)   Female 3 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.1 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 24 26.9 89.3 (57.2-132.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 4 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 10 5.6 179.8 (86.1-330.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.8 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 4 7.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 14.5 76.1 (37.9-136.1)   Male 90 104.9 85.8 (69.0-105.4) 
Female 17 15.1 112.8 (65.7-180.6)   Female 125 106.1 117.8 (98.1-140.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 6.8 nc (nc-nc)   Male 1 4.2 nc (nc-nc) 
Female 6 3.2 187.4 (68.4-408.0)   Female 3 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 7 3.7 188.3 (75.4-388.0) 
Female 28 29.4 95.2 (63.3-137.6)   Female 7 4.1 170.1 (68.1-350.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 2.9 240.6 (96.4-495.7) 
Female 1 0.9 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 7.0 70.9 (22.9-165.6)             
Female 10 9.2 108.9 (52.1-200.3)   Female 2 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.7 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 19 22.1 86.1 (51.8-134.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.5 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.6 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 2 4.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 9 6.9 131.3 (59.9-249.2) 
Lung and Bronchus            All Sites / Types     
Male 6 12.1 49.7 (18.1-108.1)   Male 71 85.9 82.6 (64.5-104.2) 
Female 9 16.2 55.7 (25.4-105.8)   Female 92 105.6 87.1 (70.2-106.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Halifax 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.1 98.9 (39.6-203.7)   Male 5 5.0 100.8 (32.5-235.2) 
Female 2 3.2 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.5 112.3 (36.2-262.0) 
Female 38 35.6 106.6 (75.5-146.4)   Female 7 4.4 158.5 (63.5-326.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.9 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 8.3 156.0 (83.0-266.8)             
Female 12 9.6 124.5 (64.2-217.4)   Female 4 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.0 nc (nc-nc)   Male 8 2.6 308.4 (132.8-607.7) 
Female 0 0.6 nc (nc-nc)   Female 3 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 36 26.7 134.9 (94.5-186.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 4.5 178.4 (76.8-351.5)   Male 1 1.8 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 2 1.2 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.0 nc (nc-nc)   Male 6 2.2 277.3 (101.3-603.6) 
Female 1 2.5 nc (nc-nc)   Female 11 6.2 177.0 (88.2-316.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 2.8 180.6 (58.2-421.5)             
Female 1 1.0 nc (nc-nc)   Female 12 7.9 152.6 (78.8-266.6) 
Lung and Bronchus            All Sites / Types     
Male 22 13.3 165.6 (103.8-250.8)   Male 143 101.2 141.3 (119.1-166.5) 
Female 20 17.1 116.7 (71.3-180.3)   Female 135 119.0 113.5 (95.2-134.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hamilton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.7 77.8 (28.4-169.3)   Male 3 5.1 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 5 4.3 117.0 (37.7-273.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.6 nc (nc-nc)   Male 5 1.6 312.8 (100.8-729.9) 
Female 3 1.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.6 131.1 (47.9-285.4) 
Female 32 33.9 94.4 (64.5-133.2)   Female 8 4.2 191.2 (82.3-376.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.7 134.8 (43.4-314.5) 
Female 1 1.1 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 8.5 70.6 (25.8-153.8)             
Female 10 8.9 111.8 (53.5-205.6)   Female 2 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.1 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 24 26.3 91.3 (58.5-135.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.4 158.5 (63.5-326.7)   Male 1 1.8 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.3 184.3 (67.3-401.1)   Male 5 2.1 241.5 (77.8-563.5) 
Female 3 2.4 nc (nc-nc)   Female 8 6.2 129.7 (55.8-255.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 7 7.7 90.8 (36.4-187.2) 
Lung and Bronchus            All Sites / Types     
Male 13 14.0 93.0 (49.5-159.0)   Male 107 103.6 103.3 (84.7-124.8) 
Female 11 16.1 68.5 (34.1-122.5)   Female 114 113.3 100.6 (83.0-120.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hampden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.6 70.0 (25.6-152.3)   Male 2 5.2 nc (nc-nc) 
Female 0 2.4 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.6 130.5 (47.7-284.1) 
Female 23 26.6 86.4 (54.7-129.6)   Female 1 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.6 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 8.7 nc (nc-nc)             
Female 5 7.1 70.1 (22.6-163.6)   Female 1 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.2 nc (nc-nc)   Male 5 2.9 170.9 (55.1-398.7) 
Female 0 0.5 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 21 28.2 74.4 (46.1-113.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.4 114.3 (36.8-266.8)   Male 3 1.9 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 5 4.4 113.9 (36.7-265.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.8 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 15 15.5 96.5 (54.0-159.2)   Male 87 107.5 80.9 (64.8-99.8) 
Female 8 12.9 61.9 (26.6-122.0)   Female 67 89.1 75.2 (58.3-95.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hancock 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.7 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.2 nc (nc-nc)   Male 8 9.2 87.2 (37.5-171.8) 
Female 2 1.4 nc (nc-nc)   Female 8 10.2 78.8 (33.9-155.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 13.6 88.0 (45.4-153.8)   Male 15 9.1 165.0 (92.3-272.1) 
Female 4 4.9 nc (nc-nc)   Female 5 7.3 68.8 (22.2-160.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.9 173.1 (55.8-404.0)   Male 2 2.9 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 5 2.2 224.2 (72.3-523.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 8 8.2 98.0 (42.2-193.0) 
Female 78 58.2 134.0 (105.9-167.2)   Female 10 7.0 143.3 (68.6-263.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.8 88.1 (32.2-191.7) 
Female 1 2.0 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 15.1 99.1 (55.4-163.4)             
Female 17 14.6 116.2 (67.7-186.1)   Female 4 5.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.8 nc (nc-nc)   Male 1 4.9 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 69 47.8 144.4 (112.3-182.8) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 8.0 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 5 4.5 111.0 (35.8-259.1)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 5 2.2 228.8 (73.7-533.8)   Male 2 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.7 104.4 (38.1-227.3)   Male 8 3.7 213.6 (92.0-420.8) 
Female 1 4.1 nc (nc-nc)   Female 10 11.0 90.9 (43.5-167.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.0 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 19 13.3 142.7 (85.8-222.8) 
Lung and Bronchus            All Sites / Types     
Male 21 24.7 85.0 (52.6-130.0)   Male 198 185.5 106.7 (92.4-122.7) 
Female 27 26.2 102.9 (67.8-149.8)   Female 207 191.2 108.3 (94.0-124.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.2 119.5 (59.6-213.8)   Male 4 6.5 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 5 4.9 102.2 (32.9-238.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.1 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.8 nc (nc-nc) 
Female 31 40.8 75.9 (51.6-107.8)   Female 5 4.4 114.4 (36.9-267.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 5.2 173.7 (79.3-329.7) 
Female 2 1.5 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 10.7 121.9 (64.8-208.4)             
Female 12 8.5 140.7 (72.6-245.9)   Female 4 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.8 nc (nc-nc)   Male 5 3.4 145.3 (46.8-339.1) 
Female 1 0.6 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 39 37.7 103.6 (73.6-141.6) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.0 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 5 3.0 167.0 (53.8-389.8)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.0 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 10 8.2 121.2 (58.0-223.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.7 135.6 (43.7-316.4)             
Female 3 1.0 nc (nc-nc)   Female 15 9.3 161.3 (90.2-266.1) 
Lung and Bronchus            All Sites / Types     
Male 26 17.3 150.0 (98.0-219.8)   Male 143 135.5 105.5 (88.9-124.3) 
Female 17 16.5 102.8 (59.8-164.6)   Female 127 125.8 100.9 (84.1-120.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hardwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.8 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 12 14.3 83.7 (43.2-146.2)   Female 2 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.9 nc (nc-nc)             
Female 4 3.7 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.2 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 7 15.3 45.8 (18.3-94.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 8.6 70.0 (25.6-152.5)   Male 37 59.6 62.0 (43.7-85.5) 
Female 6 6.6 90.3 (33.0-196.6)   Female 34 47.4 71.7 (49.6-100.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harvard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.4 nc (nc-nc)   Male 2 5.9 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.2 153.6 (66.1-302.7) 
Female 20 24.1 83.0 (50.7-128.2)   Female 2 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 9.8 nc (nc-nc)             
Female 9 5.6 160.3 (73.1-304.3)   Female 2 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.5 nc (nc-nc)   Male 0 3.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 22 33.3 66.1 (41.4-100.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.3 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.4 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 5 4.3 115.8 (37.3-270.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.4 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 6 5.5 108.9 (39.8-237.1) 
Lung and Bronchus            All Sites / Types     
Male 5 15.9 31.5 (10.2-73.6)   Male 74 121.3 61.0 (47.9-76.6) 
Female 5 10.8 46.3 (14.9-108.1)   Female 57 76.4 74.6 (56.5-96.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 21.3 121.8 (79.6-178.5)   Male 18 12.4 145.5 (86.2-230.0) 
Female 10 8.3 121.0 (57.9-222.6)   Female 19 9.7 196.5 (118.3-306.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.2 nc (nc-nc)   Male 6 4.0 149.7 (54.7-325.8) 
Female 2 3.0 nc (nc-nc)   Female 6 3.6 165.6 (60.5-360.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 15 10.8 138.5 (77.5-228.5) 
Female 102 79.1 128.9 (105.1-156.5)   Female 10 10.8 92.9 (44.5-170.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 8.0 125.4 (60.0-230.6) 
Female 1 2.2 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 20.8 101.1 (62.6-154.6)             
Female 32 23.4 136.5 (93.3-192.7)   Female 7 7.1 98.6 (39.5-203.1) 
Esophagus            Pancreas     
Male 6 5.2 115.2 (42.1-250.7)   Male 9 7.2 125.8 (57.4-238.9) 
Female 2 1.6 nc (nc-nc)   Female 10 8.3 120.8 (57.8-222.2) 
Hodgkin Lymphoma            Prostate     
Male 5 1.0 496.7 (160.1-1159.2)   Male 100 64.7 154.5 (125.7-187.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 9.9 90.9 (41.5-172.5)   Male 8 4.7 170.3 (73.3-335.6) 
Female 8 6.6 121.1 (52.1-238.6)   Female 2 3.0 nc (nc-nc) 
Larynx            Testis     
Male 2 3.0 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.6 117.7 (53.7-223.4)   Male 5 3.7 135.3 (43.6-315.8) 
Female 4 6.0 nc (nc-nc)   Female 2 11.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.2 nc (nc-nc)             
Female 2 2.5 nc (nc-nc)   Female 18 18.8 95.8 (56.8-151.5) 
Lung and Bronchus            All Sites / Types     
Male 47 38.2 123.2 (90.5-163.8)   Male 326 254.2 128.2 (114.7-142.9) 
Female 39 43.5 89.7 (63.8-122.6)   Female 311 278.6 111.6 (99.6-124.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hatfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.5 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 15 18.9 79.2 (44.3-130.6)   Female 1 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.0 100.8 (32.5-235.1)             
Female 9 4.9 182.2 (83.2-346.0)   Female 4 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.2 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 16.4 121.7 (74.3-187.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.5 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 5 1.5 338.6 (109.1-790.1)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.7 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.4 114.9 (37.0-268.2) 
Lung and Bronchus            All Sites / Types     
Male 7 8.4 83.2 (33.3-171.4)   Male 60 60.5 99.1 (75.7-127.6) 
Female 4 9.2 nc (nc-nc)   Female 57 62.7 91.0 (68.9-117.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Haverhill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 57 59.1 96.4 (73.0-124.9)   Male 24 38.7 62.0 (39.7-92.3) 
Female 27 21.7 124.5 (82.0-181.1)   Female 20 32.3 61.9 (37.8-95.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 12.1 115.8 (63.3-194.4)   Male 10 11.9 84.0 (40.2-154.6) 
Female 11 10.1 109.0 (54.3-195.0)   Female 8 9.8 81.4 (35.1-160.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.0 nc (nc-nc)   Male 40 34.9 114.8 (82.0-156.3) 
Female 255 244.4 104.3 (91.9-117.9)   Female 41 30.7 133.5 (95.8-181.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 39 28.0 139.0 (98.9-190.1) 
Female 4 8.8 nc (nc-nc)   Female 16 12.9 123.7 (70.6-200.8) 
Colon / Rectum            Ovary     
Male 77 65.7 117.3 (92.5-146.6)             
Female 67 67.7 99.0 (76.7-125.8)   Female 20 21.9 91.3 (55.8-141.1) 
Esophagus            Pancreas     
Male 12 15.5 77.2 (39.9-134.9)   Male 25 20.9 119.7 (77.5-176.8) 
Female 4 4.2 nc (nc-nc)   Female 28 22.0 127.0 (84.4-183.6) 
Hodgkin Lymphoma            Prostate     
Male 6 5.0 119.5 (43.6-260.0)   Male 165 194.1 85.0 (72.5-99.0) 
Female 3 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 32 32.8 97.6 (66.8-137.8)   Male 20 14.0 142.6 (87.1-220.2) 
Female 24 19.2 124.8 (79.9-185.7)   Female 6 8.7 68.8 (25.1-149.7) 
Larynx            Testis     
Male 9 9.0 100.4 (45.8-190.6)   Male 7 9.7 72.5 (29.1-149.4) 
Female 4 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 24.6 89.5 (56.1-135.5)   Male 16 15.7 101.8 (58.2-165.4) 
Female 19 18.6 102.0 (61.4-159.4)   Female 56 48.3 115.9 (87.6-150.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 20.6 87.2 (51.7-137.9)             
Female 4 6.9 nc (nc-nc)   Female 58 54.8 105.8 (80.3-136.8) 
Lung and Bronchus            All Sites / Types     
Male 105 103.3 101.7 (83.1-123.1)   Male 749 780.4 96.0 (89.2-103.1) 
Female 152 110.2 138.0 (116.9-161.8)   Female 896 827.6 108.3 (101.3-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hawley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.7 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.2 nc (nc-nc)   Male 4 8.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Heath 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 3.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.9 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 3.8 159.2 (58.1-346.6) 
Female 1 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 1.6 nc (nc-nc)   Male 14 12.5 112.4 (61.4-188.5) 
Female 1 1.6 nc (nc-nc)   Female 6 10.8 55.5 (20.3-120.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 30.1 96.3 (64.5-138.3)   Male 37 18.2 203.0 (142.9-279.8) 
Female 9 11.5 78.2 (35.7-148.5)   Female 25 14.2 176.6 (114.3-260.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.1 97.2 (31.3-226.9)   Male 6 5.8 103.6 (37.8-225.6) 
Female 6 4.5 134.7 (49.2-293.1)   Female 5 5.0 99.5 (32.0-232.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 18 16.2 111.2 (65.9-175.8) 
Female 116 111.4 104.2 (86.1-124.9)   Female 30 15.1 198.0 (133.6-282.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 12.4 129.4 (73.9-210.1) 
Female 3 3.4 nc (nc-nc)   Female 6 6.3 95.6 (34.9-208.1) 
Colon / Rectum            Ovary     
Male 28 31.1 90.0 (59.8-130.2)             
Female 40 34.3 116.5 (83.2-158.6)   Female 11 10.1 108.6 (54.1-194.3) 
Esophagus            Pancreas     
Male 4 7.5 nc (nc-nc)   Male 5 10.3 48.4 (15.6-113.0) 
Female 5 2.2 228.9 (73.8-534.2)   Female 10 11.7 85.7 (41.0-157.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.7 nc (nc-nc)   Male 111 90.6 122.5 (100.7-147.5) 
Female 1 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 14.8 88.0 (46.8-150.5)   Male 9 6.8 131.7 (60.1-250.1) 
Female 11 9.2 119.8 (59.7-214.3)   Female 1 4.5 nc (nc-nc) 
Larynx            Testis     
Male 2 4.3 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 11.5 129.9 (72.6-214.2)   Male 5 6.2 81.2 (26.2-189.5) 
Female 12 8.9 134.6 (69.5-235.1)   Female 29 17.9 162.2 (108.6-232.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.5 nc (nc-nc)             
Female 0 3.4 nc (nc-nc)   Female 21 25.2 83.2 (51.5-127.2) 
Lung and Bronchus            All Sites / Types     
Male 27 52.6 51.3 (33.8-74.7)   Male 367 368.7 99.5 (89.6-110.3) 
Female 41 57.9 70.8 (50.8-96.1)   Female 417 393.5 106.0 (96.0-116.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hinsdale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.5 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 16 9.5 169.1 (96.6-274.6)   Female 2 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.8 nc (nc-nc)             
Female 2 2.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.9 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 9 10.8 83.7 (38.2-158.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.4 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.2 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 5.9 168.1 (80.5-309.2)   Male 43 43.8 98.1 (71.0-132.1) 
Female 5 4.2 118.3 (38.1-276.1)   Female 40 31.0 128.9 (92.1-175.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holbrook 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 13.2 166.5 (104.3-252.1)   Male 3 8.5 nc (nc-nc) 
Female 8 4.1 193.2 (83.2-380.7)   Female 9 6.1 146.6 (66.9-278.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.5 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)   Female 7 1.9 372.4 (149.2-767.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 7.6 131.4 (62.9-241.7) 
Female 49 49.1 99.9 (73.9-132.1)   Female 8 5.8 136.8 (58.9-269.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.1 82.3 (26.5-192.0) 
Female 3 1.7 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 14.2 98.3 (53.7-164.9)             
Female 14 12.5 112.2 (61.3-188.3)   Female 9 4.3 210.4 (96.0-399.4) 
Esophagus            Pancreas     
Male 7 3.5 201.1 (80.6-414.3)   Male 5 4.6 108.9 (35.1-254.1) 
Female 1 0.8 nc (nc-nc)   Female 5 4.1 123.3 (39.7-287.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 51 42.7 119.5 (89.0-157.2) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 7.2 167.0 (86.2-291.8)   Male 2 3.1 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.2 115.7 (42.3-251.9)   Male 1 3.3 nc (nc-nc) 
Female 7 3.3 210.3 (84.3-433.4)   Female 7 9.2 75.7 (30.3-156.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.6 152.5 (61.1-314.2)             
Female 1 1.3 nc (nc-nc)   Female 11 10.9 100.6 (50.2-180.1) 
Lung and Bronchus            All Sites / Types     
Male 23 23.5 97.7 (61.9-146.7)   Male 192 171.5 112.0 (96.7-129.0) 
Female 42 22.8 184.0 (132.6-248.7)   Female 202 161.4 125.2 (108.5-143.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 19.1 89.2 (51.9-142.9)   Male 23 12.4 185.6 (117.6-278.4) 
Female 10 6.9 145.5 (69.7-267.6)   Female 8 9.7 82.3 (35.4-162.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.7 nc (nc-nc)   Male 5 3.9 127.4 (41.1-297.3) 
Female 4 3.0 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 11 11.1 98.9 (49.3-176.9) 
Female 86 76.9 111.8 (89.4-138.1)   Female 9 9.6 93.6 (42.7-177.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 9.1 132.2 (68.2-230.9) 
Female 0 2.6 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 21.0 66.8 (36.5-112.1)             
Female 25 20.9 119.5 (77.3-176.4)   Female 7 6.8 103.0 (41.3-212.3) 
Esophagus            Pancreas     
Male 8 5.1 157.5 (67.8-310.3)   Male 10 6.7 148.5 (71.1-273.2) 
Female 1 1.3 nc (nc-nc)   Female 4 6.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 63 63.8 98.7 (75.8-126.3) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.6 65.8 (26.3-135.5)   Male 2 4.5 nc (nc-nc) 
Female 6 6.1 99.0 (36.2-215.5)   Female 3 2.7 nc (nc-nc) 
Larynx            Testis     
Male 1 3.0 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.7 130.1 (62.3-239.3)   Male 2 4.9 nc (nc-nc) 
Female 4 5.6 nc (nc-nc)   Female 7 14.1 49.5 (19.8-102.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.8 73.9 (23.8-172.4)             
Female 3 2.2 nc (nc-nc)   Female 30 17.2 174.5 (117.7-249.1) 
Lung and Bronchus            All Sites / Types     
Male 33 34.1 96.7 (66.5-135.8)   Male 252 251.8 100.1 (88.1-113.2) 
Female 29 36.3 80.0 (53.6-114.9)   Female 273 258.7 105.5 (93.4-118.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.9 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 8 10.0 80.2 (34.5-158.0)   Female 2 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.2 nc (nc-nc)             
Female 1 2.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 7 10.4 67.0 (26.8-138.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 5.5 nc (nc-nc)   Male 28 40.1 69.8 (46.4-100.9) 
Female 5 3.9 127.6 (41.1-297.8)   Female 33 30.8 107.1 (73.7-150.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holliston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 13.8 123.5 (71.9-197.7)   Male 10 9.2 109.0 (52.2-200.4) 
Female 2 4.9 nc (nc-nc)   Female 6 7.4 81.0 (29.6-176.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 2.9 312.7 (142.7-593.6)   Male 4 2.9 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 11 8.3 133.3 (66.5-238.5) 
Female 71 60.2 117.9 (92.1-148.7)   Female 4 7.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.0 113.9 (49.1-224.5) 
Female 3 2.0 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 15.6 102.3 (58.4-166.2)             
Female 14 15.0 93.0 (50.8-156.1)   Female 3 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 3.8 182.9 (73.3-376.8)   Male 4 5.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 68 49.9 136.3 (105.8-172.8) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 8.1 135.4 (67.5-242.2)   Male 2 3.3 nc (nc-nc) 
Female 4 4.6 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 5 1.8 271.4 (87.5-633.4) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.7 87.8 (28.3-204.9)   Male 3 3.8 nc (nc-nc) 
Female 4 4.1 nc (nc-nc)   Female 15 11.1 135.3 (75.7-223.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.2 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 21 13.8 152.3 (94.3-232.9) 
Lung and Bronchus            All Sites / Types     
Male 15 24.9 60.2 (33.7-99.4)   Male 223 189.4 117.7 (102.8-134.2) 
Female 24 26.6 90.2 (57.8-134.2)   Female 196 195.7 100.1 (86.6-115.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holyoke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 39.9 75.2 (50.8-107.4)   Male 20 24.8 80.8 (49.3-124.8) 
Female 13 16.2 80.1 (42.6-136.9)   Female 10 22.1 45.2 (21.6-83.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 7.6 118.9 (54.3-225.8)   Male 4 7.7 nc (nc-nc) 
Female 4 7.0 nc (nc-nc)   Female 1 7.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 19 22.3 85.0 (51.2-132.8) 
Female 126 166.3 75.7 (63.1-90.2)   Female 17 22.0 77.4 (45.1-124.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 26 16.9 153.7 (100.3-225.2) 
Female 9 5.7 158.3 (72.2-300.4)   Female 4 9.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 40 42.2 94.7 (67.6-128.9)             
Female 49 48.9 100.2 (74.1-132.4)   Female 13 15.0 86.5 (46.0-147.9) 
Esophagus            Pancreas     
Male 8 9.9 80.9 (34.8-159.3)   Male 15 13.7 109.7 (61.4-181.0) 
Female 2 3.1 nc (nc-nc)   Female 23 16.4 139.9 (88.7-210.0) 
Hodgkin Lymphoma            Prostate     
Male 4 3.1 nc (nc-nc)   Male 113 120.9 93.4 (77.0-112.3) 
Female 5 2.8 178.1 (57.4-415.6)             
Kidney & Renal Pelvis            Stomach     
Male 19 20.2 93.9 (56.5-146.6)   Male 5 9.2 54.4 (17.5-127.0) 
Female 6 13.6 44.1 (16.1-96.0)   Female 10 6.4 156.6 (75.0-288.1) 
Larynx            Testis     
Male 8 5.7 140.3 (60.4-276.6)   Male 2 5.7 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 16.1 62.2 (29.8-114.3)   Male 1 9.2 nc (nc-nc) 
Female 9 13.5 66.8 (30.5-126.8)   Female 22 31.1 70.7 (44.3-107.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 25 12.7 196.6 (127.2-290.3)             
Female 7 4.9 142.4 (57.0-293.4)   Female 45 36.8 122.2 (89.1-163.5) 
Lung and Bronchus            All Sites / Types     
Male 78 68.8 113.4 (89.6-141.5)   Male 486 499.5 97.3 (88.8-106.3) 
Female 65 82.5 78.8 (60.8-100.4)   Female 493 581.7 84.7 (77.4-92.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopedale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.5 76.7 (24.7-179.0)   Male 6 4.1 146.0 (53.3-317.8) 
Female 2 2.2 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 26 24.5 106.3 (69.4-155.7)   Female 0 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 7.4 nc (nc-nc)             
Female 9 7.0 128.1 (58.5-243.2)   Female 1 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.6 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 26 19.4 134.0 (87.5-196.3) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.4 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 0.9 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.7 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 6 4.5 133.6 (48.8-290.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.2 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 8 5.4 149.3 (64.3-294.3) 
Lung and Bronchus            All Sites / Types     
Male 15 10.7 140.3 (78.5-231.4)   Male 92 82.5 111.5 (89.9-136.7) 
Female 12 11.3 106.0 (54.7-185.1)   Female 80 82.9 96.4 (76.5-120.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopkinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 11.7 102.9 (53.1-179.8)   Male 13 8.3 156.4 (83.2-267.4) 
Female 5 4.1 120.9 (38.9-282.1)   Female 11 7.0 156.6 (78.1-280.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 2.9 347.9 (166.5-639.8)   Male 2 2.6 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 7.6 79.4 (29.0-172.9) 
Female 54 57.6 93.8 (70.5-122.4)   Female 7 6.3 111.0 (44.5-228.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.7 105.1 (42.1-216.5) 
Female 3 2.1 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 14.0 35.8 (11.5-83.4)             
Female 10 13.2 75.9 (36.3-139.6)   Female 2 4.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 6 4.1 147.5 (53.8-321.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 54 45.1 119.8 (90.0-156.4) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.7 65.3 (21.0-152.3)   Male 5 2.9 171.3 (55.2-399.9) 
Female 1 4.3 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 3 2.0 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.3 nc (nc-nc)   Male 5 3.8 130.6 (42.1-304.7) 
Female 0 3.8 nc (nc-nc)   Female 16 11.7 137.3 (78.4-223.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.8 nc (nc-nc)             
Female 2 1.4 nc (nc-nc)   Female 11 12.6 87.4 (43.6-156.4) 
Lung and Bronchus            All Sites / Types     
Male 13 21.4 60.8 (32.3-103.9)   Male 167 170.7 97.8 (83.5-113.8) 
Female 18 23.2 77.7 (46.0-122.8)   Female 163 180.1 90.5 (77.1-105.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hubbardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.6 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 2.8 177.1 (57.1-413.4) 
Female 18 18.1 99.6 (59.0-157.4)   Female 1 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 7 0.9 797.4 (319.5-1643.1) 
Colon / Rectum            Ovary     
Male 0 5.2 nc (nc-nc)             
Female 6 4.3 139.3 (50.9-303.3)   Female 3 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 11 16.1 68.2 (34.0-122.1) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.8 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 5 3.6 139.7 (45.0-326.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.8 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 8.5 nc (nc-nc)   Male 42 63.4 66.3 (47.7-89.6) 
Female 9 7.0 127.8 (58.3-242.7)   Female 63 56.4 111.7 (85.9-143.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hudson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 23.1 99.7 (63.2-149.6)   Male 11 14.8 74.1 (36.9-132.6) 
Female 8 7.9 101.7 (43.8-200.5)   Female 10 11.1 89.8 (43.0-165.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 4.4 205.5 (93.8-390.1)   Male 3 4.7 nc (nc-nc) 
Female 3 3.4 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 6 13.2 45.6 (16.6-99.2) 
Female 81 89.3 90.7 (72.0-112.7)   Female 7 10.9 64.1 (25.7-132.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 10.7 112.5 (58.1-196.6) 
Female 2 3.0 nc (nc-nc)   Female 5 4.6 108.1 (34.9-252.4) 
Colon / Rectum            Ovary     
Male 31 24.6 126.1 (85.7-179.0)             
Female 28 22.9 122.4 (81.3-176.9)   Female 9 7.8 115.6 (52.8-219.5) 
Esophagus            Pancreas     
Male 5 6.2 80.8 (26.0-188.5)   Male 4 8.2 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 5 7.8 64.3 (20.7-150.2) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 77 80.5 95.6 (75.5-119.5) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 12.8 54.6 (21.9-112.5)   Male 5 5.4 92.8 (29.9-216.5) 
Female 9 7.1 126.7 (57.8-240.5)   Female 5 2.9 170.8 (55.0-398.5) 
Larynx            Testis     
Male 1 3.6 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 9.1 76.5 (30.7-157.7)   Male 4 5.7 nc (nc-nc) 
Female 1 6.3 nc (nc-nc)   Female 27 16.1 167.8 (110.5-244.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.9 76.1 (27.8-165.6)             
Female 2 2.5 nc (nc-nc)   Female 27 20.5 131.5 (86.6-191.3) 
Lung and Bronchus            All Sites / Types     
Male 31 42.4 73.2 (49.7-103.9)   Male 265 305.4 86.8 (76.6-97.9) 
Female 36 43.3 83.1 (58.2-115.0)   Female 292 297.9 98.0 (87.1-109.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hull 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 12.5 128.0 (73.1-207.8)   Male 15 8.1 185.1 (103.5-305.4) 
Female 5 5.0 99.6 (32.1-232.3)   Female 11 7.2 153.5 (76.5-274.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.3 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.4 nc (nc-nc)   Male 5 7.2 69.8 (22.5-162.9) 
Female 56 58.8 95.3 (72.0-123.8)   Female 9 7.1 127.1 (58.0-241.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.0 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 5 3.1 163.8 (52.8-382.3) 
Colon / Rectum            Ovary     
Male 13 13.5 96.3 (51.2-164.7)             
Female 9 15.0 60.0 (27.4-113.9)   Female 4 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.5 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 8 4.9 162.8 (70.1-320.7) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 45 45.2 99.5 (72.6-133.1) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 7.1 127.4 (58.1-241.9)   Male 2 3.0 nc (nc-nc) 
Female 5 4.6 108.5 (35.0-253.3)   Female 1 1.9 nc (nc-nc) 
Larynx            Testis     
Male 5 2.1 238.9 (77.0-557.4)   Male 5 1.3 381.2 (122.9-889.7) 
Female 2 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.8 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 2 3.9 nc (nc-nc)   Female 5 10.2 49.1 (15.8-114.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 4.7 301.0 (164.4-505.0)             
Female 0 1.7 nc (nc-nc)   Female 16 13.7 116.4 (66.5-189.0) 
Lung and Bronchus            All Sites / Types     
Male 24 23.2 103.5 (66.3-154.0)   Male 194 168.3 115.2 (99.6-132.7) 
Female 30 27.8 107.8 (72.7-153.9)   Female 194 193.4 100.3 (86.7-115.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Huntington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.8 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 11 9.0 122.8 (61.2-219.8)   Female 2 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.2 nc (nc-nc)             
Female 4 2.1 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 7.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 3 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 3.5 231.0 (99.5-455.2)   Male 34 27.7 122.9 (85.1-171.7) 
Female 6 4.0 148.9 (54.4-324.2)   Female 34 29.0 117.4 (81.3-164.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
152 
Ipswich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 19.1 115.3 (72.2-174.5)   Male 15 12.0 124.9 (69.8-205.9) 
Female 10 6.7 149.5 (71.6-274.9)   Female 10 8.5 117.6 (56.3-216.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.3 nc (nc-nc)   Male 1 3.8 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 8 10.6 75.2 (32.4-148.1) 
Female 86 69.7 123.4 (98.7-152.5)   Female 8 9.0 88.6 (38.2-174.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.7 91.5 (39.4-180.3) 
Female 1 2.1 nc (nc-nc)   Female 7 3.8 185.3 (74.2-381.8) 
Colon / Rectum            Ovary     
Male 13 20.5 63.6 (33.8-108.7)             
Female 15 19.8 75.8 (42.4-125.0)   Female 8 6.2 129.3 (55.7-254.7) 
Esophagus            Pancreas     
Male 9 5.1 177.9 (81.2-337.8)   Male 7 6.7 103.8 (41.6-213.9) 
Female 3 1.3 nc (nc-nc)   Female 6 6.7 89.4 (32.7-194.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 81 65.4 123.9 (98.4-154.0) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.2 68.5 (27.4-141.1)   Male 3 4.5 nc (nc-nc) 
Female 6 5.6 106.9 (39.0-232.7)   Female 5 2.5 196.4 (63.3-458.3) 
Larynx            Testis     
Male 1 3.0 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 7.3 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 6 5.1 117.8 (43.0-256.5)   Female 12 11.0 109.3 (56.4-190.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.6 nc (nc-nc)             
Female 5 2.1 240.3 (77.4-560.8)   Female 12 16.1 74.5 (38.5-130.2) 
Lung and Bronchus            All Sites / Types     
Male 24 34.4 69.8 (44.7-103.9)   Male 242 248.2 97.5 (85.6-110.6) 
Female 29 35.1 82.6 (55.3-118.6)   Female 248 238.0 104.2 (91.6-118.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
153 
Kingston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 14.6 89.3 (47.5-152.7)   Male 13 9.3 139.9 (74.4-239.3) 
Female 6 5.5 108.8 (39.7-236.8)   Female 10 7.5 133.1 (63.7-244.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.7 nc (nc-nc)   Male 0 3.0 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 3 8.2 nc (nc-nc) 
Female 60 60.2 99.8 (76.1-128.4)   Female 8 7.6 104.9 (45.2-206.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.6 90.9 (33.2-198.0) 
Female 2 2.0 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 15.5 90.3 (49.3-151.5)             
Female 14 16.9 82.9 (45.3-139.1)   Female 2 5.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.8 nc (nc-nc)   Male 14 5.1 276.5 (151.1-464.0) 
Female 5 1.0 476.5 (153.6-1112.0)   Female 10 5.5 180.7 (86.5-332.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 40 46.8 85.6 (61.1-116.5) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 7.8 116.1 (53.0-220.4)   Male 5 3.4 146.7 (47.3-342.2) 
Female 2 4.7 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.7 104.7 (38.2-227.8)   Male 4 3.5 nc (nc-nc) 
Female 6 4.4 135.9 (49.6-295.9)   Female 14 10.6 131.6 (71.9-220.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 5.1 nc (nc-nc)             
Female 1 1.7 nc (nc-nc)   Female 17 13.3 127.8 (74.4-204.6) 
Lung and Bronchus            All Sites / Types     
Male 27 26.1 103.6 (68.3-150.8)   Male 173 187.5 92.3 (79.0-107.1) 
Female 29 28.7 101.2 (67.7-145.3)   Female 218 203.4 107.2 (93.4-122.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
154 
Lakeville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 12.0 99.8 (51.5-174.3)   Male 8 7.9 101.3 (43.6-199.6) 
Female 5 3.7 135.2 (43.6-315.4)   Female 4 5.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.3 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 7.0 99.9 (40.0-205.9) 
Female 55 48.1 114.5 (86.2-149.0)   Female 4 5.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.1 98.8 (36.1-215.2) 
Female 1 1.6 nc (nc-nc)   Female 5 2.4 206.5 (66.5-481.8) 
Colon / Rectum            Ovary     
Male 13 13.1 99.2 (52.8-169.7)             
Female 10 11.3 88.2 (42.2-162.2)   Female 4 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.4 147.0 (47.4-343.0)   Male 4 4.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 5 3.7 135.9 (43.8-317.1) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 40 45.8 87.4 (62.4-119.0) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.0 71.5 (23.0-166.8)   Male 4 2.9 nc (nc-nc) 
Female 5 3.6 138.1 (44.5-322.2)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.8 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 15 9.0 166.8 (93.3-275.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.5 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 14 11.3 124.3 (67.9-208.6) 
Lung and Bronchus            All Sites / Types     
Male 13 22.3 58.3 (31.0-99.8)   Male 147 165.8 88.7 (74.9-104.2) 
Female 19 20.5 92.8 (55.9-145.0)   Female 167 153.5 108.8 (92.9-126.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
155 
Lancaster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.4 119.4 (57.2-219.6)   Male 7 5.7 122.3 (49.0-252.0) 
Female 3 2.4 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 6 5.1 117.4 (42.9-255.6) 
Female 29 28.2 102.7 (68.8-147.6)   Female 2 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.2 65.6 (23.9-142.7)             
Female 2 7.2 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 39 31.1 125.2 (89.0-171.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.0 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 4 1.4 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.5 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.1 nc (nc-nc)             
Female 2 0.8 nc (nc-nc)   Female 4 6.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 15.4 58.4 (26.6-110.8)   Male 118 117.2 100.7 (83.3-120.6) 
Female 9 12.8 70.2 (32.0-133.3)   Female 77 93.0 82.8 (65.3-103.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
156 
Lanesborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.9 nc (nc-nc)   Male 6 2.0 293.2 (107.1-638.2) 
Female 0 1.0 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 7 12.0 58.5 (23.4-120.6)   Female 2 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.3 nc (nc-nc)             
Female 2 3.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 8 12.4 64.3 (27.7-126.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 3 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 5.5 144.8 (62.3-285.3)   Male 44 43.3 101.5 (73.8-136.3) 
Female 4 5.1 nc (nc-nc)   Female 27 39.2 68.9 (45.4-100.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
157 
Lawrence 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 49 52.0 94.3 (69.7-124.6)   Male 13 35.8 36.3 (19.3-62.1) 
Female 17 20.7 82.1 (47.8-131.4)   Female 10 34.0 29.4 (14.1-54.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 12.9 69.9 (31.9-132.7)   Male 12 10.8 110.7 (57.2-193.5) 
Female 7 11.3 62.1 (24.9-127.9)   Female 18 9.5 189.7 (112.4-299.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.8 nc (nc-nc)   Male 29 32.5 89.1 (59.7-128.0) 
Female 176 251.3 70.0 (60.1-81.2)   Female 32 30.6 104.7 (71.6-147.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 31 26.2 118.1 (80.3-167.7) 
Female 15 9.8 152.9 (85.5-252.2)   Female 12 13.0 92.3 (47.6-161.2) 
Colon / Rectum            Ovary     
Male 60 58.8 102.0 (77.8-131.3)             
Female 55 64.3 85.6 (64.4-111.4)   Female 12 22.3 53.7 (27.7-93.9) 
Esophagus            Pancreas     
Male 9 14.1 63.7 (29.0-120.9)   Male 17 18.6 91.3 (53.1-146.1) 
Female 9 4.1 221.6 (101.1-420.7)   Female 13 20.8 62.4 (33.2-106.8) 
Hodgkin Lymphoma            Prostate     
Male 3 6.0 nc (nc-nc)   Male 238 179.2 132.8 (116.5-150.8) 
Female 3 5.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 30.9 71.2 (44.6-107.9)   Male 20 12.5 159.8 (97.6-246.8) 
Female 19 19.5 97.3 (58.5-151.9)   Female 14 8.3 168.5 (92.0-282.7) 
Larynx            Testis     
Male 9 8.2 109.4 (49.9-207.8)   Male 13 12.0 108.6 (57.8-185.7) 
Female 4 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 24.0 66.8 (38.1-108.5)   Male 15 15.9 94.5 (52.8-155.8) 
Female 21 19.2 109.4 (67.7-167.2)   Female 65 55.4 117.4 (90.6-149.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 34 19.2 177.5 (122.9-248.1)             
Female 15 6.8 220.6 (123.4-363.8)   Female 47 56.0 83.9 (61.7-111.6) 
Lung and Bronchus            All Sites / Types     
Male 89 93.1 95.6 (76.8-117.7)   Male 747 721.9 103.5 (96.2-111.2) 
Female 88 108.6 81.0 (65.0-99.8)   Female 715 839.5 85.2 (79.0-91.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
158 
Lee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 8.7 160.8 (87.8-269.8)   Male 7 5.4 130.3 (52.2-268.5) 
Female 1 2.5 nc (nc-nc)   Female 9 3.5 260.0 (118.6-493.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 5 1.1 454.3 (146.4-1060.1)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 1 4.7 nc (nc-nc) 
Female 21 28.0 75.1 (46.5-114.8)   Female 3 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 8.8 56.5 (18.2-131.9)             
Female 6 7.1 84.9 (31.0-184.8)   Female 1 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.3 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 29 29.5 98.2 (65.8-141.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.5 111.4 (35.9-260.0)   Male 1 2.0 nc (nc-nc) 
Female 4 2.2 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Larynx            Testis     
Male 3 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.3 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 5 4.9 102.6 (33.1-239.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.9 nc (nc-nc)             
Female 3 0.8 nc (nc-nc)   Female 4 6.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 18 15.8 114.0 (67.5-180.1)   Male 112 111.4 100.5 (82.8-120.9) 
Female 20 13.7 146.4 (89.4-226.2)   Female 96 93.5 102.6 (83.1-125.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
159 
Leicester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 10.6 85.1 (38.8-161.6)   Male 12 7.2 166.2 (85.8-290.4) 
Female 4 4.6 nc (nc-nc)   Female 8 6.5 124.0 (53.4-244.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.2 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 4 6.4 nc (nc-nc) 
Female 49 50.1 97.7 (72.3-129.2)   Female 5 6.4 78.5 (25.3-183.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 5.5 128.2 (51.4-264.2) 
Female 4 1.7 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 11.9 75.6 (34.5-143.6)             
Female 10 13.5 74.2 (35.5-136.6)   Female 5 4.5 111.4 (35.9-260.0) 
Esophagus            Pancreas     
Male 4 3.0 nc (nc-nc)   Male 1 3.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 7 4.5 155.8 (62.4-320.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 29 38.9 74.5 (49.9-107.0) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.3 94.5 (34.5-205.8)   Male 1 2.6 nc (nc-nc) 
Female 4 4.0 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 4.4 229.5 (109.9-422.1)   Male 3 3.0 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 4 9.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.1 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 14 11.8 118.9 (64.9-199.4) 
Lung and Bronchus            All Sites / Types     
Male 23 19.6 117.1 (74.2-175.7)   Male 141 147.6 95.5 (80.4-112.7) 
Female 21 24.5 85.8 (53.1-131.2)   Female 157 170.5 92.1 (78.2-107.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
160 
Lenox 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 10.3 165.5 (96.3-264.9)   Male 8 5.6 143.8 (61.9-283.4) 
Female 1 3.9 nc (nc-nc)   Female 5 4.1 121.1 (39.0-282.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.0 nc (nc-nc) 
Female 34 32.4 104.9 (72.6-146.6)   Female 4 4.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 9.7 184.9 (109.5-292.2)             
Female 16 11.3 141.1 (80.6-229.2)   Female 4 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 25 27.7 90.4 (58.5-133.5) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.2 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.6 140.0 (45.1-326.8)   Male 0 1.5 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.8 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 9 7.5 119.3 (54.4-226.4) 
Lung and Bronchus            All Sites / Types     
Male 11 17.0 64.9 (32.3-116.1)   Male 111 114.1 97.3 (80.0-117.2) 
Female 15 19.1 78.7 (44.0-129.8)   Female 117 121.3 96.4 (79.8-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
161 
Leominster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 48.3 111.7 (83.9-145.8)   Male 23 30.4 75.7 (48.0-113.6) 
Female 29 15.6 186.2 (124.7-267.4)   Female 20 22.3 89.8 (54.8-138.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 8.8 68.4 (25.0-148.8)   Male 9 9.6 94.0 (42.9-178.5) 
Female 7 6.9 101.0 (40.4-208.0)   Female 4 7.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.6 nc (nc-nc)   Male 29 27.3 106.3 (71.2-152.7) 
Female 164 172.0 95.3 (81.3-111.1)   Female 25 21.7 115.3 (74.6-170.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 21.1 99.3 (61.5-151.8) 
Female 8 6.0 133.0 (57.3-262.1)   Female 9 9.2 98.3 (44.9-186.7) 
Colon / Rectum            Ovary     
Male 41 51.8 79.1 (56.8-107.4)             
Female 37 47.9 77.2 (54.4-106.5)   Female 28 15.4 182.1 (121.0-263.2) 
Esophagus            Pancreas     
Male 12 12.3 97.9 (50.5-171.0)   Male 13 16.7 78.0 (41.5-133.5) 
Female 2 3.0 nc (nc-nc)   Female 15 15.6 96.3 (53.9-158.9) 
Hodgkin Lymphoma            Prostate     
Male 3 3.5 nc (nc-nc)   Male 149 149.1 99.9 (84.5-117.3) 
Female 4 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 25.2 99.4 (64.3-146.7)   Male 13 11.2 116.1 (61.8-198.6) 
Female 15 13.7 109.8 (61.4-181.1)   Female 5 6.1 81.4 (26.2-189.8) 
Larynx            Testis     
Male 8 7.0 113.7 (49.0-224.1)   Male 3 6.3 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 19.0 95.0 (56.3-150.1)   Male 9 11.4 78.7 (35.9-149.5) 
Female 11 12.9 85.4 (42.6-152.9)   Female 19 32.8 57.9 (34.8-90.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 15.8 44.4 (17.8-91.6)             
Female 0 4.9 nc (nc-nc)   Female 35 38.2 91.6 (63.8-127.4) 
Lung and Bronchus            All Sites / Types     
Male 91 84.0 108.3 (87.2-133.0)   Male 575 610.1 94.2 (86.7-102.3) 
Female 77 80.6 95.5 (75.4-119.4)   Female 563 583.8 96.4 (88.6-104.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
162 
Leverett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.9 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 15 10.0 150.1 (83.9-247.5)   Female 1 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.3 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.9 nc (nc-nc)             
Female 0 2.4 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 11.0 45.3 (14.6-105.6) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 5.3 93.5 (30.1-218.1)   Male 26 38.3 68.0 (44.4-99.6) 
Female 2 4.9 nc (nc-nc)   Female 36 32.6 110.4 (77.3-152.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
163 
Lexington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 42.9 58.3 (37.7-86.0)   Male 26 26.1 99.7 (65.1-146.1) 
Female 6 15.8 38.1 (13.9-82.9)   Female 25 20.1 124.7 (80.7-184.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 7.4 81.5 (29.8-177.3)   Male 13 8.4 154.8 (82.3-264.7) 
Female 5 6.3 80.0 (25.8-186.6)   Female 6 7.0 85.9 (31.4-187.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 21 23.4 89.8 (55.5-137.2) 
Female 164 162.3 101.0 (86.2-117.7)   Female 24 21.2 113.2 (72.5-168.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 18.2 82.3 (46.0-135.8) 
Female 2 5.0 nc (nc-nc)   Female 8 8.9 90.2 (38.8-177.7) 
Colon / Rectum            Ovary     
Male 35 44.7 78.2 (54.5-108.8)             
Female 31 47.3 65.5 (44.5-93.0)   Female 20 14.5 138.0 (84.3-213.2) 
Esophagus            Pancreas     
Male 3 10.9 nc (nc-nc)   Male 12 14.8 81.2 (41.9-141.9) 
Female 1 3.0 nc (nc-nc)   Female 18 15.9 113.5 (67.2-179.3) 
Hodgkin Lymphoma            Prostate     
Male 0 2.4 nc (nc-nc)   Male 140 134.3 104.3 (87.7-123.0) 
Female 1 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 21.7 96.8 (59.9-148.0)   Male 3 9.8 nc (nc-nc) 
Female 8 13.1 61.2 (26.4-120.6)   Female 8 6.1 131.0 (56.4-258.1) 
Larynx            Testis     
Male 3 6.2 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 16.4 115.5 (69.5-180.4)   Male 10 9.0 110.6 (52.9-203.4) 
Female 12 12.2 98.6 (50.9-172.3)   Female 36 26.1 137.8 (96.5-190.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 13.8 nc (nc-nc)             
Female 4 4.8 nc (nc-nc)   Female 30 36.9 81.4 (54.9-116.2) 
Lung and Bronchus            All Sites / Types     
Male 35 74.9 46.7 (32.6-65.0)   Male 428 533.9 80.2 (72.7-88.1) 
Female 48 81.3 59.1 (43.5-78.3)   Female 503 558.0 90.1 (82.4-98.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
164 
Leyden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 3.7 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.6 nc (nc-nc)   Male 11 12.4 88.7 (44.2-158.7) 
Female 2 1.6 nc (nc-nc)   Female 5 11.7 42.9 (13.8-100.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Lincoln 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 8.9 56.4 (18.2-131.7)   Male 5 5.1 98.4 (31.7-229.6) 
Female 7 2.3 305.5 (122.4-629.4)   Female 7 3.3 214.3 (85.9-441.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.4 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 5 4.6 108.6 (35.0-253.3) 
Female 41 25.2 162.9 (116.9-221.0)   Female 5 3.2 154.7 (49.9-361.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.3 153.7 (49.5-358.7) 
Female 1 0.9 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 9.0 88.9 (38.3-175.3)             
Female 8 7.2 111.2 (47.9-219.1)   Female 5 2.2 222.3 (71.6-518.8) 
Esophagus            Pancreas     
Male 1 2.0 nc (nc-nc)   Male 6 2.9 204.0 (74.5-444.1) 
Female 0 0.4 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 45 22.7 198.5 (144.8-265.7) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.9 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.4 179.1 (65.4-389.8)   Male 4 1.6 nc (nc-nc) 
Female 7 2.0 351.8 (141.0-724.9)   Female 4 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 9 5.7 158.8 (72.5-301.6) 
Lung and Bronchus            All Sites / Types     
Male 7 14.4 48.8 (19.5-100.5)   Male 122 101.0 120.8 (100.3-144.3) 
Female 8 11.6 68.7 (29.6-135.5)   Female 122 86.0 141.9 (117.8-169.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Littleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 8.8 147.7 (78.6-252.7)   Male 4 6.0 nc (nc-nc) 
Female 1 3.8 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 9 5.4 167.1 (76.3-317.3) 
Female 33 42.0 78.6 (54.1-110.4)   Female 6 5.3 113.9 (41.6-248.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.6 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 10.0 60.1 (21.9-130.8)             
Female 9 11.6 77.3 (35.3-146.8)   Female 4 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 5 3.2 156.4 (50.4-365.0) 
Female 0 0.7 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 35 31.1 112.4 (78.3-156.4) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.3 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 4 3.3 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.6 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 8 7.5 107.3 (46.2-211.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.4 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 11 9.4 117.5 (58.6-210.3) 
Lung and Bronchus            All Sites / Types     
Male 21 16.3 128.8 (79.7-196.9)   Male 124 121.6 102.0 (84.8-121.6) 
Female 9 19.7 45.6 (20.8-86.6)   Female 108 141.3 76.5 (62.7-92.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 22.2 53.9 (27.8-94.2)   Male 20 13.2 152.0 (92.8-234.7) 
Female 7 7.8 89.3 (35.8-183.9)   Female 13 9.8 132.4 (70.4-226.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.6 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 8 11.9 67.4 (29.0-132.8) 
Female 78 76.4 102.1 (80.7-127.5)   Female 14 10.3 135.4 (74.0-227.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 9.0 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 1 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 23.1 56.3 (29.9-96.2)             
Female 13 24.1 54.0 (28.7-92.3)   Female 6 7.0 85.7 (31.3-186.5) 
Esophagus            Pancreas     
Male 3 5.5 nc (nc-nc)   Male 3 7.6 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 4 8.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 66 66.5 99.3 (76.8-126.3) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 10.7 84.2 (38.4-159.8)   Male 6 5.0 119.1 (43.5-259.3) 
Female 4 6.2 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Larynx            Testis     
Male 3 3.1 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 8.3 144.6 (74.6-252.7)   Male 4 4.4 nc (nc-nc) 
Female 2 6.2 nc (nc-nc)   Female 7 12.6 55.5 (22.2-114.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.9 nc (nc-nc)             
Female 5 2.3 216.8 (69.9-506.0)   Female 9 17.0 53.0 (24.2-100.5) 
Lung and Bronchus            All Sites / Types     
Male 19 37.9 50.1 (30.2-78.3)   Male 215 269.2 79.9 (69.6-91.3) 
Female 22 38.4 57.2 (35.9-86.7)   Female 225 269.6 83.4 (72.9-95.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
168 
Lowell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 82 81.8 100.3 (79.7-124.5)   Male 34 57.0 59.7 (41.3-83.4) 
Female 46 33.0 139.5 (102.1-186.1)   Female 34 51.1 66.6 (46.1-93.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 17 19.3 87.9 (51.2-140.8)   Male 21 17.2 122.3 (75.7-187.0) 
Female 16 16.3 98.3 (56.2-159.6)   Female 21 14.9 141.1 (87.3-215.7) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.9 nc (nc-nc)   Male 53 51.2 103.6 (77.6-135.5) 
Female 312 373.9 83.5 (74.4-93.2)   Female 32 47.2 67.7 (46.3-95.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 52 41.9 124.1 (92.7-162.7) 
Female 18 14.1 127.8 (75.7-202.0)   Female 7 19.8 35.4 (14.2-73.0) 
Colon / Rectum            Ovary     
Male 91 92.7 98.2 (79.0-120.5)             
Female 102 101.2 100.8 (82.2-122.4)   Female 28 33.5 83.5 (55.5-120.7) 
Esophagus            Pancreas     
Male 23 22.4 102.5 (64.9-153.8)   Male 25 29.5 84.8 (54.8-125.1) 
Female 4 6.4 nc (nc-nc)   Female 22 33.0 66.7 (41.8-100.9) 
Hodgkin Lymphoma            Prostate     
Male 11 9.0 122.5 (61.1-219.1)   Male 223 287.8 77.5 (67.6-88.3) 
Female 4 7.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 46 49.2 93.6 (68.5-124.8)   Male 24 19.9 120.7 (77.3-179.6) 
Female 38 29.8 127.3 (90.1-174.8)   Female 28 13.0 215.4 (143.1-311.3) 
Larynx            Testis     
Male 19 13.3 142.5 (85.8-222.6)   Male 15 18.1 82.7 (46.2-136.4) 
Female 8 4.3 186.0 (80.1-366.4)             
Leukemia            Thyroid     
Male 32 36.4 87.8 (60.1-124.0)   Male 22 25.1 87.6 (54.9-132.6) 
Female 41 29.1 140.8 (101.0-191.0)   Female 74 79.5 93.1 (73.1-116.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 61 30.6 199.3 (152.5-256.1)             
Female 7 10.6 66.2 (26.5-136.5)   Female 80 83.1 96.3 (76.3-119.8) 
Lung and Bronchus            All Sites / Types     
Male 185 148.4 124.7 (107.4-144.0)   Male 1163 1142.6 101.8 (96.0-107.8) 
Female 190 173.3 109.6 (94.6-126.4)   Female 1221 1276.9 95.6 (90.3-101.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
169 
Ludlow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 26.1 111.3 (74.5-159.8)   Male 15 16.6 90.3 (50.5-148.9) 
Female 6 10.2 58.9 (21.5-128.2)   Female 15 13.3 113.0 (63.2-186.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.8 nc (nc-nc)   Male 4 5.2 nc (nc-nc) 
Female 2 4.1 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 15 14.8 101.1 (56.5-166.7) 
Female 79 106.0 74.5 (59.0-92.9)   Female 10 13.8 72.6 (34.7-133.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 12.1 58.1 (23.3-119.6) 
Female 5 3.3 149.4 (48.1-348.6)   Female 2 5.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 34 28.3 119.9 (83.0-167.6)             
Female 25 30.3 82.5 (53.4-121.7)   Female 11 9.5 116.3 (58.0-208.1) 
Esophagus            Pancreas     
Male 3 6.9 nc (nc-nc)   Male 4 9.2 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 12 10.2 117.3 (60.6-205.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 71 86.7 81.9 (63.9-103.3) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 14.0 128.3 (76.0-202.7)   Male 7 6.1 114.7 (45.9-236.3) 
Female 6 8.6 70.1 (25.6-152.7)   Female 3 3.9 nc (nc-nc) 
Larynx            Testis     
Male 3 3.9 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 10.2 58.7 (21.4-127.8)   Male 3 6.4 nc (nc-nc) 
Female 6 7.9 75.7 (27.6-164.8)   Female 5 17.8 28.2 (9.1-65.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 9.0 89.1 (38.4-175.5)             
Female 3 3.1 nc (nc-nc)   Female 21 24.2 86.9 (53.8-132.9) 
Lung and Bronchus            All Sites / Types     
Male 32 45.8 69.8 (47.7-98.6)   Male 290 338.9 85.6 (76.0-96.0) 
Female 38 53.1 71.5 (50.6-98.2)   Female 284 364.2 78.0 (69.2-87.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
170 
Lunenburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 11.9 58.9 (23.6-121.4)   Male 6 7.7 77.5 (28.3-168.6) 
Female 4 3.9 nc (nc-nc)   Female 2 5.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.3 nc (nc-nc)   Male 6 2.5 242.9 (88.7-528.7) 
Female 3 1.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 7.0 nc (nc-nc) 
Female 56 47.6 117.6 (88.9-152.8)   Female 4 5.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.8 85.8 (27.7-200.2) 
Female 1 1.6 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 13.3 120.2 (68.6-195.1)             
Female 12 12.1 99.0 (51.1-172.9)   Female 3 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.2 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 43 41.4 103.8 (75.1-139.8) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.8 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 4.7 168.5 (72.5-331.9)   Male 4 3.1 nc (nc-nc) 
Female 2 3.3 nc (nc-nc)   Female 6 8.6 69.5 (25.4-151.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.3 nc (nc-nc)             
Female 3 1.3 nc (nc-nc)   Female 17 11.3 150.6 (87.7-241.1) 
Lung and Bronchus            All Sites / Types     
Male 24 21.3 112.9 (72.3-168.1)   Male 156 159.4 97.9 (83.1-114.5) 
Female 16 21.1 75.7 (43.2-123.0)   Female 148 156.1 94.8 (80.1-111.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
171 
Lynn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 65 71.2 91.2 (70.4-116.3)   Male 43 48.7 88.2 (63.8-118.8) 
Female 24 29.4 81.6 (52.3-121.4)   Female 32 44.6 71.8 (49.1-101.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 21 16.4 128.4 (79.5-196.3)   Male 26 14.9 174.7 (114.1-256.0) 
Female 15 14.3 105.1 (58.8-173.4)   Female 13 13.3 98.0 (52.1-167.6) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.5 199.1 (64.2-464.7)   Male 54 44.0 122.8 (92.2-160.2) 
Female 319 332.7 95.9 (85.6-107.0)   Female 49 41.9 117.1 (86.6-154.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 50 35.8 139.7 (103.7-184.2) 
Female 17 12.2 139.8 (81.4-223.9)   Female 20 17.6 113.6 (69.4-175.4) 
Colon / Rectum            Ovary     
Male 110 81.0 135.8 (111.6-163.7)             
Female 109 90.1 121.0 (99.4-146.0)   Female 25 29.8 83.8 (54.2-123.8) 
Esophagus            Pancreas     
Male 24 19.3 124.2 (79.5-184.8)   Male 23 25.5 90.2 (57.2-135.4) 
Female 6 5.7 105.4 (38.5-229.4)   Female 24 29.4 81.6 (52.3-121.4) 
Hodgkin Lymphoma            Prostate     
Male 5 7.2 69.2 (22.3-161.5)   Male 305 247.5 123.2 (109.8-137.9) 
Female 2 6.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 41 42.3 96.9 (69.5-131.5)   Male 16 17.2 92.9 (53.1-150.9) 
Female 23 26.5 86.7 (54.9-130.1)   Female 21 11.6 181.8 (112.5-277.9) 
Larynx            Testis     
Male 17 11.4 148.9 (86.7-238.4)   Male 17 14.2 119.6 (69.6-191.5) 
Female 4 3.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 40 31.3 128.0 (91.4-174.3)   Male 17 21.1 80.5 (46.9-129.0) 
Female 32 25.7 124.7 (85.3-176.0)   Female 53 68.3 77.6 (58.1-101.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 56 26.0 215.1 (162.5-279.4)             
Female 18 9.4 191.3 (113.3-302.4)   Female 71 74.1 95.8 (74.8-120.8) 
Lung and Bronchus            All Sites / Types     
Male 195 128.1 152.2 (131.6-175.1)   Male 1231 982.5 125.3 (118.4-132.5) 
Female 179 155.2 115.3 (99.1-133.5)   Female 1159 1132.6 102.3 (96.5-108.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
172 
Lynnfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 15.9 94.3 (52.7-155.5)   Male 22 10.0 220.5 (138.1-333.8) 
Female 9 5.0 178.5 (81.4-338.9)   Female 12 6.8 175.8 (90.7-307.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.8 nc (nc-nc)   Male 5 3.2 155.4 (50.1-362.7) 
Female 5 2.1 233.7 (75.3-545.3)   Female 4 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 14 8.8 158.8 (86.8-266.5) 
Female 50 55.7 89.7 (66.6-118.3)   Female 15 6.9 216.2 (120.9-356.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 7.0 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 16.8 77.5 (41.2-132.5)             
Female 22 15.1 145.8 (91.4-220.8)   Female 7 4.9 143.5 (57.5-295.7) 
Esophagus            Pancreas     
Male 2 4.1 nc (nc-nc)   Male 6 5.5 108.9 (39.8-237.1) 
Female 0 1.0 nc (nc-nc)   Female 6 5.0 119.6 (43.7-260.2) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 46 51.6 89.1 (65.2-118.8) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 8.3 131.9 (65.8-236.1)   Male 3 3.7 nc (nc-nc) 
Female 2 4.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 5 1.6 320.6 (103.3-748.2) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 6.1 165.0 (79.0-303.4)   Male 6 3.6 167.7 (61.2-365.1) 
Female 5 4.0 125.9 (40.6-293.9)   Female 15 9.6 156.5 (87.5-258.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.4 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 16 12.5 127.6 (72.9-207.2) 
Lung and Bronchus            All Sites / Types     
Male 20 28.7 69.6 (42.5-107.5)   Male 200 203.0 98.5 (85.4-113.2) 
Female 28 26.8 104.3 (69.3-150.8)   Female 221 186.8 118.3 (103.2-135.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
173 
Malden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 48.6 55.5 (36.6-80.8)   Male 8 33.6 23.8 (10.3-46.9) 
Female 26 19.3 134.8 (88.0-197.5)   Female 20 30.2 66.2 (40.4-102.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 10.9 nc (nc-nc)   Male 7 10.1 69.0 (27.6-142.1) 
Female 8 9.4 85.5 (36.8-168.4)   Female 7 8.7 80.1 (32.1-165.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.7 nc (nc-nc)   Male 40 30.0 133.2 (95.1-181.3) 
Female 193 221.6 87.1 (75.2-100.3)   Female 23 27.8 82.7 (52.4-124.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 24.3 94.7 (60.0-142.2) 
Female 13 8.5 153.4 (81.6-262.3)   Female 9 11.7 77.0 (35.1-146.2) 
Colon / Rectum            Ovary     
Male 71 54.6 130.0 (101.5-163.9)             
Female 79 59.9 131.8 (104.3-164.2)   Female 16 19.9 80.5 (46.0-130.7) 
Esophagus            Pancreas     
Male 15 13.1 114.2 (63.9-188.4)   Male 21 17.3 121.2 (75.0-185.3) 
Female 8 3.7 216.4 (93.2-426.4)   Female 15 19.3 77.7 (43.5-128.2) 
Hodgkin Lymphoma            Prostate     
Male 3 5.2 nc (nc-nc)   Male 129 165.3 78.0 (65.1-92.7) 
Female 5 4.4 113.1 (36.4-263.8)             
Kidney & Renal Pelvis            Stomach     
Male 34 28.6 119.0 (82.4-166.3)   Male 15 11.7 127.8 (71.5-210.8) 
Female 18 17.4 103.2 (61.2-163.2)   Female 6 7.7 78.1 (28.5-170.0) 
Larynx            Testis     
Male 11 7.7 142.3 (70.9-254.6)   Male 8 10.8 73.8 (31.8-145.4) 
Female 5 2.5 196.7 (63.4-458.9)             
Leukemia            Thyroid     
Male 24 20.9 114.7 (73.5-170.7)   Male 15 14.8 101.4 (56.7-167.2) 
Female 16 16.7 95.7 (54.7-155.5)   Female 62 47.7 129.9 (99.6-166.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 24 17.7 135.5 (86.8-201.7)             
Female 13 6.2 211.0 (112.2-360.8)   Female 51 48.8 104.4 (77.7-137.3) 
Lung and Bronchus            All Sites / Types     
Male 117 86.9 134.6 (111.3-161.3)   Male 639 666.6 95.9 (88.6-103.6) 
Female 111 100.7 110.3 (90.7-132.8)   Female 772 752.3 102.6 (95.5-110.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Manchester by the Sea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 8.1 nc (nc-nc)   Male 14 4.7 295.1 (161.2-495.2) 
Female 1 2.6 nc (nc-nc)   Female 5 3.3 150.1 (48.4-350.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 32 27.7 115.6 (79.0-163.2)   Female 3 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.2 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 8.3 59.9 (19.3-139.8)             
Female 5 7.5 66.8 (21.5-155.8)   Female 2 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.0 nc (nc-nc)   Male 0 2.7 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 28 22.9 122.5 (81.4-177.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.0 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 9 4.4 203.1 (92.7-385.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 8 6.3 126.8 (54.6-249.9) 
Lung and Bronchus            All Sites / Types     
Male 6 13.7 43.9 (16.0-95.5)   Male 89 96.1 92.6 (74.4-114.0) 
Female 10 14.1 71.0 (34.0-130.7)   Female 95 93.3 101.8 (82.4-124.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
175 
Mansfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 15.6 128.2 (78.3-197.9)   Male 26 11.6 223.6 (146.0-327.6) 
Female 0 5.6 nc (nc-nc)   Female 20 10.3 193.6 (118.2-299.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 4.1 193.7 (83.4-381.6)   Male 3 3.5 nc (nc-nc) 
Female 7 3.3 214.9 (86.1-442.8)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.6 nc (nc-nc)   Male 14 10.6 132.6 (72.5-222.6) 
Female 89 80.2 110.9 (89.1-136.5)   Female 4 8.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.2 119.5 (59.6-213.9) 
Female 1 3.2 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 19.3 140.0 (92.2-203.7)             
Female 28 18.5 151.6 (100.7-219.2)   Female 7 6.9 102.0 (40.8-210.1) 
Esophagus            Pancreas     
Male 3 4.6 nc (nc-nc)   Male 4 5.8 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 9 5.5 162.6 (74.2-308.6) 
Hodgkin Lymphoma            Prostate     
Male 0 1.8 nc (nc-nc)   Male 57 58.5 97.4 (73.7-126.1) 
Female 2 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 10.5 132.9 (72.6-222.9)   Male 6 4.0 150.6 (55.0-327.8) 
Female 9 5.9 153.6 (70.1-291.6)   Female 3 2.3 nc (nc-nc) 
Larynx            Testis     
Male 0 2.7 nc (nc-nc)   Male 6 3.5 170.0 (62.1-370.1) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.4 121.6 (55.5-230.8)   Male 16 5.6 284.1 (162.3-461.4) 
Female 10 5.3 188.5 (90.2-346.7)   Female 19 17.9 106.3 (64.0-166.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.5 92.4 (33.7-201.2)             
Female 3 1.9 nc (nc-nc)   Female 14 17.4 80.3 (43.9-134.7) 
Lung and Bronchus            All Sites / Types     
Male 32 28.6 112.1 (76.6-158.2)   Male 279 231.9 120.3 (106.6-135.3) 
Female 38 30.2 125.8 (89.0-172.7)   Female 290 251.3 115.4 (102.5-129.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
176 
Marblehead 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 24.9 96.5 (61.8-143.5)   Male 38 15.5 244.7 (173.1-335.8) 
Female 13 8.8 147.7 (78.6-252.7)   Female 22 12.1 181.3 (113.6-274.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 4.4 nc (nc-nc)   Male 8 5.0 160.9 (69.3-317.1) 
Female 3 3.8 nc (nc-nc)   Female 8 4.0 200.1 (86.2-394.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 13 13.9 93.9 (49.9-160.5) 
Female 122 99.4 122.7 (101.9-146.6)   Female 11 12.3 89.8 (44.7-160.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 11.0 99.6 (49.7-178.3) 
Female 3 3.2 nc (nc-nc)   Female 6 5.3 114.1 (41.7-248.5) 
Colon / Rectum            Ovary     
Male 32 26.2 122.0 (83.4-172.2)             
Female 17 26.4 64.3 (37.5-103.0)   Female 6 8.8 68.5 (25.0-149.2) 
Esophagus            Pancreas     
Male 6 6.5 92.7 (33.8-201.7)   Male 13 8.6 150.4 (80.0-257.1) 
Female 3 1.7 nc (nc-nc)   Female 14 8.8 159.2 (86.9-267.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 96 81.0 118.5 (96.0-144.8) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 13.2 83.6 (41.7-149.5)   Male 7 5.8 121.3 (48.6-250.0) 
Female 5 7.8 63.9 (20.6-149.2)   Female 1 3.4 nc (nc-nc) 
Larynx            Testis     
Male 1 3.8 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 9.7 113.9 (56.8-203.8)   Male 9 5.6 160.0 (73.0-303.8) 
Female 10 7.1 141.6 (67.8-260.4)   Female 17 17.1 99.6 (58.0-159.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 8.3 nc (nc-nc)             
Female 2 2.8 nc (nc-nc)   Female 20 22.9 87.3 (53.3-134.9) 
Lung and Bronchus            All Sites / Types     
Male 25 44.4 56.3 (36.4-83.1)   Male 338 317.6 106.4 (95.4-118.4) 
Female 38 47.0 80.9 (57.3-111.1)   Female 360 331.2 108.7 (97.8-120.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
177 
Marion 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 7.2 nc (nc-nc)   Male 8 4.5 179.7 (77.4-354.0) 
Female 4 2.9 nc (nc-nc)   Female 1 3.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 4.0 201.9 (86.9-397.9) 
Female 33 26.2 126.1 (86.8-177.0)   Female 3 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.3 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 7.5 107.3 (46.2-211.5)             
Female 10 8.6 115.8 (55.4-213.0)   Female 0 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.0 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 23 27.0 85.1 (54.0-127.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.9 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 2.7 368.9 (176.6-678.5)   Male 3 1.6 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.4 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 6 6.1 98.5 (36.0-214.4) 
Lung and Bronchus            All Sites / Types     
Male 8 13.0 61.3 (26.4-120.9)   Male 86 95.3 90.2 (72.2-111.4) 
Female 18 13.4 134.3 (79.6-212.3)   Female 101 94.2 107.2 (87.3-130.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
178 
Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 40 38.1 104.9 (74.9-142.8)   Male 25 25.6 97.7 (63.2-144.3) 
Female 9 13.3 67.9 (31.0-128.9)   Female 15 20.1 74.7 (41.8-123.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 8.0 74.7 (27.3-162.6)   Male 5 7.9 63.1 (20.3-147.2) 
Female 8 6.2 128.5 (55.3-253.3)   Female 5 6.0 82.8 (26.7-193.1) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 19 22.8 83.3 (50.1-130.1) 
Female 140 154.0 90.9 (76.5-107.3)   Female 17 19.0 89.3 (52.0-143.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 18.5 97.2 (57.6-153.6) 
Female 9 5.6 159.9 (73.0-303.6)   Female 18 8.0 224.3 (132.9-354.5) 
Colon / Rectum            Ovary     
Male 46 42.4 108.5 (79.4-144.7)             
Female 61 40.9 149.1 (114.0-191.5)   Female 16 13.5 118.3 (67.6-192.1) 
Esophagus            Pancreas     
Male 12 10.2 117.5 (60.6-205.2)   Male 9 13.5 66.8 (30.5-126.8) 
Female 5 2.6 194.6 (62.7-454.0)   Female 14 13.3 105.5 (57.6-177.0) 
Hodgkin Lymphoma            Prostate     
Male 6 3.3 181.9 (66.4-396.0)   Male 128 126.9 100.9 (84.1-119.9) 
Female 2 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 21.8 114.5 (74.0-169.0)   Male 7 9.1 76.9 (30.8-158.5) 
Female 10 12.1 82.8 (39.6-152.2)   Female 6 5.2 115.1 (42.0-250.6) 
Larynx            Testis     
Male 6 6.0 100.5 (36.7-218.8)   Male 2 6.4 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 16.1 105.9 (61.6-169.5)   Male 10 10.6 94.8 (45.4-174.3) 
Female 12 11.3 106.6 (55.0-186.3)   Female 38 30.8 123.5 (87.4-169.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 13.7 80.1 (40.0-143.4)             
Female 7 4.3 163.3 (65.4-336.4)   Female 37 34.5 107.4 (75.6-148.0) 
Lung and Bronchus            All Sites / Types     
Male 48 68.4 70.1 (51.7-93.0)   Male 478 511.1 93.5 (85.3-102.3) 
Female 71 70.0 101.4 (79.2-127.9)   Female 551 515.7 106.8 (98.1-116.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
179 
Marshfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 26.4 83.2 (52.1-126.0)   Male 32 17.7 180.8 (123.6-255.2) 
Female 11 9.2 119.8 (59.7-214.3)   Female 27 14.2 190.1 (125.3-276.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 5.5 164.1 (74.9-311.4)   Male 10 5.6 179.5 (85.9-330.0) 
Female 6 4.4 135.7 (49.6-295.4)   Female 3 4.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.0 nc (nc-nc)   Male 11 15.9 69.1 (34.4-123.6) 
Female 139 116.3 119.5 (100.5-141.1)   Female 9 13.6 66.1 (30.2-125.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 14.0 71.4 (34.2-131.4) 
Female 5 3.9 127.1 (41.0-296.7)   Female 5 5.9 84.5 (27.2-197.2) 
Colon / Rectum            Ovary     
Male 25 29.9 83.5 (54.0-123.2)             
Female 29 27.7 104.6 (70.0-150.2)   Female 12 10.1 119.2 (61.5-208.2) 
Esophagus            Pancreas     
Male 5 7.6 65.8 (21.2-153.5)   Male 13 9.8 132.9 (70.7-227.2) 
Female 0 1.9 nc (nc-nc)   Female 13 9.2 142.0 (75.5-242.9) 
Hodgkin Lymphoma            Prostate     
Male 3 2.0 nc (nc-nc)   Male 119 102.3 116.4 (96.4-139.3) 
Female 4 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 16.0 143.6 (91.0-215.5)   Male 6 6.4 93.3 (34.1-203.1) 
Female 6 8.9 67.7 (24.7-147.4)   Female 3 3.5 nc (nc-nc) 
Larynx            Testis     
Male 1 4.5 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 10.9 109.7 (56.6-191.6)   Male 7 7.3 95.7 (38.3-197.1) 
Female 3 7.6 nc (nc-nc)   Female 25 21.4 116.6 (75.5-172.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 10.2 117.4 (60.6-205.0)             
Female 1 3.2 nc (nc-nc)   Female 21 27.4 76.7 (47.5-117.3) 
Lung and Bronchus            All Sites / Types     
Male 45 48.4 93.0 (67.8-124.5)   Male 389 372.1 104.5 (94.4-115.5) 
Female 59 51.7 114.1 (86.9-147.2)   Female 407 374.9 108.6 (98.3-119.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
180 
Mashpee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 22.7 118.9 (78.3-173.0)   Male 16 13.4 119.4 (68.2-193.8) 
Female 8 8.7 91.8 (39.5-181.0)   Female 20 10.3 193.4 (118.1-298.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.5 nc (nc-nc)   Male 5 4.4 114.0 (36.8-266.1) 
Female 3 3.2 nc (nc-nc)   Female 3 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 17 11.8 144.2 (83.9-230.8) 
Female 80 84.0 95.2 (75.5-118.5)   Female 16 11.3 141.7 (80.9-230.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 8.8 135.7 (70.0-237.1) 
Female 2 2.3 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 22.5 80.0 (47.4-126.4)             
Female 25 24.6 101.8 (65.9-150.3)   Female 7 7.6 92.1 (36.9-189.8) 
Esophagus            Pancreas     
Male 5 5.6 88.5 (28.5-206.6)   Male 9 7.6 117.7 (53.7-223.4) 
Female 0 1.7 nc (nc-nc)   Female 8 8.6 93.1 (40.1-183.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 79 69.3 114.0 (90.3-142.1) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.8 120.3 (64.0-205.7)   Male 4 5.0 nc (nc-nc) 
Female 8 7.1 112.6 (48.5-221.9)   Female 2 3.2 nc (nc-nc) 
Larynx            Testis     
Male 4 3.2 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 4 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.2 60.7 (19.5-141.6)   Male 3 4.2 nc (nc-nc) 
Female 10 6.4 156.5 (74.9-287.7)   Female 9 12.4 72.6 (33.1-137.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.9 86.6 (31.6-188.6)             
Female 1 2.6 nc (nc-nc)   Female 16 19.8 80.8 (46.1-131.2) 
Lung and Bronchus            All Sites / Types     
Male 34 40.4 84.1 (58.2-117.5)   Male 285 274.1 104.0 (92.2-116.8) 
Female 50 47.0 106.3 (78.9-140.1)   Female 299 295.9 101.1 (89.9-113.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
181 
Mattapoisett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 7.8 128.2 (61.4-235.9)   Male 7 4.9 142.7 (57.2-294.1) 
Female 3 2.7 nc (nc-nc)   Female 6 3.6 167.2 (61.1-364.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 1 4.3 nc (nc-nc) 
Female 45 29.9 150.5 (109.8-201.4)   Female 5 3.7 136.2 (43.9-317.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 3.4 323.9 (161.4-579.5) 
Female 1 0.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 8.0 125.0 (59.8-229.8)             
Female 11 7.7 143.1 (71.3-256.1)   Female 6 2.6 231.2 (84.4-503.3) 
Esophagus            Pancreas     
Male 2 2.1 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 44 26.1 168.8 (122.6-226.6) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.2 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 2.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.0 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.6 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 12 6.9 173.7 (89.7-303.5) 
Lung and Bronchus            All Sites / Types     
Male 16 14.5 110.4 (63.1-179.4)   Male 129 100.3 128.6 (107.3-152.8) 
Female 12 14.6 82.0 (42.3-143.3)   Female 122 99.2 122.9 (102.1-146.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
182 
Maynard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 11.5 112.8 (60.0-192.9)   Male 7 7.4 94.7 (37.9-195.1) 
Female 2 3.6 nc (nc-nc)   Female 6 5.5 108.4 (39.6-236.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.2 nc (nc-nc)   Male 0 2.4 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 8 6.6 120.6 (51.9-237.6) 
Female 49 42.4 115.6 (85.5-152.8)   Female 4 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.3 93.7 (30.2-218.6) 
Female 0 1.6 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 12.5 144.5 (85.6-228.4)             
Female 19 11.1 171.6 (103.3-268.0)   Female 2 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.1 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 5 3.6 138.8 (44.7-323.9) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 29 38.0 76.2 (51.1-109.5) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.3 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 5 3.3 151.3 (48.8-353.1)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.7 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 5 3.1 162.7 (52.4-379.6)   Female 10 8.5 117.3 (56.2-215.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.0 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 5 9.7 51.7 (16.7-120.7) 
Lung and Bronchus            All Sites / Types     
Male 9 20.4 44.1 (20.1-83.7)   Male 126 150.4 83.8 (69.8-99.7) 
Female 19 18.8 101.2 (60.9-158.0)   Female 154 141.1 109.2 (92.6-127.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
183 
Medfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 13.2 60.7 (26.1-119.5)   Male 10 8.7 115.6 (55.3-212.5) 
Female 4 3.9 nc (nc-nc)   Female 9 6.2 146.0 (66.6-277.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.6 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 4 1.9 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 3 7.8 nc (nc-nc) 
Female 54 49.8 108.4 (81.4-141.4)   Female 5 5.7 87.4 (28.2-203.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.6 106.3 (42.6-219.0) 
Female 0 1.7 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 14.7 95.0 (51.9-159.5)             
Female 13 12.5 104.2 (55.4-178.2)   Female 4 4.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.6 nc (nc-nc)   Male 3 4.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 59 46.2 127.8 (97.3-164.9) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.5 79.7 (29.1-173.4)   Male 1 3.2 nc (nc-nc) 
Female 4 3.7 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Larynx            Testis     
Male 0 2.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.4 111.4 (40.7-242.5)   Male 4 3.5 nc (nc-nc) 
Female 8 3.3 240.4 (103.5-473.7)   Female 9 9.5 94.4 (43.1-179.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 4.9 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 9 11.3 79.9 (36.5-151.7) 
Lung and Bronchus            All Sites / Types     
Male 11 23.4 47.1 (23.5-84.2)   Male 151 177.7 85.0 (72.0-99.7) 
Female 14 20.3 69.0 (37.7-115.8)   Female 152 159.5 95.3 (80.7-111.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
184 
Medford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 63 57.2 110.1 (84.6-140.8)   Male 25 36.5 68.4 (44.3-101.0) 
Female 21 22.5 93.2 (57.7-142.5)   Female 25 32.1 77.9 (50.4-115.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 11.0 109.6 (56.6-191.4)   Male 10 11.3 88.8 (42.5-163.3) 
Female 11 9.7 112.9 (56.3-202.0)   Female 11 10.0 109.5 (54.6-196.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.9 nc (nc-nc)   Male 29 32.6 88.8 (59.5-127.6) 
Female 243 237.4 102.4 (89.9-116.1)   Female 22 31.3 70.4 (44.1-106.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 24.7 133.8 (92.1-187.9) 
Female 7 8.4 82.9 (33.2-170.9)   Female 14 12.9 108.2 (59.1-181.6) 
Colon / Rectum            Ovary     
Male 72 60.9 118.2 (92.5-148.8)             
Female 81 67.4 120.2 (95.5-149.4)   Female 25 21.5 116.3 (75.3-171.7) 
Esophagus            Pancreas     
Male 13 14.3 90.7 (48.2-155.1)   Male 18 19.6 91.8 (54.4-145.1) 
Female 7 4.3 161.8 (64.8-333.3)   Female 13 22.6 57.6 (30.7-98.6) 
Hodgkin Lymphoma            Prostate     
Male 5 5.0 99.5 (32.1-232.3)   Male 155 174.1 89.0 (75.6-104.2) 
Female 5 4.4 112.9 (36.4-263.5)             
Kidney & Renal Pelvis            Stomach     
Male 27 29.6 91.2 (60.1-132.6)   Male 16 13.2 120.9 (69.0-196.3) 
Female 24 19.2 124.7 (79.9-185.5)   Female 9 8.7 103.6 (47.3-196.6) 
Larynx            Testis     
Male 10 8.3 120.5 (57.7-221.7)   Male 13 10.0 130.2 (69.3-222.7) 
Female 2 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 27 23.0 117.6 (77.5-171.1)   Male 12 14.1 85.1 (43.9-148.6) 
Female 25 18.3 137.0 (88.6-202.2)   Female 46 46.7 98.5 (72.1-131.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 18.5 102.7 (61.8-160.3)             
Female 8 7.1 113.2 (48.8-223.1)   Female 56 53.8 104.2 (78.7-135.3) 
Lung and Bronchus            All Sites / Types     
Male 101 99.8 101.2 (82.4-122.9)   Male 717 725.2 98.9 (91.8-106.4) 
Female 135 117.6 114.8 (96.2-135.9)   Female 867 826.2 104.9 (98.1-112.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
185 
Medway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 11.9 117.4 (64.2-197.1)   Male 7 8.1 86.7 (34.7-178.6) 
Female 2 4.4 nc (nc-nc)   Female 5 6.8 73.5 (23.7-171.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.6 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 12 7.3 164.0 (84.7-286.6) 
Female 54 53.4 101.1 (75.9-131.9)   Female 6 6.4 94.5 (34.5-205.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.3 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 13.7 124.1 (72.3-198.8)             
Female 16 14.2 112.8 (64.4-183.1)   Female 6 4.7 127.0 (46.4-276.3) 
Esophagus            Pancreas     
Male 7 3.4 206.1 (82.6-424.6)   Male 2 4.3 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 4.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 43 44.7 96.2 (69.6-129.6) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.3 68.7 (22.1-160.2)   Male 1 2.9 nc (nc-nc) 
Female 0 4.1 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.0 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 12 10.5 114.6 (59.1-200.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.7 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 10 11.8 84.4 (40.4-155.2) 
Lung and Bronchus            All Sites / Types     
Male 14 21.7 64.6 (35.3-108.5)   Male 153 167.7 91.2 (77.4-106.9) 
Female 25 22.3 112.3 (72.6-165.7)   Female 161 174.9 92.0 (78.4-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
186 
Melrose 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 28.4 81.1 (51.4-121.7)   Male 22 18.6 118.4 (74.2-179.3) 
Female 13 11.2 116.0 (61.7-198.3)   Female 21 15.8 133.1 (82.4-203.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.6 88.5 (28.5-206.6)   Male 5 5.8 86.2 (27.8-201.2) 
Female 7 4.8 144.6 (57.9-298.0)   Female 4 5.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 20 16.6 120.4 (73.5-186.0) 
Female 124 120.5 102.9 (85.6-122.7)   Female 16 15.6 102.7 (58.6-166.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 13.3 97.9 (52.1-167.4) 
Female 2 4.2 nc (nc-nc)   Female 5 6.5 76.5 (24.7-178.6) 
Colon / Rectum            Ovary     
Male 46 31.0 148.2 (108.5-197.6)             
Female 35 34.6 101.3 (70.5-140.8)   Female 10 10.8 92.4 (44.2-169.9) 
Esophagus            Pancreas     
Male 12 7.5 160.0 (82.6-279.5)   Male 12 10.0 120.3 (62.1-210.1) 
Female 1 2.2 nc (nc-nc)   Female 16 11.5 139.6 (79.8-226.8) 
Hodgkin Lymphoma            Prostate     
Male 0 2.2 nc (nc-nc)   Male 91 94.7 96.1 (77.3-118.0) 
Female 2 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 16.0 87.5 (47.8-146.7)   Male 5 6.7 74.8 (24.1-174.5) 
Female 10 9.6 104.6 (50.1-192.4)   Female 5 4.5 111.8 (36.0-260.9) 
Larynx            Testis     
Male 9 4.3 207.0 (94.4-392.9)   Male 4 4.2 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 11.6 164.2 (98.8-256.4)   Male 9 7.6 119.2 (54.4-226.2) 
Female 9 9.2 97.9 (44.7-185.9)   Female 25 22.6 110.6 (71.6-163.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.7 nc (nc-nc)             
Female 4 3.5 nc (nc-nc)   Female 31 27.1 114.4 (77.7-162.4) 
Lung and Bronchus            All Sites / Types     
Male 50 50.7 98.6 (73.2-130.0)   Male 397 374.8 105.9 (95.8-116.9) 
Female 46 56.7 81.1 (59.4-108.2)   Female 419 413.3 101.4 (91.9-111.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
187 
Mendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 6.9 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 3 4.0 nc (nc-nc) 
Female 21 22.9 91.7 (56.7-140.2)   Female 7 2.5 281.8 (112.9-580.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.2 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 7.7 nc (nc-nc)             
Female 5 5.0 99.2 (32.0-231.6)   Female 2 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.8 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 4 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 24 22.4 107.2 (68.7-159.6) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.7 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 2.7 219.8 (80.2-478.4)   Male 0 1.7 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.3 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 7 5.1 137.0 (54.9-282.4) 
Lung and Bronchus            All Sites / Types     
Male 4 11.5 nc (nc-nc)   Male 58 88.6 65.4 (49.7-84.6) 
Female 7 8.8 79.1 (31.7-163.1)   Female 77 70.5 109.2 (86.2-136.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
188 
Merrimac 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.7 75.0 (24.2-175.1)   Male 5 4.5 112.2 (36.2-261.9) 
Female 5 2.3 220.3 (71.0-514.2)   Female 4 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.4 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 20 29.2 68.5 (41.8-105.8)   Female 3 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.4 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 7.4 121.1 (55.2-229.8)             
Female 8 7.1 113.3 (48.8-223.3)   Female 5 2.5 197.2 (63.5-460.2) 
Esophagus            Pancreas     
Male 3 1.9 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 21 24.4 86.0 (53.2-131.5) 
Female 2 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.9 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 5 2.2 226.6 (73.0-528.9)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 3 1.1 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.7 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 4 5.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.5 nc (nc-nc)             
Female 2 0.8 nc (nc-nc)   Female 4 6.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 12.3 81.6 (39.1-150.0)   Male 87 91.7 94.9 (76.0-117.0) 
Female 20 12.7 157.4 (96.1-243.1)   Female 98 93.6 104.7 (85.0-127.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
189 
Methuen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 48 45.9 104.6 (77.1-138.6)   Male 24 30.6 78.5 (50.3-116.9) 
Female 25 18.8 132.9 (86.0-196.1)   Female 25 26.4 94.7 (61.3-139.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 9.6 125.1 (64.5-218.5)   Male 10 9.5 104.8 (50.2-192.8) 
Female 13 8.2 157.9 (84.0-270.0)   Female 8 8.4 95.0 (40.9-187.2) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.6 nc (nc-nc)   Male 29 27.4 105.8 (70.8-151.9) 
Female 188 205.9 91.3 (78.7-105.3)   Female 25 26.1 95.6 (61.9-141.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 22.7 79.2 (46.9-125.1) 
Female 8 7.1 113.4 (48.8-223.4)   Female 6 11.0 54.8 (20.0-119.3) 
Colon / Rectum            Ovary     
Male 48 51.0 94.1 (69.4-124.8)             
Female 55 57.1 96.4 (72.6-125.4)   Female 11 18.2 60.3 (30.1-107.9) 
Esophagus            Pancreas     
Male 7 12.6 55.7 (22.3-114.8)   Male 17 16.5 103.1 (60.0-165.1) 
Female 1 3.6 nc (nc-nc)   Female 18 18.9 95.4 (56.5-150.7) 
Hodgkin Lymphoma            Prostate     
Male 6 3.8 158.2 (57.8-344.2)   Male 171 162.5 105.2 (90.0-122.2) 
Female 2 3.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 26.6 82.6 (51.8-125.1)   Male 14 11.0 127.2 (69.5-213.4) 
Female 19 16.4 115.9 (69.7-180.9)   Female 5 7.3 68.2 (22.0-159.2) 
Larynx            Testis     
Male 7 7.4 94.5 (37.9-194.8)   Male 11 6.9 158.8 (79.2-284.2) 
Female 4 2.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 24 19.2 125.3 (80.2-186.4)   Male 17 12.5 135.5 (78.9-217.0) 
Female 19 15.3 123.8 (74.5-193.4)   Female 37 38.2 96.9 (68.2-133.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 16.8 89.1 (49.8-147.0)             
Female 5 5.9 84.8 (27.3-198.0)   Female 47 46.0 102.3 (75.1-136.0) 
Lung and Bronchus            All Sites / Types     
Male 99 83.0 119.3 (97.0-145.3)   Male 643 625.4 102.8 (95.0-111.1) 
Female 121 98.8 122.5 (101.6-146.4)   Female 708 699.9 101.2 (93.8-108.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
190 
Middleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 24.0 120.9 (80.9-173.6)   Male 21 16.0 131.3 (81.2-200.7) 
Female 13 8.1 159.8 (85.0-273.2)   Female 13 12.5 104.4 (55.5-178.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.0 100.6 (32.4-234.8)   Male 5 5.0 99.5 (32.1-232.3) 
Female 5 3.9 129.7 (41.8-302.7)   Female 7 3.8 185.8 (74.4-382.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 14 14.3 98.0 (53.5-164.5) 
Female 115 99.2 116.0 (95.8-139.2)   Female 9 11.8 76.5 (34.9-145.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 12.1 82.6 (39.6-152.0) 
Female 5 3.4 146.8 (47.3-342.6)   Female 9 5.1 177.3 (80.9-336.6) 
Colon / Rectum            Ovary     
Male 39 26.6 146.4 (104.1-200.2)             
Female 29 24.7 117.4 (78.6-168.6)   Female 10 8.7 115.0 (55.1-211.6) 
Esophagus            Pancreas     
Male 6 6.8 88.7 (32.4-193.0)   Male 13 8.7 149.5 (79.5-255.6) 
Female 3 1.6 nc (nc-nc)   Female 6 8.1 73.7 (26.9-160.4) 
Hodgkin Lymphoma            Prostate     
Male 1 1.9 nc (nc-nc)   Male 99 91.7 107.9 (87.7-131.4) 
Female 0 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 14.4 118.3 (68.9-189.4)   Male 6 5.8 104.2 (38.1-226.9) 
Female 3 7.6 nc (nc-nc)   Female 0 3.2 nc (nc-nc) 
Larynx            Testis     
Male 3 4.0 nc (nc-nc)   Male 5 3.3 150.7 (48.6-351.8) 
Female 5 1.2 422.8 (136.3-986.7)             
Leukemia            Thyroid     
Male 12 9.9 121.4 (62.6-212.0)   Male 8 6.5 122.4 (52.7-241.2) 
Female 17 6.8 249.8 (145.4-399.9)   Female 26 18.8 138.0 (90.1-202.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 8.8 158.6 (86.6-266.2)             
Female 7 2.7 261.3 (104.7-538.4)   Female 30 22.8 131.6 (88.8-187.9) 
Lung and Bronchus            All Sites / Types     
Male 47 44.6 105.4 (77.5-140.2)   Male 378 334.6 113.0 (101.9-125.0) 
Female 69 44.4 155.5 (121.0-196.7)   Female 408 324.4 125.8 (113.9-138.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
191 
Middlefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 2.6 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.9 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.8 nc (nc-nc)   Male 8 12.2 65.4 (28.1-128.8) 
Female 2 1.2 nc (nc-nc)   Female 7 8.4 83.2 (33.4-171.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
192 
Middleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 10.2 147.1 (82.3-242.7)   Male 8 7.2 110.9 (47.8-218.6) 
Female 3 2.5 nc (nc-nc)   Female 5 3.8 130.7 (42.1-304.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.3 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 4 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 10 6.4 155.2 (74.3-285.4) 
Female 36 31.4 114.5 (80.2-158.6)   Female 7 3.7 188.9 (75.7-389.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.6 88.5 (28.5-206.6) 
Female 2 1.1 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 11.8 93.3 (46.5-167.0)             
Female 13 7.6 171.0 (91.0-292.5)   Female 0 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.0 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 42 40.5 103.6 (74.7-140.1) 
Female 2 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.5 nc (nc-nc)   Male 5 2.5 197.6 (63.7-461.2) 
Female 5 2.4 207.2 (66.8-483.5)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.4 114.8 (37.0-267.8)   Male 4 3.3 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 6 5.8 103.6 (37.8-225.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 8 7.3 109.3 (47.0-215.3) 
Lung and Bronchus            All Sites / Types     
Male 18 18.9 95.0 (56.3-150.2)   Male 159 148.6 107.0 (91.0-125.0) 
Female 19 14.2 134.1 (80.7-209.4)   Female 126 101.9 123.7 (103.0-147.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
193 
Milford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 48 26.1 183.8 (135.5-243.7)   Male 10 17.5 57.2 (27.4-105.3) 
Female 13 9.3 139.1 (74.0-237.9)   Female 16 14.2 113.0 (64.5-183.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.6 nc (nc-nc)   Male 4 5.4 nc (nc-nc) 
Female 2 4.5 nc (nc-nc)   Female 7 4.3 164.7 (66.0-339.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 19 15.7 120.7 (72.6-188.5) 
Female 99 108.7 91.1 (74.1-110.9)   Female 22 13.5 163.5 (102.5-247.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 12.9 93.2 (48.1-162.9) 
Female 3 3.9 nc (nc-nc)   Female 6 5.7 105.8 (38.6-230.4) 
Colon / Rectum            Ovary     
Male 29 29.5 98.3 (65.8-141.2)             
Female 35 28.9 120.9 (84.2-168.2)   Female 10 9.6 104.4 (50.0-192.0) 
Esophagus            Pancreas     
Male 9 7.0 128.6 (58.7-244.2)   Male 7 9.3 74.9 (30.0-154.3) 
Female 1 1.8 nc (nc-nc)   Female 6 9.4 63.7 (23.3-138.8) 
Hodgkin Lymphoma            Prostate     
Male 4 2.3 nc (nc-nc)   Male 115 89.0 129.3 (106.7-155.2) 
Female 1 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 15.1 92.6 (50.6-155.4)   Male 14 6.3 223.1 (121.9-374.4) 
Female 10 8.5 117.9 (56.4-216.8)   Female 1 3.7 nc (nc-nc) 
Larynx            Testis     
Male 2 4.1 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.1 99.4 (49.6-177.9)   Male 3 7.3 nc (nc-nc) 
Female 12 8.0 149.5 (77.2-261.2)   Female 19 21.6 88.0 (52.9-137.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 9.3 nc (nc-nc)             
Female 1 3.0 nc (nc-nc)   Female 26 24.2 107.5 (70.2-157.5) 
Lung and Bronchus            All Sites / Types     
Male 42 46.5 90.4 (65.1-122.2)   Male 379 352.9 107.4 (96.9-118.8) 
Female 65 49.2 132.1 (101.9-168.3)   Female 388 363.9 106.6 (96.3-117.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
194 
Millbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 14.7 95.1 (52.0-159.6)   Male 4 9.7 nc (nc-nc) 
Female 4 5.3 nc (nc-nc)   Female 5 7.6 65.5 (21.1-152.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.9 nc (nc-nc)   Male 5 3.0 164.9 (53.1-384.8) 
Female 0 2.4 nc (nc-nc)   Female 6 2.4 248.7 (90.8-541.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 14 8.6 161.9 (88.5-271.7) 
Female 59 60.3 97.8 (74.5-126.2)   Female 3 7.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.2 138.7 (66.4-255.0) 
Female 4 2.1 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 16.1 49.8 (21.5-98.2)             
Female 13 15.9 81.8 (43.5-139.9)   Female 6 5.3 112.9 (41.2-245.8) 
Esophagus            Pancreas     
Male 6 4.1 147.5 (53.9-321.1)   Male 6 5.3 113.0 (41.3-245.9) 
Female 3 1.0 nc (nc-nc)   Female 11 5.2 210.1 (104.7-375.9) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 61 54.1 112.8 (86.3-144.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 8.6 150.9 (80.3-258.1)   Male 2 3.5 nc (nc-nc) 
Female 7 4.8 146.8 (58.8-302.4)   Female 3 2.0 nc (nc-nc) 
Larynx            Testis     
Male 4 2.4 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.9 101.0 (36.9-219.8)   Male 7 3.9 179.5 (71.9-369.8) 
Female 6 4.3 139.3 (50.9-303.3)   Female 8 11.3 70.7 (30.4-139.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 5.2 135.8 (54.4-279.8)             
Female 1 1.7 nc (nc-nc)   Female 10 13.8 72.4 (34.6-133.1) 
Lung and Bronchus            All Sites / Types     
Male 45 27.1 165.9 (121.0-222.0)   Male 234 200.5 116.7 (102.2-132.6) 
Female 32 28.3 113.2 (77.4-159.9)   Female 201 201.8 99.6 (86.3-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
195 
Millis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 6.7 164.9 (82.2-295.0)   Male 4 4.9 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 5 4.3 116.5 (37.5-271.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.6 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.4 114.7 (37.0-267.7) 
Female 33 34.1 96.7 (66.6-135.8)   Female 3 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.0 150.3 (54.9-327.1) 
Female 2 1.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 8.3 108.4 (49.5-205.8)             
Female 12 8.6 140.2 (72.3-244.9)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.0 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 35 26.8 130.4 (90.8-181.3) 
Female 3 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.5 155.1 (62.1-319.5)   Male 0 1.7 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.9 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 16 6.5 245.2 (140.1-398.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.9 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 6 7.8 77.1 (28.2-167.8) 
Lung and Bronchus            All Sites / Types     
Male 12 12.8 93.8 (48.4-163.9)   Male 119 100.2 118.8 (98.4-142.1) 
Female 15 15.4 97.7 (54.6-161.2)   Female 120 111.8 107.4 (89.0-128.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
196 
Millville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 1.8 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 10 11.1 90.4 (43.3-166.2)   Female 2 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 2.4 nc (nc-nc)             
Female 1 2.5 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 11 7.7 142.8 (71.2-255.6) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.4 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 1 0.3 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.4 nc (nc-nc)   Male 35 29.3 119.5 (83.2-166.1) 
Female 9 4.4 205.1 (93.6-389.3)   Female 33 34.9 94.6 (65.1-132.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
197 
Milton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 26.1 76.7 (46.9-118.5)   Male 30 16.8 179.0 (120.8-255.6) 
Female 7 10.8 64.6 (25.9-133.1)   Female 26 14.7 176.5 (115.3-258.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 5.2 nc (nc-nc)   Male 6 5.2 115.0 (42.0-250.2) 
Female 8 4.7 169.8 (73.1-334.6)   Female 13 4.8 270.8 (144.1-463.1) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 13 15.2 85.6 (45.5-146.4) 
Female 115 114.6 100.4 (82.9-120.5)   Female 11 14.9 74.0 (36.9-132.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 12.1 74.1 (33.8-140.7) 
Female 4 3.8 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 28.7 87.0 (56.3-128.4)             
Female 39 32.8 118.9 (84.5-162.5)   Female 17 10.3 165.7 (96.4-265.2) 
Esophagus            Pancreas     
Male 6 6.8 88.3 (32.3-192.3)   Male 11 9.2 119.1 (59.4-213.1) 
Female 3 2.1 nc (nc-nc)   Female 10 10.9 91.9 (44.0-169.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.1 nc (nc-nc)   Male 117 85.8 136.4 (112.8-163.5) 
Female 2 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 14.3 63.0 (28.8-119.7)   Male 4 6.1 nc (nc-nc) 
Female 14 9.2 152.0 (83.0-255.0)   Female 6 4.2 141.7 (51.7-308.4) 
Larynx            Testis     
Male 2 3.9 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 10.8 111.1 (57.3-194.1)   Male 6 6.6 90.6 (33.1-197.2) 
Female 9 8.8 102.0 (46.5-193.6)   Female 33 20.8 158.4 (109.0-222.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.0 nc (nc-nc)             
Female 2 3.4 nc (nc-nc)   Female 39 25.5 152.8 (108.6-208.9) 
Lung and Bronchus            All Sites / Types     
Male 33 45.7 72.2 (49.7-101.3)   Male 350 341.7 102.4 (92.0-113.8) 
Female 48 56.1 85.5 (63.1-113.4)   Female 435 394.5 110.3 (100.1-121.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
198 
Monroe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.1 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
199 
Monson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 10.1 88.8 (40.5-168.6)   Male 8 6.7 118.7 (51.1-233.9) 
Female 2 2.9 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.0 nc (nc-nc) 
Female 43 38.1 112.8 (81.6-152.0)   Female 6 4.4 137.2 (50.1-298.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 5.3 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 11.3 79.9 (36.5-151.7)             
Female 3 8.6 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.9 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 33 39.3 84.0 (57.8-117.9) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.1 114.9 (46.0-236.7)   Male 2 2.4 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.7 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.1 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 2 7.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.9 128.5 (41.4-300.0)             
Female 0 1.0 nc (nc-nc)   Female 8 9.2 86.6 (37.3-170.6) 
Lung and Bronchus            All Sites / Types     
Male 14 18.8 74.3 (40.6-124.6)   Male 119 141.8 83.9 (69.5-100.4) 
Female 12 16.4 73.1 (37.7-127.7)   Female 103 121.4 84.8 (69.2-102.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
200 
Montague 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.8 81.8 (35.2-161.1)   Male 8 6.2 128.9 (55.5-254.0) 
Female 6 3.7 162.0 (59.1-352.6)   Female 1 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.8 278.3 (89.7-649.6)   Male 2 2.0 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.6 89.8 (28.9-209.5) 
Female 35 40.8 85.8 (59.7-119.3)   Female 3 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.5 nc (nc-nc) 
Female 3 1.3 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 10.5 95.1 (45.5-174.9)             
Female 14 11.1 126.5 (69.1-212.3)   Female 6 3.7 163.4 (59.7-355.7) 
Esophagus            Pancreas     
Male 3 2.6 nc (nc-nc)   Male 0 3.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 25 33.0 75.8 (49.1-111.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.3 94.6 (30.5-220.8)   Male 3 2.3 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.9 155.8 (56.9-339.1)   Male 0 2.4 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 3 7.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 11 9.7 113.2 (56.4-202.6) 
Lung and Bronchus            All Sites / Types     
Male 20 17.2 116.1 (70.9-179.3)   Male 116 127.3 91.1 (75.3-109.3) 
Female 15 19.5 77.1 (43.1-127.2)   Female 120 138.2 86.8 (72.0-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
201 
Monterey 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.4 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.5 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 5.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.6 nc (nc-nc)   Male 11 18.3 60.3 (30.0-107.8) 
Female 1 2.1 nc (nc-nc)   Female 11 12.8 86.0 (42.9-153.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
202 
Montgomery 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.1 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 4.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.2 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 4.2 165.1 (66.1-340.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.0 nc (nc-nc)   Male 14 15.4 91.1 (49.8-152.8) 
Female 1 1.8 nc (nc-nc)   Female 6 13.3 45.0 (16.4-97.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
203 
Mount Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.2 nc (nc-nc)             
Female 2 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.4 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.8 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
204 
Nahant 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 4.5 154.8 (62.0-318.9)   Male 11 2.9 385.5 (192.2-689.9) 
Female 3 2.2 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 16 20.3 78.9 (45.1-128.2)   Female 2 2.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.1 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 4.8 nc (nc-nc)             
Female 5 6.6 75.9 (24.5-177.1)   Female 1 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.2 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 15.8 126.8 (77.4-195.9) 
Female 2 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 2 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.7 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 6 4.7 128.9 (47.1-280.5) 
Lung and Bronchus            All Sites / Types     
Male 9 8.1 110.9 (50.6-210.5)   Male 73 59.3 123.1 (96.5-154.8) 
Female 6 10.7 55.9 (20.4-121.6)   Female 59 72.8 81.0 (61.7-104.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
205 
Nantucket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.6 75.3 (32.4-148.4)   Male 20 7.2 278.8 (170.2-430.6) 
Female 2 3.3 nc (nc-nc)   Female 21 5.2 407.0 (251.8-622.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.2 nc (nc-nc)   Male 6 2.2 268.6 (98.1-584.7) 
Female 2 1.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 58 39.5 146.9 (111.5-189.9)   Female 5 4.8 103.4 (33.3-241.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 5.2 190.6 (91.3-350.6) 
Female 0 1.5 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 11.7 68.1 (29.3-134.2)             
Female 11 10.1 108.7 (54.2-194.4)   Female 3 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.9 nc (nc-nc)   Male 5 3.8 132.0 (42.6-308.1) 
Female 4 0.7 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 0.9 nc (nc-nc)   Male 29 36.9 78.5 (52.6-112.7) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.2 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 0 3.1 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.7 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 4.4 182.3 (78.5-359.3)   Male 3 3.0 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 10 8.0 124.6 (59.7-229.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.9 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 11 9.0 122.0 (60.8-218.3) 
Lung and Bronchus            All Sites / Types     
Male 13 19.2 67.6 (35.9-115.6)   Male 136 144.3 94.3 (79.1-111.5) 
Female 16 18.0 89.1 (50.9-144.7)   Female 162 131.8 123.0 (104.8-143.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
206 
Natick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 35.1 94.0 (64.7-132.1)   Male 21 22.8 92.1 (57.0-140.8) 
Female 10 13.0 76.9 (36.8-141.4)   Female 21 18.9 111.0 (68.7-169.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 7.0 143.1 (68.5-263.2)   Male 5 7.1 70.4 (22.7-164.3) 
Female 8 5.8 137.3 (59.1-270.6)   Female 4 5.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 14 20.4 68.6 (37.5-115.1) 
Female 154 151.5 101.6 (86.2-119.0)   Female 17 18.4 92.2 (53.7-147.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 16.3 98.1 (56.0-159.3) 
Female 1 5.2 nc (nc-nc)   Female 11 7.8 140.3 (70.0-251.1) 
Colon / Rectum            Ovary     
Male 46 38.1 120.8 (88.4-161.1)             
Female 36 39.6 91.0 (63.7-126.0)   Female 21 13.2 159.1 (98.4-243.2) 
Esophagus            Pancreas     
Male 12 9.2 130.2 (67.2-227.4)   Male 10 12.3 81.1 (38.8-149.2) 
Female 4 2.5 nc (nc-nc)   Female 9 12.9 69.7 (31.8-132.4) 
Hodgkin Lymphoma            Prostate     
Male 2 2.8 nc (nc-nc)   Male 110 114.8 95.8 (78.7-115.5) 
Female 2 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 19.3 88.2 (51.3-141.2)   Male 13 8.3 157.2 (83.6-268.8) 
Female 12 11.8 101.3 (52.3-177.0)   Female 2 5.0 nc (nc-nc) 
Larynx            Testis     
Male 4 5.4 nc (nc-nc)   Male 7 5.0 139.0 (55.7-286.3) 
Female 4 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 14.4 76.6 (38.2-137.1)   Male 16 9.0 178.2 (101.8-289.3) 
Female 7 10.6 65.9 (26.4-135.7)   Female 25 28.1 89.0 (57.6-131.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 12.1 49.7 (18.2-108.2)             
Female 3 4.2 nc (nc-nc)   Female 38 34.0 111.6 (79.0-153.2) 
Lung and Bronchus            All Sites / Types     
Male 51 62.2 82.0 (61.0-107.8)   Male 445 459.4 96.9 (88.1-106.3) 
Female 63 70.0 89.9 (69.1-115.1)   Female 493 501.7 98.3 (89.8-107.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
207 
Needham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 37.6 95.8 (67.1-132.7)   Male 35 22.7 154.5 (107.6-214.8) 
Female 12 13.3 89.9 (46.4-157.1)   Female 15 17.2 87.2 (48.8-143.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 6.5 138.6 (63.2-263.1)   Male 8 7.2 111.8 (48.2-220.4) 
Female 11 5.4 202.0 (100.7-361.4)   Female 4 5.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.3 nc (nc-nc)   Male 22 20.4 107.7 (67.5-163.0) 
Female 157 135.6 115.8 (98.4-135.4)   Female 15 17.9 83.6 (46.8-137.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 15.7 82.8 (44.0-141.6) 
Female 3 4.4 nc (nc-nc)   Female 7 7.5 93.3 (37.4-192.2) 
Colon / Rectum            Ovary     
Male 29 39.5 73.4 (49.1-105.4)             
Female 35 40.6 86.2 (60.1-119.9)   Female 12 12.3 97.9 (50.5-171.0) 
Esophagus            Pancreas     
Male 6 9.3 64.3 (23.5-140.1)   Male 9 12.9 69.6 (31.8-132.2) 
Female 2 2.6 nc (nc-nc)   Female 19 13.7 138.8 (83.5-216.8) 
Hodgkin Lymphoma            Prostate     
Male 3 2.2 nc (nc-nc)   Male 134 114.2 117.4 (98.3-139.0) 
Female 1 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 18.6 75.4 (41.2-126.5)   Male 5 8.6 58.2 (18.8-135.9) 
Female 11 10.8 101.4 (50.6-181.5)   Female 2 5.3 nc (nc-nc) 
Larynx            Testis     
Male 2 5.3 nc (nc-nc)   Male 5 3.5 142.6 (46.0-332.9) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 14.5 75.6 (37.7-135.3)   Male 9 7.9 114.2 (52.1-216.8) 
Female 15 10.6 141.1 (78.9-232.7)   Female 36 22.9 157.4 (110.2-217.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 11.8 nc (nc-nc)             
Female 1 4.0 nc (nc-nc)   Female 28 30.6 91.7 (60.9-132.5) 
Lung and Bronchus            All Sites / Types     
Male 41 63.9 64.2 (46.1-87.1)   Male 425 462.0 92.0 (83.4-101.2) 
Female 39 65.9 59.2 (42.1-80.9)   Female 464 470.3 98.7 (89.9-108.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
208 
New Ashford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.5 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 4 3.6 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
209 
New Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 111 98.2 113.0 (93.0-136.1)   Male 30 62.0 48.4 (32.6-69.1) 
Female 37 39.4 93.9 (66.1-129.4)   Female 18 53.1 33.9 (20.1-53.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 18 18.7 96.0 (56.9-151.8)   Male 21 19.4 108.3 (67.0-165.5) 
Female 14 16.8 83.2 (45.4-139.6)   Female 13 17.3 75.0 (39.9-128.3) 
Breast            Non-Hodgkin Lymphoma     
Male 4 3.3 nc (nc-nc)   Male 48 55.4 86.7 (63.9-115.0) 
Female 345 397.0 86.9 (78.0-96.6)   Female 43 53.3 80.7 (58.4-108.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 54 42.8 126.1 (94.7-164.5) 
Female 22 13.6 161.8 (101.4-245.0)   Female 28 22.0 127.1 (84.5-183.8) 
Colon / Rectum            Ovary     
Male 118 103.5 114.0 (94.4-136.5)             
Female 111 118.9 93.4 (76.8-112.5)   Female 32 36.3 88.2 (60.3-124.5) 
Esophagus            Pancreas     
Male 31 25.2 123.1 (83.6-174.7)   Male 37 33.9 109.1 (76.8-150.3) 
Female 11 7.5 147.2 (73.4-263.5)   Female 58 39.8 145.6 (110.6-188.3) 
Hodgkin Lymphoma            Prostate     
Male 10 7.6 131.7 (63.0-242.2)   Male 334 314.4 106.2 (95.1-118.3) 
Female 3 6.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 60 51.4 116.6 (89.0-150.1)   Male 40 22.7 176.5 (126.1-240.4) 
Female 40 32.5 122.9 (87.8-167.4)   Female 25 15.5 161.6 (104.5-238.5) 
Larynx            Testis     
Male 27 14.6 185.4 (122.1-269.7)   Male 9 14.1 64.0 (29.2-121.5) 
Female 12 4.8 250.9 (129.5-438.3)             
Leukemia            Thyroid     
Male 32 39.4 81.3 (55.6-114.8)   Male 18 23.2 77.5 (45.9-122.5) 
Female 21 32.2 65.1 (40.3-99.6)   Female 79 74.2 106.5 (84.3-132.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 65 32.2 201.6 (155.6-256.9)             
Female 10 11.9 83.7 (40.1-153.9)   Female 89 88.8 100.3 (80.5-123.4) 
Lung and Bronchus            All Sites / Types     
Male 251 173.8 144.4 (127.1-163.4)   Male 1418 1256.5 112.9 (107.1-118.9) 
Female 207 198.7 104.2 (90.5-119.4)   Female 1349 1399.5 96.4 (91.3-101.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
210 
New Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 2 4.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.2 nc (nc-nc)             
Female 4 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.0 nc (nc-nc)   Male 14 15.7 89.4 (48.9-150.1) 
Female 0 1.9 nc (nc-nc)   Female 13 14.1 92.4 (49.1-158.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
211 
New Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.9 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 10 8.7 115.6 (55.3-212.6)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.9 nc (nc-nc)             
Female 2 2.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 9.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.4 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 5.0 nc (nc-nc)   Male 15 35.8 42.0 (23.5-69.2) 
Female 2 4.3 nc (nc-nc)   Female 22 28.8 76.5 (47.9-115.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
212 
New Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 3 5.0 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.6 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.2 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.1 nc (nc-nc)   Male 12 15.8 76.1 (39.3-133.0) 
Female 0 2.2 nc (nc-nc)   Female 11 16.1 68.3 (34.1-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
213 
Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 8.7 80.6 (32.3-166.1)   Male 14 5.7 246.5 (134.7-413.7) 
Female 3 2.6 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.6 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.0 99.4 (32.0-231.9) 
Female 36 31.8 113.3 (79.4-156.9)   Female 4 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 9.5 84.5 (36.4-166.6)             
Female 6 7.8 77.2 (28.2-168.1)   Female 3 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.5 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 33 32.9 100.4 (69.1-140.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.0 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.4 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 7 5.6 125.5 (50.3-258.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 9 7.5 120.5 (55.0-228.7) 
Lung and Bronchus            All Sites / Types     
Male 11 16.1 68.2 (34.0-122.1)   Male 109 119.2 91.5 (75.1-110.4) 
Female 9 15.0 60.2 (27.5-114.2)   Female 95 103.7 91.7 (74.1-112.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
214 
Newburyport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 20.6 92.0 (55.4-143.7)   Male 29 13.4 216.3 (144.8-310.7) 
Female 7 8.4 83.1 (33.3-171.3)   Female 18 11.6 155.7 (92.3-246.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.9 nc (nc-nc)   Male 2 4.3 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 6 3.8 156.2 (57.0-340.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 18 11.9 151.6 (89.8-239.7) 
Female 95 93.4 101.7 (82.3-124.4)   Female 8 11.7 68.3 (29.4-134.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 10.1 118.5 (61.2-207.0) 
Female 0 2.9 nc (nc-nc)   Female 4 5.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 22.5 106.7 (68.4-158.8)             
Female 27 24.7 109.4 (72.1-159.2)   Female 5 8.3 60.2 (19.4-140.5) 
Esophagus            Pancreas     
Male 6 5.7 104.4 (38.1-227.3)   Male 9 7.4 121.0 (55.2-229.7) 
Female 1 1.7 nc (nc-nc)   Female 9 8.4 107.0 (48.8-203.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 85 76.2 111.6 (89.1-138.0) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 11.8 76.5 (34.9-145.2)   Male 6 4.9 122.4 (44.7-266.3) 
Female 3 7.4 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.4 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.1 61.6 (19.9-143.9)   Male 11 5.2 212.4 (105.9-380.1) 
Female 1 6.6 nc (nc-nc)   Female 21 15.7 133.6 (82.7-204.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.6 nc (nc-nc)             
Female 4 2.7 nc (nc-nc)   Female 22 22.3 98.5 (61.7-149.2) 
Lung and Bronchus            All Sites / Types     
Male 22 37.9 58.1 (36.4-87.9)   Male 287 280.1 102.5 (91.0-115.0) 
Female 40 45.5 87.9 (62.8-119.8)   Female 307 313.9 97.8 (87.2-109.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
215 
Newton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 88 102.1 86.2 (69.1-106.2)   Male 69 62.6 110.3 (85.8-139.6) 
Female 46 35.1 130.9 (95.8-174.6)   Female 62 48.3 128.4 (98.4-164.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 24 18.0 133.2 (85.3-198.2)   Male 26 19.9 130.6 (85.3-191.3) 
Female 16 15.4 104.0 (59.4-168.9)   Female 18 15.7 114.5 (67.8-180.9) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.4 nc (nc-nc)   Male 61 56.2 108.6 (83.1-139.5) 
Female 437 375.2 116.5 (105.8-127.9)   Female 53 48.5 109.2 (81.8-142.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 30 43.2 69.5 (46.9-99.2) 
Female 10 12.5 79.7 (38.2-146.6)   Female 28 20.4 137.2 (91.2-198.3) 
Colon / Rectum            Ovary     
Male 92 107.0 86.0 (69.3-105.5)             
Female 82 105.9 77.4 (61.6-96.1)   Female 38 33.7 112.6 (79.7-154.6) 
Esophagus            Pancreas     
Male 11 25.8 42.6 (21.2-76.3)   Male 34 35.0 97.0 (67.2-135.6) 
Female 9 6.8 132.7 (60.6-251.9)   Female 51 35.4 143.9 (107.1-189.2) 
Hodgkin Lymphoma            Prostate     
Male 4 6.9 nc (nc-nc)   Male 341 320.1 106.5 (95.5-118.4) 
Female 3 6.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 56 51.6 108.5 (81.9-140.9)   Male 20 23.3 85.7 (52.3-132.3) 
Female 21 30.1 69.7 (43.2-106.6)   Female 14 13.7 102.3 (55.9-171.7) 
Larynx            Testis     
Male 10 14.8 67.6 (32.4-124.4)   Male 11 11.7 93.8 (46.8-167.9) 
Female 1 4.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 41 39.5 103.8 (74.5-140.9)   Male 34 22.4 152.1 (105.3-212.5) 
Female 22 28.7 76.6 (48.0-115.9)   Female 81 68.0 119.1 (94.6-148.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 31 32.8 94.4 (64.1-134.0)             
Female 9 11.0 81.5 (37.2-154.7)   Female 91 85.7 106.2 (85.5-130.4) 
Lung and Bronchus            All Sites / Types     
Male 130 177.9 73.1 (61.0-86.8)   Male 1189 1278.0 93.0 (87.8-98.5) 
Female 158 182.0 86.8 (73.8-101.5)   Female 1370 1288.7 106.3 (100.8-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
216 
Norfolk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 11.2 62.3 (24.9-128.3)   Male 12 8.5 140.6 (72.6-245.7) 
Female 2 2.5 nc (nc-nc)   Female 7 4.3 161.5 (64.7-332.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.8 nc (nc-nc)   Male 4 2.6 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 8 7.7 104.5 (45.0-205.9) 
Female 46 36.0 127.9 (93.6-170.6)   Female 0 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 7.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 13.9 79.2 (39.5-141.7)             
Female 8 7.8 103.1 (44.4-203.2)   Female 1 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.6 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 44 49.3 89.3 (64.9-119.9) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 8.1 74.1 (27.1-161.4)   Male 6 2.9 205.2 (74.9-446.6) 
Female 4 2.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 5.1 118.1 (43.1-257.1)   Male 2 4.2 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 8 7.1 112.7 (48.5-222.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.1 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 7 8.5 82.6 (33.1-170.1) 
Lung and Bronchus            All Sites / Types     
Male 19 21.5 88.5 (53.2-138.2)   Male 149 176.5 84.4 (71.4-99.1) 
Female 12 14.2 84.3 (43.5-147.3)   Female 113 111.4 101.4 (83.6-121.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
217 
North Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 17.1 105.4 (62.4-166.5)   Male 6 10.4 57.6 (21.0-125.4) 
Female 12 5.9 202.8 (104.6-354.2)   Female 8 7.8 102.5 (44.1-201.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.0 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 12 9.3 129.1 (66.6-225.5) 
Female 52 60.6 85.8 (64.1-112.5)   Female 7 8.0 88.0 (35.3-181.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.9 72.8 (23.5-169.9) 
Female 1 1.9 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 17.6 153.3 (101.0-223.0)             
Female 22 17.3 127.1 (79.7-192.5)   Female 6 5.4 110.4 (40.3-240.4) 
Esophagus            Pancreas     
Male 8 4.2 191.5 (82.5-377.3)   Male 0 5.7 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 10 5.9 169.6 (81.2-311.8) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 51 49.7 102.6 (76.4-134.9) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 8.3 167.7 (91.6-281.5)   Male 6 3.9 155.8 (56.9-339.1) 
Female 2 5.0 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 4 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.6 90.9 (33.2-197.8)   Male 3 3.7 nc (nc-nc) 
Female 5 4.7 107.0 (34.5-249.7)   Female 9 10.7 84.4 (38.5-160.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 5.2 209.6 (104.5-375.1)             
Female 3 1.8 nc (nc-nc)   Female 12 13.7 87.9 (45.4-153.6) 
Lung and Bronchus            All Sites / Types     
Male 34 29.7 114.5 (79.3-160.0)   Male 230 208.2 110.5 (96.7-125.7) 
Female 47 31.4 149.8 (110.0-199.2)   Female 223 210.8 105.8 (92.4-120.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
218 
North Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 28.9 121.1 (84.3-168.4)   Male 18 18.8 95.5 (56.6-151.0) 
Female 13 11.5 112.7 (59.9-192.7)   Female 12 15.7 76.3 (39.4-133.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.8 102.9 (37.6-224.1)   Male 5 5.8 85.5 (27.5-199.5) 
Female 7 4.9 142.4 (57.1-293.4)   Female 5 5.1 97.9 (31.6-228.5) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.0 nc (nc-nc)   Male 19 17.0 111.8 (67.3-174.7) 
Female 117 123.4 94.8 (78.4-113.6)   Female 17 15.8 107.8 (62.8-172.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 13.7 80.4 (40.1-143.8) 
Female 5 4.2 119.9 (38.6-279.7)   Female 5 6.6 75.8 (24.4-176.9) 
Colon / Rectum            Ovary     
Male 29 32.0 90.6 (60.6-130.1)             
Female 45 35.2 128.0 (93.3-171.2)   Female 9 10.9 82.4 (37.6-156.4) 
Esophagus            Pancreas     
Male 7 7.6 91.9 (36.8-189.4)   Male 13 10.2 127.5 (67.8-218.0) 
Female 1 2.2 nc (nc-nc)   Female 9 11.6 77.4 (35.3-147.0) 
Hodgkin Lymphoma            Prostate     
Male 3 2.3 nc (nc-nc)   Male 102 94.6 107.8 (87.9-130.9) 
Female 3 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 16.0 118.7 (71.4-185.4)   Male 8 6.8 117.1 (50.4-230.8) 
Female 7 9.8 71.2 (28.5-146.7)   Female 6 4.6 131.4 (48.0-286.1) 
Larynx            Testis     
Male 1 4.4 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 11.9 83.7 (40.1-154.0)   Male 10 7.5 133.0 (63.7-244.6) 
Female 10 9.3 107.0 (51.2-196.8)   Female 27 22.4 120.7 (79.5-175.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 10.0 nc (nc-nc)             
Female 3 3.5 nc (nc-nc)   Female 22 27.1 81.2 (50.9-123.0) 
Lung and Bronchus            All Sites / Types     
Male 36 50.8 70.8 (49.6-98.1)   Male 375 380.0 98.7 (89.0-109.2) 
Female 52 59.2 87.8 (65.6-115.2)   Female 407 421.2 96.6 (87.5-106.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
219 
North Attleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 23.1 90.7 (56.1-138.7)   Male 17 16.3 104.1 (60.6-166.7) 
Female 7 8.2 85.1 (34.1-175.4)   Female 22 13.4 164.2 (102.9-248.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.5 108.8 (39.7-236.8)   Male 4 5.0 nc (nc-nc) 
Female 8 4.3 185.5 (79.9-365.6)   Female 3 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 17 14.7 115.6 (67.3-185.1) 
Female 103 104.5 98.5 (80.4-119.5)   Female 14 12.2 114.4 (62.5-191.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 12.7 86.9 (43.3-155.5) 
Female 2 4.0 nc (nc-nc)   Female 8 5.3 151.7 (65.3-298.9) 
Colon / Rectum            Ovary     
Male 33 26.9 122.8 (84.5-172.5)             
Female 26 26.2 99.4 (64.9-145.6)   Female 5 9.1 55.2 (17.8-128.9) 
Esophagus            Pancreas     
Male 8 6.7 119.8 (51.6-236.1)   Male 6 8.6 70.1 (25.6-152.5) 
Female 1 1.6 nc (nc-nc)   Female 10 8.3 120.6 (57.7-221.7) 
Hodgkin Lymphoma            Prostate     
Male 3 2.3 nc (nc-nc)   Male 96 88.7 108.3 (87.7-132.2) 
Female 2 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 14.8 94.7 (51.7-159.0)   Male 3 5.7 nc (nc-nc) 
Female 6 7.9 75.7 (27.6-164.7)   Female 2 3.3 nc (nc-nc) 
Larynx            Testis     
Male 8 4.0 201.9 (86.9-397.8)   Male 4 4.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 10.3 58.0 (21.2-126.3)   Male 6 7.3 81.7 (29.8-177.7) 
Female 5 7.4 67.2 (21.7-156.8)   Female 27 21.8 123.9 (81.6-180.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 9.1 110.0 (52.7-202.4)             
Female 1 2.7 nc (nc-nc)   Female 21 22.9 91.7 (56.8-140.2) 
Lung and Bronchus            All Sites / Types     
Male 45 42.9 105.0 (76.6-140.5)   Male 347 334.5 103.7 (93.1-115.2) 
Female 47 43.8 107.4 (78.9-142.8)   Female 342 339.8 100.7 (90.3-111.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
220 
North Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 4.3 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 15 20.7 72.5 (40.6-119.6)   Female 4 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.3 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.0 nc (nc-nc)             
Female 5 5.5 91.1 (29.4-212.6)   Female 4 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.2 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 18 15.6 115.5 (68.4-182.6) 
Female 2 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.7 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.7 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 8.2 97.7 (42.1-192.5)   Male 64 60.9 105.2 (81.0-134.3) 
Female 5 9.6 52.0 (16.8-121.3)   Female 57 68.6 83.1 (63.0-107.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
221 
North Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 14.4 76.5 (38.1-136.9)   Male 16 9.8 163.0 (93.1-264.8) 
Female 8 5.2 153.9 (66.3-303.4)   Female 13 8.1 160.7 (85.5-274.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.1 160.3 (51.6-374.0)   Male 4 3.1 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 8 8.8 90.6 (39.0-178.4) 
Female 76 65.9 115.4 (90.9-144.4)   Female 5 7.6 65.6 (21.1-153.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.6 66.0 (21.3-154.0) 
Female 3 2.3 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 16.3 85.6 (46.8-143.7)             
Female 15 16.1 93.4 (52.2-154.1)   Female 3 5.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 9 4.1 217.7 (99.4-413.3)   Male 3 5.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 5.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 50 54.8 91.2 (67.7-120.2) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 8.9 101.4 (46.2-192.4)   Male 2 3.5 nc (nc-nc) 
Female 3 5.0 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 5 2.4 205.4 (66.2-479.3)   Male 1 2.3 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 6.0 198.5 (102.4-346.7)   Male 4 4.3 nc (nc-nc) 
Female 7 4.3 162.0 (64.9-333.7)   Female 16 12.5 128.1 (73.2-208.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.5 nc (nc-nc)             
Female 3 1.7 nc (nc-nc)   Female 18 14.7 122.4 (72.5-193.5) 
Lung and Bronchus            All Sites / Types     
Male 19 26.5 71.7 (43.1-112.0)   Male 201 203.6 98.7 (85.5-113.4) 
Female 23 29.0 79.3 (50.2-118.9)   Female 214 211.9 101.0 (87.9-115.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
222 
Northampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 29.4 108.7 (74.3-153.5)   Male 12 18.8 63.7 (32.9-111.3) 
Female 10 11.1 90.1 (43.1-165.7)   Female 12 16.1 74.4 (38.4-130.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.5 108.4 (39.6-235.9)   Male 1 6.0 nc (nc-nc) 
Female 6 5.1 118.8 (43.4-258.6)   Female 9 5.0 180.4 (82.3-342.5) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 15 16.9 89.0 (49.8-146.8) 
Female 153 119.9 127.6 (108.2-149.5)   Female 18 15.6 115.6 (68.5-182.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 13.6 110.3 (61.7-182.0) 
Female 3 4.1 nc (nc-nc)   Female 8 6.5 122.2 (52.6-240.8) 
Colon / Rectum            Ovary     
Male 31 31.5 98.5 (66.9-139.8)             
Female 35 33.6 104.1 (72.5-144.7)   Female 15 11.0 136.4 (76.3-225.0) 
Esophagus            Pancreas     
Male 5 7.9 63.0 (20.3-147.1)   Male 9 10.4 86.9 (39.7-165.0) 
Female 5 2.2 232.3 (74.8-542.0)   Female 14 11.2 124.6 (68.0-209.0) 
Hodgkin Lymphoma            Prostate     
Male 3 2.2 nc (nc-nc)   Male 68 103.0 66.0 (51.3-83.7) 
Female 2 2.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 16.2 55.4 (25.3-105.2)   Male 5 6.9 72.8 (23.5-169.8) 
Female 9 9.5 94.4 (43.1-179.2)   Female 4 4.4 nc (nc-nc) 
Larynx            Testis     
Male 3 4.6 nc (nc-nc)   Male 6 4.0 151.6 (55.3-329.9) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 11.6 112.5 (59.8-192.4)   Male 5 7.3 68.4 (22.0-159.7) 
Female 10 9.2 108.7 (52.0-199.9)   Female 11 23.5 46.7 (23.3-83.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 10.1 69.4 (27.8-143.0)             
Female 1 3.5 nc (nc-nc)   Female 33 27.6 119.5 (82.2-167.8) 
Lung and Bronchus            All Sites / Types     
Male 47 52.8 89.1 (65.5-118.5)   Male 313 389.3 80.4 (71.7-89.8) 
Female 56 56.9 98.4 (74.3-127.8)   Female 451 413.8 109.0 (99.2-119.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
223 
Northborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 15.2 132.0 (80.6-203.9)   Male 9 9.9 91.0 (41.5-172.7) 
Female 9 5.4 166.5 (76.0-316.1)   Female 6 7.7 78.1 (28.5-170.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.0 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 5 8.9 56.0 (18.1-130.7) 
Female 71 59.7 118.9 (92.9-150.0)   Female 3 7.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 7.4 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 17.0 70.8 (36.5-123.7)             
Female 15 17.0 88.1 (49.3-145.3)   Female 3 5.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 4.0 148.7 (54.3-323.6)   Male 5 5.4 92.6 (29.8-216.0) 
Female 0 1.0 nc (nc-nc)   Female 7 5.5 127.3 (51.0-262.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 48 51.3 93.6 (69.0-124.1) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 8.5 70.6 (25.8-153.7)   Male 1 3.6 nc (nc-nc) 
Female 5 4.7 106.0 (34.1-247.3)   Female 3 2.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 6.2 193.7 (100.0-338.4)   Male 2 3.9 nc (nc-nc) 
Female 3 4.5 nc (nc-nc)   Female 8 11.0 72.4 (31.2-142.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.4 nc (nc-nc)             
Female 1 1.7 nc (nc-nc)   Female 21 13.3 157.7 (97.6-241.0) 
Lung and Bronchus            All Sites / Types     
Male 16 26.8 59.8 (34.1-97.1)   Male 172 201.7 85.3 (73.0-99.0) 
Female 18 27.5 65.6 (38.8-103.6)   Female 196 202.5 96.8 (83.7-111.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
224 
Northbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 15.8 138.8 (87.0-210.2)   Male 8 10.4 77.2 (33.2-152.0) 
Female 8 5.3 150.8 (64.9-297.1)   Female 9 8.1 111.5 (50.9-211.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.2 nc (nc-nc)   Male 8 3.3 245.6 (105.8-484.0) 
Female 1 2.6 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 5 9.3 53.7 (17.3-125.4) 
Female 52 62.0 83.9 (62.6-110.0)   Female 7 7.6 91.9 (36.8-189.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.5 133.4 (63.9-245.3) 
Female 2 2.2 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 17.4 69.0 (35.6-120.5)             
Female 27 16.4 164.5 (108.4-239.3)   Female 6 5.5 109.3 (39.9-237.9) 
Esophagus            Pancreas     
Male 5 4.2 118.9 (38.3-277.4)   Male 3 5.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 9 5.3 168.9 (77.1-320.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.2 nc (nc-nc)   Male 60 53.1 113.0 (86.2-145.5) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 8.9 224.8 (137.2-347.2)   Male 1 3.8 nc (nc-nc) 
Female 3 4.8 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.5 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.5 92.2 (33.7-200.8)   Male 2 4.1 nc (nc-nc) 
Female 4 4.6 nc (nc-nc)   Female 13 12.4 104.8 (55.7-179.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.6 nc (nc-nc)             
Female 4 1.7 nc (nc-nc)   Female 20 13.9 143.9 (87.9-222.3) 
Lung and Bronchus            All Sites / Types     
Male 32 28.3 113.2 (77.4-159.8)   Male 223 210.0 106.2 (92.7-121.1) 
Female 26 27.7 93.8 (61.2-137.4)   Female 220 207.2 106.2 (92.6-121.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
225 
Northfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 13 14.2 91.7 (48.8-156.8)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.6 108.8 (35.1-253.9)             
Female 1 3.4 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 7 15.4 45.4 (18.2-93.6) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.6 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.4 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 7.6 nc (nc-nc)   Male 33 56.4 58.5 (40.2-82.1) 
Female 4 6.5 nc (nc-nc)   Female 38 46.1 82.5 (58.4-113.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
226 
Norton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 16.8 59.4 (28.5-109.3)   Male 14 11.5 121.3 (66.3-203.6) 
Female 8 6.3 127.4 (54.9-251.1)   Female 15 9.7 155.2 (86.8-255.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.7 135.3 (43.6-315.6)   Male 1 3.6 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 7 10.4 67.5 (27.0-139.0) 
Female 68 75.9 89.6 (69.5-113.5)   Female 13 9.1 142.5 (75.8-243.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.9 89.7 (38.6-176.7) 
Female 2 2.6 nc (nc-nc)   Female 3 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 19.1 141.3 (93.1-205.6)             
Female 28 19.5 143.7 (95.5-207.7)   Female 7 6.8 103.6 (41.5-213.4) 
Esophagus            Pancreas     
Male 5 4.8 103.8 (33.4-242.2)   Male 9 6.2 146.3 (66.8-277.7) 
Female 1 1.2 nc (nc-nc)   Female 11 6.4 173.1 (86.3-309.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.6 nc (nc-nc)   Male 60 63.0 95.3 (72.7-122.6) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.3 126.7 (67.4-216.6)   Male 3 4.1 nc (nc-nc) 
Female 10 5.8 172.8 (82.7-317.7)   Female 2 2.5 nc (nc-nc) 
Larynx            Testis     
Male 2 2.8 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 7.2 83.3 (30.4-181.2)   Male 8 5.0 160.2 (69.0-315.6) 
Female 6 5.3 112.4 (41.0-244.6)   Female 15 14.7 101.8 (57.0-168.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 6.5 153.5 (73.5-282.3)             
Female 0 2.1 nc (nc-nc)   Female 25 17.4 143.5 (92.8-211.8) 
Lung and Bronchus            All Sites / Types     
Male 27 31.0 87.0 (57.3-126.6)   Male 239 237.7 100.6 (88.2-114.1) 
Female 27 33.0 81.9 (54.0-119.2)   Female 271 249.8 108.5 (96.0-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
227 
Norwell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 12.9 85.6 (42.7-153.1)   Male 5 8.1 61.7 (19.9-144.1) 
Female 2 4.6 nc (nc-nc)   Female 14 6.1 229.3 (125.3-384.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.4 250.3 (91.4-544.8)   Male 1 2.6 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 5 2.1 240.9 (77.6-562.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 6 7.3 82.7 (30.2-180.1) 
Female 45 50.0 90.1 (65.7-120.5)   Female 11 6.3 173.3 (86.4-310.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.9 85.2 (27.4-198.7) 
Female 1 1.5 nc (nc-nc)   Female 9 2.7 336.2 (153.4-638.3) 
Colon / Rectum            Ovary     
Male 10 13.9 72.1 (34.5-132.6)             
Female 8 13.8 57.9 (24.9-114.1)   Female 7 4.4 158.4 (63.5-326.3) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 4 4.5 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 6 4.7 127.7 (46.6-278.0) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 40 43.3 92.3 (65.9-125.7) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 6.9 86.7 (31.7-188.8)   Male 2 3.0 nc (nc-nc) 
Female 5 4.0 126.2 (40.7-294.4)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.1 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 3 8.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.4 114.1 (36.8-266.2)             
Female 1 1.5 nc (nc-nc)   Female 15 11.5 130.3 (72.9-214.9) 
Lung and Bronchus            All Sites / Types     
Male 13 23.0 56.5 (30.1-96.6)   Male 137 167.1 82.0 (68.8-96.9) 
Female 15 24.5 61.3 (34.3-101.1)   Female 172 168.9 101.8 (87.2-118.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
228 
Norwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 34.0 41.1 (22.5-69.0)   Male 33 21.5 153.5 (105.7-215.6) 
Female 13 12.3 105.4 (56.0-180.2)   Female 25 16.4 152.4 (98.6-225.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 6.3 159.6 (76.4-293.5)   Male 8 6.8 117.2 (50.5-231.0) 
Female 7 5.1 137.8 (55.2-283.9)   Female 5 5.4 92.1 (29.7-215.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 22 19.1 115.5 (72.3-174.8) 
Female 133 125.9 105.6 (88.4-125.2)   Female 17 16.7 102.1 (59.4-163.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 14.6 82.1 (42.4-143.4) 
Female 4 4.2 nc (nc-nc)   Female 6 6.9 87.1 (31.8-189.7) 
Colon / Rectum            Ovary     
Male 48 35.7 134.3 (99.0-178.1)             
Female 49 37.4 131.2 (97.0-173.4)   Female 15 11.3 132.2 (73.9-218.0) 
Esophagus            Pancreas     
Male 10 8.6 115.6 (55.4-212.6)   Male 18 11.6 154.9 (91.8-244.8) 
Female 3 2.4 nc (nc-nc)   Female 21 12.5 168.1 (104.0-257.0) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 93 104.5 89.0 (71.8-109.0) 
Female 3 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 17.6 85.0 (47.5-140.2)   Male 9 7.8 114.9 (52.4-218.1) 
Female 15 10.2 146.4 (81.9-241.4)   Female 7 4.8 144.5 (57.9-297.7) 
Larynx            Testis     
Male 8 5.0 159.3 (68.6-313.9)   Male 6 4.5 134.8 (49.2-293.3) 
Female 4 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 13.4 97.2 (51.7-166.2)   Male 14 7.9 177.4 (96.9-297.6) 
Female 11 9.9 111.1 (55.4-198.8)   Female 29 22.5 128.9 (86.3-185.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 11.1 134.8 (75.4-222.4)             
Female 4 3.7 nc (nc-nc)   Female 32 27.8 115.1 (78.7-162.5) 
Lung and Bronchus            All Sites / Types     
Male 62 60.5 102.4 (78.5-131.3)   Male 460 429.0 107.2 (97.7-117.5) 
Female 83 63.3 131.2 (104.5-162.6)   Female 517 439.1 117.7 (107.8-128.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
229 
Oak Bluffs 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 6.9 115.8 (49.9-228.3)   Male 10 4.3 233.9 (112.0-430.2) 
Female 0 2.4 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 26 21.8 119.5 (78.0-175.1)   Female 2 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.8 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 6.9 115.3 (49.6-227.2)             
Female 6 7.1 84.1 (30.7-183.0)   Female 3 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.7 nc (nc-nc)   Male 6 2.3 256.9 (93.8-559.3) 
Female 0 0.5 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 16 20.7 77.4 (44.2-125.6) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.4 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.6 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.2 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 8 4.9 163.5 (70.4-322.1) 
Lung and Bronchus            All Sites / Types     
Male 8 12.5 64.1 (27.6-126.4)   Male 80 84.8 94.3 (74.8-117.4) 
Female 15 11.4 131.4 (73.5-216.7)   Female 84 78.5 107.1 (85.4-132.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
230 
Oakham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 6 8.0 75.2 (27.5-163.7)   Female 2 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.4 nc (nc-nc)             
Female 2 1.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 11 8.1 135.1 (67.3-241.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.9 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 4.1 nc (nc-nc)   Male 26 30.0 86.5 (56.5-126.8) 
Female 1 3.3 nc (nc-nc)   Female 23 25.2 91.1 (57.8-136.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
231 
Orange 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 9.3 53.6 (17.3-125.0)   Male 2 6.0 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.8 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.3 150.6 (64.8-296.8) 
Female 33 33.9 97.5 (67.1-136.9)   Female 3 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 9.8 51.0 (16.4-118.9)             
Female 4 9.2 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.5 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 29 31.1 93.3 (62.5-134.1) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.1 99.0 (31.9-231.0)   Male 0 2.2 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.5 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.7 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 12 7.7 154.9 (80.0-270.7) 
Lung and Bronchus            All Sites / Types     
Male 17 17.1 99.4 (57.9-159.2)   Male 105 121.9 86.1 (70.5-104.3) 
Female 13 16.4 79.3 (42.2-135.6)   Female 100 114.3 87.5 (71.2-106.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
232 
Orleans 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 15.7 89.0 (48.6-149.3)   Male 19 8.7 218.4 (131.4-341.1) 
Female 7 5.2 133.5 (53.5-275.1)   Female 10 5.6 178.9 (85.6-329.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 7.5 132.7 (63.5-244.1) 
Female 67 46.6 143.8 (111.5-182.7)   Female 6 6.6 91.1 (33.3-198.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 14.4 90.0 (47.9-153.9)             
Female 15 14.4 104.4 (58.4-172.2)   Female 3 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.8 nc (nc-nc)   Male 4 5.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 7 5.2 135.2 (54.2-278.6) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 29 47.3 61.3 (41.1-88.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 6.8 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 2 4.1 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.2 133.5 (53.5-275.1)   Male 1 2.2 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 3 5.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 13 11.3 114.9 (61.1-196.5) 
Lung and Bronchus            All Sites / Types     
Male 12 28.3 42.5 (21.9-74.2)   Male 144 181.2 79.5 (67.0-93.6) 
Female 18 28.0 64.4 (38.1-101.8)   Female 183 168.0 108.9 (93.7-125.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
233 
Otis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.8 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 13 7.4 176.5 (93.9-301.9)   Female 3 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.9 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 9 9.6 94.1 (42.9-178.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 5.2 154.2 (66.4-303.9)   Male 30 35.8 83.9 (56.6-119.8) 
Female 4 3.7 nc (nc-nc)   Female 30 24.3 123.6 (83.4-176.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
234 
Oxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 11.0 181.7 (111.0-280.7)   Male 12 7.9 151.7 (78.3-265.0) 
Female 7 4.5 156.1 (62.5-321.7)   Female 6 7.0 85.3 (31.2-185.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.7 nc (nc-nc)   Male 5 2.4 207.4 (66.8-484.0) 
Female 0 2.2 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 8 7.1 112.4 (48.4-221.5) 
Female 60 54.9 109.3 (83.4-140.7)   Female 9 6.6 137.2 (62.6-260.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 6.2 145.5 (66.4-276.2) 
Female 0 2.0 nc (nc-nc)   Female 4 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 13.2 60.8 (26.2-119.9)             
Female 17 14.2 119.3 (69.5-191.1)   Female 6 4.8 124.4 (45.4-270.8) 
Esophagus            Pancreas     
Male 4 3.2 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 47 42.1 111.7 (82.1-148.6) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.2 83.3 (30.4-181.2)   Male 0 2.8 nc (nc-nc) 
Female 4 4.2 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Larynx            Testis     
Male 4 1.9 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.0 201.3 (96.4-370.3)   Male 6 3.6 165.1 (60.3-359.4) 
Female 7 3.9 181.6 (72.8-374.3)   Female 16 10.9 146.5 (83.7-237.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.4 159.0 (63.7-327.6)             
Female 1 1.5 nc (nc-nc)   Female 19 12.2 155.9 (93.8-243.5) 
Lung and Bronchus            All Sites / Types     
Male 37 20.4 181.8 (128.0-250.6)   Male 200 160.6 124.6 (107.9-143.1) 
Female 34 23.7 143.3 (99.2-200.2)   Female 222 180.0 123.3 (107.6-140.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
235 
Palmer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 11.9 150.6 (89.2-238.1)   Male 11 8.2 134.0 (66.8-239.7) 
Female 9 5.6 161.8 (73.8-307.1)   Female 8 7.3 110.3 (47.5-217.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.5 237.3 (86.6-516.4)   Male 0 2.6 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 1 7.3 nc (nc-nc) 
Female 58 56.4 102.8 (78.0-132.9)   Female 6 7.4 80.9 (29.6-176.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.3 111.3 (44.6-229.3) 
Female 2 1.8 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 13.6 88.5 (45.7-154.7)             
Female 14 16.6 84.4 (46.1-141.6)   Female 5 5.1 98.0 (31.6-228.7) 
Esophagus            Pancreas     
Male 4 3.4 nc (nc-nc)   Male 5 4.4 114.7 (37.0-267.6) 
Female 0 1.1 nc (nc-nc)   Female 7 5.6 124.8 (50.0-257.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 37 43.8 84.4 (59.4-116.4) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 7.2 139.2 (66.6-256.0)   Male 6 2.9 205.9 (75.2-448.3) 
Female 2 4.6 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Larynx            Testis     
Male 5 2.0 248.4 (80.0-579.6)   Male 1 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.0 100.7 (32.5-235.0)   Male 1 3.4 nc (nc-nc) 
Female 6 4.4 136.7 (49.9-297.6)   Female 9 9.8 91.5 (41.8-173.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.7 106.2 (34.2-247.7)             
Female 2 1.7 nc (nc-nc)   Female 12 12.6 95.2 (49.1-166.3) 
Lung and Bronchus            All Sites / Types     
Male 33 22.1 149.0 (102.6-209.3)   Male 179 167.1 107.1 (92.0-124.0) 
Female 16 28.1 56.9 (32.5-92.4)   Female 173 196.1 88.2 (75.6-102.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
236 
Paxton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.9 nc (nc-nc)   Male 6 3.7 162.4 (59.3-353.4) 
Female 1 1.8 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.1 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 20 19.9 100.6 (61.4-155.3)   Female 1 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 6.1 nc (nc-nc)             
Female 7 5.2 135.1 (54.1-278.3)   Female 1 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.6 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 26 19.1 136.1 (88.9-199.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Larynx            Testis     
Male 3 0.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.0 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 4 4.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 10.7 65.7 (26.3-135.3)   Male 75 75.5 99.3 (78.1-124.5) 
Female 6 9.4 63.6 (23.2-138.5)   Female 61 66.8 91.4 (69.9-117.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peabody 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 87 72.3 120.4 (96.4-148.5)   Male 38 43.0 88.4 (62.6-121.4) 
Female 36 27.9 129.1 (90.4-178.8)   Female 33 34.4 96.1 (66.1-134.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 11.7 85.2 (40.8-156.6)   Male 21 13.7 152.8 (94.6-233.6) 
Female 14 10.3 135.3 (73.9-227.0)   Female 20 12.0 166.0 (101.4-256.4) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.4 nc (nc-nc)   Male 43 38.4 112.1 (81.1-151.0) 
Female 276 262.2 105.3 (93.2-118.5)   Female 56 36.5 153.6 (116.0-199.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 35 28.4 123.0 (85.7-171.1) 
Female 12 8.3 145.4 (75.0-254.0)   Female 13 14.9 87.4 (46.5-149.4) 
Colon / Rectum            Ovary     
Male 58 73.5 78.9 (59.9-102.0)             
Female 90 84.5 106.5 (85.6-130.9)   Female 20 24.0 83.2 (50.8-128.6) 
Esophagus            Pancreas     
Male 13 17.6 73.7 (39.2-126.1)   Male 22 24.3 90.4 (56.7-136.9) 
Female 3 5.3 nc (nc-nc)   Female 33 28.6 115.5 (79.5-162.2) 
Hodgkin Lymphoma            Prostate     
Male 5 4.3 116.6 (37.6-272.0)   Male 252 211.4 119.2 (104.9-134.9) 
Female 8 3.7 215.3 (92.7-424.2)             
Kidney & Renal Pelvis            Stomach     
Male 28 34.4 81.5 (54.1-117.7)   Male 15 16.2 92.6 (51.8-152.7) 
Female 19 21.6 87.9 (52.9-137.3)   Female 8 11.1 72.2 (31.1-142.2) 
Larynx            Testis     
Male 16 10.0 160.7 (91.8-260.9)   Male 12 7.1 168.9 (87.2-295.1) 
Female 2 3.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 32 27.1 118.1 (80.8-166.8)   Male 15 14.3 105.0 (58.7-173.1) 
Female 28 21.4 131.0 (87.0-189.3)   Female 43 43.5 98.9 (71.6-133.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 23 21.8 105.4 (66.8-158.2)             
Female 9 8.2 110.3 (50.3-209.5)   Female 55 57.9 95.0 (71.6-123.7) 
Lung and Bronchus            All Sites / Types     
Male 122 124.3 98.1 (81.5-117.2)   Male 945 868.6 108.8 (102.0-116.0) 
Female 161 136.5 117.9 (100.4-137.6)   Female 1031 938.7 109.8 (103.2-116.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pelham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 4 7.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.1 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 7.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 3.5 nc (nc-nc)   Male 12 25.8 46.4 (24.0-81.1) 
Female 0 3.7 nc (nc-nc)   Female 10 25.3 39.6 (18.9-72.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pembroke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 16.2 129.5 (80.1-197.9)   Male 12 11.1 108.1 (55.8-188.8) 
Female 8 5.4 148.6 (64.0-292.8)   Female 13 9.0 143.7 (76.5-245.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.5 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 13 9.9 130.7 (69.5-223.6) 
Female 89 72.8 122.2 (98.1-150.3)   Female 8 8.3 96.9 (41.7-190.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 8.5 129.6 (64.6-232.0) 
Female 1 2.7 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 18.6 140.1 (91.5-205.3)             
Female 24 16.9 141.9 (90.9-211.1)   Female 4 6.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 4.6 109.7 (35.4-256.1)   Male 4 5.9 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.4 nc (nc-nc)   Male 68 59.4 114.6 (89.0-145.2) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 9.9 131.8 (70.1-225.3)   Male 5 4.0 126.5 (40.8-295.1) 
Female 7 5.4 129.4 (51.9-266.7)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 4 2.7 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 6.9 130.0 (59.3-246.9)   Male 6 4.7 126.8 (46.3-276.0) 
Female 6 4.8 125.7 (45.9-273.7)   Female 20 14.7 136.1 (83.1-210.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.2 nc (nc-nc)             
Female 1 1.9 nc (nc-nc)   Female 17 16.6 102.4 (59.6-163.9) 
Lung and Bronchus            All Sites / Types     
Male 36 29.7 121.2 (84.9-167.9)   Male 260 226.8 114.6 (101.1-129.4) 
Female 47 29.9 157.1 (115.4-208.9)   Female 276 231.1 119.4 (105.7-134.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pepperell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 10.5 47.4 (15.3-110.7)   Male 8 7.5 107.1 (46.1-211.0) 
Female 3 3.4 nc (nc-nc)   Female 3 5.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.4 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 6.7 103.7 (41.5-213.7) 
Female 52 47.6 109.2 (81.5-143.2)   Female 5 5.2 95.5 (30.8-222.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.2 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 12.5 87.9 (43.8-157.4)             
Female 16 10.5 152.7 (87.2-248.0)   Female 2 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.2 nc (nc-nc)   Male 5 4.0 125.1 (40.3-291.9) 
Female 0 0.7 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 31 43.6 71.1 (48.3-100.9) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.9 72.1 (23.2-168.1)   Male 3 2.6 nc (nc-nc) 
Female 5 3.5 142.6 (45.9-332.7)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.6 109.8 (35.4-256.2)   Male 7 3.4 208.3 (83.4-429.1) 
Female 4 2.9 nc (nc-nc)   Female 7 9.4 74.7 (29.9-153.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.5 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 15 11.1 135.2 (75.6-223.0) 
Lung and Bronchus            All Sites / Types     
Male 22 19.7 111.5 (69.8-168.8)   Male 141 156.8 89.9 (75.7-106.1) 
Female 19 19.5 97.5 (58.7-152.3)   Female 156 148.6 105.0 (89.1-122.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peru 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.6 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 3.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 0.8 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.2 nc (nc-nc)   Male 11 10.2 108.2 (53.9-193.6) 
Female 0 1.1 nc (nc-nc)   Female 3 9.7 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Petersham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.7 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 6 7.1 84.3 (30.8-183.6)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.8 nc (nc-nc)             
Female 0 2.3 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 5.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.5 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.8 nc (nc-nc)   Male 13 21.0 61.9 (32.9-105.9) 
Female 0 3.7 nc (nc-nc)   Female 14 25.2 55.5 (30.3-93.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Phillipston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.6 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 5 6.8 73.3 (23.6-171.0)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.9 nc (nc-nc)             
Female 0 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 6 6.3 95.9 (35.0-208.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.9 nc (nc-nc)   Male 17 23.3 73.0 (42.5-116.9) 
Female 3 2.6 nc (nc-nc)   Female 19 21.0 90.6 (54.5-141.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pittsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 62 54.6 113.5 (87.0-145.5)   Male 31 33.8 91.8 (62.3-130.3) 
Female 26 22.3 116.8 (76.3-171.1)   Female 28 28.6 97.9 (65.0-141.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 9.6 145.4 (79.4-244.0)   Male 9 10.7 83.8 (38.2-159.0) 
Female 7 8.8 79.5 (31.9-163.8)   Female 3 9.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 34 30.1 112.8 (78.1-157.6) 
Female 201 222.6 90.3 (78.2-103.7)   Female 31 29.8 104.1 (70.7-147.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 23.7 139.1 (95.7-195.3) 
Female 9 7.0 128.1 (58.5-243.2)   Female 10 12.4 80.9 (38.7-148.7) 
Colon / Rectum            Ovary     
Male 55 57.3 96.1 (72.4-125.0)             
Female 79 66.0 119.8 (94.8-149.3)   Female 13 20.2 64.3 (34.2-110.0) 
Esophagus            Pancreas     
Male 26 14.1 184.2 (120.3-270.0)   Male 20 19.0 105.5 (64.4-162.9) 
Female 5 4.3 117.5 (37.9-274.2)   Female 13 22.4 58.0 (30.8-99.1) 
Hodgkin Lymphoma            Prostate     
Male 3 3.6 nc (nc-nc)   Male 163 178.6 91.3 (77.8-106.4) 
Female 2 3.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 28.1 103.0 (69.0-148.0)   Male 8 12.6 63.6 (27.4-125.4) 
Female 19 18.2 104.1 (62.7-162.6)   Female 9 8.6 105.2 (48.0-199.7) 
Larynx            Testis     
Male 8 8.2 98.2 (42.3-193.4)   Male 8 6.2 128.1 (55.2-252.4) 
Female 3 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 21.0 85.7 (50.7-135.4)   Male 15 12.1 123.5 (69.1-203.8) 
Female 8 17.3 46.1 (19.9-90.9)   Female 32 37.6 85.2 (58.3-120.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 18.1 94.0 (54.7-150.5)             
Female 6 6.8 88.0 (32.1-191.6)   Female 52 51.0 101.9 (76.1-133.6) 
Lung and Bronchus            All Sites / Types     
Male 112 96.3 116.3 (95.8-139.9)   Male 723 694.8 104.1 (96.6-111.9) 
Female 143 114.3 125.1 (105.4-147.4)   Female 757 779.5 97.1 (90.3-104.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
245 
Plainfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.1 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.1 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.1 nc (nc-nc)   Male 12 14.8 81.2 (41.9-141.9) 
Female 2 1.8 nc (nc-nc)   Female 10 12.1 82.4 (39.4-151.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Plainville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 7.1 182.4 (97.0-311.9)   Male 5 5.0 100.2 (32.3-233.7) 
Female 2 3.0 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 8 4.5 178.2 (76.7-351.1) 
Female 39 34.8 112.0 (79.7-153.2)   Female 3 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.9 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 8.3 83.9 (33.6-172.8)             
Female 12 9.4 127.5 (65.8-222.8)   Female 6 3.1 194.0 (70.9-422.4) 
Esophagus            Pancreas     
Male 0 2.0 nc (nc-nc)   Male 7 2.6 265.7 (106.4-547.5) 
Female 0 0.6 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 31 27.3 113.6 (77.2-161.3) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 4.5 222.5 (106.5-409.1)   Male 0 1.8 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 1.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 7 2.5 276.8 (110.9-570.3)   Female 8 6.9 116.3 (50.1-229.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.8 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 6 7.8 76.9 (28.1-167.3) 
Lung and Bronchus            All Sites / Types     
Male 15 13.0 115.4 (64.5-190.3)   Male 130 102.5 126.9 (106.0-150.7) 
Female 22 15.6 140.8 (88.2-213.3)   Female 134 116.5 115.0 (96.4-136.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
247 
Plymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 71 65.2 108.9 (85.0-137.3)   Male 65 42.6 152.5 (117.7-194.4) 
Female 19 22.9 82.8 (49.8-129.3)   Female 61 32.3 188.6 (144.2-242.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 12.7 86.7 (43.2-155.1)   Male 9 13.4 67.1 (30.6-127.3) 
Female 10 10.1 98.9 (47.3-181.8)   Female 9 10.5 86.0 (39.2-163.2) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.3 nc (nc-nc)   Male 49 37.9 129.2 (95.6-170.9) 
Female 300 259.9 115.4 (102.7-129.3)   Female 35 32.2 108.8 (75.8-151.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 37 31.5 117.4 (82.6-161.8) 
Female 5 8.6 57.9 (18.7-135.2)   Female 14 13.8 101.7 (55.6-170.6) 
Colon / Rectum            Ovary     
Male 79 70.5 112.0 (88.7-139.6)             
Female 74 68.7 107.6 (84.5-135.1)   Female 31 23.0 134.6 (91.4-191.1) 
Esophagus            Pancreas     
Male 21 18.0 116.8 (72.2-178.5)   Male 26 23.4 111.1 (72.6-162.8) 
Female 1 4.5 nc (nc-nc)   Female 21 23.0 91.2 (56.4-139.4) 
Hodgkin Lymphoma            Prostate     
Male 2 4.9 nc (nc-nc)   Male 248 238.6 103.9 (91.4-117.7) 
Female 2 3.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 37.3 88.5 (60.9-124.3)   Male 10 15.4 64.9 (31.1-119.3) 
Female 19 20.4 93.0 (55.9-145.2)   Female 9 8.8 102.0 (46.5-193.6) 
Larynx            Testis     
Male 13 10.6 123.1 (65.5-210.5)   Male 5 8.8 57.1 (18.4-133.2) 
Female 1 3.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 37 26.1 141.9 (99.9-195.6)   Male 19 16.9 112.6 (67.8-175.8) 
Female 17 18.5 91.8 (53.4-146.9)   Female 70 46.2 151.6 (118.2-191.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 23.3 115.8 (76.3-168.5)             
Female 5 7.4 67.9 (21.9-158.4)   Female 70 60.3 116.0 (90.4-146.6) 
Lung and Bronchus            All Sites / Types     
Male 130 119.5 108.8 (90.9-129.2)   Male 975 884.6 110.2 (103.4-117.4) 
Female 135 121.9 110.7 (92.8-131.1)   Female 978 868.4 112.6 (105.7-119.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
248 
Plympton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.3 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 11 12.2 90.0 (44.9-161.0)   Female 0 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.7 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.6 nc (nc-nc)             
Female 3 2.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.0 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 13 12.9 100.4 (53.4-171.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.2 nc (nc-nc)   Male 38 46.1 82.4 (58.3-113.2) 
Female 6 5.4 111.8 (40.8-243.4)   Female 43 39.0 110.2 (79.8-148.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
249 
Princeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.3 150.3 (48.4-350.8)   Male 4 2.4 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 0.8 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 16 14.6 109.9 (62.8-178.5)   Female 2 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 2.0 300.5 (109.7-654.1) 
Female 1 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.0 125.2 (40.3-292.1)             
Female 2 3.1 nc (nc-nc)   Female 5 1.2 403.5 (130.0-941.6) 
Esophagus            Pancreas     
Male 3 1.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 14.4 138.9 (84.8-214.6) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 2.2 224.6 (72.4-524.2)   Male 0 0.8 nc (nc-nc) 
Female 5 1.1 473.1 (152.5-1104.0)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.4 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 5 2.7 183.3 (59.1-427.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.2 nc (nc-nc)   Male 67 50.3 133.3 (103.3-169.3) 
Female 3 5.6 nc (nc-nc)   Female 51 44.7 114.0 (84.9-149.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
250 
Provincetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 4.9 nc (nc-nc)   Male 7 3.3 214.1 (85.8-441.1) 
Female 4 1.6 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 19 16.3 116.4 (70.1-181.8)   Female 1 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 2.7 223.7 (81.7-486.9) 
Female 0 0.5 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 5.7 123.2 (49.3-253.8)             
Female 8 4.7 169.0 (72.7-332.9)   Female 3 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 14 19.6 71.5 (39.0-119.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.0 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 12 9.1 132.0 (68.1-230.7)   Male 79 69.3 113.9 (90.2-142.0) 
Female 14 8.3 168.7 (92.2-283.1)   Female 72 56.5 127.4 (99.7-160.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
251 
Quincy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 91 97.3 93.5 (75.3-114.8)   Male 51 62.8 81.2 (60.4-106.7) 
Female 31 36.7 84.6 (57.5-120.0)   Female 56 52.6 106.5 (80.4-138.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 18 18.8 95.6 (56.6-151.1)   Male 18 19.4 92.6 (54.8-146.3) 
Female 14 15.9 88.0 (48.1-147.7)   Female 11 16.4 67.0 (33.4-120.0) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.3 nc (nc-nc)   Male 49 56.0 87.5 (64.7-115.7) 
Female 379 394.1 96.2 (86.7-106.4)   Female 60 50.9 117.9 (89.9-151.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 66 43.4 152.1 (117.6-193.5) 
Female 19 13.9 136.8 (82.3-213.6)   Female 22 21.3 103.4 (64.8-156.6) 
Colon / Rectum            Ovary     
Male 145 103.9 139.6 (117.8-164.2)             
Female 108 110.9 97.4 (79.9-117.6)   Female 32 35.6 89.8 (61.4-126.7) 
Esophagus            Pancreas     
Male 28 25.0 112.0 (74.4-161.9)   Male 30 33.7 88.9 (60.0-127.0) 
Female 11 7.0 156.1 (77.8-279.3)   Female 36 36.8 97.9 (68.5-135.5) 
Hodgkin Lymphoma            Prostate     
Male 8 8.2 97.6 (42.0-192.3)   Male 265 309.3 85.7 (75.7-96.7) 
Female 8 6.7 118.8 (51.2-234.1)             
Kidney & Renal Pelvis            Stomach     
Male 47 52.0 90.4 (66.4-120.2)   Male 25 22.7 110.0 (71.2-162.5) 
Female 36 31.7 113.6 (79.5-157.3)   Female 11 14.3 77.1 (38.4-138.0) 
Larynx            Testis     
Male 19 14.6 130.1 (78.3-203.2)   Male 15 16.5 90.7 (50.7-149.6) 
Female 6 4.8 125.5 (45.8-273.2)             
Leukemia            Thyroid     
Male 23 39.1 58.8 (37.3-88.3)   Male 18 24.6 73.0 (43.3-115.4) 
Female 27 29.9 90.4 (59.5-131.5)   Female 69 76.8 89.9 (69.9-113.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 63 32.3 195.0 (149.8-249.4)             
Female 14 11.4 122.5 (66.9-205.6)   Female 89 88.7 100.4 (80.6-123.5) 
Lung and Bronchus            All Sites / Types     
Male 233 171.8 135.6 (118.8-154.2)   Male 1318 1255.8 105.0 (99.4-110.8) 
Female 230 191.4 120.2 (105.1-136.8)   Female 1374 1358.0 101.2 (95.9-106.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
252 
Randolph 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 34.2 102.2 (71.2-142.2)   Male 17 21.9 77.6 (45.2-124.2) 
Female 7 12.7 55.1 (22.1-113.5)   Female 16 18.6 86.3 (49.3-140.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.5 92.8 (33.9-201.9)   Male 7 6.9 101.3 (40.6-208.7) 
Female 4 5.8 nc (nc-nc)   Female 10 5.8 173.1 (82.9-318.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.2 nc (nc-nc)   Male 15 19.6 76.7 (42.9-126.5) 
Female 123 144.6 85.0 (70.7-101.5)   Female 16 18.1 88.4 (50.5-143.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 15.3 39.1 (14.3-85.1) 
Female 7 5.0 138.8 (55.6-285.9)   Female 8 7.7 104.4 (44.9-205.7) 
Colon / Rectum            Ovary     
Male 39 36.7 106.3 (75.6-145.4)             
Female 42 39.0 107.6 (77.5-145.4)   Female 11 12.8 86.0 (42.9-153.9) 
Esophagus            Pancreas     
Male 6 8.9 67.7 (24.7-147.4)   Male 11 11.8 93.1 (46.4-166.6) 
Female 4 2.5 nc (nc-nc)   Female 8 12.8 62.5 (26.9-123.2) 
Hodgkin Lymphoma            Prostate     
Male 1 2.6 nc (nc-nc)   Male 118 109.5 107.8 (89.2-129.1) 
Female 0 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 18.3 114.6 (70.9-175.2)   Male 8 8.0 100.0 (43.1-197.0) 
Female 11 11.3 97.1 (48.4-173.8)   Female 7 5.0 139.8 (56.0-288.1) 
Larynx            Testis     
Male 6 5.2 115.5 (42.2-251.4)   Male 0 4.8 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 13.6 73.7 (35.3-135.6)   Male 9 8.4 107.3 (49.0-203.8) 
Female 3 10.6 nc (nc-nc)   Female 33 27.4 120.5 (82.9-169.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 11.6 138.3 (79.0-224.6)             
Female 3 4.1 nc (nc-nc)   Female 29 32.6 88.8 (59.5-127.6) 
Lung and Bronchus            All Sites / Types     
Male 46 60.7 75.8 (55.5-101.1)   Male 401 441.0 90.9 (82.2-100.3) 
Female 56 66.9 83.7 (63.2-108.7)   Female 428 486.2 88.0 (79.9-96.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
253 
Raynham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 13.7 116.6 (66.6-189.4)   Male 4 9.1 nc (nc-nc) 
Female 7 5.1 137.7 (55.2-283.8)   Female 9 7.2 124.4 (56.7-236.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.8 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 8.1 111.2 (50.7-211.1) 
Female 58 57.0 101.7 (77.2-131.4)   Female 8 7.2 111.6 (48.1-220.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.8 73.9 (23.8-172.4) 
Female 3 2.0 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 15.3 156.4 (100.2-232.7)             
Female 20 15.3 130.3 (79.6-201.3)   Female 5 5.0 99.2 (32.0-231.5) 
Esophagus            Pancreas     
Male 4 3.7 nc (nc-nc)   Male 7 4.9 142.2 (57.0-292.9) 
Female 4 1.0 nc (nc-nc)   Female 3 5.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.1 nc (nc-nc)   Male 49 47.6 103.0 (76.2-136.2) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 7.9 165.5 (88.0-283.0)   Male 4 3.3 nc (nc-nc) 
Female 10 4.5 222.4 (106.5-409.0)   Female 4 2.0 nc (nc-nc) 
Larynx            Testis     
Male 2 2.2 nc (nc-nc)   Male 6 1.9 317.1 (115.8-690.3) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.7 nc (nc-nc)   Male 6 3.6 165.0 (60.2-359.1) 
Female 5 4.1 120.6 (38.9-281.4)   Female 24 10.6 226.1 (144.8-336.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.0 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 14 12.9 108.8 (59.4-182.6) 
Lung and Bronchus            All Sites / Types     
Male 34 24.8 136.9 (94.8-191.3)   Male 214 185.1 115.6 (100.6-132.2) 
Female 30 27.0 111.1 (74.9-158.6)   Female 235 192.1 122.3 (107.2-139.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
254 
Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 26.0 138.4 (96.9-191.7)   Male 18 16.9 106.3 (62.9-168.0) 
Female 6 10.5 57.3 (20.9-124.7)   Female 13 14.2 91.3 (48.5-156.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.2 96.7 (31.1-225.6)   Male 5 5.3 93.9 (30.3-219.1) 
Female 6 4.5 133.7 (48.8-291.0)   Female 4 4.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 18 15.1 119.2 (70.6-188.4) 
Female 135 111.9 120.7 (101.2-142.9)   Female 8 14.3 55.8 (24.0-109.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 12.3 57.1 (22.9-117.6) 
Female 2 3.7 nc (nc-nc)   Female 5 6.0 83.0 (26.8-193.8) 
Colon / Rectum            Ovary     
Male 28 28.1 99.7 (66.2-144.1)             
Female 22 31.5 69.8 (43.7-105.7)   Female 10 10.0 100.3 (48.0-184.5) 
Esophagus            Pancreas     
Male 10 7.0 143.4 (68.7-263.8)   Male 7 9.2 75.9 (30.4-156.5) 
Female 2 2.0 nc (nc-nc)   Female 9 10.6 85.1 (38.8-161.5) 
Hodgkin Lymphoma            Prostate     
Male 0 1.9 nc (nc-nc)   Male 56 88.3 63.4 (47.9-82.4) 
Female 4 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 14.5 89.7 (47.7-153.4)   Male 6 6.1 98.0 (35.8-213.3) 
Female 6 8.9 67.5 (24.6-146.9)   Female 1 4.1 nc (nc-nc) 
Larynx            Testis     
Male 4 4.1 nc (nc-nc)   Male 6 3.4 174.6 (63.8-380.0) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 10.6 103.8 (51.8-185.8)   Male 8 6.6 120.7 (52.0-237.8) 
Female 11 8.4 130.5 (65.0-233.4)   Female 28 20.0 140.2 (93.2-202.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 9.1 98.8 (45.1-187.5)             
Female 5 3.3 153.8 (49.6-358.9)   Female 28 25.1 111.4 (74.0-161.0) 
Lung and Bronchus            All Sites / Types     
Male 42 46.9 89.5 (64.5-121.0)   Male 311 344.4 90.3 (80.6-100.9) 
Female 47 54.0 87.1 (64.0-115.8)   Female 395 382.0 103.4 (93.4-114.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
255 
Rehoboth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 12.5 80.0 (38.3-147.1)   Male 10 8.4 118.8 (56.9-218.5) 
Female 3 3.6 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.6 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 7 7.6 92.1 (36.9-189.7) 
Female 57 47.0 121.3 (91.9-157.2)   Female 7 5.4 130.0 (52.1-267.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 6.7 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 14.2 91.4 (48.6-156.3)             
Female 12 10.9 109.7 (56.6-191.6)   Female 2 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.6 nc (nc-nc)   Male 1 4.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 39 49.2 79.3 (56.4-108.5) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.7 104.2 (44.9-205.4)   Male 1 3.0 nc (nc-nc) 
Female 6 3.5 172.0 (62.8-374.3)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.2 nc (nc-nc)   Male 1 3.6 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 8 9.1 87.8 (37.8-173.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.8 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 16 11.0 146.0 (83.4-237.1) 
Lung and Bronchus            All Sites / Types     
Male 26 22.8 114.0 (74.4-167.0)   Male 139 177.6 78.3 (65.8-92.4) 
Female 19 19.6 96.9 (58.3-151.4)   Female 161 149.5 107.7 (91.7-125.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
256 
Revere 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 50 47.8 104.6 (77.7-138.0)   Male 23 32.5 70.8 (44.8-106.2) 
Female 16 19.7 81.2 (46.4-131.8)   Female 27 28.3 95.5 (62.9-139.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 10.3 106.7 (53.2-190.9)   Male 6 9.8 61.2 (22.3-133.2) 
Female 11 8.6 127.9 (63.8-228.8)   Female 11 8.8 125.0 (62.3-223.7) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.7 nc (nc-nc)   Male 31 29.0 106.9 (72.7-151.8) 
Female 208 213.8 97.3 (84.5-111.4)   Female 27 27.5 98.3 (64.7-143.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 23.1 95.3 (59.7-144.2) 
Female 3 7.5 nc (nc-nc)   Female 16 11.4 139.8 (79.9-227.1) 
Colon / Rectum            Ovary     
Male 67 53.3 125.7 (97.4-159.6)             
Female 45 59.8 75.3 (54.9-100.8)   Female 17 19.1 89.0 (51.8-142.6) 
Esophagus            Pancreas     
Male 11 12.6 87.1 (43.4-155.9)   Male 23 16.9 135.8 (86.1-203.8) 
Female 5 3.8 130.9 (42.2-305.6)   Female 17 19.9 85.6 (49.8-137.0) 
Hodgkin Lymphoma            Prostate     
Male 5 4.7 107.2 (34.5-250.2)   Male 116 158.0 73.4 (60.6-88.0) 
Female 4 3.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 35 27.4 127.6 (88.8-177.4)   Male 20 11.5 174.5 (106.6-269.5) 
Female 32 17.1 187.2 (128.0-264.2)   Female 8 7.7 103.9 (44.7-204.7) 
Larynx            Testis     
Male 10 7.4 134.8 (64.5-247.9)   Male 7 9.5 73.9 (29.6-152.3) 
Female 9 2.5 353.9 (161.5-671.9)             
Leukemia            Thyroid     
Male 31 20.3 152.7 (103.7-216.8)   Male 11 13.9 79.4 (39.6-142.1) 
Female 11 16.2 68.0 (33.9-121.7)   Female 44 41.2 106.9 (77.7-143.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 16.9 160.0 (105.4-232.8)             
Female 6 6.2 96.9 (35.4-210.9)   Female 35 47.7 73.3 (51.1-102.0) 
Lung and Bronchus            All Sites / Types     
Male 127 85.0 149.4 (124.6-177.8)   Male 683 642.7 106.3 (98.5-114.6) 
Female 139 103.2 134.7 (113.2-159.0)   Female 742 733.0 101.2 (94.1-108.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
257 
Richmond 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 3.0 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 5 9.4 53.3 (17.2-124.5)   Female 1 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.9 nc (nc-nc)             
Female 2 2.6 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 13 9.6 135.6 (72.1-231.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.4 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.3 nc (nc-nc)   Male 27 36.0 75.1 (49.4-109.2) 
Female 2 4.9 nc (nc-nc)   Female 17 32.1 52.9 (30.8-84.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
258 
Rochester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 6.0 nc (nc-nc)   Male 5 3.9 127.6 (41.1-297.8) 
Female 4 2.1 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 24 24.0 100.1 (64.1-148.9)   Female 3 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 6.5 107.9 (43.2-222.4)             
Female 8 6.4 124.5 (53.6-245.4)   Female 2 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.7 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 23 22.6 101.9 (64.6-152.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.5 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.4 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.2 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 3 5.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 13 11.0 117.7 (62.6-201.3)   Male 78 82.4 94.7 (74.8-118.2) 
Female 3 10.7 nc (nc-nc)   Female 65 80.2 81.1 (62.6-103.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
259 
Rockland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 17.6 119.0 (73.6-181.9)   Male 15 11.8 127.1 (71.1-209.7) 
Female 11 7.2 152.7 (76.1-273.2)   Female 17 10.0 169.3 (98.5-271.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.6 164.9 (60.2-359.0)   Male 3 3.6 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 0 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 12 10.5 114.4 (59.1-199.9) 
Female 81 79.5 101.9 (81.0-126.7)   Female 16 10.1 158.6 (90.6-257.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 8.8 136.1 (70.3-237.8) 
Female 1 2.7 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 19.5 128.2 (82.9-189.2)             
Female 25 21.5 116.4 (75.3-171.9)   Female 4 7.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 4.9 122.6 (44.8-266.9)   Male 8 6.4 125.2 (53.9-246.7) 
Female 1 1.4 nc (nc-nc)   Female 7 7.2 96.8 (38.8-199.5) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 71 65.3 108.7 (84.9-137.1) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 10.3 126.0 (67.0-215.5)   Male 3 4.2 nc (nc-nc) 
Female 16 6.3 252.1 (144.0-409.4)   Female 7 2.7 255.3 (102.3-526.1) 
Larynx            Testis     
Male 4 2.9 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 7.2 194.3 (106.1-326.1)   Male 4 4.8 nc (nc-nc) 
Female 12 5.8 206.5 (106.6-360.7)   Female 22 14.3 154.0 (96.5-233.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.5 76.6 (24.7-178.8)             
Female 3 2.3 nc (nc-nc)   Female 24 18.4 130.8 (83.8-194.6) 
Lung and Bronchus            All Sites / Types     
Male 34 32.4 104.9 (72.6-146.6)   Male 282 243.6 115.8 (102.6-130.1) 
Female 48 38.5 124.8 (92.0-165.4)   Female 328 269.1 121.9 (109.1-135.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
260 
Rockport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 12.4 97.1 (50.1-169.6)   Male 10 7.3 136.7 (65.4-251.4) 
Female 2 4.7 nc (nc-nc)   Female 7 5.5 127.6 (51.1-262.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.4 nc (nc-nc)   Male 4 6.4 nc (nc-nc) 
Female 45 44.1 102.1 (74.5-136.6)   Female 5 6.1 82.5 (26.6-192.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 5.0 120.6 (44.0-262.5) 
Female 0 1.2 nc (nc-nc)   Female 6 2.5 240.5 (87.8-523.5) 
Colon / Rectum            Ovary     
Male 10 12.3 81.2 (38.9-149.3)             
Female 8 13.8 58.1 (25.0-114.4)   Female 2 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.1 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 5 4.8 104.9 (33.8-244.8) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 40 39.8 100.5 (71.8-136.9) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.0 134.4 (57.9-264.9)   Male 0 2.8 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.4 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 5 6.4 78.5 (25.3-183.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.0 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 7 10.2 68.9 (27.6-142.0) 
Lung and Bronchus            All Sites / Types     
Male 17 22.1 77.0 (44.8-123.2)   Male 139 151.8 91.6 (77.0-108.1) 
Female 7 23.7 29.5 (11.8-60.8)   Female 128 156.2 82.0 (68.4-97.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
261 
Rowe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.9 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.9 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.6 nc (nc-nc)   Male 7 10.7 65.2 (26.1-134.4) 
Female 0 1.1 nc (nc-nc)   Female 4 7.7 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rowley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 5.5 128.4 (51.4-264.6)   Male 4 3.9 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 6 3.4 178.9 (65.3-389.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 27 27.2 99.4 (65.5-144.6)   Female 3 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.3 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 6.4 93.9 (34.3-204.4)             
Female 6 6.8 88.8 (32.4-193.2)   Female 4 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.7 nc (nc-nc)   Male 5 2.1 235.2 (75.8-549.0) 
Female 0 0.4 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 26 24.4 106.7 (69.7-156.4) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 3.7 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 7 5.2 134.9 (54.1-278.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.4 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 5 6.2 80.7 (26.0-188.3) 
Lung and Bronchus            All Sites / Types     
Male 7 10.5 66.7 (26.7-137.4)   Male 78 83.2 93.8 (74.1-117.1) 
Female 5 11.2 44.7 (14.4-104.4)   Female 87 86.9 100.1 (80.2-123.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Royalston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 8 5.0 160.7 (69.2-316.7)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.5 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 5.1 138.6 (55.5-285.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.4 nc (nc-nc)   Male 18 18.5 97.3 (57.6-153.7) 
Female 2 2.1 nc (nc-nc)   Female 19 15.9 119.5 (71.9-186.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Russell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.4 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 9 6.6 136.6 (62.3-259.3)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.7 nc (nc-nc)             
Female 6 1.5 390.9 (142.7-850.8)   Female 2 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 5.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.7 nc (nc-nc)   Male 16 21.0 76.2 (43.5-123.7) 
Female 3 2.8 nc (nc-nc)   Female 28 21.1 132.8 (88.2-192.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rutland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 7.7 104.5 (45.0-205.9)   Male 5 5.3 94.9 (30.6-221.3) 
Female 2 2.1 nc (nc-nc)   Female 0 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.7 126.4 (46.1-275.0) 
Female 37 28.8 128.4 (90.4-177.0)   Female 3 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 8.7 114.4 (54.8-210.4)             
Female 5 6.7 75.0 (24.2-175.1)   Female 1 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 23 28.9 79.5 (50.4-119.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.8 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.3 180.7 (66.0-393.4)   Male 2 2.3 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 3 6.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.8 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 9 6.4 139.7 (63.7-265.2) 
Lung and Bronchus            All Sites / Types     
Male 11 14.1 78.2 (39.0-139.9)   Male 93 108.3 85.8 (69.3-105.2) 
Female 10 11.6 86.5 (41.4-159.0)   Female 82 90.9 90.2 (71.8-112.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 34.8 112.0 (79.6-153.1)   Male 25 23.4 106.6 (69.0-157.4) 
Female 10 15.9 62.9 (30.1-115.7)   Female 26 23.5 110.7 (72.3-162.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 7.5 159.8 (82.5-279.1)   Male 4 7.2 nc (nc-nc) 
Female 5 7.2 69.2 (22.3-161.4)   Female 12 7.2 166.6 (86.0-291.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.2 nc (nc-nc)   Male 36 21.2 170.2 (119.2-235.6) 
Female 188 177.2 106.1 (91.4-122.4)   Female 25 22.5 111.2 (71.9-164.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 17.2 98.6 (57.4-157.9) 
Female 3 6.2 nc (nc-nc)   Female 12 9.5 125.9 (65.0-220.0) 
Colon / Rectum            Ovary     
Male 42 39.3 106.8 (77.0-144.4)             
Female 40 48.4 82.7 (59.0-112.6)   Female 10 16.0 62.3 (29.8-114.7) 
Esophagus            Pancreas     
Male 18 9.4 191.8 (113.6-303.2)   Male 11 12.5 88.2 (44.0-157.8) 
Female 4 3.1 nc (nc-nc)   Female 17 16.0 106.2 (61.8-170.0) 
Hodgkin Lymphoma            Prostate     
Male 4 3.4 nc (nc-nc)   Male 151 120.4 125.4 (106.2-147.1) 
Female 7 3.2 215.6 (86.4-444.1)             
Kidney & Renal Pelvis            Stomach     
Male 23 20.2 114.1 (72.3-171.3)   Male 13 8.4 155.4 (82.7-265.7) 
Female 17 14.0 121.5 (70.7-194.5)   Female 3 6.2 nc (nc-nc) 
Larynx            Testis     
Male 5 5.5 90.8 (29.3-212.0)   Male 6 6.8 88.5 (32.3-192.7) 
Female 4 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 14.8 108.2 (61.8-175.6)   Male 11 10.0 110.2 (54.9-197.1) 
Female 16 13.2 121.0 (69.1-196.5)   Female 37 34.7 106.5 (75.0-146.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 12.6 126.5 (72.3-205.5)             
Female 5 5.1 97.8 (31.5-228.2)   Female 45 40.8 110.4 (80.5-147.8) 
Lung and Bronchus            All Sites / Types     
Male 73 62.1 117.6 (92.2-147.8)   Male 571 475.0 120.2 (110.6-130.5) 
Female 90 82.5 109.0 (87.7-134.0)   Female 624 603.2 103.5 (95.5-111.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 10.5 85.4 (39.0-162.1)   Male 10 6.9 145.2 (69.5-267.0) 
Female 4 3.4 nc (nc-nc)   Female 4 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.0 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.1 81.6 (26.3-190.4) 
Female 42 41.0 102.5 (73.9-138.6)   Female 9 4.8 186.6 (85.1-354.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 5.3 227.7 (117.5-397.8) 
Female 3 1.3 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 11.5 121.9 (66.6-204.5)             
Female 14 10.0 139.8 (76.4-234.6)   Female 9 3.6 252.5 (115.2-479.4) 
Esophagus            Pancreas     
Male 2 3.0 nc (nc-nc)   Male 1 3.8 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 5 3.4 148.0 (47.7-345.4) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 33 40.5 81.5 (56.1-114.5) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.1 130.7 (56.3-257.5)   Male 1 2.5 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.1 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 2 7.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.9 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 8 9.7 82.8 (35.7-163.2) 
Lung and Bronchus            All Sites / Types     
Male 17 19.6 86.7 (50.5-138.9)   Male 130 145.3 89.5 (74.7-106.2) 
Female 27 18.7 144.1 (95.0-209.7)   Female 151 133.1 113.4 (96.0-133.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandisfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 4.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.0 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 5.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.5 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.3 nc (nc-nc)   Male 13 22.2 58.5 (31.1-100.1) 
Female 3 1.9 nc (nc-nc)   Female 10 13.6 73.8 (35.3-135.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 22.9 153.0 (106.5-212.7)   Male 23 14.9 154.4 (97.8-231.6) 
Female 6 7.6 79.3 (29.0-172.6)   Female 17 11.3 150.3 (87.5-240.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 4.5 201.4 (91.9-382.4)   Male 4 4.7 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 18 13.4 134.7 (79.8-213.0) 
Female 111 91.9 120.8 (99.4-145.5)   Female 18 11.0 163.3 (96.8-258.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 11.3 97.4 (48.5-174.2) 
Female 0 3.1 nc (nc-nc)   Female 8 4.8 167.8 (72.2-330.6) 
Colon / Rectum            Ovary     
Male 17 25.2 67.6 (39.3-108.2)             
Female 25 23.0 108.6 (70.3-160.4)   Female 8 8.1 98.9 (42.6-195.0) 
Esophagus            Pancreas     
Male 6 6.3 94.9 (34.7-206.5)   Male 12 8.2 145.7 (75.2-254.5) 
Female 2 1.5 nc (nc-nc)   Female 9 7.5 119.5 (54.5-226.9) 
Hodgkin Lymphoma            Prostate     
Male 1 1.6 nc (nc-nc)   Male 107 81.8 130.8 (107.2-158.1) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 13.1 84.2 (42.0-150.6)   Male 4 5.4 nc (nc-nc) 
Female 4 7.1 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Larynx            Testis     
Male 2 3.7 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 9.2 173.2 (98.9-281.3)   Male 3 5.9 nc (nc-nc) 
Female 5 6.3 79.4 (25.6-185.3)   Female 10 16.8 59.5 (28.5-109.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 8.4 95.3 (41.1-187.9)             
Female 1 2.5 nc (nc-nc)   Female 26 21.4 121.3 (79.2-177.8) 
Lung and Bronchus            All Sites / Types     
Male 26 41.5 62.7 (40.9-91.8)   Male 354 308.9 114.6 (103.0-127.2) 
Female 49 41.3 118.8 (87.9-157.0)   Female 331 300.5 110.1 (98.6-122.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Saugus 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 34.1 137.9 (101.3-183.4)   Male 14 21.6 64.8 (35.4-108.8) 
Female 23 13.2 174.0 (110.3-261.1)   Female 22 17.7 124.3 (77.9-188.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 6.0 nc (nc-nc)   Male 6 6.9 87.5 (32.0-190.5) 
Female 9 5.5 164.8 (75.2-312.8)   Female 3 6.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 24 19.0 126.2 (80.8-187.8) 
Female 144 141.3 101.9 (86.0-120.0)   Female 24 18.1 132.3 (84.7-196.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 15.0 133.0 (81.2-205.4) 
Female 4 4.5 nc (nc-nc)   Female 4 7.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 48 35.6 135.0 (99.5-178.9)             
Female 33 38.9 84.7 (58.3-119.0)   Female 7 12.7 55.3 (22.1-113.9) 
Esophagus            Pancreas     
Male 13 8.8 147.1 (78.2-251.6)   Male 15 11.8 127.4 (71.3-210.2) 
Female 4 2.6 nc (nc-nc)   Female 14 13.2 105.8 (57.8-177.5) 
Hodgkin Lymphoma            Prostate     
Male 2 2.2 nc (nc-nc)   Male 86 109.3 78.7 (63.0-97.2) 
Female 4 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 17.9 139.4 (90.2-205.7)   Male 8 7.9 101.1 (43.5-199.1) 
Female 8 11.4 70.1 (30.2-138.1)   Female 2 5.0 nc (nc-nc) 
Larynx            Testis     
Male 7 5.2 134.0 (53.7-276.1)   Male 10 3.9 253.7 (121.5-466.7) 
Female 2 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 13.0 153.9 (94.0-237.7)   Male 9 7.9 114.1 (52.1-216.6) 
Female 4 10.3 nc (nc-nc)   Female 19 23.9 79.6 (47.9-124.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 11.4 139.9 (79.9-227.2)             
Female 4 4.2 nc (nc-nc)   Female 26 33.3 78.1 (51.0-114.4) 
Lung and Bronchus            All Sites / Types     
Male 70 61.4 114.0 (88.8-144.0)   Male 478 434.6 110.0 (100.4-120.3) 
Female 90 70.7 127.2 (102.3-156.4)   Female 494 482.4 102.4 (93.6-111.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Savoy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.2 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.4 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 0.6 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.0 nc (nc-nc)   Male 7 13.9 50.2 (20.1-103.5) 
Female 0 1.4 nc (nc-nc)   Female 7 9.8 71.7 (28.7-147.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Scituate 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 22.9 96.1 (60.2-145.5)   Male 36 14.4 250.7 (175.5-347.1) 
Female 12 8.4 143.3 (73.9-250.3)   Female 29 11.1 261.2 (174.9-375.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.1 145.9 (53.3-317.6)   Male 5 4.6 109.0 (35.1-254.4) 
Female 2 3.5 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 10 12.8 78.2 (37.4-143.8) 
Female 99 90.8 109.0 (88.6-132.7)   Female 10 11.5 86.8 (41.5-159.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 10.4 125.4 (66.7-214.5) 
Female 1 2.8 nc (nc-nc)   Female 7 4.9 142.8 (57.2-294.3) 
Colon / Rectum            Ovary     
Male 24 24.4 98.5 (63.1-146.5)             
Female 19 25.2 75.5 (45.4-117.8)   Female 7 8.1 86.9 (34.8-179.0) 
Esophagus            Pancreas     
Male 5 6.0 83.1 (26.8-193.9)   Male 8 8.0 100.1 (43.1-197.2) 
Female 0 1.6 nc (nc-nc)   Female 7 8.4 83.6 (33.5-172.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 67 74.9 89.5 (69.3-113.6) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 12.1 nc (nc-nc)   Male 5 5.3 94.0 (30.3-219.5) 
Female 6 7.2 83.5 (30.5-181.7)   Female 4 3.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.5 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.9 112.4 (53.8-206.8)   Male 1 5.2 nc (nc-nc) 
Female 7 6.6 106.1 (42.5-218.6)   Female 18 15.0 120.2 (71.2-190.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.8 nc (nc-nc)             
Female 2 2.7 nc (nc-nc)   Female 20 20.9 95.5 (58.3-147.4) 
Lung and Bronchus            All Sites / Types     
Male 36 40.7 88.5 (62.0-122.6)   Male 288 293.6 98.1 (87.1-110.1) 
Female 42 43.8 95.9 (69.1-129.7)   Female 318 306.6 103.7 (92.6-115.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Seekonk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 17.2 81.2 (44.4-136.3)   Male 6 11.1 53.9 (19.7-117.3) 
Female 2 5.4 nc (nc-nc)   Female 8 7.9 101.5 (43.7-200.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 2 3.6 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 14 9.8 142.8 (78.0-239.6) 
Female 48 63.3 75.8 (55.9-100.5)   Female 5 7.7 64.5 (20.8-150.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.0 62.3 (20.1-145.4) 
Female 2 2.1 nc (nc-nc)   Female 5 3.3 150.0 (48.3-350.0) 
Colon / Rectum            Ovary     
Male 13 18.2 71.6 (38.1-122.4)             
Female 10 16.0 62.3 (29.8-114.6)   Female 7 5.6 125.9 (50.4-259.4) 
Esophagus            Pancreas     
Male 1 4.7 nc (nc-nc)   Male 3 6.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 9 5.4 166.2 (75.9-315.6) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 40 60.0 66.7 (47.6-90.8) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 9.6 62.7 (22.9-136.5)   Male 2 4.0 nc (nc-nc) 
Female 0 4.9 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.7 89.2 (32.6-194.1)   Male 2 4.2 nc (nc-nc) 
Female 2 4.4 nc (nc-nc)   Female 11 11.4 96.5 (48.1-172.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.1 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 11 14.8 74.3 (37.0-133.0) 
Lung and Bronchus            All Sites / Types     
Male 20 32.1 62.2 (38.0-96.1)   Male 156 228.1 68.4 (58.1-80.0) 
Female 25 30.1 83.1 (53.8-122.6)   Female 158 210.1 75.2 (63.9-87.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sharon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 17.9 66.9 (34.5-116.8)   Male 11 12.1 90.7 (45.2-162.4) 
Female 7 6.0 116.3 (46.6-239.6)   Female 18 9.5 189.3 (112.1-299.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.7 nc (nc-nc)   Male 7 3.9 181.5 (72.7-373.9) 
Female 1 3.0 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 15 10.8 138.4 (77.4-228.3) 
Female 86 77.3 111.2 (88.9-137.3)   Female 8 8.9 89.5 (38.6-176.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 9.6 62.2 (22.7-135.5) 
Female 0 2.7 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 20.5 63.6 (33.8-108.7)             
Female 9 18.8 47.8 (21.8-90.8)   Female 8 6.7 119.6 (51.5-235.6) 
Esophagus            Pancreas     
Male 3 5.2 nc (nc-nc)   Male 9 6.7 134.7 (61.5-255.7) 
Female 2 1.2 nc (nc-nc)   Female 8 6.1 132.0 (56.8-260.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 68 71.0 95.7 (74.3-121.3) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 11.1 54.2 (19.8-117.9)   Male 3 4.4 nc (nc-nc) 
Female 8 5.8 137.2 (59.1-270.4)   Female 2 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 3.1 nc (nc-nc)   Male 5 2.0 246.9 (79.6-576.3) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.3 95.3 (38.2-196.4)   Male 8 5.0 159.9 (68.8-315.0) 
Female 5 5.2 96.2 (31.0-224.5)   Female 26 14.7 177.0 (115.6-259.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.1 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 16 17.7 90.2 (51.5-146.5) 
Lung and Bronchus            All Sites / Types     
Male 18 33.5 53.7 (31.8-84.8)   Male 220 255.4 86.1 (75.1-98.3) 
Female 35 32.7 107.0 (74.5-148.8)   Female 261 248.3 105.1 (92.8-118.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sheffield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 4.8 125.0 (45.7-272.2)   Male 3 3.0 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 16 16.4 97.6 (55.7-158.5)   Female 1 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.1 nc (nc-nc)             
Female 4 3.9 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 20 16.5 121.2 (74.0-187.2) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.6 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 5 4.0 125.4 (40.4-292.7) 
Lung and Bronchus            All Sites / Types     
Male 5 8.5 58.5 (18.9-136.6)   Male 56 62.2 90.0 (68.0-116.9) 
Female 15 7.7 195.2 (109.2-322.0)   Female 59 53.4 110.5 (84.2-142.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shelburne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.7 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 4 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 9 11.0 82.1 (37.5-155.9)   Female 2 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.9 nc (nc-nc)             
Female 4 3.0 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.8 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 14 10.2 137.6 (75.2-230.9) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 6 2.6 229.3 (83.7-499.0) 
Lung and Bronchus            All Sites / Types     
Male 4 5.0 nc (nc-nc)   Male 40 36.6 109.2 (78.0-148.7) 
Female 5 5.5 91.6 (29.5-213.7)   Female 44 37.3 118.1 (85.8-158.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sherborn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.1 156.7 (67.5-308.8)   Male 5 3.2 156.0 (50.3-364.2) 
Female 1 1.6 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.9 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 24 19.4 123.6 (79.1-183.8)   Female 4 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 5.5 144.7 (62.3-285.1)             
Female 3 4.7 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 19 16.7 113.8 (68.5-177.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.7 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.0 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 5 3.4 147.1 (47.4-343.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 9.0 55.5 (17.9-129.6)   Male 66 65.7 100.4 (77.7-127.7) 
Female 6 8.7 69.0 (25.2-150.3)   Female 63 62.4 100.9 (77.6-129.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
278 
Shirley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 6.0 201.4 (103.9-351.8)   Male 3 4.8 nc (nc-nc) 
Female 6 1.9 314.3 (114.8-684.0)   Female 1 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.6 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 8 4.3 186.7 (80.4-367.9) 
Female 28 23.3 119.9 (79.7-173.3)   Female 2 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 7.7 129.3 (61.9-237.8)             
Female 8 5.8 136.9 (58.9-269.7)   Female 2 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.8 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 27 24.0 112.3 (74.0-163.4) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.4 136.6 (49.9-297.3)   Male 0 1.6 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.8 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 5 4.6 109.4 (35.2-255.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 2.7 300.5 (129.4-592.1)             
Female 0 0.6 nc (nc-nc)   Female 12 5.3 227.4 (117.4-397.3) 
Lung and Bronchus            All Sites / Types     
Male 22 11.2 196.9 (123.4-298.2)   Male 120 93.8 127.9 (106.0-152.9) 
Female 11 10.3 106.4 (53.0-190.4)   Female 94 76.5 122.9 (99.3-150.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
279 
Shrewsbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 34.5 112.9 (80.3-154.4)   Male 17 22.6 75.2 (43.8-120.5) 
Female 14 12.5 111.7 (61.0-187.5)   Female 20 18.4 108.9 (66.5-168.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 7.0 99.4 (39.8-204.8)   Male 11 7.0 157.2 (78.4-281.3) 
Female 2 5.8 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.2 nc (nc-nc)   Male 29 20.5 141.5 (94.8-203.2) 
Female 151 142.0 106.3 (90.0-124.7)   Female 15 17.7 84.6 (47.3-139.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 16.4 73.1 (37.7-127.6) 
Female 4 5.0 nc (nc-nc)   Female 5 7.5 67.1 (21.6-156.5) 
Colon / Rectum            Ovary     
Male 35 38.3 91.3 (63.6-126.9)             
Female 27 38.7 69.9 (46.0-101.6)   Female 13 12.5 104.0 (55.3-177.8) 
Esophagus            Pancreas     
Male 12 9.1 131.6 (67.9-229.9)   Male 9 12.2 73.7 (33.6-140.0) 
Female 5 2.4 206.1 (66.4-481.0)   Female 11 12.6 87.2 (43.5-156.0) 
Hodgkin Lymphoma            Prostate     
Male 1 2.9 nc (nc-nc)   Male 124 115.1 107.7 (89.6-128.4) 
Female 4 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 28 19.5 143.9 (95.6-208.0)   Male 3 8.2 nc (nc-nc) 
Female 11 11.2 98.6 (49.2-176.4)   Female 2 5.0 nc (nc-nc) 
Larynx            Testis     
Male 0 5.3 nc (nc-nc)   Male 6 5.3 113.7 (41.5-247.5) 
Female 0 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 14.4 76.6 (38.2-137.1)   Male 15 9.2 162.6 (90.9-268.2) 
Female 15 10.6 142.0 (79.4-234.2)   Female 14 27.6 50.8 (27.7-85.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 11.8 92.8 (46.3-166.1)             
Female 3 4.0 nc (nc-nc)   Female 27 31.1 86.8 (57.2-126.3) 
Lung and Bronchus            All Sites / Types     
Male 59 60.7 97.2 (74.0-125.4)   Male 483 457.9 105.5 (96.3-115.3) 
Female 64 66.0 97.0 (74.7-123.9)   Female 445 478.4 93.0 (84.6-102.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
280 
Shutesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 8 8.9 90.0 (38.7-177.3)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.9 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 3 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 7.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.1 nc (nc-nc)   Male 12 25.2 47.7 (24.6-83.3) 
Female 1 3.6 nc (nc-nc)   Female 18 28.0 64.4 (38.1-101.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
281 
Somerset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 24.4 102.4 (66.2-151.1)   Male 11 15.1 72.9 (36.4-130.5) 
Female 13 10.1 128.7 (68.5-220.2)   Female 8 12.1 66.1 (28.4-130.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.2 118.3 (38.1-276.0)   Male 1 4.7 nc (nc-nc) 
Female 3 3.7 nc (nc-nc)   Female 5 4.4 114.6 (36.9-267.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 13 13.4 97.1 (51.7-166.1) 
Female 88 95.8 91.8 (73.7-113.2)   Female 14 13.1 107.0 (58.5-179.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 10.5 57.4 (21.0-125.0) 
Female 0 2.9 nc (nc-nc)   Female 7 5.3 131.0 (52.5-270.0) 
Colon / Rectum            Ovary     
Male 23 25.5 90.1 (57.1-135.2)             
Female 30 29.6 101.3 (68.3-144.6)   Female 8 8.6 92.8 (39.9-182.8) 
Esophagus            Pancreas     
Male 7 6.2 112.6 (45.1-231.9)   Male 10 8.4 118.4 (56.7-217.8) 
Female 0 1.9 nc (nc-nc)   Female 15 10.2 147.1 (82.3-242.7) 
Hodgkin Lymphoma            Prostate     
Male 4 1.6 nc (nc-nc)   Male 81 77.8 104.1 (82.7-129.4) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 12.5 128.2 (73.2-208.2)   Male 11 5.6 196.7 (98.1-352.0) 
Female 7 8.0 87.7 (35.1-180.8)   Female 4 3.9 nc (nc-nc) 
Larynx            Testis     
Male 4 3.6 nc (nc-nc)   Male 6 2.6 229.3 (83.7-499.2) 
Female 2 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 9.3 128.5 (66.3-224.4)   Male 4 5.3 nc (nc-nc) 
Female 10 7.6 131.5 (62.9-241.8)   Female 19 15.0 126.6 (76.2-197.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.8 76.8 (28.0-167.1)             
Female 0 3.0 nc (nc-nc)   Female 19 21.4 88.9 (53.5-138.9) 
Lung and Bronchus            All Sites / Types     
Male 54 43.3 124.7 (93.6-162.7)   Male 325 307.0 105.8 (94.7-118.0) 
Female 40 51.6 77.6 (55.4-105.7)   Female 320 339.8 94.2 (84.1-105.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
282 
Somerville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 38 49.9 76.2 (53.9-104.6)   Male 30 35.8 83.9 (56.6-119.8) 
Female 19 19.7 96.3 (58.0-150.5)   Female 20 34.6 57.8 (35.3-89.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 12.5 64.1 (27.6-126.3)   Male 11 10.2 107.7 (53.7-192.7) 
Female 13 10.5 124.4 (66.2-212.7)   Female 11 8.9 123.0 (61.3-220.2) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.7 nc (nc-nc)   Male 40 31.9 125.2 (89.5-170.5) 
Female 176 227.3 77.4 (66.4-89.8)   Female 21 29.4 71.5 (44.2-109.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 25 24.0 104.3 (67.5-154.0) 
Female 10 10.1 99.3 (47.5-182.7)   Female 11 12.0 91.7 (45.7-164.0) 
Colon / Rectum            Ovary     
Male 52 56.1 92.6 (69.2-121.5)             
Female 48 61.4 78.2 (57.7-103.7)   Female 23 20.7 110.9 (70.3-166.5) 
Esophagus            Pancreas     
Male 11 12.9 85.6 (42.6-153.1)   Male 19 17.3 109.7 (66.0-171.3) 
Female 5 3.8 130.7 (42.1-304.9)   Female 21 19.8 106.1 (65.6-162.2) 
Hodgkin Lymphoma            Prostate     
Male 11 7.5 146.9 (73.3-262.9)   Male 144 157.2 91.6 (77.2-107.8) 
Female 4 6.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 29.1 123.8 (86.7-171.3)   Male 15 12.0 125.1 (70.0-206.3) 
Female 24 18.3 131.5 (84.2-195.7)   Female 14 7.9 178.0 (97.3-298.7) 
Larynx            Testis     
Male 11 7.6 145.6 (72.6-260.5)   Male 7 17.5 40.1 (16.1-82.6) 
Female 2 2.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 22.7 70.5 (40.3-114.5)   Male 14 17.0 82.2 (44.9-137.9) 
Female 20 18.1 110.2 (67.3-170.2)   Female 50 58.7 85.1 (63.2-112.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 26 17.1 152.4 (99.5-223.3)             
Female 16 6.3 252.3 (144.1-409.8)   Female 48 49.4 97.2 (71.7-128.9) 
Lung and Bronchus            All Sites / Types     
Male 105 87.5 120.0 (98.1-145.2)   Male 669 683.0 97.9 (90.7-105.7) 
Female 100 103.8 96.3 (78.4-117.1)   Female 723 792.0 91.3 (84.8-98.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
283 
South Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 21.0 90.6 (54.5-141.4)   Male 18 12.8 140.6 (83.3-222.2) 
Female 11 8.2 134.0 (66.8-239.7)   Female 10 11.1 90.4 (43.3-166.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 3 3.5 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 9 11.4 78.8 (36.0-149.6) 
Female 96 85.3 112.5 (91.1-137.4)   Female 11 11.1 98.9 (49.3-177.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 8.9 67.7 (24.7-147.4) 
Female 5 2.7 183.7 (59.2-428.7)   Female 6 4.6 129.6 (47.3-282.2) 
Colon / Rectum            Ovary     
Male 21 22.0 95.6 (59.2-146.2)             
Female 32 24.0 133.1 (91.0-187.9)   Female 3 7.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 5.3 nc (nc-nc)   Male 3 7.2 nc (nc-nc) 
Female 3 1.6 nc (nc-nc)   Female 8 8.2 97.9 (42.2-192.9) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 62 64.7 95.8 (73.4-122.8) 
Female 0 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.5 66.5 (26.6-137.0)   Male 5 4.8 104.0 (33.5-242.8) 
Female 8 7.0 114.8 (49.4-226.2)   Female 2 3.1 nc (nc-nc) 
Larynx            Testis     
Male 6 3.0 197.2 (72.0-429.2)   Male 1 2.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 7.9 63.7 (20.5-148.6)   Male 3 4.5 nc (nc-nc) 
Female 8 6.6 121.7 (52.4-239.8)   Female 11 15.4 71.4 (35.6-127.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.7 nc (nc-nc)             
Female 0 2.5 nc (nc-nc)   Female 26 19.5 133.2 (87.0-195.2) 
Lung and Bronchus            All Sites / Types     
Male 37 36.6 101.2 (71.3-139.5)   Male 239 259.9 92.0 (80.7-104.4) 
Female 40 43.2 92.5 (66.1-126.0)   Female 304 295.9 102.7 (91.5-114.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
284 
Southampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.7 74.2 (23.9-173.0)   Male 1 4.4 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.9 nc (nc-nc) 
Female 20 26.1 76.6 (46.8-118.4)   Female 2 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.2 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 7.2 97.7 (39.1-201.3)             
Female 9 6.2 145.2 (66.3-275.6)   Female 2 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.5 nc (nc-nc)   Male 25 23.7 105.6 (68.3-155.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.8 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 4 2.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.7 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 1 4.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.4 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 6 6.1 98.6 (36.0-214.6) 
Lung and Bronchus            All Sites / Types     
Male 5 12.2 41.0 (13.2-95.8)   Male 74 90.3 81.9 (64.3-102.8) 
Female 13 11.9 109.5 (58.2-187.2)   Female 72 84.6 85.1 (66.6-107.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
285 
Southborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.3 78.0 (33.6-153.8)   Male 8 6.8 118.4 (51.0-233.3) 
Female 2 3.2 nc (nc-nc)   Female 2 5.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.1 nc (nc-nc) 
Female 45 40.3 111.7 (81.5-149.5)   Female 4 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 5.1 116.6 (42.6-253.7) 
Female 2 1.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 11.6 51.8 (18.9-112.8)             
Female 12 10.0 120.2 (62.0-209.9)   Female 1 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.8 nc (nc-nc)   Male 1 3.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 5 3.1 159.3 (51.3-371.8) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 37 35.7 103.7 (73.0-142.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 5.9 135.5 (58.3-267.0)   Male 3 2.5 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.6 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.2 119.1 (38.4-278.0)   Male 5 2.7 181.9 (58.6-424.6) 
Female 1 2.8 nc (nc-nc)   Female 6 7.8 77.0 (28.1-167.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.8 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 5 8.9 55.9 (18.0-130.5) 
Lung and Bronchus            All Sites / Types     
Male 13 18.2 71.5 (38.1-122.3)   Male 129 138.3 93.3 (77.9-110.8) 
Female 18 17.1 105.2 (62.3-166.2)   Female 117 129.7 90.2 (74.6-108.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
286 
Southbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 16.1 111.9 (66.3-176.9)   Male 6 10.4 57.4 (21.0-125.0) 
Female 10 6.6 152.3 (72.9-280.0)   Female 4 9.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 10 9.4 106.9 (51.2-196.6) 
Female 59 69.7 84.7 (64.5-109.2)   Female 13 9.1 143.5 (76.3-245.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.5 134.2 (64.3-246.8) 
Female 2 2.4 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 17.5 91.7 (52.4-148.9)             
Female 21 20.0 104.9 (64.9-160.4)   Female 7 6.3 111.5 (44.7-229.7) 
Esophagus            Pancreas     
Male 3 4.2 nc (nc-nc)   Male 7 5.6 124.1 (49.7-255.7) 
Female 1 1.3 nc (nc-nc)   Female 2 6.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 1.3 nc (nc-nc)   Male 50 52.1 95.9 (71.2-126.5) 
Female 3 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.8 79.9 (32.0-164.7)   Male 6 3.8 158.2 (57.8-344.4) 
Female 10 5.6 180.0 (86.2-331.1)   Female 5 2.6 191.1 (61.6-446.0) 
Larynx            Testis     
Male 8 2.5 326.3 (140.5-642.9)   Male 3 2.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.7 120.1 (51.7-236.6)   Male 1 4.1 nc (nc-nc) 
Female 11 5.5 201.1 (100.3-359.9)   Female 10 13.1 76.2 (36.5-140.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 5.6 125.4 (50.2-258.4)             
Female 0 2.0 nc (nc-nc)   Female 20 15.7 127.6 (77.9-197.1) 
Lung and Bronchus            All Sites / Types     
Male 43 28.5 150.8 (109.1-203.1)   Male 233 210.3 110.8 (97.0-126.0) 
Female 28 33.0 84.8 (56.3-122.6)   Female 233 240.4 96.9 (84.9-110.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
287 
Southwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.0 99.8 (49.7-178.5)   Male 5 7.0 71.2 (22.9-166.2) 
Female 2 4.1 nc (nc-nc)   Female 3 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.3 nc (nc-nc) 
Female 40 42.5 94.0 (67.2-128.0)   Female 6 5.6 107.8 (39.4-234.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.0 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 11.9 67.4 (29.0-132.8)             
Female 11 12.4 88.8 (44.3-158.9)   Female 4 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.9 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 32 35.2 91.0 (62.2-128.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.9 118.5 (47.5-244.2)   Male 2 2.6 nc (nc-nc) 
Female 2 3.4 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Larynx            Testis     
Male 0 1.7 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.3 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 6 3.2 186.2 (68.0-405.3)   Female 5 7.6 65.7 (21.2-153.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.7 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 8 9.4 85.4 (36.8-168.3) 
Lung and Bronchus            All Sites / Types     
Male 19 19.3 98.4 (59.2-153.6)   Male 117 141.7 82.6 (68.3-99.0) 
Female 16 20.7 77.1 (44.0-125.2)   Female 121 146.4 82.6 (68.6-98.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
288 
Spencer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 11.2 178.3 (108.9-275.4)   Male 10 7.7 129.8 (62.1-238.7) 
Female 11 4.2 263.0 (131.1-470.5)   Female 4 6.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.4 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.8 nc (nc-nc) 
Female 46 47.5 96.9 (71.0-129.3)   Female 6 5.9 101.6 (37.1-221.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 5.8 171.5 (82.1-315.5) 
Female 1 1.6 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.4 80.8 (38.7-148.6)             
Female 11 12.5 87.9 (43.8-157.2)   Female 1 4.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.2 155.4 (50.1-362.7)   Male 5 4.1 122.6 (39.5-286.0) 
Female 1 0.8 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 32 42.4 75.5 (51.6-106.6) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 6.9 145.9 (69.8-268.3)   Male 1 2.7 nc (nc-nc) 
Female 8 3.7 215.4 (92.8-424.5)   Female 2 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 4.7 316.8 (177.2-522.6)   Male 1 3.3 nc (nc-nc) 
Female 5 3.5 141.4 (45.6-330.0)   Female 6 9.0 66.7 (24.4-145.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 4.3 140.7 (51.4-306.2)             
Female 1 1.4 nc (nc-nc)   Female 18 10.8 167.2 (99.0-264.3) 
Lung and Bronchus            All Sites / Types     
Male 27 20.9 129.0 (85.0-187.7)   Male 168 158.1 106.2 (90.8-123.6) 
Female 24 22.1 108.7 (69.6-161.7)   Female 170 159.5 106.6 (91.2-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
289 
Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 94 122.5 76.7 (62.0-93.9)   Male 36 81.2 44.3 (31.0-61.4) 
Female 40 47.7 83.9 (59.9-114.3)   Female 33 72.8 45.3 (31.2-63.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 27 27.2 99.3 (65.4-144.5)   Male 25 25.1 99.8 (64.6-147.3) 
Female 22 24.0 91.7 (57.5-138.9)   Female 26 21.7 120.0 (78.4-175.8) 
Breast            Non-Hodgkin Lymphoma     
Male 7 4.2 166.1 (66.6-342.3)   Male 77 73.5 104.8 (82.7-131.0) 
Female 512 546.6 93.7 (85.7-102.1)   Female 67 68.6 97.6 (75.6-124.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 67 58.5 114.5 (88.7-145.4) 
Female 35 19.9 175.5 (122.2-244.1)   Female 20 29.0 68.9 (42.1-106.4) 
Colon / Rectum            Ovary     
Male 150 134.8 111.3 (94.2-130.6)             
Female 158 145.3 108.7 (92.4-127.1)   Female 32 49.0 65.3 (44.7-92.2) 
Esophagus            Pancreas     
Male 37 32.7 113.2 (79.7-156.1)   Male 48 43.3 110.7 (81.6-146.8) 
Female 12 9.3 129.0 (66.6-225.3)   Female 43 47.8 89.9 (65.1-121.1) 
Hodgkin Lymphoma            Prostate     
Male 16 12.1 132.6 (75.8-215.4)   Male 388 414.2 93.7 (84.6-103.5) 
Female 16 10.8 148.2 (84.7-240.7)             
Kidney & Renal Pelvis            Stomach     
Male 85 69.2 122.8 (98.1-151.8)   Male 34 29.0 117.3 (81.2-163.9) 
Female 51 43.3 117.8 (87.7-154.9)   Female 25 18.7 133.7 (86.5-197.3) 
Larynx            Testis     
Male 17 19.0 89.5 (52.1-143.4)   Male 12 22.6 53.1 (27.4-92.8) 
Female 7 6.4 109.8 (44.0-226.1)             
Leukemia            Thyroid     
Male 52 53.1 98.0 (73.2-128.5)   Male 12 33.6 35.7 (18.4-62.4) 
Female 41 42.0 97.5 (70.0-132.3)   Female 81 111.9 72.4 (57.5-90.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 58 43.3 134.0 (101.8-173.3)             
Female 16 15.5 103.0 (58.9-167.3)   Female 120 124.0 96.8 (80.2-115.7) 
Lung and Bronchus            All Sites / Types     
Male 253 218.7 115.7 (101.8-130.8)   Male 1620 1648.6 98.3 (93.5-103.2) 
Female 254 251.7 100.9 (88.9-114.1)   Female 1758 1853.7 94.8 (90.5-99.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
290 
Sterling 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 7.9 139.0 (69.3-248.7)   Male 5 5.3 94.1 (30.3-219.7) 
Female 4 2.7 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.7 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.8 145.1 (58.1-299.0) 
Female 42 33.8 124.2 (89.5-167.9)   Female 2 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.1 65.8 (24.0-143.2)             
Female 4 8.5 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.3 nc (nc-nc)   Male 6 2.9 207.2 (75.7-451.0) 
Female 0 0.5 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 49 30.3 161.6 (119.6-213.7) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 4.9 143.3 (57.4-295.3)   Male 1 1.9 nc (nc-nc) 
Female 5 2.5 197.8 (63.7-461.5)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.3 182.7 (66.7-397.7)   Male 3 2.3 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 6 6.5 92.3 (33.7-200.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.0 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 9 7.5 120.1 (54.8-227.9) 
Lung and Bronchus            All Sites / Types     
Male 11 14.5 76.1 (37.9-136.1)   Male 134 111.5 120.2 (100.7-142.3) 
Female 18 14.1 127.8 (75.7-202.0)   Female 111 109.1 101.7 (83.7-122.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
291 
Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.2 nc (nc-nc)   Male 7 1.9 362.5 (145.2-747.0) 
Female 2 1.3 nc (nc-nc)   Female 6 1.5 406.8 (148.6-885.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 11 11.8 93.4 (46.6-167.1)   Female 3 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.2 nc (nc-nc)             
Female 8 3.8 212.0 (91.3-417.7)   Female 3 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 15 10.5 143.2 (80.1-236.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.2 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 5.8 nc (nc-nc)   Male 45 40.1 112.2 (81.8-150.1) 
Female 1 6.9 nc (nc-nc)   Female 48 43.0 111.7 (82.4-148.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
292 
Stoneham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 30.5 65.5 (40.0-101.2)   Male 11 18.5 59.6 (29.7-106.6) 
Female 13 10.0 129.8 (69.1-222.0)   Female 14 13.4 104.7 (57.2-175.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.1 138.0 (55.3-284.3)   Male 7 5.9 119.3 (47.8-245.8) 
Female 4 4.1 nc (nc-nc)   Female 5 4.5 112.1 (36.1-261.5) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 16 16.4 97.4 (55.7-158.2) 
Female 133 104.9 126.7 (106.1-150.2)   Female 10 13.6 73.5 (35.2-135.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 12.8 117.6 (65.8-193.9) 
Female 6 3.4 175.7 (64.1-382.4)   Female 8 5.7 140.1 (60.3-276.1) 
Colon / Rectum            Ovary     
Male 36 31.6 113.9 (79.8-157.7)             
Female 33 30.1 109.7 (75.5-154.1)   Female 13 9.4 138.3 (73.6-236.5) 
Esophagus            Pancreas     
Male 7 7.7 90.3 (36.2-186.2)   Male 6 10.5 57.1 (20.9-124.3) 
Female 1 1.9 nc (nc-nc)   Female 11 10.1 108.9 (54.3-194.8) 
Hodgkin Lymphoma            Prostate     
Male 4 1.8 nc (nc-nc)   Male 65 96.6 67.3 (51.9-85.8) 
Female 2 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 15.1 92.6 (50.6-155.3)   Male 11 6.9 159.3 (79.4-285.1) 
Female 9 8.4 107.1 (48.9-203.3)   Female 5 3.9 128.0 (41.2-298.6) 
Larynx            Testis     
Male 4 4.3 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 3 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 11.5 139.4 (79.6-226.3)   Male 10 6.3 157.6 (75.5-289.9) 
Female 10 7.9 126.5 (60.6-232.7)   Female 21 18.2 115.2 (71.3-176.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 9.7 62.0 (22.6-135.0)             
Female 4 3.1 nc (nc-nc)   Female 35 23.9 146.2 (101.8-203.3) 
Lung and Bronchus            All Sites / Types     
Male 46 53.2 86.5 (63.3-115.4)   Male 351 378.8 92.7 (83.2-102.9) 
Female 52 51.2 101.5 (75.8-133.1)   Female 420 360.5 116.5 (105.6-128.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
293 
Stoughton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 31.6 91.8 (61.5-131.9)   Male 17 20.1 84.4 (49.1-135.1) 
Female 13 12.6 102.9 (54.7-175.9)   Female 22 17.1 128.3 (80.4-194.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.9 102.1 (37.3-222.2)   Male 8 6.4 125.7 (54.1-247.8) 
Female 8 5.2 152.4 (65.6-300.3)   Female 7 5.7 123.4 (49.4-254.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 15 18.0 83.6 (46.7-137.8) 
Female 139 136.1 102.1 (85.9-120.6)   Female 20 17.4 115.0 (70.2-177.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 14.3 97.7 (53.4-163.9) 
Female 6 4.5 134.4 (49.1-292.5)   Female 5 7.3 68.3 (22.0-159.4) 
Colon / Rectum            Ovary     
Male 34 33.7 100.9 (69.8-140.9)             
Female 36 38.0 94.7 (66.3-131.1)   Female 12 12.1 99.2 (51.2-173.3) 
Esophagus            Pancreas     
Male 11 8.3 132.0 (65.8-236.2)   Male 13 11.1 117.6 (62.5-201.1) 
Female 5 2.5 202.8 (65.4-473.4)   Female 18 12.8 140.3 (83.1-221.7) 
Hodgkin Lymphoma            Prostate     
Male 4 2.3 nc (nc-nc)   Male 98 106.7 91.9 (74.6-112.0) 
Female 5 1.9 269.6 (86.9-629.1)             
Kidney & Renal Pelvis            Stomach     
Male 27 17.1 158.0 (104.1-229.8)   Male 5 7.4 67.9 (21.9-158.4) 
Female 15 10.8 138.4 (77.4-228.3)   Female 8 4.9 163.2 (70.3-321.5) 
Larynx            Testis     
Male 9 4.9 184.8 (84.3-350.9)   Male 4 4.1 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 12.4 104.8 (55.7-179.2)   Male 9 7.6 117.8 (53.7-223.6) 
Female 9 10.0 89.7 (40.9-170.3)   Female 33 23.7 139.3 (95.9-195.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 10.7 102.5 (51.1-183.4)             
Female 1 4.0 nc (nc-nc)   Female 20 31.1 64.2 (39.2-99.2) 
Lung and Bronchus            All Sites / Types     
Male 65 56.6 114.8 (88.6-146.3)   Male 431 412.2 104.6 (94.9-114.9) 
Female 56 66.0 84.8 (64.1-110.2)   Female 485 463.1 104.7 (95.6-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
294 
Stow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 7.3 192.1 (104.9-322.3)   Male 4 4.7 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.4 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 34 29.2 116.4 (80.6-162.7)   Female 4 3.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 3.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 8.0 87.2 (34.9-179.6)             
Female 9 6.7 133.8 (61.1-254.1)   Female 6 2.5 239.5 (87.5-521.4) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 35 24.5 142.6 (99.3-198.3) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.1 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.0 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 3 5.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 10 6.9 144.6 (69.2-266.0) 
Lung and Bronchus            All Sites / Types     
Male 4 12.9 nc (nc-nc)   Male 90 95.9 93.8 (75.4-115.3) 
Female 10 12.3 81.1 (38.8-149.2)   Female 103 92.7 111.1 (90.7-134.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
295 
Sturbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 10.5 180.4 (108.6-281.7)   Male 9 6.9 130.8 (59.7-248.4) 
Female 4 4.0 nc (nc-nc)   Female 8 5.5 144.5 (62.2-284.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.1 82.3 (26.5-192.0) 
Female 42 44.9 93.6 (67.5-126.5)   Female 5 5.6 89.7 (28.9-209.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.1 97.7 (31.5-228.1) 
Female 1 1.5 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 11.3 97.0 (48.3-173.5)             
Female 8 11.8 68.1 (29.3-134.1)   Female 2 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.9 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 5 3.9 127.0 (40.9-296.3) 
Hodgkin Lymphoma            Prostate     
Male 3 0.7 nc (nc-nc)   Male 40 38.2 104.8 (74.9-142.7) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.0 117.0 (46.9-241.0)   Male 1 2.5 nc (nc-nc) 
Female 7 3.6 196.2 (78.6-404.2)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.2 118.2 (38.1-275.8)   Male 2 2.7 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 5 7.9 63.4 (20.4-148.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.9 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 18 10.4 173.5 (102.8-274.2) 
Lung and Bronchus            All Sites / Types     
Male 19 19.4 98.2 (59.1-153.3)   Male 150 142.4 105.4 (89.2-123.6) 
Female 15 21.7 69.0 (38.6-113.8)   Female 135 150.4 89.8 (75.3-106.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
296 
Sudbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 19.9 80.4 (45.9-130.6)   Male 19 13.0 145.7 (87.7-227.6) 
Female 0 6.1 nc (nc-nc)   Female 8 9.2 87.1 (37.5-171.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.0 150.4 (54.9-327.3)   Male 5 4.2 120.5 (38.8-281.1) 
Female 5 3.0 169.3 (54.6-395.1)   Female 2 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 10 11.6 86.0 (41.2-158.3) 
Female 122 75.8 161.0 (133.7-192.2)   Female 11 8.9 123.9 (61.8-221.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 9.8 51.1 (16.5-119.1) 
Female 0 2.6 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 21.8 114.5 (74.1-169.1)             
Female 14 19.0 73.8 (40.3-123.9)   Female 6 6.5 91.9 (33.6-200.1) 
Esophagus            Pancreas     
Male 3 5.5 nc (nc-nc)   Male 9 7.2 125.5 (57.3-238.2) 
Female 1 1.2 nc (nc-nc)   Female 3 6.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 72 71.6 100.6 (78.7-126.7) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 11.5 121.7 (66.5-204.2)   Male 2 4.7 nc (nc-nc) 
Female 6 5.8 103.6 (37.8-225.5)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 2 3.2 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 8.1 61.8 (19.9-144.2)   Male 6 5.1 118.3 (43.2-257.5) 
Female 8 5.2 154.7 (66.6-304.7)   Female 17 13.8 122.8 (71.5-196.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.3 nc (nc-nc)             
Female 3 2.0 nc (nc-nc)   Female 16 17.1 93.6 (53.5-152.0) 
Lung and Bronchus            All Sites / Types     
Male 10 36.8 27.2 (13.0-50.0)   Male 228 269.5 84.6 (74.0-96.3) 
Female 31 33.2 93.4 (63.4-132.6)   Female 286 245.0 116.8 (103.6-131.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
297 
Sunderland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 3.5 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 18 10.9 164.9 (97.7-260.6)   Female 0 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.8 nc (nc-nc)             
Female 1 3.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 10 11.5 86.8 (41.5-159.6) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.5 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.9 nc (nc-nc)   Male 33 46.1 71.6 (49.3-100.6) 
Female 3 5.3 nc (nc-nc)   Female 31 38.7 80.1 (54.4-113.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
298 
Sutton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.3 118.7 (59.2-212.4)   Male 9 6.4 141.2 (64.4-268.1) 
Female 6 2.3 264.1 (96.4-574.8)   Female 4 4.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.7 140.1 (60.3-276.1) 
Female 39 33.9 115.1 (81.8-157.3)   Female 4 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.2 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 4 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 10.6 66.1 (26.5-136.2)             
Female 8 7.0 113.6 (48.9-223.9)   Female 1 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.8 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 27 37.9 71.3 (47.0-103.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.9 100.9 (36.9-219.7)   Male 2 2.3 nc (nc-nc) 
Female 6 2.5 244.4 (89.3-532.1)   Female 2 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 3.9 180.3 (72.2-371.4)   Male 4 2.7 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 7 7.1 99.1 (39.7-204.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.7 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 14 7.9 177.4 (96.9-297.6) 
Lung and Bronchus            All Sites / Types     
Male 19 17.5 108.5 (65.3-169.4)   Male 127 134.6 94.3 (78.6-112.2) 
Female 14 13.0 107.7 (58.8-180.7)   Female 125 104.3 119.8 (99.7-142.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
299 
Swampscott 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 16.2 160.8 (105.0-235.6)   Male 14 10.1 138.7 (75.8-232.8) 
Female 13 6.2 211.2 (112.3-361.2)   Female 16 8.6 187.1 (106.9-303.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.0 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 4 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 16 9.0 177.2 (101.2-287.7) 
Female 83 67.3 123.4 (98.3-153.0)   Female 12 8.5 141.2 (72.9-246.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.3 82.6 (30.2-179.8) 
Female 3 2.2 nc (nc-nc)   Female 4 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 17.3 92.3 (52.7-149.9)             
Female 19 18.7 101.7 (61.2-158.8)   Female 3 6.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 4.2 nc (nc-nc)   Male 6 5.6 106.3 (38.8-231.5) 
Female 2 1.2 nc (nc-nc)   Female 6 6.2 97.5 (35.6-212.3) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 50 52.3 95.6 (70.9-126.0) 
Female 3 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 8.5 129.8 (64.7-232.3)   Male 4 3.7 nc (nc-nc) 
Female 6 5.3 112.3 (41.0-244.4)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.4 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.4 78.2 (25.2-182.5)   Male 8 3.7 216.6 (93.3-426.8) 
Female 8 4.9 162.1 (69.8-319.5)   Female 21 12.1 173.2 (107.2-264.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.5 nc (nc-nc)             
Female 2 1.9 nc (nc-nc)   Female 22 15.2 144.7 (90.6-219.0) 
Lung and Bronchus            All Sites / Types     
Male 27 28.2 95.7 (63.1-139.3)   Male 221 206.6 107.0 (93.3-122.1) 
Female 37 31.9 115.9 (81.6-159.8)   Female 286 227.7 125.6 (111.4-141.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
300 
Swansea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 18.4 113.9 (70.5-174.1)   Male 10 12.1 82.4 (39.4-151.5) 
Female 14 7.2 193.3 (105.6-324.4)   Female 4 10.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.5 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 4 3.0 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 14 10.7 130.3 (71.2-218.7) 
Female 73 81.6 89.5 (70.1-112.5)   Female 10 10.0 99.8 (47.8-183.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 9.1 99.2 (45.2-188.2) 
Female 2 2.6 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 19.9 95.3 (57.3-148.8)             
Female 17 21.7 78.5 (45.7-125.7)   Female 5 7.1 70.0 (22.6-163.5) 
Esophagus            Pancreas     
Male 7 5.1 136.4 (54.7-281.1)   Male 7 6.7 105.2 (42.2-216.8) 
Female 0 1.4 nc (nc-nc)   Female 7 7.2 96.9 (38.8-199.6) 
Hodgkin Lymphoma            Prostate     
Male 3 1.3 nc (nc-nc)   Male 85 68.3 124.4 (99.4-153.8) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 10.7 168.3 (99.7-266.0)   Male 5 4.4 113.5 (36.6-264.9) 
Female 5 6.4 78.1 (25.2-182.3)   Female 4 2.8 nc (nc-nc) 
Larynx            Testis     
Male 4 3.1 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 7.2 nc (nc-nc)   Male 2 4.8 nc (nc-nc) 
Female 4 5.7 nc (nc-nc)   Female 10 14.2 70.2 (33.6-129.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.7 74.5 (24.0-173.9)             
Female 2 2.3 nc (nc-nc)   Female 14 18.6 75.5 (41.2-126.6) 
Lung and Bronchus            All Sites / Types     
Male 26 34.2 75.9 (49.6-111.3)   Male 269 251.6 106.9 (94.5-120.5) 
Female 34 38.6 88.2 (61.0-123.2)   Female 238 271.5 87.7 (76.9-99.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
301 
Taunton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 57 56.3 101.3 (76.7-131.2)   Male 25 37.4 66.9 (43.3-98.7) 
Female 22 21.1 104.3 (65.4-158.0)   Female 28 30.9 90.7 (60.3-131.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 11.5 104.3 (53.9-182.3)   Male 10 11.6 86.0 (41.2-158.1) 
Female 9 9.5 94.5 (43.1-179.5)   Female 14 9.6 146.4 (80.0-245.6) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.0 254.0 (81.9-592.7)   Male 38 33.4 113.7 (80.5-156.1) 
Female 232 239.2 97.0 (84.9-110.3)   Female 42 29.8 141.2 (101.7-190.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 37 27.5 134.6 (94.7-185.5) 
Female 10 8.4 119.1 (57.0-219.1)   Female 9 12.6 71.5 (32.6-135.7) 
Colon / Rectum            Ovary     
Male 69 61.9 111.5 (86.8-141.1)             
Female 83 64.6 128.5 (102.3-159.3)   Female 16 21.2 75.5 (43.1-122.6) 
Esophagus            Pancreas     
Male 16 15.3 104.4 (59.7-169.6)   Male 27 20.0 134.7 (88.7-196.0) 
Female 3 4.1 nc (nc-nc)   Female 24 21.2 113.0 (72.4-168.1) 
Hodgkin Lymphoma            Prostate     
Male 9 4.7 191.7 (87.5-363.9)   Male 165 196.4 84.0 (71.7-97.8) 
Female 5 3.8 133.2 (42.9-310.8)             
Kidney & Renal Pelvis            Stomach     
Male 37 32.4 114.2 (80.4-157.5)   Male 13 13.4 96.9 (51.6-165.8) 
Female 24 18.8 127.8 (81.9-190.2)   Female 7 8.3 84.2 (33.7-173.4) 
Larynx            Testis     
Male 14 9.0 155.3 (84.8-260.6)   Male 10 8.6 116.1 (55.6-213.6) 
Female 5 2.8 180.0 (58.0-420.1)             
Leukemia            Thyroid     
Male 19 23.2 81.8 (49.2-127.7)   Male 21 15.2 138.4 (85.6-211.5) 
Female 13 17.5 74.4 (39.6-127.2)   Female 65 45.7 142.2 (109.7-181.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 21 20.2 104.1 (64.4-159.1)             
Female 6 6.7 89.6 (32.7-195.0)   Female 42 53.9 77.9 (56.1-105.3) 
Lung and Bronchus            All Sites / Types     
Male 134 102.2 131.1 (109.9-155.3)   Male 806 760.7 106.0 (98.8-113.5) 
Female 126 110.0 114.5 (95.4-136.3)   Female 848 803.7 105.5 (98.5-112.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
302 
Templeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.6 114.1 (56.9-204.1)   Male 4 6.3 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 0 4.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.8 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.6 nc (nc-nc) 
Female 27 36.4 74.2 (48.9-108.0)   Female 5 4.3 117.3 (37.8-273.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.9 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.5 85.5 (39.0-162.3)             
Female 12 8.9 135.3 (69.8-236.4)   Female 6 3.2 189.8 (69.3-413.1) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 28 37.5 74.7 (49.6-107.9) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 5.7 159.1 (72.6-302.1)   Male 2 2.3 nc (nc-nc) 
Female 1 2.8 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.8 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 5 6.8 73.1 (23.6-170.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.6 139.8 (45.0-326.2)             
Female 0 1.0 nc (nc-nc)   Female 11 8.4 131.1 (65.4-234.6) 
Lung and Bronchus            All Sites / Types     
Male 19 17.9 106.3 (64.0-166.0)   Male 115 133.4 86.2 (71.2-103.5) 
Female 25 16.6 150.8 (97.6-222.6)   Female 118 118.5 99.5 (82.4-119.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
303 
Tewksbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 29.3 133.1 (94.6-182.0)   Male 16 19.8 80.9 (46.2-131.4) 
Female 12 13.0 92.6 (47.8-161.8)   Female 16 17.6 90.7 (51.8-147.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.0 115.9 (46.4-238.8)   Male 4 6.1 nc (nc-nc) 
Female 6 5.4 110.8 (40.5-241.3)   Female 6 5.8 104.3 (38.1-227.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.0 nc (nc-nc)   Male 21 17.6 119.6 (74.0-182.8) 
Female 131 138.6 94.5 (79.0-112.2)   Female 21 17.7 118.3 (73.2-180.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 14.8 114.6 (66.7-183.6) 
Female 8 4.5 175.9 (75.7-346.6)   Female 8 7.4 107.6 (46.3-212.1) 
Colon / Rectum            Ovary     
Male 34 32.8 103.8 (71.9-145.0)             
Female 31 39.0 79.4 (54.0-112.7)   Female 16 12.3 130.1 (74.3-211.3) 
Esophagus            Pancreas     
Male 11 8.1 135.5 (67.5-242.4)   Male 14 10.6 132.1 (72.2-221.7) 
Female 4 2.5 nc (nc-nc)   Female 8 13.1 61.0 (26.3-120.3) 
Hodgkin Lymphoma            Prostate     
Male 0 2.4 nc (nc-nc)   Male 116 105.8 109.7 (90.6-131.6) 
Female 3 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 28 17.2 162.6 (108.0-235.0)   Male 6 7.1 84.8 (31.0-184.6) 
Female 11 11.0 99.6 (49.6-178.2)   Female 6 5.1 118.6 (43.3-258.2) 
Larynx            Testis     
Male 6 4.8 124.1 (45.3-270.0)   Male 4 4.4 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 26 12.0 216.3 (141.3-316.9)   Male 6 8.1 73.9 (27.0-161.0) 
Female 14 10.4 135.0 (73.8-226.6)   Female 30 24.5 122.7 (82.7-175.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 11.0 63.8 (25.5-131.4)             
Female 1 4.0 nc (nc-nc)   Female 29 31.1 93.2 (62.4-133.8) 
Lung and Bronchus            All Sites / Types     
Male 64 53.8 118.9 (91.6-151.8)   Male 464 403.2 115.1 (104.8-126.0) 
Female 79 67.6 116.9 (92.6-145.7)   Female 488 473.0 103.2 (94.2-112.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
304 
Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 3.8 156.4 (57.1-340.3)   Male 8 2.7 301.8 (129.9-594.7) 
Female 0 1.5 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 32 18.1 176.7 (120.8-249.4)   Female 2 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 2.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.3 nc (nc-nc)             
Female 5 4.3 115.8 (37.3-270.1)   Female 3 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.1 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 14.0 142.8 (87.2-220.5) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.3 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.6 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.5 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.4 113.7 (36.7-265.4) 
Lung and Bronchus            All Sites / Types     
Male 4 7.2 nc (nc-nc)   Male 70 53.8 130.2 (101.5-164.5) 
Female 10 8.4 118.6 (56.8-218.2)   Female 78 59.3 131.5 (103.9-164.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
305 
Tolland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 2.4 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.5 nc (nc-nc)   Male 9 11.2 80.7 (36.8-153.1) 
Female 1 1.0 nc (nc-nc)   Female 3 7.7 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
306 
Topsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.0 nc (nc-nc)   Male 6 5.0 119.9 (43.8-261.1) 
Female 4 2.7 nc (nc-nc)   Female 4 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.4 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.5 133.6 (48.8-290.8) 
Female 27 29.1 92.8 (61.2-135.1)   Female 3 3.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 8.6 nc (nc-nc)             
Female 6 8.3 72.2 (26.4-157.1)   Female 4 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.1 nc (nc-nc)   Male 0 2.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 29 27.2 106.5 (71.3-152.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.1 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 3 5.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.7 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 6 6.5 92.8 (33.9-201.9) 
Lung and Bronchus            All Sites / Types     
Male 18 14.3 126.0 (74.6-199.1)   Male 97 103.9 93.3 (75.7-113.9) 
Female 17 13.5 125.7 (73.2-201.2)   Female 96 98.2 97.7 (79.2-119.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
307 
Townsend 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 6.9 145.5 (69.7-267.7)   Male 3 5.2 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 6 4.4 137.4 (50.2-299.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.8 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 10 4.7 212.0 (101.5-390.0) 
Female 35 35.0 99.9 (69.6-138.9)   Female 3 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.5 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 3 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 8.5 165.6 (90.4-277.8)             
Female 11 8.1 136.4 (68.0-244.0)   Female 4 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 7 2.3 308.8 (123.7-636.2)   Male 2 2.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 22 32.2 68.4 (42.8-103.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.1 97.8 (31.5-228.3)   Male 2 1.8 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.4 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.2 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 9 7.3 123.0 (56.1-233.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.1 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 4 7.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 14 13.4 104.4 (57.0-175.1)   Male 117 110.7 105.7 (87.4-126.7) 
Female 15 13.6 110.4 (61.8-182.2)   Female 114 109.6 104.0 (85.8-125.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
308 
Truro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.4 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 19 11.5 164.9 (99.2-257.4)   Female 2 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.4 145.1 (46.8-338.6)             
Female 3 2.8 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 0.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 6 11.5 52.1 (19.0-113.3) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.2 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 6.0 nc (nc-nc)   Male 37 42.7 86.6 (60.9-119.3) 
Female 2 5.5 nc (nc-nc)   Female 49 37.1 132.2 (97.8-174.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
309 
Tyngsborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 9.5 157.8 (88.2-260.3)   Male 5 7.0 71.0 (22.9-165.7) 
Female 7 3.7 191.6 (76.8-394.9)   Female 7 5.9 117.9 (47.2-243.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.3 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.4 nc (nc-nc) 
Female 37 47.6 77.7 (54.7-107.0)   Female 3 5.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.0 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 11.9 101.2 (52.2-176.7)             
Female 7 11.6 60.5 (24.2-124.6)   Female 4 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.0 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 32 41.9 76.3 (52.2-107.8) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.7 119.2 (51.3-234.8)   Male 3 2.5 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.2 166.8 (66.8-343.8)   Male 1 3.4 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 8 9.4 85.3 (36.7-168.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.3 164.3 (65.8-338.5)             
Female 1 1.2 nc (nc-nc)   Female 11 10.8 101.6 (50.7-181.8) 
Lung and Bronchus            All Sites / Types     
Male 23 18.1 127.3 (80.7-191.0)   Male 141 148.2 95.2 (80.1-112.2) 
Female 21 19.7 106.6 (66.0-163.0)   Female 131 152.3 86.0 (71.9-102.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
310 
Tyringham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 4 3.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.9 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.6 nc (nc-nc)   Male 3 10.8 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)   Female 6 12.2 49.4 (18.0-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
311 
Upton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 6.0 99.7 (36.4-217.1)   Male 5 4.4 113.2 (36.5-264.2) 
Female 2 2.3 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.5 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 7 4.0 177.0 (70.9-364.6) 
Female 38 31.1 122.1 (86.4-167.6)   Female 3 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.6 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 7.1 98.0 (39.3-202.0)             
Female 4 7.1 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 20 26.1 76.7 (46.8-118.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.2 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 2 2.3 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.7 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 5 6.2 81.1 (26.1-189.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 2.6 228.5 (83.4-497.4)             
Female 1 0.8 nc (nc-nc)   Female 14 7.0 199.4 (108.9-334.6) 
Lung and Bronchus            All Sites / Types     
Male 12 11.6 103.1 (53.2-180.1)   Male 86 92.4 93.1 (74.5-115.0) 
Female 12 12.9 93.1 (48.1-162.7)   Female 108 97.9 110.4 (90.5-133.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
312 
Uxbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 12.5 128.0 (73.1-207.9)   Male 13 8.6 150.7 (80.1-257.6) 
Female 3 4.9 nc (nc-nc)   Female 4 7.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 7 7.7 90.5 (36.3-186.5) 
Female 61 58.4 104.4 (79.9-134.1)   Female 5 7.1 70.5 (22.7-164.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 6.6 165.8 (82.7-296.8) 
Female 1 2.0 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 14.3 111.7 (63.8-181.3)             
Female 15 15.3 98.2 (54.9-162.0)   Female 4 5.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.5 nc (nc-nc)   Male 4 4.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 5 5.0 100.4 (32.4-234.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 58 46.3 125.3 (95.1-162.0) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 7.6 144.0 (71.8-257.6)   Male 5 3.1 163.3 (52.6-381.1) 
Female 5 4.5 110.8 (35.7-258.5)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 1 2.1 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.3 132.4 (53.0-272.8)   Male 2 3.8 nc (nc-nc) 
Female 6 4.1 145.8 (53.2-317.3)   Female 9 10.7 84.4 (38.5-160.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.9 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 13 13.3 98.1 (52.2-167.7) 
Lung and Bronchus            All Sites / Types     
Male 29 22.9 126.8 (84.9-182.1)   Male 219 176.3 124.2 (108.3-141.8) 
Female 23 26.3 87.4 (55.4-131.2)   Female 176 192.6 91.4 (78.4-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
313 
Wakefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 29.0 110.3 (75.4-155.7)   Male 27 19.0 142.2 (93.7-206.9) 
Female 8 9.0 88.9 (38.3-175.1)   Female 26 13.8 188.4 (123.0-276.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.6 142.8 (61.5-281.3)   Male 3 6.0 nc (nc-nc) 
Female 8 4.3 187.1 (80.6-368.8)   Female 4 4.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 10 16.8 59.6 (28.5-109.7) 
Female 125 109.1 114.6 (95.4-136.5)   Female 18 13.0 138.3 (81.9-218.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 13.7 94.8 (50.5-162.2) 
Female 4 3.8 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 33 31.0 106.4 (73.2-149.4)             
Female 34 27.3 124.7 (86.4-174.3)   Female 6 9.6 62.6 (22.9-136.2) 
Esophagus            Pancreas     
Male 4 7.8 nc (nc-nc)   Male 7 10.3 68.0 (27.2-140.1) 
Female 1 1.8 nc (nc-nc)   Female 11 9.0 122.6 (61.1-219.3) 
Hodgkin Lymphoma            Prostate     
Male 2 2.2 nc (nc-nc)   Male 76 100.2 75.8 (59.8-94.9) 
Female 0 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 16.2 49.4 (21.3-97.4)   Male 5 6.8 73.1 (23.6-170.6) 
Female 9 8.4 107.0 (48.8-203.2)   Female 2 3.5 nc (nc-nc) 
Larynx            Testis     
Male 5 4.6 108.2 (34.9-252.5)   Male 4 3.8 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 11.6 86.2 (41.3-158.6)   Male 5 7.4 67.7 (21.8-158.0) 
Female 6 7.6 79.4 (29.0-172.8)   Female 22 21.0 104.7 (65.6-158.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 10.4 57.8 (21.1-125.9)             
Female 4 3.0 nc (nc-nc)   Female 17 25.1 67.6 (39.4-108.3) 
Lung and Bronchus            All Sites / Types     
Male 39 52.9 73.7 (52.4-100.7)   Male 323 386.0 83.7 (74.8-93.3) 
Female 58 48.7 119.1 (90.4-154.0)   Female 396 358.0 110.6 (100.0-122.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
314 
Wales 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.5 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 7 8.2 85.1 (34.1-175.3)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.7 nc (nc-nc)             
Female 6 2.1 292.0 (106.6-635.7)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.7 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 3 10.1 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 2 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 6 2.0 298.9 (109.1-650.5) 
Lung and Bronchus            All Sites / Types     
Male 6 4.7 127.0 (46.4-276.4)   Male 26 35.0 74.3 (48.5-108.9) 
Female 4 3.7 nc (nc-nc)   Female 30 26.9 111.3 (75.1-158.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
315 
Walpole 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 27.4 76.7 (47.4-117.2)   Male 24 17.8 134.5 (86.1-200.1) 
Female 12 10.0 120.4 (62.1-210.3)   Female 13 13.7 95.0 (50.5-162.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.3 113.5 (41.4-247.0)   Male 6 5.6 106.6 (38.9-232.0) 
Female 5 4.3 115.1 (37.1-268.5)   Female 5 4.5 111.5 (35.9-260.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 12 15.9 75.3 (38.8-131.5) 
Female 137 107.7 127.2 (106.8-150.3)   Female 11 13.8 79.5 (39.6-142.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 13.2 67.9 (31.0-129.0) 
Female 1 3.6 nc (nc-nc)   Female 5 5.8 86.5 (27.9-201.8) 
Colon / Rectum            Ovary     
Male 35 30.1 116.3 (81.0-161.7)             
Female 32 30.4 105.2 (71.9-148.5)   Female 12 9.6 125.6 (64.8-219.3) 
Esophagus            Pancreas     
Male 5 7.4 67.1 (21.6-156.7)   Male 11 9.8 112.2 (55.9-200.8) 
Female 2 1.9 nc (nc-nc)   Female 8 10.1 79.6 (34.3-156.8) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 117 96.0 121.8 (100.8-146.0) 
Female 1 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 15.5 109.9 (64.0-176.0)   Male 6 6.5 92.4 (33.7-201.1) 
Female 6 8.6 69.8 (25.5-151.9)   Female 3 3.9 nc (nc-nc) 
Larynx            Testis     
Male 7 4.3 161.7 (64.8-333.2)   Male 3 3.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 11.0 63.9 (25.6-131.6)   Male 6 7.1 85.0 (31.1-185.1) 
Female 11 8.1 135.8 (67.7-243.0)   Female 19 19.2 99.2 (59.7-154.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.8 71.2 (28.5-146.7)             
Female 3 3.1 nc (nc-nc)   Female 22 24.4 90.2 (56.5-136.6) 
Lung and Bronchus            All Sites / Types     
Male 40 49.2 81.2 (58.0-110.6)   Male 376 366.6 102.6 (92.5-113.5) 
Female 47 51.5 91.2 (67.0-121.3)   Female 384 367.0 104.6 (94.4-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
316 
Waltham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 61 52.5 116.2 (88.9-149.3)   Male 25 35.8 69.9 (45.2-103.2) 
Female 21 20.2 104.0 (64.3-158.9)   Female 14 30.7 45.6 (24.9-76.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 15 11.4 132.0 (73.8-217.8)   Male 9 10.7 83.8 (38.3-159.1) 
Female 13 9.5 136.8 (72.8-233.9)   Female 4 9.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.8 nc (nc-nc)   Male 26 31.7 82.0 (53.5-120.1) 
Female 234 221.2 105.8 (92.7-120.2)   Female 32 28.6 111.8 (76.4-157.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 25.4 63.1 (36.0-102.4) 
Female 9 8.2 109.7 (50.1-208.3)   Female 8 11.9 67.0 (28.9-132.1) 
Colon / Rectum            Ovary     
Male 60 57.2 104.8 (80.0-134.9)             
Female 56 60.8 92.1 (69.6-119.6)   Female 18 20.1 89.4 (52.9-141.3) 
Esophagus            Pancreas     
Male 13 14.1 92.1 (49.0-157.4)   Male 21 18.7 112.5 (69.6-171.9) 
Female 3 3.9 nc (nc-nc)   Female 25 20.4 122.8 (79.4-181.2) 
Hodgkin Lymphoma            Prostate     
Male 4 5.6 nc (nc-nc)   Male 146 181.6 80.4 (67.9-94.5) 
Female 5 4.8 104.2 (33.6-243.1)             
Kidney & Renal Pelvis            Stomach     
Male 36 30.1 119.6 (83.7-165.5)   Male 18 12.5 144.2 (85.4-227.9) 
Female 16 17.8 89.9 (51.4-146.1)   Female 9 7.9 114.2 (52.1-216.9) 
Larynx            Testis     
Male 5 8.3 60.1 (19.4-140.2)   Male 12 11.3 105.8 (54.6-184.8) 
Female 2 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 22.2 85.5 (51.4-133.5)   Male 17 15.2 112.1 (65.3-179.5) 
Female 13 17.3 75.3 (40.1-128.8)   Female 53 46.6 113.7 (85.1-148.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 18.6 102.0 (61.4-159.3)             
Female 5 6.4 77.6 (25.0-181.2)   Female 41 50.5 81.2 (58.3-110.2) 
Lung and Bronchus            All Sites / Types     
Male 93 95.6 97.3 (78.5-119.2)   Male 667 715.5 93.2 (86.3-100.6) 
Female 109 105.4 103.4 (84.9-124.7)   Female 750 765.7 98.0 (91.1-105.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
317 
Ware 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 10.5 66.4 (26.6-136.8)   Male 4 7.0 nc (nc-nc) 
Female 4 4.0 nc (nc-nc)   Female 2 5.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.1 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 7 6.3 111.6 (44.7-230.0) 
Female 34 47.4 71.8 (49.7-100.3)   Female 4 5.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.4 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 11.8 127.5 (71.3-210.3)             
Female 16 12.2 131.1 (74.9-212.9)   Female 5 4.2 118.7 (38.2-277.0) 
Esophagus            Pancreas     
Male 2 3.0 nc (nc-nc)   Male 8 3.8 208.1 (89.6-410.0) 
Female 2 0.8 nc (nc-nc)   Female 6 4.0 149.9 (54.7-326.3) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 29 39.4 73.7 (49.3-105.8) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.2 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 8 3.7 216.5 (93.2-426.6)   Female 0 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.3 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 2 8.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.0 125.2 (40.3-292.1)             
Female 1 1.3 nc (nc-nc)   Female 9 10.9 82.8 (37.8-157.2) 
Lung and Bronchus            All Sites / Types     
Male 21 19.3 109.0 (67.4-166.6)   Male 134 145.8 91.9 (77.0-108.9) 
Female 16 21.8 73.3 (41.8-119.0)   Female 134 156.2 85.8 (71.9-101.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
318 
Wareham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 38 29.7 128.0 (90.6-175.7)   Male 17 18.2 93.2 (54.3-149.3) 
Female 15 10.1 148.3 (82.9-244.6)   Female 14 13.8 101.6 (55.5-170.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.0 158.4 (68.2-312.2)   Male 10 5.9 170.7 (81.7-314.0) 
Female 3 4.2 nc (nc-nc)   Female 2 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 17 16.2 104.9 (61.1-167.9) 
Female 94 109.9 85.5 (69.1-104.6)   Female 8 13.9 57.4 (24.7-113.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 12.5 119.6 (66.9-197.3) 
Female 2 3.5 nc (nc-nc)   Female 6 5.9 101.9 (37.2-221.8) 
Colon / Rectum            Ovary     
Male 33 30.8 107.2 (73.8-150.5)             
Female 39 30.3 128.7 (91.5-175.9)   Female 9 9.8 92.0 (42.0-174.7) 
Esophagus            Pancreas     
Male 7 7.5 93.1 (37.3-191.8)   Male 10 10.2 98.2 (47.0-180.6) 
Female 2 2.0 nc (nc-nc)   Female 12 10.1 118.5 (61.2-207.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.9 nc (nc-nc)   Male 87 92.4 94.1 (75.4-116.1) 
Female 3 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 14.9 107.3 (61.3-174.2)   Male 6 6.8 88.3 (32.3-192.3) 
Female 15 8.8 171.2 (95.7-282.3)   Female 2 3.9 nc (nc-nc) 
Larynx            Testis     
Male 5 4.4 114.1 (36.8-266.2)   Male 4 3.1 nc (nc-nc) 
Female 4 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 11.2 80.3 (36.7-152.5)   Male 7 6.3 110.5 (44.3-227.8) 
Female 18 8.0 226.0 (133.9-357.3)   Female 18 18.9 95.0 (56.3-150.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 9.7 144.5 (78.9-242.5)             
Female 5 3.2 155.9 (50.2-363.7)   Female 20 25.3 79.2 (48.3-122.3) 
Lung and Bronchus            All Sites / Types     
Male 79 52.7 150.0 (118.7-186.9)   Male 412 370.2 111.3 (100.8-122.6) 
Female 82 53.7 152.6 (121.4-189.4)   Female 401 372.6 107.6 (97.4-118.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
319 
Warren 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.2 116.5 (42.5-253.6)   Male 2 3.4 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 15 22.0 68.1 (38.1-112.3)   Female 1 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.7 nc (nc-nc)             
Female 7 5.7 123.5 (49.5-254.4)   Female 1 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 7 1.8 380.8 (152.6-784.7) 
Female 1 0.4 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 15 18.7 80.3 (44.9-132.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 6 5.0 120.1 (43.8-261.3) 
Lung and Bronchus            All Sites / Types     
Male 9 9.3 96.4 (44.0-183.0)   Male 61 69.8 87.4 (66.8-112.2) 
Female 8 9.9 81.1 (34.9-159.8)   Female 51 72.4 70.5 (52.5-92.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
320 
Warwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 4 4.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.2 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.1 148.0 (54.1-322.2) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.1 nc (nc-nc)   Male 14 14.6 95.7 (52.3-160.6) 
Female 3 2.1 nc (nc-nc)   Female 14 14.2 98.3 (53.7-164.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.9 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.6 nc (nc-nc)   Male 4 11.8 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 8 9.0 88.7 (38.2-174.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Watertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 33.3 105.2 (73.2-146.3)   Male 14 21.7 64.6 (35.3-108.5) 
Female 9 13.1 68.7 (31.4-130.4)   Female 21 19.0 110.8 (68.5-169.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 6.5 153.1 (73.3-281.7)   Male 5 6.7 74.3 (23.9-173.4) 
Female 9 5.6 161.1 (73.5-305.7)   Female 5 5.9 85.2 (27.4-198.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 20 19.3 103.7 (63.3-160.1) 
Female 149 141.2 105.5 (89.2-123.9)   Female 21 18.4 114.4 (70.8-174.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 14.8 101.5 (56.8-167.4) 
Female 8 5.1 155.8 (67.1-307.0)   Female 3 7.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 45 36.2 124.3 (90.6-166.3)             
Female 38 39.0 97.5 (69.0-133.8)   Female 15 12.7 118.3 (66.2-195.1) 
Esophagus            Pancreas     
Male 9 8.4 106.9 (48.8-202.9)   Male 12 11.4 105.4 (54.4-184.1) 
Female 1 2.5 nc (nc-nc)   Female 18 13.1 137.1 (81.2-216.8) 
Hodgkin Lymphoma            Prostate     
Male 4 2.8 nc (nc-nc)   Male 92 102.0 90.2 (72.7-110.7) 
Female 2 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 17.9 128.2 (81.2-192.3)   Male 8 7.8 102.4 (44.1-201.8) 
Female 4 11.4 nc (nc-nc)   Female 11 5.0 220.3 (109.8-394.3) 
Larynx            Testis     
Male 5 5.0 100.8 (32.5-235.2)   Male 5 5.8 86.4 (27.9-201.7) 
Female 1 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 13.4 89.3 (46.1-156.0)   Male 12 8.6 139.2 (71.9-243.2) 
Female 10 10.4 95.8 (45.8-176.1)   Female 24 28.1 85.5 (54.8-127.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 11.0 90.8 (43.5-167.1)             
Female 6 4.1 146.0 (53.3-317.7)   Female 26 31.9 81.5 (53.2-119.4) 
Lung and Bronchus            All Sites / Types     
Male 52 58.7 88.7 (66.2-116.3)   Male 417 427.2 97.6 (88.5-107.4) 
Female 61 70.1 87.1 (66.6-111.8)   Female 470 487.1 96.5 (88.0-105.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
323 
Wayland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 17.7 45.1 (19.4-88.9)   Male 15 10.9 137.6 (76.9-226.9) 
Female 5 6.2 80.2 (25.8-187.2)   Female 16 8.3 192.8 (110.1-313.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.0 nc (nc-nc)   Male 5 3.5 141.1 (45.5-329.2) 
Female 4 2.6 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 10 9.8 102.3 (49.0-188.1) 
Female 83 69.3 119.7 (95.3-148.4)   Female 11 8.6 127.2 (63.4-227.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 7.7 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 18.7 64.1 (33.1-112.0)             
Female 9 18.5 48.6 (22.2-92.2)   Female 4 6.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 4.6 nc (nc-nc)   Male 4 6.2 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 5 6.3 80.0 (25.8-186.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 67 56.6 118.3 (91.7-150.3) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.2 87.3 (37.6-172.0)   Male 3 4.1 nc (nc-nc) 
Female 4 5.5 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.6 nc (nc-nc)   Male 4 1.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.7 118.5 (51.0-233.6)   Male 7 3.9 181.6 (72.8-374.3) 
Female 2 4.9 nc (nc-nc)   Female 11 11.1 99.3 (49.5-177.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.9 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 12 16.1 74.4 (38.4-130.0) 
Lung and Bronchus            All Sites / Types     
Male 20 31.3 63.9 (39.0-98.6)   Male 197 223.5 88.2 (76.3-101.4) 
Female 21 33.9 61.9 (38.3-94.6)   Female 205 231.5 88.6 (76.8-101.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
324 
Webster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 31 19.7 157.6 (107.1-223.7)   Male 10 12.3 81.5 (39.0-149.9) 
Female 7 7.6 92.4 (37.0-190.4)   Female 6 10.1 59.4 (21.7-129.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 2 3.9 nc (nc-nc) 
Female 0 3.1 nc (nc-nc)   Female 7 3.3 210.8 (84.5-434.4) 
Breast            Non-Hodgkin Lymphoma     
Male 4 0.7 nc (nc-nc)   Male 12 11.0 109.2 (56.3-190.7) 
Female 78 76.6 101.8 (80.5-127.1)   Female 9 10.2 87.9 (40.1-166.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 8.6 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 5 4.2 118.9 (38.3-277.4) 
Colon / Rectum            Ovary     
Male 28 21.0 133.3 (88.6-192.7)             
Female 27 23.0 117.2 (77.2-170.5)   Female 9 6.9 130.4 (59.5-247.5) 
Esophagus            Pancreas     
Male 7 5.0 139.1 (55.7-286.6)   Male 7 6.8 103.2 (41.4-212.7) 
Female 1 1.4 nc (nc-nc)   Female 9 7.7 116.2 (53.0-220.6) 
Hodgkin Lymphoma            Prostate     
Male 4 1.4 nc (nc-nc)   Male 56 62.5 89.6 (67.7-116.4) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.2 97.6 (46.7-179.6)   Male 3 4.5 nc (nc-nc) 
Female 7 6.2 113.1 (45.3-233.0)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 5 2.9 172.4 (55.5-402.2)   Male 3 2.5 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 7.6 144.8 (72.2-259.0)   Male 6 4.6 131.7 (48.1-286.7) 
Female 7 6.1 115.6 (46.3-238.2)   Female 12 14.0 85.7 (44.2-149.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 6.5 154.5 (74.0-284.1)             
Female 6 2.3 264.1 (96.4-574.9)   Female 18 16.8 107.1 (63.4-169.2) 
Lung and Bronchus            All Sites / Types     
Male 42 34.6 121.3 (87.4-164.0)   Male 282 249.6 113.0 (100.2-127.0) 
Female 48 37.9 126.5 (93.3-167.8)   Female 284 268.1 105.9 (94.0-119.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
325 
Wellesley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 29.7 70.8 (43.8-108.2)   Male 30 18.5 162.2 (109.4-231.6) 
Female 5 9.9 50.5 (16.3-118.0)   Female 31 14.0 221.7 (150.6-314.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.5 nc (nc-nc)   Male 5 5.9 84.9 (27.4-198.2) 
Female 4 4.8 nc (nc-nc)   Female 7 4.4 159.3 (63.8-328.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 16 16.7 96.1 (54.9-156.1) 
Female 134 108.5 123.5 (103.5-146.3)   Female 12 13.8 86.8 (44.8-151.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 13.3 60.2 (25.9-118.6) 
Female 2 3.6 nc (nc-nc)   Female 5 5.8 85.9 (27.7-200.4) 
Colon / Rectum            Ovary     
Male 20 31.5 63.4 (38.7-98.0)             
Female 25 29.8 83.8 (54.2-123.8)   Female 10 9.7 102.9 (49.3-189.3) 
Esophagus            Pancreas     
Male 2 7.8 nc (nc-nc)   Male 10 10.4 96.5 (46.2-177.6) 
Female 2 1.9 nc (nc-nc)   Female 11 9.9 111.5 (55.6-199.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 122 97.8 124.7 (103.6-148.9) 
Female 3 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 15.8 50.8 (21.9-100.1)   Male 4 6.9 nc (nc-nc) 
Female 8 8.6 92.8 (40.0-182.9)   Female 1 3.9 nc (nc-nc) 
Larynx            Testis     
Male 2 4.5 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.8 101.4 (52.3-177.1)   Male 10 6.8 147.7 (70.7-271.6) 
Female 12 8.4 142.7 (73.6-249.2)   Female 17 20.6 82.4 (48.0-132.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 9.9 60.7 (22.2-132.2)             
Female 1 3.1 nc (nc-nc)   Female 17 24.1 70.6 (41.1-113.1) 
Lung and Bronchus            All Sites / Types     
Male 17 52.5 32.4 (18.8-51.8)   Male 327 381.3 85.8 (76.7-95.6) 
Female 33 52.0 63.4 (43.6-89.0)   Female 367 370.5 99.1 (89.2-109.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wellfleet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.2 97.8 (39.2-201.4)   Male 4 4.2 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 5 3.0 164.3 (52.9-383.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.6 nc (nc-nc) 
Female 22 25.2 87.4 (54.7-132.3)   Female 2 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 6.7 165.4 (82.4-295.9)             
Female 6 7.7 78.4 (28.6-170.6)   Female 2 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 5 2.8 177.5 (57.2-414.3) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 21 24.7 85.1 (52.7-130.1) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.4 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.4 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.2 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 3 6.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 13.5 36.9 (11.9-86.2)   Male 71 88.2 80.5 (62.9-101.6) 
Female 12 14.7 81.4 (42.0-142.3)   Female 71 90.4 78.6 (61.3-99.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wendell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.5 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 5.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.7 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 6.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.8 nc (nc-nc)   Male 11 21.0 52.4 (26.1-93.9) 
Female 3 2.1 nc (nc-nc)   Female 10 15.9 63.0 (30.2-115.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wenham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.1 156.4 (67.3-308.1)   Male 6 3.1 191.3 (69.8-416.3) 
Female 0 1.6 nc (nc-nc)   Female 6 2.3 264.3 (96.5-575.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 22 17.3 127.1 (79.6-192.5)   Female 2 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 5.2 nc (nc-nc)             
Female 7 4.8 145.1 (58.2-299.1)   Female 0 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 14.8 162.1 (103.8-241.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.5 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 5 3.4 148.8 (48.0-347.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 8 3.9 207.3 (89.3-408.6) 
Lung and Bronchus            All Sites / Types     
Male 4 9.0 nc (nc-nc)   Male 67 62.8 106.6 (82.6-135.4) 
Female 10 8.1 123.7 (59.2-227.5)   Female 73 59.0 123.6 (96.9-155.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 9.0 210.3 (126.6-328.4)   Male 5 6.1 82.3 (26.5-192.1) 
Female 3 3.2 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.9 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.4 92.6 (29.8-216.0) 
Female 31 30.3 102.3 (69.5-145.1)   Female 4 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 9.8 nc (nc-nc)             
Female 6 9.4 63.9 (23.3-139.1)   Female 5 2.8 181.0 (58.3-422.4) 
Esophagus            Pancreas     
Male 3 2.4 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 20 30.9 64.7 (39.5-100.0) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 5.1 137.1 (54.9-282.6)   Male 0 2.1 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.8 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 11 4.8 229.1 (114.2-409.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.2 nc (nc-nc)             
Female 2 1.0 nc (nc-nc)   Female 5 7.0 71.6 (23.1-167.1) 
Lung and Bronchus            All Sites / Types     
Male 20 16.1 123.9 (75.6-191.3)   Male 114 121.7 93.7 (77.3-112.5) 
Female 12 16.2 74.3 (38.3-129.7)   Female 109 107.8 101.1 (83.0-121.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 8.9 78.9 (31.6-162.6)   Male 10 5.5 183.4 (87.8-337.3) 
Female 3 2.9 nc (nc-nc)   Female 4 4.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.6 317.9 (102.4-741.8)   Male 0 1.7 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.9 102.5 (33.0-239.2) 
Female 34 31.5 108.1 (74.8-151.0)   Female 8 4.0 200.4 (86.3-394.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.8 131.6 (42.4-307.1) 
Female 1 1.1 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.2 75.8 (30.4-156.1)             
Female 16 8.6 186.7 (106.7-303.2)   Female 1 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 2.3 263.3 (96.2-573.2)   Male 1 3.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 27 28.4 95.0 (62.6-138.2) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.5 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 4 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.4 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 11 5.6 196.9 (98.2-352.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 3 7.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 15 15.6 96.4 (53.9-159.0)   Male 111 111.8 99.3 (81.7-119.6) 
Female 18 15.1 119.5 (70.8-188.8)   Female 121 106.5 113.6 (94.2-135.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 5.4 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 0 2.9 nc (nc-nc) 
Female 13 16.7 77.7 (41.4-132.9)   Female 2 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.6 108.1 (39.5-235.3)             
Female 3 5.1 nc (nc-nc)   Female 4 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 11 16.9 65.0 (32.4-116.3) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.7 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 6 3.9 154.5 (56.4-336.3) 
Lung and Bronchus            All Sites / Types     
Male 9 9.5 94.5 (43.1-179.3)   Male 50 67.3 74.3 (55.2-98.0) 
Female 15 8.5 177.3 (99.2-292.5)   Female 61 59.4 102.6 (78.5-131.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.6 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.0 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 22 17.4 126.5 (79.3-191.6)   Female 0 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.3 nc (nc-nc)             
Female 1 4.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 17 18.0 94.4 (55.0-151.2) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 2.8 180.8 (58.3-422.0)   Male 1 1.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 8.3 nc (nc-nc)   Male 55 65.0 84.6 (63.7-110.1) 
Female 5 7.2 69.6 (22.4-162.4)   Female 50 55.1 90.7 (67.3-119.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 30.4 111.8 (77.4-156.3)   Male 14 19.6 71.5 (39.0-119.9) 
Female 6 11.7 51.5 (18.8-112.0)   Female 12 16.0 75.2 (38.8-131.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.0 116.7 (46.7-240.4)   Male 3 6.1 nc (nc-nc) 
Female 4 4.9 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 15 17.5 85.9 (48.1-141.7) 
Female 102 122.7 83.1 (67.8-100.9)   Female 8 15.9 50.3 (21.7-99.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 14.1 127.7 (75.6-201.8) 
Female 10 4.1 242.2 (116.0-445.5)   Female 9 6.6 136.2 (62.2-258.6) 
Colon / Rectum            Ovary     
Male 41 32.4 126.5 (90.8-171.7)             
Female 41 35.0 117.3 (84.1-159.1)   Female 9 11.0 81.8 (37.3-155.3) 
Esophagus            Pancreas     
Male 11 8.1 135.5 (67.5-242.5)   Male 12 10.7 112.2 (57.9-196.0) 
Female 1 2.2 nc (nc-nc)   Female 9 11.6 77.4 (35.3-146.9) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 82 103.8 79.0 (62.9-98.1) 
Female 2 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 16.6 84.2 (46.0-141.2)   Male 4 7.1 nc (nc-nc) 
Female 9 10.0 90.4 (41.3-171.7)   Female 4 4.5 nc (nc-nc) 
Larynx            Testis     
Male 4 4.8 nc (nc-nc)   Male 5 4.4 113.4 (36.6-264.7) 
Female 2 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 12.3 64.9 (28.0-128.0)   Male 9 7.6 118.9 (54.2-225.7) 
Female 10 9.4 106.8 (51.1-196.4)   Female 21 22.6 93.1 (57.6-142.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 10.6 122.5 (65.1-209.4)             
Female 3 3.6 nc (nc-nc)   Female 27 27.6 98.0 (64.6-142.6) 
Lung and Bronchus            All Sites / Types     
Male 48 54.8 87.7 (64.6-116.2)   Male 371 401.6 92.4 (83.2-102.3) 
Female 85 60.6 140.3 (112.1-173.5)   Female 411 423.2 97.1 (88.0-107.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
334 
West Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.9 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 7 7.7 91.3 (36.6-188.0)   Female 3 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.0 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 11 7.1 155.4 (77.5-278.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 3.6 169.0 (61.7-367.9)   Male 30 25.6 117.2 (79.1-167.3) 
Female 3 3.9 nc (nc-nc)   Female 24 25.9 92.7 (59.4-138.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
335 
West Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 2.4 254.5 (92.9-554.0)   Male 3 1.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.4 nc (nc-nc) 
Female 20 14.5 137.7 (84.0-212.6)   Female 2 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.6 nc (nc-nc)             
Female 3 3.6 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 11 10.7 103.1 (51.4-184.5) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 1.5 403.5 (147.4-878.4)   Male 0 0.6 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.4 nc (nc-nc)   Male 2 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 4.6 nc (nc-nc)   Male 48 34.9 137.7 (101.5-182.5) 
Female 7 6.5 107.2 (42.9-220.9)   Female 51 48.2 105.8 (78.8-139.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
336 
Westborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 17.4 68.9 (35.6-120.4)   Male 13 11.7 111.3 (59.2-190.3) 
Female 7 6.6 105.3 (42.2-217.0)   Female 5 9.6 52.0 (16.8-121.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.6 137.6 (44.4-321.2)   Male 7 3.6 192.2 (77.0-396.1) 
Female 3 3.1 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 10 10.5 95.3 (45.6-175.2) 
Female 84 73.8 113.8 (90.8-140.9)   Female 7 9.3 75.3 (30.2-155.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.5 82.3 (33.0-169.6) 
Female 1 2.6 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 19.8 85.8 (50.0-137.4)             
Female 25 20.8 120.2 (77.7-177.4)   Female 5 6.6 75.9 (24.5-177.1) 
Esophagus            Pancreas     
Male 4 4.6 nc (nc-nc)   Male 5 6.1 81.3 (26.2-189.8) 
Female 2 1.3 nc (nc-nc)   Female 6 6.8 88.0 (32.1-191.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.5 nc (nc-nc)   Male 54 56.6 95.4 (71.7-124.5) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 10.0 79.9 (34.4-157.5)   Male 3 4.2 nc (nc-nc) 
Female 2 5.7 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Larynx            Testis     
Male 1 2.7 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.3 123.9 (56.6-235.3)   Male 8 4.9 163.6 (70.4-322.3) 
Female 9 5.6 159.7 (72.9-303.2)   Female 12 14.2 84.3 (43.5-147.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.2 80.5 (25.9-187.8)             
Female 0 2.1 nc (nc-nc)   Female 19 16.2 117.4 (70.7-183.4) 
Lung and Bronchus            All Sites / Types     
Male 23 30.8 74.6 (47.3-112.0)   Male 215 232.1 92.6 (80.7-105.9) 
Female 33 32.7 100.9 (69.5-141.8)   Female 241 249.4 96.6 (84.8-109.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
337 
Westfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 44 41.8 105.2 (76.5-141.3)   Male 24 26.9 89.1 (57.1-132.6) 
Female 14 15.0 93.1 (50.8-156.2)   Female 20 21.4 93.3 (57.0-144.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 8.3 60.5 (19.5-141.3)   Male 9 8.4 107.1 (48.9-203.3) 
Female 7 6.8 102.6 (41.1-211.4)   Female 0 6.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.4 nc (nc-nc)   Male 21 24.2 86.7 (53.6-132.5) 
Female 183 165.1 110.8 (95.3-128.1)   Female 19 21.0 90.3 (54.4-141.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 19.4 66.9 (35.6-114.4) 
Female 8 5.5 146.1 (62.9-287.9)   Female 9 8.9 101.7 (46.4-193.0) 
Colon / Rectum            Ovary     
Male 47 45.3 103.9 (76.3-138.1)             
Female 52 45.3 114.7 (85.7-150.4)   Female 19 14.8 128.1 (77.1-200.1) 
Esophagus            Pancreas     
Male 15 11.1 135.6 (75.9-223.7)   Male 9 14.7 61.1 (27.9-115.9) 
Female 3 2.9 nc (nc-nc)   Female 13 15.2 85.8 (45.6-146.7) 
Hodgkin Lymphoma            Prostate     
Male 6 3.5 173.7 (63.4-378.0)   Male 124 140.7 88.2 (73.3-105.1) 
Female 1 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 22.8 74.5 (43.4-119.2)   Male 15 9.8 152.9 (85.5-252.1) 
Female 10 13.1 76.1 (36.4-139.9)   Female 6 5.9 102.4 (37.4-223.0) 
Larynx            Testis     
Male 3 6.4 nc (nc-nc)   Male 5 6.3 80.0 (25.8-186.6) 
Female 3 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 22 17.1 128.9 (80.8-195.2)   Male 6 10.5 56.9 (20.8-124.0) 
Female 11 12.5 88.3 (44.0-158.1)   Female 19 30.7 61.8 (37.2-96.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 14.5 82.6 (42.6-144.3)             
Female 2 4.8 nc (nc-nc)   Female 33 38.0 86.9 (59.8-122.1) 
Lung and Bronchus            All Sites / Types     
Male 79 74.3 106.3 (84.2-132.5)   Male 529 550.9 96.0 (88.0-104.6) 
Female 81 78.8 102.8 (81.6-127.8)   Female 547 562.9 97.2 (89.2-105.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
338 
Westford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 19.3 62.3 (32.1-108.8)   Male 19 13.8 137.6 (82.8-214.9) 
Female 4 6.4 nc (nc-nc)   Female 12 10.9 109.9 (56.7-191.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.5 nc (nc-nc)   Male 7 4.4 160.7 (64.4-331.2) 
Female 6 3.5 171.2 (62.5-372.6)   Female 3 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 13 12.4 104.5 (55.6-178.7) 
Female 88 89.9 97.9 (78.5-120.6)   Female 8 9.9 80.7 (34.8-159.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 11.4 87.8 (42.0-161.5) 
Female 1 3.2 nc (nc-nc)   Female 5 4.4 113.4 (36.5-264.6) 
Colon / Rectum            Ovary     
Male 21 22.9 91.5 (56.6-139.9)             
Female 21 20.2 104.1 (64.4-159.2)   Female 6 7.7 78.1 (28.5-170.0) 
Esophagus            Pancreas     
Male 3 5.9 nc (nc-nc)   Male 8 7.4 108.8 (46.8-214.4) 
Female 1 1.3 nc (nc-nc)   Female 7 6.4 110.2 (44.1-227.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.7 nc (nc-nc)   Male 76 81.8 92.9 (73.2-116.3) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 13.1 84.2 (42.0-150.7)   Male 6 4.9 123.2 (45.0-268.2) 
Female 3 6.6 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Larynx            Testis     
Male 6 3.6 166.9 (61.0-363.4)   Male 3 2.8 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 8.4 154.9 (82.4-264.9)   Male 9 6.2 144.6 (66.0-274.5) 
Female 11 5.7 193.1 (96.3-345.6)   Female 15 17.7 84.8 (47.4-139.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 8.2 61.3 (19.8-143.1)             
Female 0 2.3 nc (nc-nc)   Female 35 20.8 168.4 (117.3-234.2) 
Lung and Bronchus            All Sites / Types     
Male 36 37.1 97.0 (68.0-134.3)   Male 283 290.7 97.4 (86.3-109.4) 
Female 28 35.9 78.0 (51.8-112.8)   Female 275 280.7 98.0 (86.7-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
339 
Westhampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.8 nc (nc-nc)   Male 6 1.2 503.9 (184.0-1096.8) 
Female 1 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 11 7.6 145.5 (72.5-260.4)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.0 nc (nc-nc)             
Female 2 1.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 7.0 114.3 (49.2-225.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.3 nc (nc-nc)   Male 25 25.1 99.6 (64.4-147.0) 
Female 0 3.1 nc (nc-nc)   Female 17 23.9 71.2 (41.4-114.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
340 
Westminster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.5 93.7 (37.5-193.1)   Male 6 5.1 118.0 (43.1-256.9) 
Female 1 2.1 nc (nc-nc)   Female 6 3.6 166.9 (61.0-363.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.6 130.3 (47.6-283.7) 
Female 43 29.2 147.3 (106.6-198.4)   Female 2 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 5 1.4 347.4 (111.9-810.7) 
Colon / Rectum            Ovary     
Male 8 8.7 91.9 (39.6-181.1)             
Female 7 6.5 106.9 (42.8-220.3)   Female 4 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 26 26.8 97.1 (63.4-142.3) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.5 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 3 2.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.2 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 7 5.9 118.9 (47.6-244.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 8 6.9 116.3 (50.1-229.2) 
Lung and Bronchus            All Sites / Types     
Male 9 13.2 68.0 (31.0-129.1)   Male 100 103.5 96.6 (78.6-117.5) 
Female 14 11.2 125.4 (68.5-210.4)   Female 111 90.9 122.1 (100.4-147.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
341 
Weston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 15.3 98.2 (54.9-161.9)   Male 11 9.3 118.1 (58.9-211.3) 
Female 2 4.8 nc (nc-nc)   Female 10 6.5 154.4 (73.9-284.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 9 8.3 108.4 (49.5-205.8) 
Female 50 52.1 95.9 (71.2-126.4)   Female 4 6.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.6 91.4 (33.4-198.8) 
Female 0 1.6 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 15.9 75.5 (39.0-132.0)             
Female 13 14.4 90.4 (48.1-154.6)   Female 2 4.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.9 nc (nc-nc)   Male 4 5.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 8 4.8 166.8 (71.8-328.8) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 55 48.9 112.5 (84.7-146.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.7 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 3 4.1 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 3 2.3 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.9 153.2 (69.9-290.9)   Male 6 3.2 189.1 (69.1-411.6) 
Female 10 3.9 258.2 (123.6-474.8)   Female 6 8.9 67.7 (24.7-147.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.0 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 7 12.0 58.2 (23.3-119.9) 
Lung and Bronchus            All Sites / Types     
Male 22 27.2 80.9 (50.7-122.5)   Male 195 191.8 101.7 (87.9-117.0) 
Female 20 25.0 79.9 (48.8-123.3)   Female 153 176.6 86.6 (73.5-101.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
342 
Westport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 23.4 128.2 (86.4-183.0)   Male 16 14.2 112.4 (64.2-182.5) 
Female 10 7.5 132.9 (63.6-244.4)   Female 9 9.9 90.5 (41.3-171.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.9 nc (nc-nc)   Male 5 4.6 108.6 (35.0-253.3) 
Female 2 3.1 nc (nc-nc)   Female 6 3.4 175.6 (64.1-382.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 15 12.6 119.2 (66.6-196.6) 
Female 74 80.9 91.5 (71.8-114.8)   Female 16 10.4 154.3 (88.1-250.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.9 70.8 (28.4-145.9) 
Female 3 2.5 nc (nc-nc)   Female 6 4.4 135.9 (49.6-295.9) 
Colon / Rectum            Ovary     
Male 20 23.7 84.3 (51.5-130.3)             
Female 17 22.0 77.2 (45.0-123.7)   Female 4 7.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 9 6.1 148.1 (67.6-281.2)   Male 11 8.1 135.7 (67.6-242.8) 
Female 1 1.5 nc (nc-nc)   Female 8 7.5 106.6 (45.9-210.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 91 77.8 116.9 (94.2-143.6) 
Female 0 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 11.9 84.0 (40.2-154.5)   Male 6 5.3 112.5 (41.1-245.0) 
Female 5 6.5 77.1 (24.8-179.8)   Female 4 2.8 nc (nc-nc) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 8.7 92.0 (39.6-181.3)   Male 7 4.9 143.5 (57.5-295.7) 
Female 3 5.8 nc (nc-nc)   Female 15 13.4 112.1 (62.7-184.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.6 65.8 (21.2-153.6)             
Female 1 2.4 nc (nc-nc)   Female 11 19.2 57.2 (28.5-102.4) 
Lung and Bronchus            All Sites / Types     
Male 34 41.9 81.2 (56.2-113.5)   Male 299 295.2 101.3 (90.1-113.5) 
Female 38 40.4 94.2 (66.6-129.2)   Female 249 274.8 90.6 (79.7-102.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
343 
Westwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 20.0 99.8 (60.9-154.1)   Male 24 12.0 200.6 (128.5-298.4) 
Female 5 7.5 66.7 (21.5-155.6)   Female 22 9.1 242.8 (152.1-367.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.4 nc (nc-nc)   Male 5 3.8 131.0 (42.2-305.8) 
Female 4 2.9 nc (nc-nc)   Female 5 3.2 154.5 (49.8-360.5) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 9 10.8 83.0 (37.9-157.6) 
Female 95 71.4 133.0 (107.6-162.6)   Female 4 9.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.3 84.6 (33.9-174.3) 
Female 2 2.2 nc (nc-nc)   Female 6 4.0 148.8 (54.3-323.9) 
Colon / Rectum            Ovary     
Male 28 21.3 131.7 (87.5-190.4)             
Female 27 22.9 117.7 (77.6-171.3)   Female 9 6.5 139.2 (63.5-264.2) 
Esophagus            Pancreas     
Male 2 4.9 nc (nc-nc)   Male 11 6.9 160.5 (80.0-287.3) 
Female 1 1.4 nc (nc-nc)   Female 4 7.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 4 1.1 nc (nc-nc)   Male 64 58.4 109.5 (84.4-139.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.7 102.7 (49.2-188.9)   Male 3 4.6 nc (nc-nc) 
Female 6 5.8 103.5 (37.8-225.2)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 2 2.8 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.7 117.3 (53.5-222.7)   Male 5 4.1 121.8 (39.3-284.2) 
Female 10 5.8 171.9 (82.3-316.2)   Female 19 11.3 167.7 (100.9-261.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 6.3 nc (nc-nc)             
Female 4 2.2 nc (nc-nc)   Female 19 15.6 121.5 (73.1-189.8) 
Lung and Bronchus            All Sites / Types     
Male 25 33.7 74.2 (48.0-109.5)   Male 260 242.7 107.1 (94.5-121.0) 
Female 37 36.2 102.1 (71.9-140.8)   Female 296 252.9 117.0 (104.1-131.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
344 
Weymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 57.7 91.8 (68.7-120.1)   Male 40 37.5 106.7 (76.2-145.3) 
Female 39 24.3 160.6 (114.2-219.6)   Female 45 33.5 134.5 (98.1-180.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 11.2 89.1 (42.6-163.8)   Male 16 11.8 135.7 (77.5-220.4) 
Female 10 10.3 96.9 (46.4-178.3)   Female 7 11.0 63.9 (25.6-131.6) 
Breast            Non-Hodgkin Lymphoma     
Male 1 2.0 nc (nc-nc)   Male 45 33.4 134.6 (98.2-180.1) 
Female 275 264.7 103.9 (92.0-116.9)   Female 27 33.8 79.9 (52.6-116.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 27.1 121.7 (83.7-170.9) 
Female 5 8.8 56.8 (18.3-132.6)   Female 20 14.2 140.5 (85.8-217.0) 
Colon / Rectum            Ovary     
Male 66 62.9 104.9 (81.1-133.4)             
Female 77 73.2 105.2 (83.1-131.5)   Female 26 23.5 110.4 (72.1-161.8) 
Esophagus            Pancreas     
Male 14 15.4 91.1 (49.8-152.9)   Male 22 20.3 108.2 (67.8-163.8) 
Female 4 4.7 nc (nc-nc)   Female 21 24.3 86.5 (53.5-132.2) 
Hodgkin Lymphoma            Prostate     
Male 6 4.4 137.6 (50.2-299.5)   Male 179 194.0 92.3 (79.3-106.8) 
Female 1 3.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 35 31.9 109.7 (76.4-152.6)   Male 13 13.6 95.4 (50.8-163.2) 
Female 27 21.0 128.4 (84.6-186.8)   Female 5 9.4 53.4 (17.2-124.7) 
Larynx            Testis     
Male 17 9.0 189.4 (110.3-303.2)   Male 8 7.9 100.6 (43.3-198.3) 
Female 3 3.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 23.2 81.8 (49.2-127.7)   Male 15 14.6 102.5 (57.3-169.0) 
Female 13 19.3 67.4 (35.9-115.3)   Female 54 47.1 114.7 (86.1-149.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 20.4 93.3 (56.2-145.7)             
Female 9 7.7 116.4 (53.1-221.0)   Female 64 60.5 105.8 (81.4-135.0) 
Lung and Bronchus            All Sites / Types     
Male 112 103.5 108.2 (89.1-130.3)   Male 796 761.6 104.5 (97.4-112.0) 
Female 155 128.0 121.1 (102.8-141.7)   Female 955 898.6 106.3 (99.6-113.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
345 
Whately 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.8 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 5 6.8 73.7 (23.8-172.0)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 2.1 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 7.2 83.1 (30.4-180.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.3 nc (nc-nc)   Male 25 25.6 97.6 (63.1-144.0) 
Female 1 3.0 nc (nc-nc)   Female 15 22.0 68.1 (38.1-112.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
346 
Whitman 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 14.4 208.6 (140.7-297.9)   Male 7 9.6 73.1 (29.3-150.6) 
Female 5 4.6 107.9 (34.8-251.8)   Female 12 7.3 163.9 (84.6-286.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.0 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 3 8.6 nc (nc-nc) 
Female 54 57.3 94.3 (70.8-123.1)   Female 5 6.9 73.0 (23.5-170.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.1 70.0 (22.6-163.3) 
Female 5 2.1 243.4 (78.5-568.1)   Female 7 2.9 238.3 (95.5-491.1) 
Colon / Rectum            Ovary     
Male 16 16.0 99.8 (57.0-162.1)             
Female 20 14.4 139.3 (85.1-215.2)   Female 2 5.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 4.0 151.6 (55.3-329.9)   Male 3 5.2 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 5 4.6 107.8 (34.7-251.5) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 51 51.4 99.2 (73.9-130.5) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 8.4 225.7 (135.8-352.5)   Male 4 3.4 nc (nc-nc) 
Female 3 4.4 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 5 2.3 217.1 (70.0-506.7)   Male 0 2.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.0 132.8 (57.2-261.7)   Male 2 4.0 nc (nc-nc) 
Female 3 4.0 nc (nc-nc)   Female 10 11.4 87.9 (42.1-161.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.2 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 12 13.2 91.2 (47.1-159.4) 
Lung and Bronchus            All Sites / Types     
Male 35 26.0 134.8 (93.9-187.5)   Male 213 196.5 108.4 (94.3-124.0) 
Female 37 25.2 147.0 (103.5-202.6)   Female 196 187.9 104.3 (90.2-120.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
347 
Wilbraham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 21.6 69.3 (38.8-114.3)   Male 22 13.0 168.8 (105.7-255.6) 
Female 9 7.3 123.5 (56.4-234.5)   Female 9 9.3 97.2 (44.3-184.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.5 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 7 2.8 246.2 (98.6-507.2)   Female 2 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 8 11.6 69.0 (29.7-136.0) 
Female 83 74.9 110.8 (88.2-137.3)   Female 11 9.7 113.4 (56.5-202.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 9.1 66.2 (24.2-144.1) 
Female 0 2.2 nc (nc-nc)   Female 1 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 22.2 80.9 (47.9-127.9)             
Female 15 21.9 68.5 (38.3-113.0)   Female 4 6.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 5.5 nc (nc-nc)   Male 4 7.5 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 13 7.4 175.5 (93.4-300.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 50 68.7 72.8 (54.0-95.9) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.7 93.2 (44.6-171.4)   Male 5 4.9 101.5 (32.7-236.9) 
Female 4 6.0 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 1 3.2 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 8.1 nc (nc-nc)   Male 5 4.3 115.1 (37.1-268.6) 
Female 8 5.6 142.7 (61.4-281.2)   Female 10 11.8 84.4 (40.4-155.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 7.0 114.9 (49.5-226.4)             
Female 2 2.2 nc (nc-nc)   Female 12 17.2 70.0 (36.1-122.2) 
Lung and Bronchus            All Sites / Types     
Male 26 38.2 68.0 (44.4-99.7)   Male 211 268.4 78.6 (68.4-90.0) 
Female 24 37.1 64.7 (41.5-96.3)   Female 240 257.1 93.3 (81.9-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
348 
Williamsburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.3 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 18 14.0 128.5 (76.1-203.1)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.6 nc (nc-nc)             
Female 5 3.8 133.2 (42.9-310.9)   Female 5 1.3 398.3 (128.4-929.5) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 8 12.8 62.6 (26.9-123.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 6.1 nc (nc-nc)   Male 32 45.7 70.0 (47.9-98.8) 
Female 2 6.3 nc (nc-nc)   Female 45 46.5 96.7 (70.5-129.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
349 
Williamstown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 11.9 67.3 (29.0-132.7)   Male 4 6.6 nc (nc-nc) 
Female 4 4.1 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 6.0 100.7 (36.8-219.2) 
Female 26 35.0 74.3 (48.5-108.8)   Female 5 5.2 96.2 (31.0-224.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 11.6 60.5 (24.2-124.7)             
Female 8 12.0 66.7 (28.7-131.5)   Female 4 3.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.8 nc (nc-nc)   Male 1 3.9 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 36 33.1 108.9 (76.3-150.8) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.1 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 3.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.3 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 5 5.5 91.7 (29.6-214.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.3 nc (nc-nc)             
Female 3 1.2 nc (nc-nc)   Female 3 8.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 19.9 45.3 (20.7-86.0)   Male 99 136.0 72.8 (59.2-88.6) 
Female 15 19.9 75.4 (42.2-124.3)   Female 93 131.1 71.0 (57.3-86.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
350 
Wilmington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 21.8 123.9 (81.7-180.3)   Male 11 14.4 76.3 (38.1-136.6) 
Female 8 8.1 98.4 (42.4-193.9)   Female 15 12.1 124.3 (69.5-205.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 4.6 nc (nc-nc)   Male 4 4.5 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 8 3.7 215.3 (92.7-424.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 8 13.1 61.3 (26.4-120.7) 
Female 110 96.5 114.0 (93.7-137.4)   Female 16 11.6 138.1 (78.9-224.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 10.8 83.5 (38.1-158.4) 
Female 2 3.3 nc (nc-nc)   Female 6 5.0 121.1 (44.2-263.5) 
Colon / Rectum            Ovary     
Male 24 24.5 98.0 (62.8-145.9)             
Female 27 24.8 108.7 (71.6-158.1)   Female 8 8.4 95.0 (40.9-187.1) 
Esophagus            Pancreas     
Male 5 5.9 84.9 (27.4-198.2)   Male 6 7.8 77.0 (28.1-167.7) 
Female 0 1.6 nc (nc-nc)   Female 9 8.1 111.3 (50.8-211.3) 
Hodgkin Lymphoma            Prostate     
Male 3 1.7 nc (nc-nc)   Male 62 74.4 83.3 (63.9-106.8) 
Female 3 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 18 12.6 142.5 (84.4-225.2)   Male 5 5.2 95.7 (30.8-223.3) 
Female 8 7.5 106.8 (46.0-210.4)   Female 5 3.2 157.4 (50.7-367.3) 
Larynx            Testis     
Male 3 3.4 nc (nc-nc)   Male 0 3.0 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 9.2 141.1 (75.0-241.2)   Male 8 5.9 135.0 (58.1-266.0) 
Female 5 6.8 73.5 (23.7-171.5)   Female 14 18.1 77.4 (42.3-129.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.8 nc (nc-nc)             
Female 2 2.6 nc (nc-nc)   Female 23 21.7 106.1 (67.2-159.2) 
Lung and Bronchus            All Sites / Types     
Male 51 38.7 131.6 (98.0-173.1)   Male 291 293.3 99.2 (88.1-111.3) 
Female 48 43.7 109.8 (80.9-145.5)   Female 347 317.8 109.2 (98.0-121.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
351 
Winchendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 11.6 103.4 (53.4-180.6)   Male 1 7.8 nc (nc-nc) 
Female 3 3.6 nc (nc-nc)   Female 3 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.4 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 1 6.9 nc (nc-nc) 
Female 32 45.3 70.7 (48.3-99.8)   Female 3 5.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 5.9 101.3 (37.0-220.4) 
Female 4 1.5 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 13.0 61.5 (26.5-121.3)             
Female 15 11.0 136.3 (76.2-224.8)   Female 6 3.9 153.2 (55.9-333.4) 
Esophagus            Pancreas     
Male 2 3.3 nc (nc-nc)   Male 8 4.2 190.1 (81.9-374.6) 
Female 2 0.7 nc (nc-nc)   Female 5 3.5 142.5 (45.9-332.5) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 32 42.1 76.1 (52.0-107.4) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.8 73.6 (23.7-171.7)   Male 1 2.8 nc (nc-nc) 
Female 5 3.5 144.1 (46.4-336.3)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.8 146.6 (58.7-302.0)   Male 3 3.1 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 8 8.3 95.9 (41.3-188.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.5 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 10 10.3 97.3 (46.6-179.0) 
Lung and Bronchus            All Sites / Types     
Male 13 21.4 60.7 (32.3-103.9)   Male 118 159.7 73.9 (61.1-88.5) 
Female 23 20.4 112.6 (71.3-168.9)   Female 139 145.8 95.3 (80.1-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
352 
Winchester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 23.6 101.5 (65.0-151.0)   Male 19 15.0 126.4 (76.1-197.4) 
Female 5 9.2 54.1 (17.4-126.2)   Female 15 12.3 121.9 (68.2-201.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.4 nc (nc-nc)   Male 5 4.8 104.2 (33.6-243.2) 
Female 11 4.0 276.8 (138.0-495.4)   Female 6 4.1 146.8 (53.6-319.6) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 19 13.5 140.7 (84.7-219.8) 
Female 115 98.8 116.4 (96.1-139.7)   Female 13 12.6 103.4 (55.0-176.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 10.6 nc (nc-nc) 
Female 2 3.3 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 25.7 93.3 (59.7-138.8)             
Female 27 28.2 95.6 (63.0-139.1)   Female 9 8.7 103.6 (47.3-196.6) 
Esophagus            Pancreas     
Male 3 6.1 nc (nc-nc)   Male 5 8.2 61.0 (19.7-142.4) 
Female 0 1.8 nc (nc-nc)   Female 8 9.3 85.6 (36.9-168.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 81 74.6 108.5 (86.2-134.9) 
Female 1 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 12.8 62.6 (27.0-123.4)   Male 4 5.5 nc (nc-nc) 
Female 9 7.9 114.3 (52.2-217.1)   Female 5 3.7 136.5 (44.0-318.5) 
Larynx            Testis     
Male 1 3.6 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 9.4 170.4 (97.3-276.8)   Male 3 5.7 nc (nc-nc) 
Female 5 7.5 66.4 (21.4-154.9)   Female 22 17.2 127.6 (79.9-193.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.9 nc (nc-nc)             
Female 2 2.8 nc (nc-nc)   Female 24 21.5 111.8 (71.6-166.3) 
Lung and Bronchus            All Sites / Types     
Male 29 41.9 69.2 (46.3-99.4)   Male 285 302.8 94.1 (83.5-105.7) 
Female 41 47.5 86.4 (62.0-117.1)   Female 351 336.0 104.5 (93.8-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
353 
Windsor 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.4 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 4.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 1.5 nc (nc-nc)             
Female 2 1.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 0 5.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.4 nc (nc-nc)   Male 11 18.5 59.6 (29.7-106.6) 
Female 3 1.9 nc (nc-nc)   Female 16 14.3 111.8 (63.9-181.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
354 
Winthrop 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 22.7 101.2 (64.1-151.8)   Male 28 14.7 190.2 (126.3-274.8) 
Female 7 7.0 99.4 (39.8-204.9)   Female 18 10.2 176.3 (104.4-278.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.2 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 8 3.2 250.7 (107.9-494.0) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 4 12.9 nc (nc-nc) 
Female 88 79.2 111.0 (89.1-136.8)   Female 11 9.9 110.8 (55.2-198.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 10.7 93.0 (44.5-171.1) 
Female 4 2.7 nc (nc-nc)   Female 1 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 24.1 111.9 (73.7-162.8)             
Female 28 20.9 133.8 (88.9-193.4)   Female 12 7.0 170.7 (88.1-298.3) 
Esophagus            Pancreas     
Male 6 6.2 96.6 (35.3-210.2)   Male 14 8.1 173.0 (94.5-290.3) 
Female 1 1.4 nc (nc-nc)   Female 7 7.0 100.5 (40.2-207.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.5 nc (nc-nc)   Male 74 81.5 90.8 (71.3-114.0) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 12.7 196.7 (127.2-290.3)   Male 5 5.4 93.4 (30.1-218.0) 
Female 13 6.3 206.2 (109.7-352.6)   Female 3 2.7 nc (nc-nc) 
Larynx            Testis     
Male 4 3.7 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 8.9 67.7 (24.7-147.4)   Male 9 5.6 161.3 (73.6-306.2) 
Female 6 5.7 105.7 (38.6-230.1)   Female 15 14.9 100.8 (56.4-166.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 8.1 98.7 (42.5-194.4)             
Female 3 2.3 nc (nc-nc)   Female 19 18.2 104.2 (62.7-162.8) 
Lung and Bronchus            All Sites / Types     
Male 55 42.0 130.9 (98.6-170.4)   Male 331 304.0 108.9 (97.5-121.3) 
Female 49 38.3 127.8 (94.5-169.0)   Female 321 267.4 120.0 (107.3-133.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
355 
Woburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 49 40.7 120.3 (89.0-159.1)   Male 31 26.6 116.7 (79.2-165.6) 
Female 23 15.8 145.2 (92.0-217.8)   Female 21 22.0 95.5 (59.1-145.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.0 nc (nc-nc)   Male 9 8.2 109.5 (50.0-208.0) 
Female 11 6.7 163.7 (81.6-292.9)   Female 7 7.1 99.0 (39.7-203.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.4 nc (nc-nc)   Male 32 23.7 135.1 (92.4-190.7) 
Female 208 167.5 124.2 (107.9-142.3)   Female 28 21.8 128.3 (85.3-185.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 18.8 100.8 (60.7-157.4) 
Female 9 5.7 156.7 (71.5-297.6)   Female 10 9.1 109.9 (52.6-202.0) 
Colon / Rectum            Ovary     
Male 60 44.4 135.1 (103.1-173.9)             
Female 51 48.1 106.1 (79.0-139.4)   Female 16 15.1 105.9 (60.5-172.0) 
Esophagus            Pancreas     
Male 12 10.6 112.8 (58.2-197.0)   Male 15 14.3 105.0 (58.7-173.2) 
Female 1 3.0 nc (nc-nc)   Female 21 16.0 131.2 (81.2-200.5) 
Hodgkin Lymphoma            Prostate     
Male 3 3.3 nc (nc-nc)   Male 125 133.4 93.7 (78.0-111.6) 
Female 2 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 22.3 120.9 (79.7-175.9)   Male 11 9.6 114.4 (57.1-204.8) 
Female 15 13.5 111.3 (62.3-183.7)   Female 6 6.2 96.7 (35.3-210.4) 
Larynx            Testis     
Male 3 6.2 nc (nc-nc)   Male 9 6.5 137.8 (62.9-261.6) 
Female 5 2.0 250.3 (80.7-584.2)             
Leukemia            Thyroid     
Male 20 16.5 121.5 (74.2-187.7)   Male 12 10.6 113.4 (58.5-198.0) 
Female 15 12.8 117.0 (65.4-192.9)   Female 33 31.1 106.2 (73.1-149.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 14.0 121.5 (70.7-194.5)             
Female 1 4.9 nc (nc-nc)   Female 40 37.9 105.7 (75.5-143.9) 
Lung and Bronchus            All Sites / Types     
Male 98 72.1 136.0 (110.4-165.7)   Male 621 533.7 116.3 (107.4-125.9) 
Female 81 81.4 99.5 (79.0-123.7)   Female 675 578.1 116.8 (108.1-125.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
356 
Worcester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 181 152.2 118.9 (102.2-137.6)   Male 65 100.7 64.6 (49.8-82.3) 
Female 62 61.8 100.4 (77.0-128.7)   Female 56 90.8 61.7 (46.6-80.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 30 32.7 91.6 (61.8-130.8)   Male 25 30.8 81.3 (52.6-120.0) 
Female 24 28.9 82.9 (53.1-123.4)   Female 25 27.6 90.7 (58.7-133.9) 
Breast            Non-Hodgkin Lymphoma     
Male 2 5.2 nc (nc-nc)   Male 103 91.1 113.1 (92.3-137.1) 
Female 590 667.2 88.4 (81.4-95.9)   Female 80 86.5 92.4 (73.3-115.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 67 72.3 92.7 (71.8-117.7) 
Female 32 24.2 132.5 (90.6-187.0)   Female 40 36.2 110.6 (79.0-150.6) 
Colon / Rectum            Ovary     
Male 138 168.5 81.9 (68.8-96.8)             
Female 190 189.6 100.2 (86.5-115.5)   Female 60 60.8 98.8 (75.4-127.1) 
Esophagus            Pancreas     
Male 54 40.1 134.7 (101.2-175.8)   Male 56 53.7 104.3 (78.7-135.4) 
Female 11 11.8 93.1 (46.4-166.6)   Female 62 62.3 99.5 (76.3-127.6) 
Hodgkin Lymphoma            Prostate     
Male 16 14.9 107.4 (61.3-174.4)   Male 495 503.8 98.3 (89.8-107.3) 
Female 19 13.5 140.5 (84.6-219.5)             
Kidney & Renal Pelvis            Stomach     
Male 85 85.0 100.0 (79.8-123.6)   Male 36 36.1 99.8 (69.9-138.1) 
Female 61 53.6 113.8 (87.0-146.1)   Female 24 24.5 97.8 (62.7-145.6) 
Larynx            Testis     
Male 22 23.2 94.9 (59.4-143.7)   Male 21 29.2 72.0 (44.5-110.0) 
Female 9 7.9 113.9 (52.0-216.2)             
Leukemia            Thyroid     
Male 70 65.0 107.6 (83.9-136.0)   Male 41 41.9 97.7 (70.1-132.6) 
Female 54 53.0 101.9 (76.6-133.0)   Female 119 136.3 87.3 (72.3-104.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 86 53.2 161.5 (129.2-199.5)             
Female 21 19.3 109.1 (67.5-166.8)   Female 156 148.2 105.3 (89.4-123.2) 
Lung and Bronchus            All Sites / Types     
Male 330 266.6 123.8 (110.8-137.9)   Male 2085 2029.7 102.7 (98.4-107.2) 
Female 354 317.2 111.6 (100.3-123.8)   Female 2222 2311.3 96.1 (92.2-100.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Worthington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 4 6.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.9 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 4 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 3.2 190.2 (69.4-413.9)   Male 24 23.1 103.7 (66.4-154.3) 
Female 0 2.9 nc (nc-nc)   Female 18 20.9 86.1 (51.0-136.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wrentham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.9 100.9 (48.3-185.5)   Male 6 7.0 85.7 (31.3-186.6) 
Female 2 4.1 nc (nc-nc)   Female 11 6.1 179.0 (89.2-320.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.3 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 3 1.9 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 9 6.4 141.6 (64.6-268.8) 
Female 59 49.4 119.5 (90.9-154.1)   Female 4 6.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.7 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 5 2.5 196.2 (63.2-457.9) 
Colon / Rectum            Ovary     
Male 22 12.1 181.9 (113.9-275.4)             
Female 11 13.2 83.2 (41.5-148.9)   Female 3 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 2.9 208.7 (76.2-454.2)   Male 4 3.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 45 37.3 120.6 (88.0-161.4) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.3 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 2 3.8 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.3 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 1 3.4 nc (nc-nc)   Female 5 9.0 55.7 (18.0-130.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.2 nc (nc-nc)             
Female 2 1.4 nc (nc-nc)   Female 6 11.1 54.2 (19.8-117.9) 
Lung and Bronchus            All Sites / Types     
Male 17 17.9 94.7 (55.1-151.7)   Male 158 143.2 110.3 (93.8-128.9) 
Female 15 21.7 69.2 (38.7-114.2)   Female 149 162.1 91.9 (77.8-107.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Yarmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 49 49.4 99.1 (73.3-131.1)   Male 41 27.3 150.2 (107.7-203.7) 
Female 25 17.7 140.9 (91.1-208.0)   Female 50 19.4 257.9 (191.4-340.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.6 75.8 (24.4-176.9)   Male 8 9.0 89.3 (38.4-175.9) 
Female 9 5.8 154.0 (70.3-292.3)   Female 7 7.6 92.6 (37.1-190.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.6 nc (nc-nc)   Male 23 24.3 94.8 (60.1-142.2) 
Female 178 154.6 115.1 (98.8-133.3)   Female 23 22.3 103.1 (65.4-154.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 16.6 126.4 (78.2-193.2) 
Female 2 4.2 nc (nc-nc)   Female 8 9.0 89.1 (38.4-175.6) 
Colon / Rectum            Ovary     
Male 42 47.6 88.3 (63.6-119.4)             
Female 45 51.1 88.1 (64.3-117.9)   Female 11 14.1 77.9 (38.8-139.4) 
Esophagus            Pancreas     
Male 19 11.2 168.9 (101.7-263.8)   Male 18 16.0 112.4 (66.6-177.7) 
Female 6 3.3 181.2 (66.2-394.4)   Female 14 17.8 78.6 (42.9-131.9) 
Hodgkin Lymphoma            Prostate     
Male 4 2.1 nc (nc-nc)   Male 147 127.9 114.9 (97.1-135.1) 
Female 3 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 20.5 68.2 (37.2-114.4)   Male 8 10.7 74.9 (32.2-147.5) 
Female 10 13.3 75.1 (35.9-138.1)   Female 7 6.7 105.0 (42.1-216.4) 
Larynx            Testis     
Male 4 6.2 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 31 17.1 181.0 (123.0-256.9)   Male 11 7.5 146.7 (73.1-262.4) 
Female 18 12.7 142.1 (84.2-224.6)   Female 11 21.4 51.3 (25.6-91.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 13.4 134.7 (79.8-212.9)             
Female 8 5.1 156.8 (67.5-308.9)   Female 32 34.8 92.0 (62.9-129.9) 
Lung and Bronchus            All Sites / Types     
Male 86 82.6 104.1 (83.3-128.6)   Male 592 548.8 107.9 (99.4-116.9) 
Female 93 90.5 102.8 (82.9-125.9)   Female 610 565.4 107.9 (99.5-116.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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